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Abstract 
Systems biology has become a powerful scientific method using a more holistic 
perspective to tackle biological and biomedical research. Complex data obtained from 
different types of experiments using multiple interdisciplinary tools such as metabonomics 
and transcriptomics can be integrated and analysed to give a better understanding of the 
biological problem at hand. 
This PhD thesis comprises closely related project parts that utilise tools of systems biology 
(NMR-based metabonomics, gene expression profiling, and multivariate analysis) to 
investigate how growth hormone deficiency (GHD) and obesity can cause alterations in 
metabolism of children and adolescence. In addition, method development of collecting 
and storage of human urine samples for NMR-based metabonomic studies were also 
investigated to aid in achieving accurate metabolic fingerprints.  
The first project established a novel standard procedure of collection, storage and 
preservation of human urine samples to ensure the measurement of true metabolic 
fingerprints in NMR-based metabonomic studies. Human urine samples are susceptible to 
metabolite changes when left at room temperature for less than 24 hours even with the 
addition of different preservatives and I have successfully established the minimum 
requirements to maintain the stability of urine samples for 48 hours at room temperature. 
Once a standard procedure of sample handling was established, a NMR-based 
metabonomics pilot study was performed in which the metabolic profiles of a growth 
hormone (GH)-deficient adolescent subject were tracked with NMR-based urinary 
metabonomics during five years of GH therapy . Detection of urinary metabolites related to 
GHD provided a clearer picture of the impact GH therapy has on metabolism. 
Metabonomics was able to differentiate the metabolic profiles of healthy controls from the 
GHD subject indicating that metabonomics has the capability to be utilised as a platform to 
identify the effects of GH treatment on metabolism in humans.  
 The main project of this PhD was a study of metabolic changes in children with obesity 
and used tools of systems biology such as NMR-based urinary metabonomics and 
peripheral blood mononuclear cell (PBMC) gene expression analysis to investigate 
samples collected as part of the KOALA childhood obesity program. Results from both 
metabonomics and gene expression profiling studies were combined with clinical data 
using multivariate analysis (O2PLS) to provide a clearer picture of how obesity can disrupt 
metabolism in children. The outcome(s) of this study support the utilisation of NMR-based 
metabonomics as a potential diagnostic and prognostic tool not only in the context of 
obesity, but make the technique also available for the study of other diseases. In addition, 
gene expression studies of PBMCs identified significant NRs and NR-dependent pathways 
that may improve our understanding of the underlying molecular mechanisms in metabolic 
dysfunction in obesity.  
In summary, using tools of systems biology, a better understand can be achieved of how a 
disease or changes to body composition alter the metabolism of humans. In addition, by 
combining more than one type of ‘omics with multivariate analysis, one can obtain more 
information regarding the state of the subjects that could potentially be useful in predicting 
clinical risk factors for related diseases.  
 
3 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published 
or written by another person except where due reference has been made in the text. I 
have clearly stated the contribution by others to jointly-authored works that I have included 
in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional 
editorial advice, and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of 
my research higher degree candidature and does not include a substantial part of work 
that has been submitted to qualify for the award of any other degree or diploma in any 
university or other tertiary institution. I have clearly stated which parts of my thesis, if any, 
have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University 
Library and, subject to the policy and procedures of The University of Queensland, the 
thesis be made available for research and study in accordance with the Copyright Act 
1968 unless a period of embargo has been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this thesis. 
 
4 
 
Publications during candidature 
Chapters 2 and 3 will be or have been submitted to respective journals and therefore have 
been written in manuscript format. 
Chapter 2 to be submitted to J. Pharmaceut. Biomed. Anal.  in June 2015. 
Chapter 3 submitted to Growth Hormone & IGF Research in September 2012 and 
published in February 2013. (Abd Rahman S, Schirra HJ, Lichanska AM, Huynh T, Leong 
GM. Urine Metabonomic Profiling of a Female Adolescent with PIT-1 Mutation before and 
during Growth Hormone Therapy: Insight into the Metabolic Effects of Growth Hormone. 
Growth Hormone and IGF Research. 2013 Feb-Apr, 23(1-2):29-36.) 
  
Publications included in this thesis 
Chapter 2. 
Contributor Statement of contribution 
Shaffinaz Abd Rahman (Candidate) Designed experiments (60%) 
Wrote the paper (70%) 
Horst J Schirra Designed experiments (40%) 
Wrote and edited paper (30%) 
Gary M Leong Designed experiments (40%) 
Wrote and edited paper (30%) 
 
Chapter 3.  
Contributor Statement of contribution 
Shaffinaz Abd Rahman (Candidate) Designed experiments (60%) 
Wrote the paper (70%) 
Horst J Schirra Designed experiments (40%) 
Wrote and edited paper (30%) 
Lichanska AM Designed experiments (20%) 
Edited paper (20%) 
Tony Huynh Collection of biochemical parameters and 
body composition 
Gary M Leong Designed experiments (40%) 
Wrote and edited paper (30%) 
 
 
5 
 
Contributions by others to the thesis  
 
Contributor Statement of Contribution 
Shaffinaz Abd Rahman (candidate) Writing of the manuscripts and thesis 
Designed and performed experiments in 
Chapters 2-6 
Made Figures (including Supplementary) 
in Chapters 2-6 
Collated data for database and appendix 
of thesis 
Nick Martel Assisted in design of experiments in 
Chapter 4 
Assisted in RNA extraction in Chapter 4 
(15%) 
Natalie Eriksson Assisted in TLDA analysis in Chapter 4 
Melissa Davis Assisted in TLDA analysis in Chapter 4 
Assisted in pair-wise analysis in Chapter 
5 
Kim-Ahn Le Cao Assisted in TLDA analysis in Chapter 4 
Assisted in pair-wise analysis in Chapter 
5 
Tony Huynh Clinical measurements in Chapter 3 
Co-Author of Chapter 3 
Agnieszka Lichanska Assisted in design of experiments in 
Chapter 3 
Co-Author of Chapter 3 
George Muscat Design of experiments in Chapter 4 
Horst Schirra Co-Author of Chapters 2 and 3 
Co-supervision and design of all 
experiments 
Editing of the thesis 
Gary Leong Co-Author of Chapters 2 and 3 
Co-supervision and design of all 
experiments 
Editing of the thesis 
Collected samples and clinical data for 
Chapters 3-5 
Made Figure 1 in Chapter 3 
 
Statement of contribution by others – Nick Martel and Natalie Eriksson were responsible 
for my training in gene expression experiments and analysis. Dr Horst Schirra and Dr Peta 
Harvey were responsible for my training in NMR spectroscopy. Dr Horst Schirra was 
responsible for my training in multivariate analysis. Prof Johan Trygg (Umeå University 
6 
 
Sweden) contributed to my training in O2PLS analysis. Associate Professor Gary Leong, 
Dr Horst Schirra, Dr David Hansen and Professor George Muscat were responsible for the 
conception and designs of experiments. Associate Professor Gary Leong and Dr Horst 
Schirra were responsible for editing of this thesis and overall supervision of this PhD 
project.  
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
None. 
 
7 
 
Acknowledgements 
Firstly, I would like to thank Allah swt for giving me the strength and patience the past 5 
years to charge ahead despite all the obstacles that I faced especially towards the end 
when I nearly gave up on everything. I have always believed that you can get through the 
challenges He gives you and this thesis is one solid proof. 
I would like to thank CSIRO Preventive Health Flagship, the University of Queensland and 
the Institute for Molecular Bioscience for awarding me scholarships that allowed me to 
undertake this PhD. Without their financial help, I would only be dreaming about this PhD 
and probably slogging away back in a lab in Singapore as a technician! 
I would like to expressly thank my supervisors Assoc. Prof. Gary Leong, Dr Horst Schirra 
and Dr David Hansen for giving me the opportunity to undertake a PhD. Without their 
financial and moral support and also contributing their expertise and time, it would not 
have been possible to complete this thesis. 
I would also like to thank Prof. George Muscat, Dr Melissa Davis, Dr Kim-Anh Le Cao, Dr 
Peta Harvey, Dr Agnieszka Lichanska, Dr Tony Huynh, Natalie Eriksson and Nick Martel 
for assisting me in my lab work, analysis and interpretation of my data. Not forgetting 
everyone else in Groups Muscat, Leong and Schirra that have helped me one way or 
another.  
A personal thank you to Dr Amanda Carozzi for providing a helping hand with the 
administrative side of my PhD and taking care of all my worries.  
To the friends and “family” I’ve made in Brisbane, thank you for all the great advice, moral 
support, help and also the fun times I’ve had during my stay there. A special shout out to 
Seha, Jace, Yan, Mez, Mary and Mai for being there for me when I needed to de-stress. I 
am going to miss all of you very much! 
To my family and friends back in Singapore, especially my parents, brother and ‘twin’ 
cousin, thank you for the never ending moral support and encouragements even though 
we are more than 6000km away. All of you have been my rock!  
To my husband Nazri, thank you for all the sacrifices you’ve made to make sure I was 
alright being far away from home. Thank you for being patient with me while I try to 
achieve my dreams and standing by me when times were tough.  
Lastly, I specially dedicate this PhD to my parents who had tirelessly sacrificed a whole lot 
to make sure I achieved my dreams. Thank you Ayah and Ibu!!   
 
 
 
8 
 
Keywords 
NMR, metabonomics, childhood obesity, growth hormone, nuclear receptor, TLDA, 
multivariate analysis 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 060114 (Systems Biology) 40%  
ANZSRC code: 110199 (Medicinal Biochemistry and Metabolomics) 40%  
ANZSRC code: 060405 (Gene Expression) 20% 
 
 
Fields of Research (FoR) Classification 
FoR code: 1101 (Medical Biochemistry and Metabolomics) 70% 
FoR code:  1103 (Clinical Sciences) 20% 
FoR code:  0604 (Genetics) 10% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Table of Contents 
Abstract            2 
Keywords            3 
Declaration           4 
Statement of Contributions to Works Contained in the Thesis (Including Manuscripts)  5 
Statement of Contributions by Others to the Thesis as a Whole     6 
Statement of Parts of the Thesis Submitted to Qualify for the Award of another Degree  6 
Published Works by the Author Incorporated into the Thesis     6 
Additional Published Works by the Author Relevant to the Thesis but not Forming Part of it 6 
Acknowledgments           7 
Australian and New Zealand Standard Research Classifications (ANZSRC)   8 
Fields of Research (FoR) Classification        8 
Table of Contents           9 
List of Figures           15 
List of Tables           20 
Abbreviations           21 
1. Chapter 1: Introduction         25 
1.1 Obesity           25 
1.1.1 Definition, Prevalence and Health Impacts of Obesity     25 
1.1.2 Genetics and Obesity         25 
1.1.3 Obesity and Inflammation        28 
1.1.4 Gut Microbiota and Obesity        29 
1.1.5 Nuclear Receptor, Inflammation and Metabolism in Obesity    30 
1.1.6 Gene Expression in Peripheral Blood Mononuclear Cells (PBMCs) and Disease  32 
1.2 Obesity-related Diseases         33 
1.2.1 Cardiovascular Disease (CVD)        33 
1.2.2 Type 2 Diabetes Mellitus (T2DM)       34 
1.2.3 Hormonal Factors and Metabolism       36 
1.2.3.1 Growth Hormone         37 
1.3 Metabonomics & Systems Biology        40 
1.3.1 Metabonomics          40 
1.3.1.1 Definition of Metabonomics       40 
1.3.1.2 Biological Fluids         42 
1.3.1.3 Techniques in Metabonomics       43 
1.3.1.4 Data Processing         44 
1.3.2 Application of Metabonomics        45 
1.3.2.1 Physiological Variations        45 
1.3.2.2 Disease Diagnosis         46 
10 
 
1.3.3 Obesity and Metabonomics        47 
1.3.3.1 Animal Studies of Obesity        47 
1.3.3.2 Human Studies of Obesity        48 
1.3.4 Systems Biology         49 
1.3.5 Hypothesis-Driven vs. Data Driven Science      51 
1.4 Rationale           52 
1.4.1 Hypothesis          52 
1.4.2 Aims           52 
1.4.3 Project Structure/Rationale        53 
1.4.4 Significance          53 
1.5 KOALA Childhood Obesity Program        54 
2 Chapter 2:  Ensuring the Short-Term Stability of Human Urine Samples in NMR-based 
Metabonomics           57 
2.1 Abstract           58 
2.2 Introduction           59 
2.3 Results            60 
2.3.1 Experiment 1: Metabolic profiles of human urine samples alter at room temperature within 
48 hours even with the addition of preservatives      61 
2.3.2 Experiment 2: Storage for 24 hours at -20°C suppresses alterations to metabolic profiles of 
urine samples          63 
2.3.3 Experiment 3: Levels of key metabolites in urine changed as early as 11.5 hours post storage 
at room temperature, even with the addition of preservatives    65 
2.3.4 Experiment 4 and 5: A minimum concentration of 100 mM sodium borate is required to 
maintain the stability of urine samples at room temperature for 48 hours   67 
2.3.5 Effect of borate addition on multivariate analysis     69                                      
2.4 Discussion           70 
2.5 Materials and Methods         74 
2.5.1 Ethics Statement – Samples Collection       74 
2.5.2 Materials          74 
2.5.3 NMR Sample Preparation        74 
2.5.3.1 48 Hour Experiment (Experiment 1)       74 
2.5.3.2 72 Hour Experiment (Experiment 2)       75 
2.5.3.3 24 Hour Experiment (Experiment 3)       75 
2.5.3.4 Borate as Preservative  (Experiment 4)      75 
2.5.3.5 Borate Concentration Experiments (Experiments 4 and 5)    75 
2.5.4 NMR Spectroscopy         76 
2.5.5 NMR Analysis          76 
2.5.5.1 Data Processing         76 
11 
 
2.5.5.2 Principals Components Analysis       76 
2.5.5.3 Identification of Metabolites       76 
2.5.6 Microbiology          77 
2.6 Acknowledgments          77 
2.7 References           78 
2.8 Supplementary Information         81 
2.9 Addition Work          86 
2.9.1. Additional Figures to the Work Presented in the Manuscript    86 
          2.9.2. Ageing effects of urine samples stored at -20°C       89 
          2.9.3. The ideal pH for phosphate buffers to maintain stability of urine samples   91 
3 Chapter 3: Urine Metabonomic Profiling of a Female Adolescent with PIT-1 Mutation before 
and during Growth Hormone Therapy: Insights into the Metabolic Effects of Growth Hormone 
(Published Article)          93 
3.1 Additional Work         105 
3.1.1 Comments on Chapter 3       105 
3.1.2     O2PLS Analysis of Metabonomic and Clinical Data    105 
3.1.3 Univariate Analysis of Metabolite       106 
4 Chapter 4: KOALA Childhood Obesity Nuclear Receptor (NR) Gene Expression Study 
            109 
4.1 Introduction          109 
4.2 Materials and Methods        111 
4.2.1 Sample Collection        111 
4.2.2 RNA Extraction and cDNA Synthesis      111 
4.2.3 Quantitative RT-PCR        111 
4.2.4 Statistical Analysis        112 
4.3 Results           112  
4.3.1 Relative Quantification and Expression of Obese vs. Healthy Weight Children113 
4.3.1.1 Male Cohort        113 
4.3.1.2 Female Cohort        116 
4.3.1.3 Combined Cohort        119 
4.3.2 Manual RT-PCR of Obese Male Children after a 12 month Lifestyle Intervention 122 
4.4 Discussion          123 
4.5 Supplementary Information        127 
5 Chapter 5: Analysis of the KOALA Childhood Obesity Cohort with NMR-based Metabonomics         
130 
5.1 Introduction          130 
5.2 Materials and Methods        130 
12 
 
5.2.1 Sample Collection        130 
5.2.2 Sample Preparation        131 
5.2.3 NMR Spectroscopy        131 
5.2.3.1 Data Processing        131 
5.2.3.2 Data Reduction        132 
5.2.4 Principal Components Analysis (PCA)      132 
5.2.5 Partial Least Squares (PLS) Analysis      132 
5.2.6 Orthogonal-PLS (OPLS/O2PLS)      132 
5.2.7 Metabolite Identification       133 
5.2.8 Pathway Analysis        133 
5.3 Results           133 
5.3.1 Metabolite Identification       133 
5.3.2 KOALA Metabonomics (Baseline)      136 
5.3.2.1 Arms A vs. B        137 
5.3.2.2 Arms A vs. Healthy Weight       139 
5.3.2.3 Arms B vs. Healthy Weight       141 
5.3.2.4 Arms A & B vs. Healthy Weight      143 
5.3.3 KOALA Metabonomics (After 12 months Lifestyle Intervention)  145 
5.3.3.1 Lost Weight vs. Healthy Weight      145 
5.3.3.2 Gained Weight vs. Healthy Weight      147 
5.3.3.3 Gained Weight vs. Lost Weight      149 
5.3.4 Clinical Data (Baseline)        151 
5.3.4.1 Males         151 
5.3.4.2 Females         153 
5.3.4.3 Combined Cohorts        153 
5.3.5 KOALA NR (Baseline)        154 
5.3.5.1 Males         154 
5.3.5.2 Females         156 
5.3.5.3 Combined Cohorts        158 
5.3.6 MetaboAnalyst Pathway Analysis      160 
5.4 Discussion          161 
5.4.1 Obese vs. Healthy Weight Children at Baseline     161 
5.4.2 Obese vs. Healthy Weight Children after 12 Months Lifestyle Intervention  165 
5.4.3. Limitations and Future Outlook       166 
6 Chapter 6: Integration of KOALA Childhood Obesity Data    168 
6.1 Introduction          168 
6.2 Materials and Methods        168 
6.2.1 General Notation        170 
13 
 
6.2.2 Pre-processing of individual data matrices     170 
6.2.2.1 Metabonomics        170 
6.2.2.2 Clinical         170 
6.2.2.3 Nuclear Receptor        170 
6.2.3 Pair-wise Analysis        171 
6.2.4 Addition of Third Dataset       171 
6.3 Results           172 
6.3.1 Pairwise Analysis        172 
6.3.1.1 Combined Cohort        175 
6.3.1.1.1 Nuclear Receptor vs. Clinical Data     175 
6.3.1.1.2 Nuclear Receptor vs. Metabonomics Data    177 
6.3.1.1.3 Clinical vs. Metabonomics Data     178 
6.3.1.2 Male Cohort        179 
6.3.1.2.1 Nuclear Receptor vs. Clinical Data     179 
6.3.1.2.2 Nuclear Receptor vs. Metabonomics Data    180 
6.3.1.2.3 Clinical vs. Metabonomics Data     180 
6.3.1.3 Female Cohort        182 
6.3.1.3.1 Nuclear Receptor vs. Clinical Data     182 
6.3.1.3.2 Nuclear Receptor vs. Metabonomics Data    183 
6.3.1.3.3 Clinical vs. Metabonomics Data     184 
6.3.2 Integration of Third Dataset       185 
6.3.2.1 Combined Cohort        187 
6.3.2.1.1 Nuclear Receptor + Clinical vs. Metabonomics Data   187 
6.3.2.1.2 Nuclear Receptor + Metabonomics vs. Clinical Data   188 
6.3.2.1.3 Clinical + Metabonomics vs. Nuclear Receptor Data   189 
6.3.2.2 Male Cohort        190 
6.3.2.2.1 Nuclear Receptor + Clinical vs. Metabonomics Data   190 
6.3.2.2.2 Nuclear Receptor + Metabonomics vs. Clinical Data   191 
6.3.2.2.3 Clinical + Metabonomics vs. Nuclear Receptor Data   193 
6.3.2.3 Female Cohort        193 
6.3.2.3.1 Nuclear Receptor + Clinical vs. Metabonomics Data   193 
6.3.2.3.2 Nuclear Receptor + Metabonomics vs. Clinical Data   195 
6.3.2.3.3 Clinical + Metabonomics vs. Nuclear Receptor Data   196 
6.4 Discussion          197 
6.4.1 Pairwise Analysis        197             
6.4.2 Integration         199 
6.4.2.1 Biological Effects        199 
6.4.2.2 Limitations         200 
14 
 
6.4.2.3 Future Studies        201 
7 Chapter 7: General Conclusions       203 
7.1 Conclusions          203 
7.1.1 Urine Stability in NMR-Based Metabonomics     204 
7.1.2 Effects of Growth Hormone (GH) Therapy on Metabolism of a GH Deficient 205 
7.1.3 NR Gene Expression and Metabolism of Children with Obesity – the KOALA study 
          205 
7.1.3.1 NR Gene Expression of Children with Obesity    206 
7.1.3.2 Metabonomics and Multi-Model Analysis of Children with Obesity  206 
7.1.3.2.1 Obese vs. Healthy Weight Children at Baseline   207 
7.1.3.2.2 Obese vs. Healthy Weight Children after 12 Months Lifestyle Intervention 
         207 
7.1.3.2.3 Pairwise and Integration Analysis of Children with Obesity  207 
7.1.4 General Conclusions        208 
7.1.4.1 Cost Benefits of Project       208 
7.2 Future Aims          209 
7.2.1 Urine Stability in NMR-Based Metabonomics Studies    209 
7.2.2 Effects of GH Therapy on Metabolism of a GHD Patient    209 
7.2.3 NR Gene Expression of Children with Obesity     209 
7.2.4 Metabonomics and Multi-modal Analysis of Children with Obesity  209 
8 References          211 
9 Appendices          242 
9.1 Appendix A – Nuclear Receptor and Clinical Database    242 
9.2 Appendix B – S-plots for Chapter 5 and 6      253 
 
 
 
 
 
 
 
 
 
15 
 
List of Figures 
 
Chapter 1 
Figure 1.1: Genome-wide significant associated loci associating with BMI, waist circumference and waist 
hip ratio (WHR), respectively, identified in individual GWAS (black squares), in both individual GWAS and 
meta-analysis (green squares) and in meta-analyses alone (blue squares) from GWAS Waves 1-4 from 2007-
2010 with BMI effect Size (Odds-ratio-OR) and number of individuals studied shown on left and right Y 
axes, respectively 
Figure 1.2: An outline on the effects of cytokines and proteins on body weight. 
Figure 1.3: The human nuclear hormone receptor superfamily. 
Figure 1.4: Incidence of type II diabetes and prevalence of obesity in Japanese children from 1976 to 1995 
Figure 1.5: Schematic diagram of the hypothalamic-pituitary axis illustrating the different types of hormones 
controlled by the hypothalamic-pituitary axis and the target endocrine organs and their respective secreted 
hormones.  
Figure 1.6: The effects of GH and IGF1 on growth and metabolism based on the new somatomedin 
hypothesis  
Figure 1.7: A urine chart used by the Ancient Greeks to diagnose diseases. 
Figure 1.8: An overview of how hypothesis-driven and data-driven science can be complementary of each 
other.  
Figure 1.9: Design of the KOALA lifestyle intervention program and its time line. 
Chapter 2 
Figure 2.1: A. Outline of the 48 hour, B. 72 hour, C. 24 hour experiments and D. time course overview of all 
experiments. 
Figure 2.2: Changes in signal intensities of metabolites during 48 hours storage. 
Figure 2.3: Changes in signal intensities of metabolites during experiment 2. 
Figure 2.4: Continuous monitoring of changes in metabolite concentrations during 24 hours. 
Figure 2.5: Metabolite concentrations after 48 hours storage at 25°C and 30°C as a function of sodium borate 
concentration. 
Figure 2.6: Effect of borate addition on urine NMR spectra 
Figure S2.1: Overlay of 0hr (blue) and 48hr (red) 1D NMR spectrum of untreated male sample at 25°C. 
Figure S2.2: LB agar plates streaked with male urine incubated at 37°C. 
Figure S2.3: Metabolite changes in male urine samples after addition of 2.5% (w/v) sodium tetraborate 
(262 mM borate) during 48 hours storage A. at 25°C and B. at 30°C. 
Figure S2.4: Chemical shifts of NMR signals with the addition of 100 mM borate at 25 and 30°C. 
Chapter 2 (Additional Work) 
Figure 2.7: Stack plots of untreated urine samples measured at 25°C and 30°C over a period of 24 hours. 
Figure 2.8: Stack plots of urine samples with 0.06% sodium fluoride measured at 25°C and 30°C over a 
period of 24 hours. 
16 
 
Figure 2.9: Overlay spectra of 0 hour (red) and 24 hours (blue) urine samples. 
Figure 2.10: Overlays of a 0hr (red spectrum) with a 24hr (blue spectrum) untreated 25°C male sample A. 
between 0.9 – 2 ppm, B. 2 – 4 ppm and C. 6.5 – 8.5 ppm showing changes in intensities of metabolites after 
24 hours of storage. 
Figure 2.11: Plots of the shifts in the creatine and creatinine signals for pH 6 – 8.4 in human urine samples. 
Chapter 3 (As in manuscript) 
Figure 1: Height chart (2-18 years) showing growth of GHD subject correlated with commencement and 
cessation of GH therapy while on T4 (F – Father’s height, M – Mother’s height, MPH – Mid parental 
height). 
Figure 2: Multivariate statistical analysis of 1D NMR spectra of urine samples from the GH-deficient female 
subject collected over a period of 5 years. 
Figure 3: Metabolic pathway of possible effects of GH on lipolysis and the TCA cycle. 
Figure S1: Validation plots with 200 permutations of the PLS analysis presented in Fig 2 (c) and (d). 
Figure S2: Signal intensity of the citrate NMR signals of the latest two urine samples, collected at 22.01 
years age. 
Chapter 3 (Additional Work) 
Figure 3.1: O2PLS (pareto scaling) of urine samples of GHD female subject compared with clinical data 
recorded over a period of 5 years. 
Figure 3.2: Concentrations of ten selected metabolites in urine samples of the subject during withdrawal of 
GH therapy (off GH), at 22.01 years age (2 samples), during GH therapy, and in urine samples of healthy 
control subjects. 
Chapter 4 
Figure 4.1: Changes in BMI and total body fat of obese children (Arms A and B) after a 12 month lifestyle 
intervention. 
Figure 4.2: Relative quantification (log10), i.e. calculated fold differences of nuclear receptor genes of obese 
male children (n = 33) vs. male healthy weight control children (n = 18). 
Figure 4.3: Relative expression of Nuclear Receptor mRNA expression in pre-pubertal male obese (n = 33) 
[black] and healthy weight children (n = 18) [white] normalised against the median of GUSB, HPRT1 and 
PGK1. 
Figure 4.4: Relative quantification (log10), i.e. calculated fold differences of nuclear receptor genes of obese 
female children (n = 38) vs. female healthy weight control children (n = 16). 
Figure 4.5: Ranked relative expression of Nuclear Receptor mRNA expression in pre-pubertal female obese 
(n = 38) [black] and healthy weight (n = 16) [white] children normalised against the median of B2M, 
GAPDH and PGK1. 
Figure 4.6: Relative quantification (log10), i.e. calculated fold differences of nuclear receptor genes of obese 
children (n = 71) vs. healthy weight control children (n = 34). 
17 
 
Figure 4.7: Ranked relative expression of Nuclear Receptor mRNA expression in pre-pubertal obese (n = 71) 
[black] and healthy weight (n = 34) [white] children normalised against the median of GAPDH, PGK1 and 
UBC. 
Figure 4.8: RT-PCR expression of (a) PXR, (b) TRα and (c) TRβ in male obese children before and after a 
12 month lifestyle intervention compared to healthy weight children relative to the endogenous control 
PGK1 (n = 11 for each cohort). 
Chapter 5 
Figure 5.1: Representative 500 MHz 
1
H NMR spectra of a urine sample obtained from an obese subject: (a) 
aromatic region of the spectrum and (b) aliphatic region of the spectrum. 
Figure 5.2: PCA (M1) and OPLS (M3) (Pareto scaled) of baseline urine samples of obese children from 
Arms A and B.  
Figure 5.3: PCA (M4) and OPLS (M6) (Pareto scaled) of baseline urine samples of obese children from Arm 
A compared to healthy weight children.   
Figure 5.4 PCA (M7) and OPLS (M9) (Pareto scaled) of baseline urine samples of obese children from Arm 
B compared to healthy weight children.   
Figure 5.5: PCA (M10) and OPLS (M12) (Pareto scaled) of baseline clinical data of pre-pubertal obese 
children vs. healthy weight counterparts. 
Figure 5.6: PCA (M13) and OPLS (M15) (Pareto scaled) of 12 months urine samples of obese children that 
lost weight vs. baseline healthy weight counterparts. 
Figure 5.7: PCA (M16) and OPLS (M18) (Pareto scaled) of 12 months urine samples of obese children that 
gained weight vs. baseline healthy weight counterparts. 
Figure 5.8: PCA (M19) and OPLS (M21) (Pareto scaled) of 12 months urine samples of obese children that 
lost weight vs. those that gained weight. 
Figure 5.9: PCA (M22) and OPLS (M24) (UV scaled) of baseline clinical data of pre-pubertal obese male 
children vs. healthy weight counterparts. 
Figure 5.10: PCA (M25) (UV scaled) of baseline clinical data of pre-pubertal obese female children vs. 
healthy weight counterparts. 
Figure 5.11: PCA (M28) (UV scaled) of baseline clinical data of pre-pubertal obese children vs. healthy 
weight counterparts. 
Figure 5.12: PCA (M31) and OPLS (M33) (UV scaled) of baseline NR relative expression data of pre-
pubertal obese male children vs. healthy weight counterparts. 
18 
 
Figure 5.13: PCA (M34) and OPLS (M36) (UV scaled) of baseline NR relative expression data of pre-
pubertal obese female children vs. healthy weight counterparts. 
Figure 5.14: PCA (M37) and OPLS (M39) (UV scaling) of baseline NR relative expression data of pre-
pubertal obese children vs. healthy weight counterparts. 
Figure 5.15: Metabolite Pathway Analysis. 
Figure 5.16: Outline on how creatine is synthesized in the human body. 
Chapter 6 
Figure 6.1: Outline of the bootstrapping analysis performed on the three types of datasets. 
Figure 6.2: Plots of Q
2
X vs. Q
2
Y to determine the best models for each type of pairwise analysis. 
Figure 6.3: O2PLS [1+0+0] of baseline nuclear receptor and clinical data of children from the KOALA 
obesity program. 
Figure 6.4: O2PLS [1+0+0] of baseline nuclear receptor and metabonomics data of children from the 
KOALA obesity program. 
Figure 6.5: O2PLS [1+0+0] of baseline clinical and metabonomics data of children from the KOALA obesity 
program. 
Figure 6.6: O2PLS [2+0+0] of baseline nuclear receptor and clinical data of male children from the KOALA 
obesity program. 
Figure 6.7: O2PLS [2+0+0] of baseline nuclear receptor and metabonomics data of male children from the 
KOALA obesity program. 
Figure 6.8: O2PLS [1+0+0] of baseline clinical and metabonomics data of male children from the KOALA 
obesity program. 
Figure 6.9: O2PLS of baseline nuclear receptor and clinical data of female children from the KOALA 
obesity program. 
Figure 6.10: O2PLS [1+0+0] of baseline nuclear receptor and metabonomics data of female children from 
the KOALA obesity program. 
Figure 6.11: O2PLS [1+0+0] of baseline clinical and metabonomics data of female children from the 
KOALA obesity program. 
Figure 6.12: Plots of Q
2
X vs. Q
2
Y to determine the best models for each type of integration analysis. 
Figure 6.13: O2PLS [1+0+0] of t and u scores from the N vs. C pairwise analysis with metabonomics data of 
children from the KOALA obesity program. 
19 
 
Figure 6.14: O2PLS [1+0+0] of t and u scores from the N vs. M pairwise analysis with clinical data of 
children from the KOALA obesity program.  
Figure 6.15: O2PLS [1+0+0] of t and u scores from the C vs. M pairwise analysis with nuclear receptor data 
of children from the KOALA obesity program. 
Figure 6.16: O2PLS [1+0+1] of t and u scores from the N vs. C pairwise analysis with metabonomics data of 
male children from the KOALA obesity program. 
Figure 6.17: O2PLS [1+0+0] of t and u scores from the N vs. M pairwise analysis with clinical data of male 
children from the KOALA obesity program. 
Figure 6.18: O2PLS [1+0+0] of t and u scores from the C vs. M pairwise analysis with nuclear receptor data 
of male children from the KOALA obesity program. 
Figure 6.19: O2PLS [1+0+0] of t and u scores from the N vs. C pairwise analysis with metabonomics data of 
female children from the KOALA obesity program. 
Figure 6.20: O2PLS [1+1+0] of t and u scores from the N vs. M pairwise analysis with clinical data of female 
children from the KOALA obesity program. 
Figure 6.21: O2PLS [1+1+0] of t and u scores from the C vs. M pairwise analysis with nuclear receptor data 
of female children from the KOALA obesity program. 
 
 
 
 
 
 
 
 
 
 
 
20 
 
List of Tables 
Chapter 2 
Table S2.1. Summary of the number of urine samples collected for the study (Experiments 1 – 5). 
Table S2.2. Summary of results of male and female urine samples under different room temperatures and 
preservative treatments (Experiment 3). 
Chapter 3 
Table 1: Auxology, biochemical parameter and body composition of GH-deficient subject over a period of 5 
years on and off GH therapy 
Table S1: Timeline of urine samples collected from GHD and healthy control subjects. 
Table S2: Identified metabolites with corresponding concentration changes identified from loadings 
coefficients in both PCA and PLS  
Chapter 4 
Table 4.1: Analysis of human NR gene expression in male obese children vs. male healthy weight control 
children 
Table 4.2: Analysis of human NR gene expression in female obese children vs. female healthy weight 
control children 
Table 4.3: Analysis of human NR gene expression in obese children vs. healthy weight control children 
Table S4.1: List of NRs mRNA relative expression of pre-pubertal male children normalised against the 
median of GUSB, HPRT1 and PGK1 
Table S4.2: List of NRs mRNA relative expression of female pre-pubertal children normalised against the 
median of B2M, GAPDH and PGK1. 
Table S4.3: List of NRs mRNA relative expression of male and female pre-pubertal children (pooled data) 
normalised against the median of GAPDH, PGK1 and UBC 
Chapter 5 
Table 5.1: Identified metabolites with significant loadings coefficients in PCA/OPLS loadings plot 
Table 5.2: Overview of multivariate analyses performed with metabonomics, nuclear receptor and clinical 
data collected from the KOALA childhood obesity program 
Chapter 6 
Table 6.1: Overview of pairwise and integrated multivariate analyses performed with metabonomics, nuclear 
receptor and clinical data collected from the KOALA childhood obesity program 
Table 6.2: Results from pairwise O2PLS analysis showing Q
2
X and Q
2
Y values and if the analysis was 
significant according to the rules set by SIMCAP+ 12.0.1. 
Table 6.3: Results from integration O2PLS analysis showing Q
2
X and Q
2
Y values and if the analysis was 
significant according to the rules set by SIMCAP+ 12.0.1. 
 
21 
 
List of Abbreviations 
 
°C degree Celsius 
1D  1 dimensional 
2D  2 dimensional 
1
H hydrogen 1 
31
P phosphorous 31 
ACTH Adrenocorticotropic hormone 
ADP  adenosine diphosphate 
ALT alanine transaminase 
ANIT  alpha-napthylisothiocyanate 
AST  Aspartate transaminase 
ATP  adenosine-5'-triphosphate 
B2M  beta-2 microglobulin 
BAT  brown adipose tissue 
BCAA branched chain amino acid 
BDNF  brain-derived neurotrophic factor 
BIA bioelectrical impendence analysis 
BMD  bone mineral density 
BMI  Body Mass Index 
C clinical 
CCA canonical correlation analysis 
CDC  Centre for Disease Control and Prevention 
cDNA  complementary deoxyribonucleic acid 
CE  capillary electrophoresis 
CH2 methylene group 
CH3 methyl group 
CHD  coronary heart disease 
CoA Coenzyme A 
COSY  correlation spectroscopy 
COUP-TFs  chicken ovalbumin upstream promoter transcription factors 
CPHD  combined pituitary hormone deficiency 
CPMG  Carr-Purcell-Meiboom-Gill 
CRP  C-reactive proteins 
CSF  cerebrospinal fluid 
CSIRO Commonwealth Scientific and Industrial Research Organisation 
Ct cycle threshold  
CVD  Cardiovascular Disease 
D2O  deuterium oxide dioxygenase  
DIGE difference gel electrophoresis 
DMA  dimethylamine 
DNA  deoxyribonucleic acid 
DSS  2,2-dimethyl-2-sila-3,3,4,4,5,5-hexadeuteropentane-5-sulfonic acid 
DXA  Dual-energy X-ray absorptiometry 
ERR  estrogen related receptor 
FFA  free fatty acids 
FFM  fat free mass 
FM  fat mass 
FSH Follicle-stimulating hormone 
FTO  Fat mass and obesity-associated protein/alpha-ketoglutarate-dependent  
FXR farnesoid X receptor 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
22 
 
GC  gas chromatography 
GCNF  germ cell nuclear factor 
GH  growth hormone 
GHD  growth hormone deficiency 
GHRH  growth hormone-releasing hormone 
GR  glucocorticoid receptor 
GUSB  beta-glucuronidase 
GW  gain weight 
GWAS  Genome-Wide Association Study 
HDL  high density lipoprotein 
HDL-C  high-density lipoprotein-cholesterol 
HOMA homeostatic model assessment 
HPA hypothalamic-pituitary-adrenal axis 
HPCA  hierarchical principal components analysis 
Hr hour 
HPRT1  hypoxanthine-guanine phosphoribosyltransferase1 
HRMAS  high-resolution magic angle spinning 
HW  healthy weight 
IFG  impaired fasting glucose 
IGF-1  insulin-like growth factor-1 
IGFBP3  insulin-like growth factor-binding protein 3 
IGT  impaired glucose tolerance 
IHD  ischaemic heart disease 
IL-1beta  interleukin-1beta 
IL-6  interleukin-6 
IL-8  interleukin-8 
IL-10 interleukin-10 
IMT  intima-media thickness 
IR  insulin resistance 
K Kelvin 
KOALA  Kinder for children and their families, Overweight: overcoming and being OK, 
Active mind and body, Lifestyle a life-giving diet and Actions all together and 
ahead 
LB  lysogeny broth 
LC  liquid chromatography 
LCD  low calorie diet 
LDL  low density lipoprotein 
LH Luteinizing hormone 
LW  lost weight 
LXR  liver X receptors 
LYPLAL1 lysophospholipase-like protein 1 
M model 
M metabonomics 
MC4R  melanocortin receptor 4 
mM millimolar  
MR mineralocorticoid receptor 
MRI  Magnetic Resonance Imaging 
mRNA  messenger ribonucleic acid 
MS  mass spectrometry 
MSI  Metabolomics Standard Initiative 
Myf5 myogenic factor 5 
N nuclear receptor 
23 
 
n number of samples 
NASH  non-alcoholic steatohepatitis 
NF  nuclear factor 
NIH National Institute of Health 
NMR Nuclear Magnetic Resonance 
NOESY  nuclear Overhauser enhancement spectroscopy 
NOR-1  neuron-derived orphan receptor-1 
NR  Nuclear receptor 
NS Not significant 
Nur77  nerve Growth factor IB 
NURR1  nuclear receptor related 1 
OB  overweight and obese  
OECD organisation for economic co-operation and development 
OPLS  orthogonal- partial least squares 
OPLS-DA  orthogonal- partial least squares-discriminant analysis 
O2PLS orthogonal-2-partial least squares 
O2PLS-DA orthogonal-2- partial least squares-discriminant analysis 
PAI-1 Plasminogen activator inhibitor-1 
PBMCs  peripheral blood mononuclear cells 
PC  principal components 
PCA  principal components analysis 
PCR  Polymerase Chain Reaction 
PGC  progenitor cells 
PGC-1alpha  peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PGK1  phosphoglycerate kinase1 
PIT-1  pituitary-specific positive transcription factor 
PLS  partial least squares 
PLS-DA  partial least squares-discriminant analysis 
POU1F1 pituitary-specific positive transcription factor 1 
PPARs  peroxisome proliferator activated receptors 
ppm  parts per million 
PR  pattern recognition 
PRDM16 PR domain-containing protein 16 
PRL  prolactin 
PXR  pregnane X receptor 
Q2  fraction of the total variation of the X (principal components analysis) or Y 
(partial least squares) that can be predicted by each component 
Q2X the predicted variation 
Q2Y the cumulative predicted fraction (cross-validation) of the variation of Y 
QLD  Queensland 
R2X  fraction of sum of squares of X explained by each component 
R2Y  fraction of sum of squares of Y explained by each component 
RAR  retinoic acid receptor 
RE  relative expression 
RIPK3  receptor-interacting serine/threonine-protein kinase 1 
RNA ribonucleic acid 
ROR  receptor tyrosine kinase-like orphan receptor  
RQ  relative quantification 
RT-PCR  Real Time- Polymerase Chain Reaction 
RXR  retinoid X receptor 
S seconds 
SF-1 steroidogenic factor 1 
24 
 
SH2B1 SH2-B signalling protein 1 
STAT5  signal transducer and activator of transcription 5 
T  score components  
T1DM type 1 diabetes mellitus  
T3/T4 triiodothyronine/ thyroxine 
T2DM  Type 2 Diabetes Mellitus 
TCA  tricarboxylic acid 
TG triglycerides 
TLDA  Taqman Low Density Array 
TLR4 toll-like receptor 4 
TMA  trimethylamine 
TMAO  trimethylamine-N-oxide 
TNF-alpha  tumor necrosis factor-alpha 
TNIP1 TNFAIP3 interacting protein 1 
TOCSY  total correlation spectroscopy 
TR/THR  thyroid hormone receptor 
TSH  thyroid stimulating hormone 
TSOD  Tsumura, Suzuki, obese, diabetes 
TSP  3-(Trimethylsilyl)-2,2,3,3-tetradeuteropropionic acid 
UBC  ubiquitin 
UCP1  uncoupling protein 1 
UK  United Kingdom 
ULDA uncorrelated linear discriminant analysis 
US  United States 
UV  univariate 
VDR  vitamin D receptor 
WAT  white adipose tissue 
WHO  World Health Organisation 
WHR  waist-hip ratio 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
1. Introduction 
1.1 Obesity 
1.1.1 Definition, Prevalence and Health Impacts of Obesity 
The World Health Organization (WHO) defines overweight and obesity as ‘abnormal or 
excessive fat accumulation that presents a risk to health’. Over the last 30 years, there has been an 
alarming increase in the number of overweight and obese individuals in the developed world and to 
increasing degrees in other parts of the world. Thus obesity has become one of the most visible yet 
neglected global public health problems. Worldwide, more than 1 billion adults are overweight and 
one in six is obese (World Health Statistics, WHO, 2012). Australia is one of the many countries 
facing this epidemic with an adult obesity prevalence of more than 20% and an estimated 
$58.2 billion cost in total burden of care and lost productivity in Australia (Access Economics 2008, 
OECD 2009).  
Obesity is one of the risk factors for a number of chronic life threatening diseases such as 
Type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and cancer. Obesity has been 
estimated to have contributed to 23.8% of T2DM, 21.3% of CVD and 24.5% of osteoarthritis cases, 
and to 20.5% of colorectal, breast, kidney and uterine cancers in Australia (Access Economics, 
2008).  
In 2010, the WHO estimated that around 43 million children, worldwide, under the age of 5 
were overweight (de Onis, 2010). According to the Centres for Disease Control and Prevention 
(CDC), in the United States an estimated 17% of children and adolescents between the ages of 2 to 
19 years old were classified as obese with a body mass index (BMI) greater than 95
th
 percentile 
(Ogden et al., 2012). In Australia, 24.9% of children were found to be overweight or obese 
according to the National Health Survey (2009). As obesity during childhood increases the risk of 
obesity in adulthood, it is anticipated that this will contribute significantly to the burden of CVD 
and T2DM in later life (Baker et al., 2007; Ludwig, 2007; Mattsson et al., 2008, 
Garnnet et al., 2011).  
1.1.2 Genetics and Obesity 
Regulation of whole body weight and fat mass involves a complex interplay of biological 
and environmental factors that include genetic (polygenic and monogenic polymorphisms and/or 
gene mutations), epigenetic (perinatal factors), hormonal (hypothalamic-pituitary-axis and appetite-
regulators) and environmental (socio-cultural and ethnic; nutritional and physical activity) factors.  
Previously, identification of genes related to obesity was performed by biological candidate 
gene methods or linkage studies. In 2007, the first genome-wide association study (GWAS) to study 
26 
 
gene variants associated with obesity identified the FTO gene associated with obesity 
(Frayling et al., 2007, Scuteri et al., 2007, Hinney et al., 2007). Increase in FTO expression has 
been associated with the regulation of energy intake and also upregulated in hypothalamus of rats 
after food deprivation (Fredriksson et al., 2008, Olszewski et al., 2009). Since then, four obesity 
GWAS “waves” have yielded a total of 43 loci that are significantly associated with different 
measures of adiposity, including BMI, waist circumference and waist-hip ratio (WHR), while 18 
loci have been associated with visceral fat accumulation (Figure 1.1) (Frayling et al., 2007, 
Scuteri et al., 2007, Hinney et al., 2007, Chambers et al., 2008, Willer et al., 2009, 
Thorleifsson et al., 2009, Lindgren et al., 2009, Heard-Costa et al., 2009, Speliotes et al., 2010, 
Heid et al., 2010, Scherag et al., 2010, Jiao et al., 2011, Bradfield et al., 2012). The genes identified 
in the obesity GWAS included genes involved in neural differentiation (BDNF) and hypothalamic 
appetite regulation, leptin and insulin signalling (MC4R, SH2B1). THEM18 and LYPLAL1 were 
also found to be associated with obesity in children and adolescents (den Hoed et al., 2010, 
Farooqi 2008, Gratacos et al., 2007, Maures et al., 2007).While these GWAS have identified 
important genes associated with obesity, the exact functional mechanism(s) for these genes in the 
development of obesity remains unclear. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Genome-wide significant associated loci associating with BMI, waist circumference and waist hip 
ratio (WHR), respectively, identified in individual GWAS (black squares), in both individual GWAS and meta-
analysis (green squares) and in meta-analyses alone (blue squares) from GWAS Waves 1-4 from 2007-2010 with 
BMI effect Size (Odds-ratio-OR) and number of individuals studied shown on left and right Y axes, respectively  
(Taken from Sandholt et al., 2012). 
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Obesity occurs when there is a disruption between the balance between energy consumption 
and expenditure. Although it is accepted that lifestyle and environmental factors play a role in the 
prevalence of obesity, the correlation between such factors with genetic interactions increases the 
susceptibility to obesity. This includes genetic and hormonal influences on appetite regulated by the 
hypothalamus and the influence of nuclear hormone receptors (NRs) on metabolism, inflammation 
and energy expenditure in metabolic tissues such as adipose tissue, skeletal muscle and liver 
(Bensinger and Tontonoz, 2008; Flier and Maratos-Flier, 1998). However, the underlying 
mechanisms how these gene-environment interactions affect body weight remain unclear 
(Qi et al., 2012).  
Adipose tissue can be classified into two types: white adipose tissue (WAT), brown adipose 
tissue (BAT). Previously, it was thought that adipose tissue simply functions as a reservoir of 
energy where triglycerides are stored. However, adipose tissue also serves as a secretory organ that 
releases numerous peptides and cytokines or adipokines that play important roles in determining 
insulin sensitivity, metabolism and risk for obesity (Flier, 1995; Mohamed-Ali et al., 1998).  
BAT though especially abundant in newborns, was until recently not thought to be present 
or physiologically relevant in children beyond the neonatal period or in adults 
(Virtanen et al., 2009, Drubach et al., 2011). However compelling recent evidence supports a clear 
role for BAT in regulating energy expenditure beyond infancy into adulthood.  Moreover, 
molecular studies suggest BAT and skeletal muscle arise from a common precursor cell that 
requires the specific action of key transcriptional regulators for tissue-specific commitment 
(Nedergaard et al., 2007, Kajimura et al., 2009).  Both skeletal muscle and brown fat cells, but not 
white cells arise from precursors that express the muscle factor Myf5 indicating that BAT and 
skeletal muscle cells arise from the same stem cell. Upon expression of the zinc finger protein 
PRDM16, myoblast cells are converted into brown fat cells whilst PRDM16-deficient brown fat 
cells are converted to skeletal muscle cells (Seale et al., 2008, 2011). PRDM16 activates a brown 
fat thermogenic phenotype including the induction of uncoupling protein 1 (UCP1) and PGC-1α 
when expressed in white fat cell progenitors (Seale et al., 2007, 2011).  
In another study, a new exercise-induced secreted myokine called irisin was identified in 
mice and humans (Bostrom et al., 2012). In mice, expression of PGC-1α in skeletal muscle 
stimulates the secretion of irisin to act upon adipose cells to increase UCP1 expression and induced 
brown fat-like development into so-called “beige cells” (Bostrom et al., 2012 ; Wu et al., 2012). 
These beige cells have a gene expression pattern that are distinct from either white or brown fat and 
are preferentially sensitive to the hormone irisin. 
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1.1.3 Obesity and Inflammation 
Several studies have shown that the expression of inflammatory and stress-response genes is 
up-regulated in adipose tissues of obese animals suggesting that obesity is associated with a state of 
chronic low-level systemic inflammation (Soukas et al., 2000; Weisberg et al., 2003; 
Xu et al., 2003).  
The pro-inflammatory cytokines tumor necrosis factor–alpha (TNF–α) and interleukin-6 
(IL–6) are over-expressed in adipose tissues of rodent models of obesity and in obese humans 
(Hotamisligil et al., 1995; Hotamisligil et al., 1993; Kern et al., 1995; Saghizadeh et al., 1996; 
Weisberg et al., 2003; Xu et al., 2003). Increased levels of IL-6 are associated with increased 
adiposity, and as much as a third of the total circulating concentrations of this cytokine originates 
from adipose tissue (Mohamed-Ali et al., 1997). IL-6 regulates the synthesis of C-reactive proteins 
(CRP), a sensitive marker for systemic inflammation (Hiura et al., 2003). Visser et al. (1999) have 
shown that higher BMI levels are associated with an increase in CRP, supporting the hypothesis of 
a state of low-level systemic inflammation in overweight and obese individuals. A study also found 
an association between higher BMI and elevated levels of IL-6, IL-8 and IL-10 in 15 year old 
females (Tam et al., 2010).  
 Obese rodents that had an elevated TNF-α concentration were also found to be insulin 
resistant (Hotamisligil et al., 1993; Hotamisligil and Spiegelman, 1994). Mice that lacked the TNF-
α ligand were reported to be protected from obesity-induced insulin resistance (Moller, 2000; 
Uysal et al., 1997). There has also been growing evidence stating that there is an association of 
obesity, inflammation and insulin resistance in adults (Fernandez-Real and Ricart, 2003; Ravussin 
and Smith, 2001). Levels of elevated CRP were associated with the development of T2DM as a 
result of insulin resistance (Pradhan et al., 2001). A study performed by Rubin et al. (2008) 
indicated that increased adiposity in obese adolescents is related to a drop in adiponectin levels and 
increased TNF-α concentrations which link these cytokines to the an inflammatory pathogenesis of 
insulin resistance. 
Adipose tissues also release adipokines such as leptin and adiponectin 
(Morrison and Farmer, 1999). Leptin is produced by the ob gene (Zhang et al., 1994) mainly in 
WAT and plays a role in regulating energy intake and energy expenditure including appetite and 
metabolism (Margetic et al., 2002). Leptin circulates in proportion to body fat content and 
influences energy balance by decreasing appetite (Friedman and Halaas, 1998). Mice that were ob 
deficient develop massive weight gains and a five-fold increase in body fat when compared to wild-
type mice (Friedman and Leibel, 1992). Congenital leptin deficiency has also been reported in a 
small number of children who develop early-onset severe obesity and hypogonadism, which 
responds to recombinant leptin therapy (Farooqi et al., 2007). Several human studies have shown a 
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lower level of leptin during fasting or whilst on a low calorie diet (Dubuc et al., 1998; 
Pratley et al., 1997; Weigle et al., 1997). The leptin levels in individuals with polygenic obesity are 
actually elevated consistent with elevated total body fat and a state of leptin resistance 
(Considine et al., 1996, Yanovski J, 2002)  
Adiponectin which is found usually in plasma is involved in glucose regulation and fatty 
acid catabolism (Diez and Iglesias, 2003). In contrast to leptin, adiponectin levels are lower in obese 
children and adolescents with a marked increase in CRP levels (Winer et al., 2006). Weiss and 
Caprio (2005) demonstrated that levels of fasting glucose, fasting insulin, insulin resistance (IR), 
systolic blood pressure, triglycerides, CRP and IL-6 were significantly increased in obese children 
with  metabolic syndrome. Interestingly, levels of adiponectin were lower and were positively 
related to peripheral insulin sensitivity. Therefore, adiponectin and leptin perform complementary 
actions in obese individuals (Figure 1.2).  
 
 
 
 
 
 
 
 
 
Figure 1.2: An outline on the effects of cytokines and proteins on body weight. In the presence of increased leptin, 
more inflammatory cytokines (IL-6 and TNF-α) are secreted while adiponectin levels are low indicating that obesity is 
associated with a state of chronic low-level systemic inflammation. 
1.1.4 Gut Microbiota and Obesity  
Emerging evidence strongly implicates a role for gut microbiota in controlling risk for 
chronic diseases, including obesity and inflammatory disorders (Claesson et al., 2012). Gut 
microbiota consist of many types of microorganisms such as bacteria, archaea and viruses. It has 
been recently proposed that gut microbiota may play a role in the development of weight gain and 
obesity as it has the capability to alter metabolism and immune system (Suau et al., 1999, 
Andersson et al., 2008). Faecal gut microbiota in obese subjects revealed an increase in 
Bacteriodes/Prevotella group species after weight loss (Ley at al., 2006, Nadal et al., 2009, 
Santacruz et al., 2009). The type of food consumed also has an effect on the type and amount of 
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microbiota found in mice where a diet high in fat resulted in a significant shift in bacterial profiles 
when compared to mice on a normal diet (Turnbaugh et al., 2008, Murphy et al., 2010). To date, no 
human studies have been performed to investigate the effects of food intake and energy expenditure 
on gut microbiota, though murine studies are now emerging suggesting a direct link between dietary 
composition and gut microbiota species and metabolic phenotype (Serino et al., 2012).  
 Metabolites produced by these gut microbiota have been linked with obesity and its related 
diseases such as CVD and T2DM (Tremaroli and Backhed, 2012). Trimethylamine (TMA) is 
usually metabolised when gut microbiota releases choline from dietary phosphatidylcholine. TMA 
is then oxidised to trimethylamine-N-oxide (TMAO) in the liver. Higher levels of plasma choline 
and TMAO have been associated with the development of CVD in both human and mice studies 
(Dumas et al., 2006, Wang et al., 2011). Gut microbiota are responsible for fermenting indigestible 
materials in the colon to produce short chain fatty acids such as acetate, propionate, butyrate and 
succinate. A NMR-based metabonomic study on mice fecal matter showed that the levels of 
butyrate, propionate and succinate were altered when these mice were colonised with L. Paracasei 
indicating that gut microbiota plays a role in the composition of bacterial metabolites in the gut 
(Martin et al., 2010). Interestingly, propionate and butyrate have also been shown to increase the 
expression levels of leptin gene (Xiong et al., 2004). Higher levels of acetate are also correlated 
with an increase in total and LDL cholesterol (Jenkins et al., 1991, Wolever et al., 1996). 
Urinary hippurate is another marker of gut microbiota activity. Benzoate and glycine are 
conjugated to form hippurate in the gut, enters the bloodstream and eventually is secreted in the 
urine (Williams et al., 2002). Both in mice and human studies, lower levels of urinary hippurate 
have been associated with obesity when compared with lean or healthy controls 
(Waldram et al., 2009, Calvani et al., 2010). Overall, the emerging evidence strongly suggests that 
gut microbiota may be a modifiable risk factor involved in the development of obesity and 
metabolic diseases (Tremaroli and Backhed, 2012). 
1.1.5 Nuclear Receptors, Inflammation and Metabolism in Obesity 
The Nuclear Hormone Receptors (NRs) (Figure 1.3) superfamily plays  roles in regulating 
the expression of genes that control development, reproduction, inflammation, immunity and 
metabolism (Mangelsdorf and Evans, 1995; Mangelsdorf et al., 1995). NRs have the ability to 
directly bind to DNA that in the presence of a ligand undergoes a conformational change to up- or 
down-regulate gene expression. NRs can be classified into three groups: (1) endocrine receptors, (2) 
adopted orphan receptors and (3) orphan receptors whose regulatory ligands are undefined or 
appears not be required (Sonoda et al., 2008).  
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Figure 1.3: The human nuclear hormone receptor superfamily. (Adapted from Sonoda et al., 2008) 
 
Endocrine receptors include steroid receptors like estrogen (α and β) and glucocorticoid 
receptors. In addition, heterodimeric receptors such as thyroid hormone receptors (TR α and β), 
retinoic acid receptor (RAR) and vitamin D receptor (VDR) form heterodimers with the retinoid X 
receptors (RXR (α, β and γ).   
Peroxisome proliferator activated receptors (PPARs α, γ and δ) and liver X receptors (LXR 
α, β) are part of adopted orphan receptors. The PPARs family is involved in regulating energy, lipid 
and glucose metabolism (Auwerx et al., 2003) while LXRs play a role in regulating the expression 
of genes involved in cholesterol metabolism (Peet et al., 1998; Repa et al., 2002). PPAR-γ is 
involved in controlling the differentiation of adipocytes (Barak et al., 1999; Tontonoz et al., 1994) 
and mice lacking the gene encoding PPAR-δ have decreased amounts of adipose tissue 
(Barak et al., 2002; Peters et al., 2000). In addition, PPARs and LXRs have shown to inhibit the 
expression of several inflammatory genes (Glass and Ogawa, 2006; Joseph et al., 2003; 
Ogawa et al., 2005). A study by Odegaard et al. (2007) showed that a macrophage-specific deletion 
of the gene encoding PPAR-γ in BALB/c mice regulated diet-induced obesity and insulin sensitivity 
which contributes to the development of T2DM and metabolic syndrome. Studies also found that 
the activation of LXRs results in the suppression of inflammatory gene expression downstream of 
TLR4, IL-1β mediated and TNF-α mediated signalling pathways (Joseph et al., 2003; 
Ogawa et al., 2005). Other orphan NRs such as NR4As (Nur77, NOR-1), COUP-TFs, ROR-α and 
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Rev-erb-α and –β were also recently identified to be involved in regulating glucose and lipid 
metabolism, energy expenditure and inflammation in skeletal muscle, adipose tissue, liver and 
immune cells (Lau et al., 2008. 2011; Myers et al., 2009; Myers et al., 2006; Pearen et al., 2006; 
Raichur et. al., 2010). Studies mentioned above suggest that NRs have therapeutic properties that 
can be useful for the treatment of dyslipidaemia, diabetes, obesity and CVD 
(Smith and Muscat, 2005). This is highlighted by the fact that a large number of the NR superfamily 
or their downstream gene pathways have and are being used by the pharmaceutical industry as drug 
targets to develop novel drug therapies in metabolic disorders (Hong and Tontonoz, 2014).   
1.1.6 Gene Expression in Peripheral Blood Mononuclear Cells (PBMCs) and Disease 
The peripheral blood transcriptome expresses a large percentage (about 80%) of genes 
encoded in the human genome (Liew et al., 2006). Moreover, 80% of the transcriptome is shared by 
many tissues (Liew et al., 2006). Importantly, the diagnostic capacity of peripheral blood 
mononuclear cells (PBMCs) has been underscored, and several studies have highlighted that PBMC 
gene expression footprints respond to environmental influences (e.g. diet, exercise exposure), and 
mirror >40 disease states in adults, including obesity and diabetes, inflammation, oxidative stress 
and phosphorylation disorders and hypertension (Crujeiras et al., 2008). PBMCs thus provide a 
valid alternative, accessible and non-invasive 'surrogate tissue’ that responds to and reflects the 
molecular and physiological changes induced by obesity, insulin resistance and T2DM 
(Liew et al., 2006). 
Gene expression studies involving peripheral blood mononuclear cells (PBMCs) have been 
extensively used to understand the molecular mechanisms underlying several human diseases 
(Chiappini et al., 2006; Horwitz et al., 1997; Maes et al., 2006). However, studies involving gene 
expression profiles in PBMCs of obese subjects are scarce, including in children. Thus the analysis 
of the effects of obesity on metabolic and inflammatory gene expression using PBMCs, particularly 
in children, provides an attractive relatively non-invasive alternative to obtaining other metabolic 
tissues such as adipose tissue, skeletal muscle or liver tissue. 
A gene-expression study of PBMCs involving weight loss of obese men due to a low-caloric 
diet (LCD) demonstrated a down-regulation in oxidative stress and inflammation related 
genes(Crujeiras et al., 2008). Genes such as RIPK3 and TNIP1, which are involved in the TNF-α 
and nuclear factor (NF)-αB signalling cascade pathways were down-regulated. The expression of 
IL-8, a type of pro-inflammatory cytokine, also decreased after weight loss. Decreased IL-8 
secretion in adipose tissue has been associated with a hypocaloric diet in humans 
(Arvidsson et al., 2004). In another study, Goyenechea et al. (2009) investigated the effect of 
inflammatory status on changes in weights of obese individuals on LCD. mRNA expression levels 
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of TNF-α and NF-κB were initially decreased at the end of the intervention but increased after 6 
months when these individuals gained back 10% of the weight lost. Recently, an analysis on the 
effects of BMI on the levels of circulating progenitor cells (PGCs) in PBMCs revealed that obesity 
promotes the mobilization and recruitment of PGCs which plays a role in disease progression 
(Bellows et al., 2011). The role of adipokine genes in obesity and inflammation have been 
investigated in PBMCs of obese and healthy-weight children with positive correlations between 
TNF-α and IL-6 expression. It was also shown that TNF-α and visfatin expression were correlated 
with monosaturated fatty acids, n- fatty acids and docosahexaenoic acid indicating that adipokine 
expression in PBMCs were correlated with increasing weight and fatty acid content 
(Dedoussis et al., 2009, 2010).  Overall, these studies highlight the insights that can be obtained into 
the underlying mechanisms of obesity and inflammation by studying gene expression profiles of 
PBMCs. 
1.2 Obesity-Related Diseases 
1.2.1 Cardiovascular Disease (CVD) 
 Obesity is a multisystem disease that can have harmful health consequences in later life of 
an individual. The risk of these consequences increases progressively as the BMI increases 
(Olshansky et al., 2005). Obesity can cause hypertension, dyslipidemia, chronic inflammation, 
increased blood clotting tendency, endothelial dysfunction and hyperinsulinaemia (Burke, 2005). 
These are risk factors that contribute to the development of CVD, and world-wide is the number 
one cause of death with 17 million deaths per year (WHO).  
 One of the risk factors for CVD in adults and children is hypertension 
(Chobanian et al., 2003; Falker et al., 2004; Muntner et al., 2004). A study performed by 
Rosner et al. (2000) showed that children with a BMI of 90
th
 percentile or higher have a 
significantly higher blood pressure. Other ‘adult’ risk factors for CVD now appearing in children 
and adolescents with obesity include left ventricular hypertrophy where fat mass and systolic blood 
pressure play a significant role in the progression of CVD (Daniels et al., 1997). Several studies 
have also shown that adults with dyslipidemia had increased adiposity during childhood 
(Viikari et al., 2003). Dyslipidemia is usually associated with increased levels of triglycerides and 
lower levels of high-density lipoprotein-cholesterol (HDL-C), and this has been observed in 
overweight and obese children as young as 8 years of age (Burke, 2005). 
 The most crucial process for developing CVD in adults is atherosclerosis where the walls of 
the coronary arteries thicken and harden from the build-up of fatty streaks. With an increase in 
childhood obesity, this risk factor is now observed in children and adolescents. Fatty streaks were 
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observed in children as young as 3 years of age (Holman et al., 1958) and also in adolescents and 
young adults (McGill et al., 1997).  The Bogalusa Heart study from autopsy data of adolescents and 
young adults found an association of overweight, high blood pressure and high cholesterol with 
atherosclerosis (Berenson et al., 1998).  In a related study, Freedman et al. (2008) investigated the 
association of childhood obesity with increased risk for coronary heart disease in later life. This 
study showed that measurements of the carotid artery intima-media thickness (IMT) correlate with 
BMI in both childhood and adulthood with an independent effect of childhood BMI on adult IMT. 
Another indicator of the progression of atherosclerosis is calcium build up in arteries. In a group of 
healthy young adults (overweight and non-overweight), Mahoney et al. (1996) found that 30% of 
the males and 10% of the females had coronary calcium deposits. A correlation was found between 
a high BMI during childhood and adulthood with an increased risk of calcium build-up in the 
coronary arteries in these adults.  
 Development of CVD may be facilitated by elevated levels of pro-inflammatory cytokines 
released by adipocytes. A study performed by Esposito et al. (2003) provided evidence that a 
decrease in BMI levels was associated with an increase in the levels of adiponectin and decrease in 
markers of vascular inflammation such as IL-6 and free fatty acids. In addition, Danesh et al. (1998) 
showed that an increase in serum CRP concentration was able to predict future risk of CVD. 
Another example that obesity and inflammation can contribute to the development of CVD is that 
increased carotid IMT is not only related to weight gain but also to CRP levels 
(Jarvisalo et al., 2002; Mangge et al., 2004). Such findings have also been reported in obese 
children (Reinehr et al., 2006) with a drop in CRP levels correlating with weight loss 
(Reinehr et al., 2005).  
 Thus childhood obesity appears to lead to increased risk of heart disease in adulthood (Baker 
et al., 2007) with a linear relationship between childhood BMI and ischaemic heart disease (IHD) in 
adulthood independent of gender (Gunnell et al., 1998). 
1.2.2 Type 2 Diabetes Mellitus (T2DM) 
 The metabolic endocrine system consists of complicated homeostatic processes that control 
how the body uses and stores energy. Disruptions in this system secondary to obesity usually result 
in metabolic disorders such dyslipidaemia, insulin resistance and impaired glucose tolerance, all of 
which comprise components of the Metabolic Syndrome (Klein et al., 2004). Metabolic syndrome 
is an important factor for development of CVD and T2DM in adults (Grundy et al., 2004). Though 
metabolic syndrome was previously thought to be rare in children, is now detectable in more obese 
children especially during adolescence (Zimmet et al., 2007, Cali and Caprio, 2009).  
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 In a study by Cook et al. (2003), only 4% of children had metabolic syndrome, but 30% 
were obese. More recent studies suggest a much greater prevalence especially in those with non-
alcoholic steatohepatitis (NASH) and visceral obesity (Cali and Caprio, 2009). It has been 
demonstrated that obesity is one of the most important risk factors for T2DM in adults 
(Felber et al., 1993). However, with an increase in the number of overweight and obese children, 
the number of children with T2DM has also risen recently (Pinhas Hamiel et al., 1996, 
Craig et al., 2007). Children as young as 7 years of age have been diagnosed with T2DM 
(Dean et al., 1992), and visceral fat seems to have an influence over insulin secretion and insulin 
resistance (Caprio et al., 1995).  
 In a healthy individual, an inverse relationship exists between insulin sensitivity and insulin 
secretion to provide a constant glucose regulation. A disturbance in this relationship results in 
impaired glucose tolerance (IGT) prior to frank diabetes (Edelstein et al., 1997). Individuals 
suffering from T2DM usually have insulin resistance with normal or elevated serum insulin 
concentration as well as impaired insulin secretion. Although the aetiology of T2DM is still unclear, 
obesity and a decrease in physical activities are important factors that are responsible for its 
occurrence in children and adolescents (Young et al., 2000). Recently, there has been a rise in the 
number of overweight and obese children and adolescents with insulin resistance syndrome 
(Bloomgarden, 2004), which usually continues in adulthood (Steinberger et al., 2001). Studies have 
shown that 25% of obese children between the ages of 4 – 10 had IGT and impaired fasting glucose 
(IFG). In addition, 4% of these children had silent diabetes (Sinha et al., 2002; 
Wiegand et al., 2004).   
 The American Diabetes Association predicts that T2DM will become the most common 
form of newly diagnosed diabetes in children and youths in the US within 10 years, with about 85% 
of children with T2DM being either overweight or obese (Rosenbloom et al., 2000), though recent 
reports argue against there being a dramatic rise in T2DM in the paediatric population 
(Goran et al., 2008). In an Australian study, 11% of children were newly diagnosed with diabetes 
was due to T2DM with 90% being overweight and obese and the highest rate of T2DM occurring in 
indigenous children (Craig et al., 2007). In the UK, T2DM diagnosed in children also correlated 
with an increase in adiposity (Haines et al., 2007). A study in Japan demonstrated that there is a 
parallel rise in T2DM incidence in children and the levels of obesity from 1975 to 1995 
(Kitagawa et al., 1996), and this increase mirrors the increase in the consumption of foods high in 
fats and animal proteins among Japanese youths (Tajima, 2002) (Figure 1.4). 
 The Bogalusa Heart Study showed that most adults with T2DM were overweight or obese as 
children with high blood pressure, fasting insulin and glucose and triglycerides 
(Srinivasan et al., 2003). A study by Glowinska et al. provided evidence that 28% of the children 
36 
 
with T2DM had a family history of CVD (2002). Thus childhood obesity not only increases the risk 
factors for the development of T2DM at a younger age but also increases the probability of having 
other detrimental diseases such as CVD.  
 
 
  
 
 
 
 
 
Figure 1.4: Incidence of type II diabetes and prevalence of obesity in Japanese children from 1976 to 1995 
[Figure taken from Kitagawa et al., 1996]. 
1.2.3 Hormonal Factors & Metabolism 
The endocrine system comprises of a series of glands throughout the body controlled by the 
hypothalamic-pituitary axis that secretes different types of hormones that regulate all aspects of 
bodily function and homeostasis. These include important hypothalamic-pituitary factors that 
control thyroid hormone metabolism, growth, puberty and reproduction and adrenal function 
(Figure 1.5). 
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Figure 1.5: Schematic diagram of the hypothalamic-pituitary axis illustrating the different types of hormones 
controlled by the hypothalamic-pituitary axis and the target endocrine organs and their respective secreted 
hormones. TSH = Thyroid-stimulating hormone; LH = Luteinising hormone; FSH = Follicle stimulating hormone: 
ACTH = Adrenocorticotropic hormone; GH = Growth hormone; T3 = Triiodothyronine; T4 = Thyroxine; IGF-1 – 
Insulin-like-growth factor-1. 
 
Each gland in the body secretes specific types of hormones to regulate growth, tissue 
development and metabolism to transfer information and instructions from one set of cells to 
another. Disruptions in the endocrine system can cause these hormones producing glands to produce 
too little or too much of the different types of hormones that are required to maintain homeostasis in 
the body thus altering metabolism and cause the development of endocrine disorders such as thyroid 
diseases and growth hormone deficiency (Vance, 1994).  
1.2.3.1 Growth Hormone 
Growth hormone (GH) is an anabolic hormone consisting of a 191-amino acid, single-chain 
protein that plays an important role in growth, body composition, cell reproduction and regeneration 
(Press M., 1988). Somatotroph cells found in the anterior pituitary gland are responsible for the 
synthesis, secretion and storage of GH (Strobl et al., 1994).  GH release from the pituitary is 
regulated by the balance of opposing hypothalamic neuropeptide factors, GH-releasing hormone 
(GHRH) which activates GH release and a GH-inhibitory hormone called somatostatin 
(Sperling MA, 2014).   
Other peripheral factors that stimulate the secretion and release of GH include the presence 
of the peptide hormone ghrelin, increased secretion of sex hormones during puberty, deep slow-
wave sleep, fasting and vigorous exercise (Muller et al., 1999). In contrast, GH release is inhibited 
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when there is a high circulating concentration of GH and insulin-like growth factor-1 (IGF-1) which 
works as negative feedback on the pituitary and hypothalamus (Ohlsson et al., 2009). 
GH plays a major role in linear body growth and organ growth during childhood and body 
composition throughout life. This is achieved by regulation of bone growth through induction of 
chondrocyte proliferation in cartilage and osteoblast proliferation in bone (Olney, 2003), which is 
both mediated directly by GH (i.e. IGF-1-independent effects of GH) and indirectly via GH-
induction of IGF-1. GH induction of IGF-1 is rapid within minutes involving an increase in IGF-1 
gene expression which is mediated by GH binding to its receptor, the GHR, and induction of a 
series of intracellular phosphoreceptor-signalling cascades, involving JAK2 and the transcription 
factor Stat5b.  Individuals with Stat5b inactivating mutations have confirmed the critical role of 
Stat5b in GH-dependent IGF-1 induction, as these individuals are characterised by severe short 
stature, GH-resistance and low levels of circulating IGF-1, as well as STAT5-dependent immune 
dysfunction (Nadeau et al., 2011). 
The other major direct function of GH in the body is the regulation of metabolism. GH 
stimulates lipolysis and ketogenesis to stimulate the breakdown of triglycerides and increases levels 
of free fatty acids (FFA) and ketone bodies in the blood (Moller et al., 1990; Ho et al., 1996). GH 
has an anabolic effect in skeletal muscles increasing amino acid uptake, protein synthesis and 
decreasing protein oxidation (Moller et al., 1990; Ho et al., 1996). In addition, GH is also involved 
in maintaining blood glucose levels by inhibiting glucose uptake in peripheral tissues and 
decreasing glucose oxidation which in turn enhances gluconeogenesis in the liver 
(Moller et al., 1990; Ho et al., 1996; Copeland et al., 1994; Moller et al., 1992; Butler et al., 1991).  
The actions of GH on target tissues are either direct through the GH receptor which is 
expressed in every tissue in the body or through induction of IGF-I, largely in the liver, but also 
IGF-1 produced locally as IGF-1 is produced from virtually every tissue in the body. The original or 
classical somatomedin hypothesis was proposed over 50 years ago to explain the actions of GH on 
cartilage and other tissues that was thought to be largely mediated through IGF-1 synthesised from 
the liver and present in the circulation, and not by a direct action of GH on tissues 
(Murphy et al., 1956, Daughday et al., 1972, Salmon and Daughday, 1957).  
Since the original somatomedin hypothesis was proposed, a large body of evidence suggests 
a more complicated interaction between GH and IGF-1 than proposed in the classical model of the 
somatomedin hypothesis. Based on this newer evidence, Kaplan and Cohen more recently proposed 
a modified hypothesis based on data suggesting what they describe as “augmentative-counteractive” 
actions between GH and IGF-1 in different tissues (2007). This updated model takes into account 
the observations, amongst others, that IGF-1 augments the anabolic action of GH on protein 
synthesis and inhibition of proteolysis in skeletal muscle, while counteracting the hyperglycaemic 
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and lipolytic effects of GH, with IGF-1 causing hypoglycaemia and promoting lipohypertrophy 
(Figure 1.6). Thus, GH has been shown to have direct biological roles independent of IGF-1 in 
various cell models and functions (Brooks AJ and MJ Waters, 2010). These include GH effects on 
ovarian prenatal follicular development (Slot et al., 2006), fusion of myoblasts with nascent 
myotubes to increase muscle fibre size (Sotiropuolos et al., 2006), and chondrocyte generation of 
the growth plate (Wang et al., 2004). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The effects of GH and IGF1 on growth and metabolism based on the new somatomedin hypothesis 
(+), Stimulatory effect; (-), inhibitory effect; AN, anabolic effect; GLU, glucose utilization; LIP, lipogenesis (Figure 
adapted from Kaplan and Cophen, 2007). 
 
Congenital GH deficiency (GHD) in children arises from genetic conditions that interfere 
with pituitary development and if left untreated results in severe short stature 
(Kelberman et al., 2009). The effects of GHD on growth, body composition and metabolism can be 
treated with replacement therapy in children and in adolescents while GH treatment in adults with 
GHD has been advocated for general well-being and prevention of osteoporosis and cardiovascular 
disease (Ross et al., 2010). In adolescents who have reached final height or in adult subjects with 
GHD withdrawal of GH therapy leads to adverse changes on body composition and increases 
cardiovascular disease and metabolic disease risk factors (Verhelst et al., 2009; Leong et al., 2003). 
GH therapy in adolescents and adults with GHD reduces fat mass, increases lean mass and bone 
density, improves lipid profile and psychosocial well-being (Mauras N., 2010; Conway et al., 2009; 
Nelson et al., 1988).  
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1.3 Metabonomics & Systems Biology 
1.3.1 Metabonomics 
1.3.1.1 Definition of Metabonomics 
 Until recently, transcriptomics and proteomics have been the major experimental approaches 
to identify the function of genetic and metabolic processes involved in living biological systems 
(Lindon et al., 2000). However, these technologies can be labour-intensive and expensive to 
implement. They also do not provide information on the metabolic status of the whole organism and 
thus do not provide an integration of gene-environmental interaction with biological endpoints 
(Lindon and Nicholson, 2008). Metabonomics is a quantitative method of measuring complex 
metabolic responses of an organism to a stimulus or a genetic change (Nicholson et al., 1999). It is 
the study of the metabolite composition of biological fluids and tissues with the data being 
interpreted by chemometric techniques that provides an overall view of the whole biological 
system. In fact, the study of how tissues and biological fluids are indicative of a disease state goes 
as far back in time as the period of the ancient Greeks (Nicholson and Lindon, 2008). During the 
Middle Ages, a urine chart with links to the global properties of urine, such as colour, smell and 
taste was used as a diagnostic tool (Figure 1.7). In metabonomics, a similar global diagnostic 
approach is utilised, but with the application of modern analytical techniques more information can 
be extracted from samples. The analysis of data from metabonomics provides a powerful platform 
for clinical research and diagnostic applications (Griffin et al., 2001; Holmes et al., 1994; Holmes 
et al., 2001; Robertson et al., 2002). 
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Figure 1.7: A urine chart used in the Middle Ages to diagnose diseases (Taken from Nicholson and Lindon, 
2008). 
 
 Metabonomics data are commonly generated through the use of analytical techniques such 
as Nuclear Magnetic Resonance (NMR) spectroscopy and mass spectrometry (MS) and analysed 
with multivariate statistical methods to detect differences between different groups of samples 
(Lindon et al., 2004). The types of biological fluids that can be analysed include urine, saliva, 
plasma and serum, which can all be obtained relatively easily and non-invasively, require little or 
no preparation and utilize small sample sizes, thus making  metabonomic studies ideally suited for 
studies in children (Lindon, 2004). However, other types of biological fluids such as amniotic fluid, 
seminal fluid, bile, cerebrospinal fluid (CSF) and gastric juices have also been analysed in 
metabonomic studies (Jordan and Cheng, 2007; Lindon et al., 2000; Romero et al., 2005; 
Wikoff et al., 2008). Furthermore, metabolic profiling of tissue biopsies is possible using high-
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resolution magic angle spinning (HR-MAS) NMR spectroscopy, displaying the flexibility of the 
technique (Mortishire-Smith et al., 2004; Schirra et al., 2008; Wu et al., 2006). 
1.3.1.2 Biological Fluids 
 The human body is thought to contain around 3000 to 5000 detectable metabolites 
(Wishart et al., 2007). In biological fluids, a wide range of these metabolites can be detected with 
metabonomics that correspond to any alterations due to diseases, drugs or environmental changes. 
Metabolites in biological fluids are in equilibrium with those inside of cells and tissues. Thus any 
abnormal cellular processes in an organism which result in a toxic or metabolic insult will be 
reflected in altered biological fluid compositions. Global analysis of such alterations can help with 
the identification of significantly different metabolites. Urine in particular will exhibit altered 
metabolic fingerprints as the body tries to eliminate unwanted compounds in order to maintain 
homeostasis (Lindon et al., 2000). Variations in the metabolic fingerprints of urine samples not only 
reflect the numerous biological processes taking place in the kidneys but in the entire body 
(Lindon et al., 2000). However, the composition of urine is complex and highly variable between 
individuals due to different types of physiological conditions such as age, diet, species and lifestyle 
(Bollard et al., 2005). 
The stability of urine samples can also be affected through factors such as pH and 
temperature, encouraging bacterial growth and altering the metabolic profile (Lindon et al., 2000). 
Urinary pH varies according to the physiological condition of an individual. The normal range is 
between pH 6.5 – 7.5, and pH stability can be maintained through the addition of phosphate buffer 
(Lindon et al., 2000). A pH of more than 9 usually indicates the decomposition of urea to ammonia 
due to bacterial contamination, which can be prevented by proper sample handling. Storage 
conditions, such as temperature, storage time and concentration of preservatives play important 
roles in maintaining the stability of a urine sample. It was shown that human urine samples that 
were stored at 4°C without any preservatives exhibited increased concentrations of metabolites such 
as acetate and formate, possibly as a result of airborne bacterial 
contamination (Lauridsen et al., 2007). Such bacterial growth in the sample will alter the levels of 
metabolites in the sample, and analysis will thus not yield a true metabolic fingerprint.  
Standard collection and storage procedures for biofluids, including the collection of human 
urine samples, have recommended that sodium azide is used as anti-bacterial preservative and that 
samples should be stored at -40 °C until analysed (Ebbels et al., 2007). Apart from sodium azide, 
other commonly used preservatives for biofluids are sodium tetraborate and sodium 
fluoride (Porter and Brodie, 1969, Lum and Meers, 1989, Gillespie et al., 1999, 
de Laurentiis et al., 2008).  
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In clinical metabonomic studies, urine samples are often collected at home over a period of 
time. Often instructions on collection of samples are not strictly followed and therefore, samples 
could be left at room temperature for up to 24 hours before they arrive at the clinic. Previous studies 
found that urine samples stored at room temperature for 24 hours had minimal variations and 
remained relatively stable (Maher et al., 2007).
 
However, recently it was shown that urine sample 
degradation occurs within 24 hours storage at room temperature (Rasmussen et al., 2011, 
Bernini et al., 2011). It is therefore crucial to ensure that the identification of biomarkers in 
metabonomic studies is not confounded by problems in sample handling or bacterial contamination, 
as this could lead to changes in the metabolite profile that compromise interpretation. 
1.3.1.3 Techniques in Metabonomics 
 The analytical techniques applied in metabonomics include NMR spectroscopy, MS, liquid 
chromatography-NMR (LC-NMR), gas chromatography-MS (GC-MS), liquid chromatography-MS 
(LC-MS) and capillary electrophoresis-MS (CE-MS) (Manini et al., 1999; Plumb et al., 2003; 
Weckwerth and Morgenthal, 2005). Both NMR spectroscopy and MS are rapid and have been 
shown to be extremely successful in monitoring biofluids and yielding “metabolic fingerprints” that 
is specific to different metabolic states (Nicholson et al., 1999). Results are generated in the form of 
a spectrum consisting of peaks that correspond to compounds found in the tested sample. NMR 
spectroscopy is by nature non-targeted, spectra are inherently quantitative, highly reproducible, and 
sample preparation is minimal but MS is more sensitive than NMR. Sample preparation in MS 
involves multiple steps, including hyphenation and derivatisation, which reduce sample complexity 
for more efficient detection. MS without any pre-treatment generates data that are far too complex 
to analyse. However, the combination of both NMR spectroscopy and MS has been able to provide 
more comprehensive, complementary and valid information on the metabolic status of living 
systems (Karakach et al., 2009; Lin et al., 2008; McKelvie et al., 2009; Pan et al., 2007).  
 NMR spectroscopy is used widely in chemistry to provide information on molecular 
structures of pure compounds as well as complex mixtures. NMR spectroscopy is especially suited 
for metabonomic studies as it is rapid and non-destructive. More importantly, a separation step is 
not required and the samples can be measured with no or little preparation. Only a small volume of 
sample (less than 1 ml) is required to generate data. Samples can either be placed into 96-well plates 
or into conventional 5-mm capillary NMR tubes with the use of an automatic sampler changer to 
provide rapid measurement. The resulting spectrum contains thousands of sharp peaks from 
predominantly low molecular weight metabolites. Each signal’s position in the spectrum is 
measured in frequency terms, in parts per million, so as to be independent of the field strength of 
each particular NMR spectrometer. 3-(Trimethylsilyl)-2,2,3,3-tetradeuteropropionic acid (TSP) or 
2,2-dimethyl-2-sila-3,3,4,4,5,5-hexadeuteropentane-5-sulfonic acid (DSS) are usually added to 
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samples as a standard chemical shift reference. In addition, deuterium oxide (D2O) is added as lock 
substance.  
When measuring urine samples, a broad water signal is usually present in the spectrum and this can 
obscure information of other metabolites. A simple 1-dimensional (D) nuclear Overhauser 
enhancement spectroscopy (NOESY) sequence with water suppression is most commonly used in 
NMR metabonomic studies to overcome this problem. Other standard water suppression pulse 
sequences include presaturation or WATERGATE (Aranibar et al., 2006). Serum samples contain 
proteins and lipids in addition to small-molecule metabolites that result in both narrow and broad 
signals in the spectrum (Lindon et al., 2000). Therefore, a Carr-Purcell-Meiboom-Gill (CPMG) 
sequence is used for tissue or serum samples to aid in the suppression of broad signals from large 
molecules.  
NMR signals are classified as singlets, doublets, triplets or multiplets depending on their 
internal signal structures. Signals in a 1D NMR spectrum are assigned to specific metabolic species 
based on their position in the spectrum, their coupling pattern and relative intensity, along with 
additional information gained from 2D NMR spectra. 2D NMR methods consist of a series of 1D 
experiments which are highly useful for reducing the spectral complexity and thus helpful for 
metabolite assignments (Van et al., 2008). Examples include homonuclear correlation spectroscopy 
(COSY), J-spectroscopy, total correlation Spectroscopy (TOCSY) and the 2D NOESY experiments. 
However, 2D NMR usually requires a longer acquisition time and leads to a larger data size. 
Therefore it is not feasible to measure a large number of samples using 2D NMR methods in 
metabonomic studies. Thus 2D NMR spectra are usually solely used for metabolite identification, 
whereas 1D NMR is usually the method of choice for high-throughput metabolite profiling (Van et 
al., 2008). 
1.3.1.4 Data Processing 
The data generated from both NMR spectroscopy and MS experiments contain thousands of 
peaks with information on hundreds of metabolites and are therefore generally complex. Pattern 
recognition (PR) and multivariate statistical methods such as principal components analysis (PCA), 
partial least squares (PLS) analysis, partial least squares-discriminant analysis (PLS-DA), 
orthogonal-PLS (OPLS) and orthogonal-PLS-DA (OPLS-DA) are thus used for data reduction and 
to separate complex sample groups in order to identify which significant metabolites are causing the 
separation (Trygg and Wold, 2002, Trygg et al., 2006, De Iorio et al., 2008, Liland, 2011). These 
statistical methods are available as either commercially or publicly available programmes and they 
aid in filtering large amounts of data and in accessing the subtle biochemical perturbations latent in 
the spectra.  
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PCA is an unsupervised method that allows sample data (X variables) to naturally cluster 
into groups without any previous knowledge of the sample class and summaries data by looking for 
underlying trends (Liland, 2011). PLS and PLS-DA, are supervised methods that separate samples 
based on the knowledge of the sample class (Y variables) (Liland, 2011). Both types of analysis 
generate matrices called scores and loadings plots. The scores plot provides the coordinates for the 
samples in the statistical (metabolic) space, and each point represents a sample or spectrum. The 
loadings plot defines how the samples are being separated in the scores plot and each point 
represents a metabolite. The metabolites identified by either statistical analysis provide an insight 
into the basis underlying any changes or differences in metabolic profile. This can then lead to the 
identification of significant biomarkers that reflect the mechanism of cause of a disease or toxicity.  
OPLS and OPLS-DA are modifications of the PLS/PLS-DA methods where the systemic 
variation in the X-block is divided into two model parts (one that models the co-variation between X 
and Y and another that expresses the X variation that is orthogonal or not related to Y (Trygg and 
Wold, 2002, Trygg et al., 2006). OPLS and OPLS-DA usually deal with one type of dataset and 
even if there was more than one type of dataset, OPLS had to be performed separately on each 
dataset before they can be integrated (Rantalainen et al., 2006). However, recently multivariate 
analysis of two datasets was made possible through the O2PLS and O2PLS-DA methods (Bylesjo 
et al., 2007, 2008). Here datasets from different analytical platforms can be integrated to investigate 
any correlations between the different data and aid in the interpretation of the model. In addition, 
O2PLS/O2PLS-DA is bi-directional, therefore, the first dataset (X) can be used to predict the 
second dataset (Y) and vice versa. Another advantage of O2PLS/O2PLS-DA is that the systematic 
variation in X and Y can be divided into three sections, (1) the X/Y joint predictive variation, (2) the 
Y-orthogonal variation in X, and (3) the X-unrelated variation in Y. 
1.3.2 Applications of Metabonomics 
1.3.2.1 Physiological Variations 
 Metabonomic techniques are widely used in both animals and human clinical studies 
(Griffin et al., 2001; Holmes et al., 1994; Holmes et al., 2001; Robertson et al., 2002). The 
metabolic composition of biological fluids can be altered due to a wide range of physiological 
variations and environmental effects (Lindon et al., 2004). A study by Griffin et al. (2001) observed 
correlations between the metabolic profiles of laboratory animals and their diet, age, gender and 
environment.  
 Factors such as diet, lifestyle and culture, gender and environment cause changes to the 
metabolic profiles that can be identified through metabonomics. The identified metabolites can then 
be related back to their relevant metabolic pathways to determine which pathways are affected and 
if the affected pathways are independent of others or if a specific defect in one pathway causes 
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disruption in others. However, these factors can also contribute to the variability of the metabolic 
fingerprint of the subjects and such factors are not as easily controlled in physiological variation 
studies involving humans. In order to obtain accurate results, these factors have to be taken into 
consideration before performing metabonomic analysis, and having a larger sample size can also 
help to increase the power of a study. This is especially crucial in human clinical studies where the 
aim is to identify valid biomarkers. Unfortunately, there is no formal algorithm for calculating sample 
sizes for metabolomic data, as power calculations do not apply to multivariate data. The standard 
method is to estimate sample sizes from pilot studies or from published studies on related biological 
effects. Several studies with human subjects show that it is possible to obtain significant results with 
comparatively small sample sizes: For example, metabolic differences were detectable between 
healthy subjects from Britain and Sweden (n=30) due to differences in their respective cultural diets 
(Lenz et al., 2004) and there were significant differences in the rate of lipid biosynthesis in males 
and females. The metabolic profiles of athletes (n=28 (16 athletes, 12 controls)) undergoing long-
term training were also analysed with altered glucose metabolism, oxidative stress, energy 
metabolism, lipid metabolism, amino acid metabolism (Yan et al., 2008). 
1.3.2.2 Disease Diagnosis 
 NMR-based metabonomics has been used to aid in disease diagnosis. One early 
metabonomics study demonstrated the possibility of using 
1
H-NMR-based metabonomics to 
diagnose the presence and severity of coronary heart disease (CHD) in patients (Brindle et al., 
2002). Using PR methods, NMR spectra of serum samples of CHD patients with triple vessel 
disease could be separated and differentiated from angiographically normal coronary arteries 
patients with more than 90% sensitivity and specificity. The severity of CHD was also separated 
into three groups (mild, moderate and severe stenosis) after PR analysis. However, as recently 
highlighted, this study had upon closer look many limitations such as sample size and the way the 
analysis was performed thus this study has to be interpreted with caution (Griffin et al., 2011). Of 
course with a larger samples size, one can improve the statistical significance of a metabonomics 
study and while this study showed that sample size do provide limitations to the quality of the 
study, majority of other metabonomic studies as mentioned above, were able to provide robust 
results even with a smaller sample size of n=30 or less, indicating that the technique is still useful 
and practical to apply in clinical settings (Lenz et al., 2004, Yan et al., 2008).  In another study, 
T2DM patients were successfully discriminated from healthy controls by differences in serum lipid 
metabolites (Yang et al., 2004). Novel metabolites (carnitine and tranexamic acid) were identified 
as potential predictors for development of acute kidney injury after cardiac surgery in urine samples 
collected from patients after cardiac surgery (Zacharius et al., 2013). Similarly, high levels of 
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urinary protein and methanol revealed to be potential biomarkers for autosomal dominant polycystic 
kidney disease that is usually caused by kidney failure (Gronwald et al., 2011). 
 Metabonomics has also been useful in discovery and diagnosis of inborn errors of 
metabolism. Discrimination between phenylketonuric newborns, maple syrup urine disease children 
and controls was achieved through the application of 
1
H NMR-based metabonomics 
(Constantinou et al., 2005). Consequently, metabonomics is already being used routinely as a new 
promising screening tool for inborn errors and as an alternative to the blood spot test that can be 
painful for newborns and eliminates the extensive sample preparation step.  
With respect to the aforementioned discussion about sample size, high sensitivity and 
specificity of NMR spectroscopy was demonstrated in the studies mentioned above even with a 
small number of patients in the respective cohorts. With sample numbers as small as 28, metabolic 
alterations in subjects can be observed with metabonomics. Factors such as age and sex did not 
affect the outcome of these studies since patients were selected based on the status of their disease.  
With advancements in instrumentation and software for studies involving clinical 
metabonomics, an accurate snapshot of a subject’s health status can be obtained at any particular 
point in time by investigating metabolic fingerprints of body fluids or tissues collected from 
subjects.  Ultimately, the aim is that the health status and disease risk of each individual can be 
predicted in a personalised manner. In addition, metabonomics data can be used to monitor and 
predict the efficacy of a particular therapy in a patient. This means that metabonomics has the 
potential to play an important role in personalising of all three areas of medical patient 
management: diagnosis, prognosis and theranosis.   
1.3.3 Obesity and Metabonomics 
 The versatility of metabonomics makes it an ideal tool for investigating animal models of 
obesity or the biochemical changes in obese individuals (Schirra et al., 2008). The progression of a 
disease can be monitored through the changes in metabolism of tissues or biofluids of an animal or 
individual.  A disorder like obesity that affects not only a single organ but the entire body, can be 
easily defined through the changes in metabolism and these changes can be illustrated through 
metabonomics. Alongside that, obesity-related diseases such as insulin resistance, cardiovascular 
diseases and dyslipidaemia can also be potentially analysed. Even though obesity-related research 
using metabonomics is a fairly new area of research, there are a number of publications that focus 
on this subject.  
1.3.3.1 Animal Studies of Obesity 
 Using a combination of 
1
H NMR spectroscopy and LC-MS techniques to analyse urine in 
Wistar and obese Zucker fa/fa rats, a large number of metabolites can be detected 
(Williams et al., 2006). Data were analysed through multivariate statistical methods, and significant 
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differences were noted between controls and mutant rat strains with an increase in glucose and 
proteins (NMR), fumarate, malate, furoic acid, ribose, suberic acid, carnitine and pyrimidine 
nucleosides (LC-MS) and a decrease in taurine (NMR) concentration in the obese rats.  
 In another study, both tissue samples and biological fluids of lean and obese Zucker fa/fa 
rats were analysed using both 
1
H and 
31
P NMR spectroscopy (Serkova et al., 2006).  A marked 
decrease of the ATP/ADP ratio was noted in the liver tissues of obese rats. Along with that, there 
was a decrease in glutathione and a drop in the ratio of polyunsaturated fatty acids to 
monounsaturated fatty acids in these animals. An increase in methionine together with a decrease in 
betaine in these obese rats was indicative of a change in 1-carbon metabolism within the liver 
tissue.   
 To investigate the effects of body weight loss on the metabolic profiles of animals, Conner 
et al. (2004) compared the urinary profiles of Wistar Han rats that were given a toxic dose of either 
alpha-napthylisothiocyanate (ANIT), carbon tetrachloride, hydrazine or 1,2-dimethylhydrazine to a 
control group. Both group of animals consumed the same amount of food but due to the toxicity of 
the chemicals, the treated animals had a loss of weight as compared to the controls. PCA and PLS-
DA analysis gave proof that in the treated group, there was an alteration to the metabolites that were 
involved in energy metabolism such as those in the TCA cycle, TMAO, creatine, creatinine, 
phenylacetylglycine, fumarate, glucose, taurine, fatty acids and N-methylnicotinamide indicative of 
how weight loss can affect the metabolism of an individual.  
 A recent metabonomic study was performed in GH-deficient mice where the intracellular 
domain of the growth hormone receptor was truncated, impairing STAT5 signalling 
(Schirra et al., 2008). These mice became obese due to resulting metabolic changes arising from 
severe GH deficiency. Using metabonomics, the metabolic profiles of these mice were analysed and 
changes in taurine levels were identified as particularly significant. Decreased taurine levels have 
been recently shown to induce obesity (Tsuboyama-Kasaoka et al., 2006). Based on this, it is clear 
that metabonomics can define the physiological changes in obesity.   
1.3.3.2 Human Studies of Obesity 
 Recently, obesity-related metabonomic studies have been explored in humans. With the aid 
of LC-MS, the metabolic profiles of serum samples from two groups of young adult monozygotic 
twins (discordant versus concordant for obesity) were analysed (Pietiläinen et al., 2007). Using such 
cohorts, genetic and environmental factors contributing to the prevalence of obesity can be 
excluded. Regardless of genetic background, obese individuals had an increased concentration of 
lysophosphatidylcholines which contributes to pro-inflammation and atherogenesis and a decrease 
in ether phospholipids, which are metabolites known for their antioxidant properties. These changes 
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were also associated with insulin resistance. Thus obesity can have deleterious effects on lipid 
metabolism even without any genetic influences 
 Holmes et al. (2008) investigated the metabolic phenotype variations of 4630 participants 
(obtained from the INTERMAP epidemiological study) from four different countries and linked the 
metabolic patterns with prevalence of increased blood pressure. Acetate, formate, hippurate and N-
methylnicotinate were significantly associated with blood pressure, a known risk factor of CVD.   
 Another type of study that uses a similar approach to metabonomics is called lipidomics. 
Lipidomics is the study of cellular lipids pathways in biological systems (Wenk, 2005). Lipidomics 
seeks to identify cellular lipid molecular species and investigate how they interact with other lipids, 
proteins and metabolites. Lipidomics is classified to be under the umbrella of metabonomics 
however it is unique in its focus on lipids. It also uses analytical platforms similar to metabonomics 
(MS and NMR spectroscopy). It is a highly sensitive technology that allows the detection of 
differences in subcutaneous adipose tissues samples from healthy non-diabetic obese individuals 
(Kolak et al., 2007). LC-MS identified 154 lipid species where an increase in the concentrations of 
triacylglycerol and ceramides which is known to contribute to the prevalence of insulin resistance 
and inflammation were noted in individuals with fatty liver. 
 Recently, Zeng et al., (2010) profiled plasma samples collected from obese children using 
GC/MS. Metabolites such as isoleucine, glyceric acid, serine, 2,3,4-trihydroxybutyic acid and 
phenylalanine were considered as potential biomarkers of childhood obesity. In addition, clinical 
factors such as waist-hip-ratio, triglyceride, total cholesterol, high density lipoprotein (HDL) and 
low density lipoprotein (LDL) were associated with metabolic alterations in childhood obesity.  A 
similar study profiling serum metabolic fingerprints of obese children showed association of 
glutamine, methionine, proline, 9 phospholipids and 2 acylcarnitines with the obese cohort 
indicating that alterations occurred probably in the pathways associated with energy production and 
oxidative stress (Wahl et al., 2011). 
1.3.4 Systems Biology 
 Systems biology has emerged as a powerful scientific method using a more holistic 
perspective to tackle biological and biomedical research that focuses on systems level 
understanding of biology (Chong and Ray, 2002). Usually one would implement transcriptomics to 
examine the expression levels of mRNA in a given cell population, use proteomics to study the 
structure and functions of proteins, metabonomics to study the chemical processes in metabolites, 
and metagenomics and metatranscriptomics to study role of gut microbiota in health and disease 
(Ivashuta et al., 2011, Sun et al., 2011, Griffin et al., 2001; Holmes et al., 2001, 
Yu and Zhang, 2012). Each of these technologies is limited to examining only a specific type of –
omics and thus interpretation is constricted.  In order to obtain a better understanding of biology at a 
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systems level, utilising more than one technique or platform will be beneficial. Systems biology 
allows the integration of all of these -omics with other forms of complex data from other analytical 
platforms and even clinical data that was collected in typical clinical studies. By using advanced 
statistical tools such as multivariate analysis, interpretation of these complex data from more than 
one platform will ultimately aid in the achieving a clearer picture of the different chemical and 
biological processes involved in a biological system and how they are correlated (dos Santos et al., 
2010, Ghosh et al., 2011). 
 Large amounts of complex data are usually generated through these high throughput –omics 
technologies with high sensitivity and specificity. Therefore, one of the challenges is to convert the 
large amount of data collected from different platforms and experiments into useful knowledge that 
can be used to provide a better understanding of the biological system of interest. Robust and 
flexible bioinformatic processes are required to study and understand such vast amount of data. This 
includes processing the data, performing statistical data analysis, generating pathway networks and 
lastly modelling the data in a system wide context. However, it is also important to make sure that 
bottlenecks do not occur while collecting, processing and analysing these data. Thus, it is important 
to choose the appropriate representation of the data before running any form of analysis. Performing 
statistical analysis can help with identification of patterns in the data and by researching through 
biological databases and comparing gene sequences, proteins and/or metabolites any differences 
between diseased versus healthy or between different phenotypes can be identified. Overall, it is 
hoped that by integrating data from different –omics technologies, the complexity to interpret data 
can be resolved and bioinformatics tools and systems biology can make these interpretations 
biologically and clinically relevant.  
 Chemometric methods such as PCA, PLS and PLS-DA among others can be utilized to 
navigate through large datasets that are generated from genetics, proteomics and metabonomic 
studies respectively (Eriksson et al., 2004). However, results from each platform can also be 
combined in a further multivariate analysis to find any correlations between the different datasets. 
Variables of OPLS-DA data obtained from NMR metabolomics and 2D-DIGE proteomic 
experiments respectively, were integrated with OPLS analysis and provided insights on human 
tumor xenograft mouse model of prostate cancer (Rantalainen et al., 2006). 
 Integration of data obtained from transcriptomics and metabolomics experiments 
investigating the effects of a hybrid of two different species of plants through the use of O2PLS 
analysis showed strong multivariate correlation patterns between the two datasets which is related 
to the underlying molecular functions of the processes involved in the hybridization 
(Bylesjo et al., 2007). In a similar study, 3 different types of datasets (transcriptomics, proteomics 
and metabonomics) were integrated using O2PLS to identify joint variations and also platform 
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specific variations to aid in the profiling of a steady-state system of three different genotypes of 
hybrid aspen (Bylesjo et al., 2009). By using these statistical methods to create the multivariate 
models, it is easier to interpret and find correlations between datasets collected from different 
analytical platforms thus providing the possibility to uncover the underlying mechanism of a variety 
of biological systems. 
1.3.5 Hypothesis-Driven vs. Data-Driven Science 
For many years, the accepted protocol in any successful scientific investigation involved 
hypothesis-driven research. The hypothesis is evaluated by careful design and execution of 
controlled experiments to generate validated results using strict statistical criteria that can prove or 
reject the hypothesis. Hypothesis-driven science has indeed provided many valuable and significant 
discoveries. Exploratory or data-driven science on the other hand, looks at patterns or associations 
between the data sets tested.  However, some believe that such ‘fishing expeditions’ are dangerous 
with possible false correlations when investigating large amounts of data without proper designed 
experiments and hypothesis (Allen JF, 2001, Valencia A, 2002, Kell and Oliver, 2004, 
Weinberg RA, 2010) Results generated also might not have a strong statistical value that could 
validate the data tested. Despite such criticism, several landmark data-driven studies have been 
undertaken. One such study was The Human Genome Project which was initially thought to be a 
flawed based on the fact that it was not hypothesis-driven. Despite these reservations, the Human 
Genome Project has yielded information that has revolutionised genomics and human biological 
research (International Human Genome Sequencing Consortium et al., 2001).  
With the advancement in research technologies, larger and larger amount of different types 
of data have been generated and stored and publicly accessible for investigational studies. A type of 
data generated more commonly nowadays are called ‘omics’ data where the usage of machines and 
software to look at patterns or associations can generate useful predictions regarding the data 
without necessarily starting with posing a traditional hypothesis (Golub TR, 2010). In reality, both 
types of data – hypothesis-led and data-driven science are complementary of each other and 
generate validated results with potential for  deeper insights (Figure 1.8).  
It is more practical to use the same ‘omics’ methods with proper hypotheses before any data 
collection to generate data that can be used in quantitative biological models especially in the 
context of systems biology where one will look at the overall system of an organism under defined 
conditions. Another way of complementing both types of sciences would be to use ‘omics’ to 
generate data to provide pilot or novel patterns or associations before proceeding to investigate the 
functions using hypothesis-driven methods. It is therefore logical to think that such a union could 
potentially give a better understanding of the underlying mechanism of a particular biological 
system than when the method is implemented on its own. No matter which method is chosen, 
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ultimately their aim is to provide significant, sound and accurate results that can give an insight on 
complicated biological systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: An overview of how hypothesis-driven and data-driven science can be complementary of each other.  
 
1.4 Rationale 
1.4.1 Hypothesis 
Diseases, toxins or changes to the body composition due to environmental factors can cause 
alterations to metabolism which alter an individual’s overall risk for metabolic disease, such as 
obesity and Type 2 Diabetes Mellitus. Thus the central hypothesis of this project is that specific 
metabolic changes occur in children and adolescents due to childhood obesity and obesity-related 
diseases (i.e. GH deficiency) compared to healthy weight children. We hypothesise these changes 
can be detected using techniques of systems biology such as NMR metabonomics and gene 
expression profiling, which when correlated to clinical disease risk factor may identify early 
biomarkers for metabolic disease.  
 
1.4.2 Aim 
The general aim of this project is to use tools of systems biology to investigate how metabolism of 
children and adolescents are altered due to changes in body composition or disease, such as obesity 
or GH deficiency, and as a result of environmental changes e.g. lifestyle.  
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The specific project aims are: 
1. Stability Study 
To determine the optimal storage conditions and handling methods for human urine samples 
for metabonomic analysis or studies.  
2. Growth Hormone (GH) Deficiency Study 
To determine the metabolic profile of a female adolescent with severe GH deficiency due to 
a PIT-1 gene mutation and to study the effects of GH therapy on metabolism by NMR-based 
urine metabonomics. 
3. KOALA Childhood Obesity Study 
Technique (a) NMR 
Metabonomics 
(b) Nuclear Receptor Gene 
Expression Profiling 
Research 
Question 
Determine metabolic 
profiles in urine  
Determine gene expression profile from 
peripheral blood mononuclear cells 
(PBMCs) 
Subjects Obese and non-obese age- and sex-matched healthy weight 
children at baseline and after a 12 month lifestyle intervention 
 
c. Perform a comparative  study of the effects of obesity in a cohort of children with 
BMI >95
th
 centile and compared to age- and sex-matched non-obese control children 
by analysing clinical, metabonomic and gene expression data using: 
i. Multivariate analysis 
ii. Network analysis and systems biology 
 
1.4.3. Project Structure/Rationale 
The KOALA childhood obesity project (Aim 3) forms the centrepiece of this PhD thesis. The 
stability study (Aim 1) is necessary groundwork to be able to successfully undertake the sample 
collection in KOALA, while Aim 2 is an application of metabolomics to a practical problem and 
demonstrates the direct clinical applicability of the methods employed in this thesis. 
 
1.4.4 Significance 
Obesity is one of the major public health problems in the world and now occurs in more than 
40 million children and adolescents worldwide. Childhood obesity increases the risk of 
cardiovascular disease and Type 2 Diabetes in later life. Thus, huge benefits will arise nationally 
from early recognition and diagnosis of obesity and its related complications and the improved 
monitoring of treatment outcomes. 
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This PhD project is the first to study the metabolic changes in children with obesity or GH 
deficiency utilising metabonomics and/or PBMC gene expression analysis. The outcome(s) of this 
study may establish NMR-based metabonomics as a diagnostic and prognostic tool not only in the 
context of obesity and its related complications i.e. Type 2 Diabetes Mellitus (T2DM) and 
cardiovascular diseases, but make the technique also available for the study of other hormonal 
diseases. Moreover, gene expression studies of PBMCs may identify significant NRs and NR 
dependent pathways that can improve our understanding of the underlying molecular mechanisms 
in metabolic dysfunction in obesity.  Overall, the use of multivariate analysis and integration of 
datasets from different types of experiments and platforms can aid our understanding of underlying 
mechanism of obesity and its related diseases.  
 
1.5 KOALA Childhood Obesity Program  
The KOALA (Kinder for children and their families, Overweight: overcoming and being 
OK, Active mind and body, Lifestyle a life-giving diet and Actions all together and ahead) 
childhood obesity and lifestyle intervention program is the central clinical study that forms the 
foundation of this thesis. KOALA is a randomised control trial where 72 overweight and obese 
(OB) children (BMI>95
th
 percentile according to CDC BMI centiles) aged 7 to 12 years were 
randomised into two different treatment arms to investigate the benefits of a 12 month healthy 
lifestyle program on BMI and body fat in children (Smibert et al., 2010) and was conducted at the 
Mater Children’s Hospital, South Brisbane. Both arms underwent a baseline paediatric medical 
consultation with Arm A designated as ‘Care As Usual’ while children and parents in Arm B 
undertook a 12-month intensive lifestyle program (Lifestyle Triple P (Positive Parenting Program) 
(West et al., 2010) and attended three family Scouts QLD Active Camp program during the first 6 
months of the program and were given information and strategies for promoting healthy eating and 
increasing physical activity in their whole family) (Figure 1.8). In addition, 34 sex- and age-
matched healthy weight (HW) children (BMI >3-85th centile) were also recruited as controls (Arm 
C) at baseline.  
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Figure 1.9: Design of the KOALA lifestyle intervention program and its time line. 
Both OB and HW cohorts completed a baseline clinical assessment which included 
measurement of height, weight and waist circumferences and obtaining fasting peripheral blood 
samples for glucose, inclusion and lipids and peripheral blood mononuclear cells (PBMCs) to 
determine gene expression of nuclear receptors (NR). Total body fat and fat free mass were 
assessed at baseline and at 6 and 12 month assessments (Schaefer et al., 1994). In addition, baseline 
urine samples were also collected from both cohorts for metabonomic analysis. Clinical data, blood 
and urine samples were collected again from the OB cohort (both arms A and B) after 12 months.  
To successfully be able to conduct such a complex project and analyse the resulting data, I 
worked first on two smaller studies that laid the important groundwork for the work conducted in 
conjunction with the KOALA childhood obesity research program. 
I first improved the methodology of working with human urine samples and established a 
novel standard procedure of collection, storage and preservation. This ensured our ability to 
measure true metabolic fingerprints before we start any NMR-based metabonomics studies.  
Once the methodology of sample handling was established, I moved on to a pilot/proof of 
principle study, in which I tracked the metabolic profiles of a GH-deficient adolescent subject 
during 5 years of GH therapy using NMR-based urinary metabonomics to apply the knowledge 
gained in the samples stability project.  
Both these studies produced important data and enabled the central part of this PhD project, 
the multi-stream analysis of data from the KOALA cohort. In this project, results from both 
metabonomics and gene expression profiling studies were combined with clinical data using 
multivariate analysis such as O2PLS to possibly provide a clearer picture of how obesity can disrupt 
metabolism in children. The outcomes of this study support the utilisation of NMR-based 
{ [ 
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metabonomics as a potential diagnostic and prognostic tool not only in the context of obesity, but 
make the technique also available for the study of other diseases. In addition, the combination of 
both data streams identified significant NRs and NR-dependent pathways that can improve our 
understanding of the underlying molecular mechanisms in metabolic dysfunction in obesity.  
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Abstract 
Background: Improper sample storage and handling conditions are one of the main sources of 
errors confounding results in metabonomic studies of biological fluids. Especially in human clinical 
studies, problems can arise when subjects fail to store urine samples at 4°C before delivery to the 
clinic. In addition, urine samples often remain overnight at room temperature while in a queue on a 
sample changer in NMR-based metabonomic studies.  
Methodology/Principal Findings: We used NMR spectroscopy to investigate the short term 
stability of human urine samples under conditions typically employed in metabonomic clinical 
studies. We demonstrate that at room temperature urine samples are susceptible to metabolite 
changes on a short-term time scale (within 24 hours) even with the addition of preservatives such as 
sodium azide, sodium borate or sodium fluoride. This problem can be solved by preserving urine 
samples in a minimum of 100 mM sodium borate upon collection. Afterwards, urine samples 
should be stored immediately at a maximum temperature of -20°C until analysed and NMR spectra 
be recorded within a 24 hour time period after being thawed.  
Conclusion/Significance: Following this standard procedure for treatment of urine samples, 
samples will remain stable and an accurate metabolic fingerprint can be recorded even if subjects do 
not comply with sample handling instructions or if a sample has been left at room temperature for 
24 hours.  
Keywords: Metabonomics, Nuclear Magnetic Resonance, Urine, Sample handling 
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Introduction 
Metabonomics is rapidly becoming more widespread in clinical settings such as diagnosing 
inborn errors of metabolism, biomarker discovery in type 2 diabetes, coronary heart disease, and 
other diseases [1-5]. Data are commonly generated from different biological fluids, predominantly 
urine and plasma, through the use of analytical platforms such as Nuclear Magnetic Resonance 
(NMR) spectroscopy and mass spectrometry and analysed with multivariate statistical methods to 
detect differences between different groups of samples [6]. Often the aim of metabonomic studies is 
to provide valuable insights into metabolites that could serve as biomarkers of diseases [3,7-9]. It is 
therefore important to ensure that the identification of biomarkers is not confounded by problems in 
sample handling or bacterial contamination as this could lead to changes in the metabolite profile 
that compromise interpretation.  
Urine is a commonly analysed biological fluid because it can be obtained relatively easily, 
non-invasively, in relatively large quantities, requires little or no preparation, and can provide 
important insights to metabolism, as urine integrates the metabolic response of the whole body. 
Storage conditions, such as temperature, storage time and concentration of preservatives play 
important roles in maintaining the stability of a urine sample, and previous studies have investigated 
the stability of human urine and plasma samples and the effects of storage temperature or storage 
time [10-15]. They showed that human urine samples that were stored at 4°C without any 
preservatives exhibited increased concentrations of metabolites such as acetate and formate, 
possibly as a result of airborne bacterial contamination [10]. Such bacterial growth in the sample 
will alter the levels of metabolites in the sample, and analysis will thus not yield a true metabolic 
fingerprint. Indeed, sample handling including collection, storage and processing may be a major 
source of error in metabonomic studies that impacts on the validity of the data [10,24]. As it is 
crucial for any successful study to provide valid data, the effects of improper sample handling 
should be minimized in order to obtain bona fide metabonomic data. 
The Metabolomics Standard Initiative (MSI) [16-18] provides comprehensive guidelines on 
planning and reporting of metabolomic/metabonomic studies including methods of collecting 
different types of samples in the biology, plant and environmental areas. In addition, standard 
collection and storage procedures for biofluids, including the collection of human urine samples, 
recommend that a minimum total concentration of 0.05% (w/v) (7.7 mM) sodium azide is used as 
anti-bacterial preservative and that samples should be stored at -40 °C until analysed [19]. Apart 
from sodium azide, other commonly used preservatives for biofluids are sodium tetraborate and 
sodium fluoride [20-23].  
It has been shown that urine samples stored at low temperatures retain their original 
metabolic profiles [10,24]. For example, samples stored at -25°C remain stable for up to 26 weeks 
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even without the addition of any preservatives [10]. Urine samples containing the anti-bacterial 
agent sodium azide were able to be stored for up to 3 months with minimal variations if stored 
frozen [11]. Storage of urine samples at -80°C has been shown to best reflect the original metabolic 
profile, but requires avoidance of repeated freeze-thaw cycles [24].  
In clinical metabonomic studies, urine samples are often collected outside the laboratory 
(e.g. at home) over a period of time. Subjects are in this case usually provided with collection jars to 
collect their urine before transfer to the clinic, with instructions to keep the sample on ice or in the 
freezer at all times [9,25-29]. Often these instructions are not strictly followed, and therefore 
samples could be left at room temperature for up to 24 hours before they arrive at the clinic. 
Previous studies found that urine samples stored at room temperature for 24 hours had minimal 
variations and remained relatively stable [11].
 
Conversely, it was shown recently that urine sample 
degradation occurs within 24 hours storage at room temperature [30,31]. However, these studies did 
not provide a solution that would maintain the stability of urine samples at room temperature.  
Here we investigate the short-term stability of human urine samples under conditions 
typically employed in clinical studies and demonstrate that at room temperature these samples are 
susceptible to metabolite changes on a short-time scale (within 24 hours), even with the addition of 
preservatives. To alleviate this problem, we have developed the following method to maintain the 
stability of urine samples: (1) Add the appropriate minimum concentration of sodium tetraborate as 
preservative into the empty sample container before collection. (2) Upon delivery to the clinic, store 
the sample immediately at a maximum temperature of -20°C until analysed. (3) Record NMR 
spectra within 24 hours after thawing. Our study shows that following this standard procedure, even 
if subjects do not comply with instructions given, or if a sample has been left at room temperature 
for 24 hours, an accurate metabolic fingerprint can be recorded.  
 
Results 
 Urine samples left at room temperature undergo bacterial contamination that alters the 
metabolite profile and therefore interpretation of the metabonomic data. Thus, we investigated in a 
series of experiments whether commonly used preservatives are able to maintain the stability of 
urine samples and their metabolite profiles at room temperature over a period of 24-72 hours.     
“Normal” room temperature i.e. the ambient temperature of the room or laboratory depends 
on a number of factors, e.g. whether air conditioning is present, the local environment, geographical 
location (=climate) and seasonal variation. Therefore, 25°C and 30°C were employed as two 
common temperatures representative of a range of room temperatures in different parts of the 
world. 
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We conducted five different experiments that investigated different scenarios of sample 
storage and other aspects of sample handling (Fig. 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. A. Outline of the 48 hour, B. 72 hour, C. 24 hour experiments and D. time course overview of all 
experiments. Morning urine samples were collected from a male and female volunteer, centrifuged, prepared with or 
without different types of preservatives (final concentration 0.06% (w/v), and NMR spectra were recorded at different 
temperatures at time points 0, 24, 48 and 72 hours in experiments 1,2 and 5. A. In the first experiment samples were 
continuously exposed to room temperature for 48 hours. B. In the second experiment 24 hours storage at -20˚C were 
inserted after the first 24 hours of room temperature storage. C. In the third experiment samples were collected on 
different occasions from both male and female volunteers and NMR spectra were recorded at different temperatures 
every half hour for 24 hours. Samples labeled 30°C were stored at -20°C for 24 hours before spectra were recorded at 
30°C. D. Overview of the time course of all experiments in this study with yellow and blue bars representing periods, 
during which samples were stored at room temperature or -20°C, respectively. Vertical lines in the bars represent the 
time points at which NMR spectra were measured. 
 
Experiment 1: Metabolic profiles of human urine samples alter at room temperature within 48 
hours even with the addition of preservatives.  
The first of these experiments (Figure 2.1A) investigated the effects of continuous storage at 
room temperature for 48 hours on the stability of the sample. 2 urine samples each were collected 
from an adult male and an adult female volunteer. Samples were aliquoted and had a final 
concentration of either 0.06% (w/v) of sodium azide, sodium tetraborate or sodium fluoride (n = 32) 
(Table S2.1). In addition, untreated samples were also prepared as controls.  1-dimensional (1D) 
NMR spectra were recorded after 0, 24 and 48 hours storage at 25°C and 30°C.  
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Noticeable changes were observed in the signal intensity of several metabolites in the urine 
samples of both volunteers when stored at 25°C and 30°C (Figure S2.1). Graphs of the signal 
intensity of metabolites that had changed noticeably during the experiment are shown in Figure 2.2. 
During storage at 25°C, all samples from both the male and female volunteers exhibited metabolite 
profile changes over the 24 hour period (Figure 2.2, left hand panels) with the untreated and the 
sodium fluoride containing samples showing the greatest change. Acetate was the main metabolite 
observed to be increasing in these profiles with smaller alterations to levels of other metabolites 
such as ethanol, lactate, formate, succinate, trimethylamine (TMA) and trimethylamine-N-
oxide (TMAO).  
Samples containing sodium azide and sodium tetraborate showed smaller alterations of 
metabolite levels compared to the untreated and sodium fluoride containing 
samples (Figure 2.2E, F, I and J). Male urine samples containing sodium azide showed a significant 
decrease in the levels of TMAO when compared to the corresponding female sample (Figure 2.2). 
The metabolite profiles of all urine samples changed faster when stored at 30°C (Figure 2.2 right 
hand panels). 
To test whether the observed metabolite changes were of bacterial origin, a male urine 
sample was aliquoted and left either untreated or had 0.06% (w/v) sodium azide added. These 
aliquots were streaked onto LB agar plates and incubated overnight at 37°C together with control 
plates. White bacterial colonies were observed after 24 hours on all plates containing urine, 
indicating bacterial growth despite the presence of sodium azide as an antibacterial 
agent (Figure S2.2). The plates containing untreated urine showed a higher number of colonies 
compared to the plates containing urine with sodium azide. The absence of colonies growing on the 
control plates indicates that the source of bacteria was not from the incubator or during the 
preparation and streaking of the agar plates.  
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Figure 2.2. Changes in signal intensities of metabolites during 48 hours storage. Urine samples of the male and 
female volunteer contained different preservatives (without preservatives, 0.06% (w/v) sodium azide, sodium 
tetraborate or sodium fluoride) and were stored at 25 ˚C and 30 ˚C. Acetate: red filled circles, formate: green open 
diamonds, succinate: orange filled triangles, TMA: blue filled squares, TMAO: open blue squares, lactate: open 
turquoise triangles, ethanol: open red circles, and 3.79 ppm: filled black diamonds. Each graph represents an aliquot 
from the same urine samples collected from the volunteers. Note the different intensity scales for each preservative 
treatment. All samples were measured with identical experimental parameters, thus signal intensities are comparable 
across all samples. 
 
Experiment 2: Storage for 24 hours at -20°C suppresses alterations to metabolic profiles of urine 
samples. 
  
The previous experiment established that urine samples experience changes in metabolite 
concentrations when stored at room temperature for 48 hours. However, even if urine samples for 
clinical metabonomic studies are collected at home, 48 hours of uninterrupted room temperature 
storage is a worst case assumption. A more realistic scenario is that samples are stored at room 
temperature until delivery to the clinic (up to 24 hours), where they are typically immediately stored 
in a freezer. If the metabolic profile of the samples is being determined by NMR spectroscopy then 
samples are often queued in an automatic sample changer to minimize human resources. Depending 
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on the experiments conducted, some of these samples can be left overnight on the sample changer, 
effectively exposing them to a second period of room temperature “storage” if the sample changer 
has no cooling unit. To investigate the stability of urine samples under these conditions, we 
conducted a second experiment that was similar to experiment 1 (n = 32), except that 24 hours of 
storage at -20°C were inserted between the first and second 24 hour periods of storage at room 
temperature (Figure 2.1B, D). 
The metabolites affected in experiment 2 are the same metabolites as in experiment 1. At 
25°C, the changes in metabolic profiles of the urine samples were less pronounced in the samples 
containing either sodium azide or sodium tetraborate when compared to the untreated and sodium 
fluoride containing samples (Figure 2.3, left hand panels). Even though the metabolite profiles of all 
the samples were changing over the first 24 hour period, storing the samples at -20°C for 24 hours 
unsurprisingly minimized any alterations to the metabolite profiles during that period. However, 
metabolite levels started to change again once samples were thawed again and left at 25°C for a 
further 24 hours. For the 30°C samples, the -20°C storage for 24 hours had little impact on 
stabilizing the metabolic profiles of the urine samples with greater alterations especially to acetate 
levels (Figure 2.3, right hand panels). Metabolite profiles changed faster in the samples stored at 
30°C compared to those samples stored at 25°C, especially in the untreated and sodium fluoride 
containing samples.  
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Figure 2.3. Changes in signal intensities of metabolites during experiment 2. 72 hours total storage time split into 
24 hours storage at temperatures of 25°C and 30°C, followed by storage at -20°C for 24 hours, and a second period of 
storage at 25°C or 30°C for 24 hours. Urine samples are from the male and female volunteer and contained different 
preservatives (without preservatives, 0.06% (w/v) sodium azide, sodium tetraborate or sodium fluoride). The color 
coding is identical to Figure 2.2. Each graph represents an aliquot from the same urine samples collected from the 
volunteers. Note the different intensity scales for each preservative treatment. All samples were measured with identical 
experimental parameters, thus signal intensities are comparable across all samples. 
 
Experiment 3: Levels of key metabolites in urine changed as early as 11.5 hours post storage at 
room temperature, even with the addition of preservatives. 
  
In both Experiment 1 and 2 metabolite changes in samples were evident after 24 hours. To 
determine at what time alterations become apparent within these 24 hours we monitored samples 
every half hour for 24 hours (Figure 2.1C, D). Samples were prepared similarly to the first two 
studies (n = 8). For the samples monitored at 25°C, NMR spectra were recorded immediately over 
the 24-hour period, while the 30°C samples were stored at -20°C and measured the next day the 
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same way as the 25°C samples. Metabolite levels that changed noticeably over time are shown in 
Figure 4, and a summary of the results is listed in Table S2.2. During storage at 25°C, only the 
untreated and sodium fluoride containing samples of both volunteers exhibited changes to their 
metabolic profiles over the 24 hour period (Figure 2.4 A, B, M and N) while the other four 
samples (Figure 2.4 E, F, I and J) remained stable. In the untreated sample of the female volunteer, 
concentrations of acetate, TMA and formate increased (Figure 2.4B), while in the female sample 
containing sodium fluoride, only acetate levels increased after 20.5 hours (Figure 2.4N). Acetate 
and formate levels started increasing after 14 and 11.5 hours respectively in the untreated sample of 
the male volunteer (Figure 2.4A). The same metabolites increased in the male sample containing 
sodium fluoride when compared to the untreated sample, with additional increases in the 
concentrations of succinate after 21 hours and TMA after 20.5 hours (Figure 2.4M). 
 Samples containing sodium azide (Figures 2.4E and F) or sodium tetraborate (Figures 2.4I 
and J) remained stable for 24 hours in urine samples of both the male and female volunteers. 
Similarly, the female urine samples containing sodium azide (Figure 2.4H) or sodium 
tetraborate (Figure 2.4L) remained stable for 24 hours at 30°C. 
 When the untreated sample of the female volunteer was stored at 30°C, levels of the same 
metabolites changed that did so at 25°C, but this happened earlier and with a faster rate. In addition, 
ethanol signals became apparent after 18.5 hours (Figure 2.4D). The sodium fluoride-preserved 
sample of the female volunteer also showed increasing levels of formate after 19.5 hours storage at 
30°C (Figure 2.4P). 
 Changes in the metabolite profiles were observed in all samples of the male volunteer after 
24 hours storage at 30°C with the untreated sample exhibiting the most dramatic 
changes (Figure 2.4 and Table S2.2). The levels of all metabolites that changed during storage at 
25°C in the untreated and sodium fluoride-preserved samples of the male volunteer increased at a 
faster rate at 30°C. There was also an increase of the levels of succinate and a decrease in an 
unknown singlet at 3.79 ppm in the untreated sample (Figure 2.4C), while lactate increased in the 
sample containing sodium fluoride (Figure 2.4O). Levels of TMAO decreased during storage at 
30°C in the untreated sample of the male volunteer after 17.5 hours, whereas the sodium azide- or 
tetraborate-preserved samples of the male volunteer were stable for 24 hours at 25°C. At 30°C 
storage, the sodium azide-containing sample of the male volunteer showed a significant increase in 
the levels of acetate, succinate, formate and lactate after 16 hours (Figure 2.4G), and the tetraborate-
preserved sample exhibited increased acetate concentrations after 15 hours (Figure 2.4K). 
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Figure 2.4. Continuous monitoring of changes in metabolite concentrations during 24 hours. Urine samples of the 
male and female volunteer that contained different preservatives (without preservatives, 0.06% (w/v) sodium azide, 
sodium borate or sodium fluoride) were stored at temperatures of 25°C and 30°C. The color coding is identical to 
Figure 2.2. Each graph represents urine samples collected from the volunteers on different occasions. Note the different 
intensity scales for the samples with different preservatives. All samples were measured with identical experimental 
parameters, thus signal intensities are comparable across all samples. 
 
Experiments 4 and 5: A minimum concentration of 100 mM sodium borate is required 
to maintain the stability of urine samples at room temperature for 48 hours.  
The experiments performed so far demonstrate that a concentration of 0.06% (w/v) sodium 
azide or sodium tetraborate is not effective enough to ensure sample stability over 48 hours at room 
temperature. Therefore, we aimed to identify which preservative conditions are able to guarantee 
sample stability over that time period. In the previous experiments, samples containing sodium 
tetraborate showed the best behavior in terms of sample stability. In addition, samples of the male 
volunteer exhibited the most pronounced metabolite profile changes in the experiments described 
above. Thus, we focused on samples of the male volunteer to establish a suitable protocol for 
ensuring sample stability. Stability of urine samples of the male volunteer (n =3) was investigated at 
Unknown (3.79 ppm) 
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2.5% (w/v) sodium tetraborate (262 mM sodium borate), which is the highest possible 
concentration of sodium tetraborate, by monitoring the samples every half hour during storage at 
both 25°C and 30°C for 48 hours. The metabolic profiles of these samples remained stable at both 
temperatures throughout the 48-hour period (Figure S2.3). 
 As this concentration of sodium tetraborate is impractical in routine experiments, we 
investigated the minimum concentration of sodium tetraborate needed to maintain the stability of 
urine samples over 48 hours at room temperature. We added sodium borate ranging in final 
concentrations from 0-200 mM to aliquots of urine samples of both volunteers and measured the 
metabolic profile of those samples after 0 and 48 hours storage at 25°C and 30°C (n = 16). As can 
be seen in Figure 5, in both volunteers, changes in the levels of acetate, ethanol, lactate, formate, 
succinate, TMA and TMAO were still evident after 48 hours in the samples containing 10 to 50 mM 
sodium borate. In contrast, the metabolic profiles of urine samples containing 100 and 200 mM 
sodium borate remained stable when measured after 48 hours storage at both 25°C and 
30°C (Figure 2.5). Therefore, a minimum concentration of 100 mM sodium borate is required to 
maintain the stability of urine samples at room temperature for 48 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Metabolite concentrations after 48 hours storage at 25°C and 30°C as a function of sodium borate 
concentration. A. Male and C. female urine samples stored at 25°C and B. male and D. female samples stored at 30°C. 
Color coding is identical to Figure 2.2. Each graph represents urine samples collected from the respective volunteer on 
different occasions.  
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Effect of borate addition on multivariate analysis 
We also investigated what influence the addition of 100 mM sodium borate had on 
multivariate analysis of urine samples. When samples collected from three different volunteers and 
containing 0 mM and 100 mM borate were analysed with PCA, we found that metabolite profile 
differences due to gender and between different volunteers were more pronounced than sample 
differences due to the addition of borate (Figure 2.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Effect of borate addition on urine NMR spectra. Freshly collected urine samples containing 0 mM and 
100 mM borate, collected from three volunteers (2 males, 1 female) were compared with PCA. (a). PC1 vs PC2 and (b) 
PC3 vs. PC4 scores plots colour coded by borate concentration: blue squares: 0mM, red circles: 100mM borate, (c) PC1 
vs. PC2,and (d) PC1 vs. PC3 scores plots colour coded by gender: blue squares: male, red circles: female, and (e) PC1 
vs. PC2 and (f) PC1 vs. PC3 scores plots colour coded by volunteer: blue squares: 37 year old male,  red triangles: 24 
year old male, green circles: 24 year old female. Systematic sample differences due to gender (in PC1), sample outliers 
(in PC2) or between the volunteers (in PC1 & PC3) were more pronounced than the difference due to borate (in PC4).  
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Discussion 
It is critical in metabonomic studies that the obtained metabolic fingerprint is a true 
reflection of the disease or toxic insult that is being investigated and not distorted due to improper 
sample handling, residual enzymatic activities, chemical transformation of metabolites or bacterial 
contamination [31]. This is especially crucial in a clinical setting where factors such as sample 
collection and storage can be a major source of error for example in field studies or when samples 
are collected in proper hospital conditions. Previously conducted long-term stability studies of urine 
samples recommended that samples be kept at low temperatures (-25 or -80°C) and preservatives 
such as sodium azide be added [10-11,24].  
Ensuring the short-term stability of urine samples over 24 to 48 hours at room temperature is 
important, especially in clinical applications where samples are often collected at home before 
being returned to the clinic, or in studies where samples are left at room temperature on an NMR 
sample changer overnight. Previous studies showed that urine samples stored over a period of 
24 hours at room temperature had minimal variations and remained stable [11]. However, a recent 
study investigating the stability of urine metabolic profile for 24 hours with the addition of 3 mM 
sodium azide showed that the concentrations of acetate and succinate increased with time, 
indicating that even with the addition of preservatives, urine samples are still susceptible to 
bacterial contamination [32].  In the present study, we investigated the stability of human urine 
samples over a 24-hour period stored at different temperatures (25°C and 30°C) and containing 
different preservatives using conditions typically employed in clinical studies.  
Room temperature (25°C or greater) is ideal for bacteria to thrive, and our results together 
with previous studies demonstrate that storing human urine samples at room temperature without 
preservatives will alter their metabolic profiles [10,24]. Increasing the temperature from 25°C to 
30°C also increased the severity of alterations in the samples’ metabolic profiles. Specifically, we 
observed among others, changes in levels of acetate, formate and ethanol i.e. metabolites typical of 
bacterial fermentation. Acetate metabolism commonly occurs in yeasts and bacteria and takes place 
when oxygen is absent and this pathway becomes the main producer of ATP when the TCA cycle is 
not in use. This is commonly observed in spoilage of fishes due to microbial processes.  In a study 
in fishes, it was demonstrated that levels of TMAO and lactate were reduced while levels of acetate 
increased till all the amount of lactate was consumed due to bacterial growth where acetate was 
proposed to be the end product during TMAO reduction into TMA, the chemical responsible for the 
‘fishy smell’ by the bacteria [33].  
Proving the bacterial contamination, LB agar plates streaked with urine containing 
0.06% (w/v) sodium azide exhibited bacterial colonies after 24 hours. These results indicate that 
urine samples, which are usually considered to be sterile, are still susceptible to bacterial 
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contamination. Potential bacteria sources that could contaminate the samples upon collection 
include airborne microorganisms, skin microflora, gut microflora or asymptomatic urinary tract 
infection. In addition, it has been recently shown that the urinary tract of humans is often colonized 
by its own microflora [34,35].  Similar microbiomes were observed in urine and urethral swab pairs 
indicating that urine can contain microbes from the upper urogenital tract and bladder and the 
bacteria found in urine were found to be similar to those commonly residing in the vagina, colon 
and also skin. As there are many possible sources of bacterial contamination, our studies highlight 
that it is important to maintain the stability of urine samples in order to obtain accurate 
interpretations, no matter what the source of bacterial contamination.  
Most importantly, our results indicate that even with the addition of sodium azide or other 
commonly used preservatives at a concentration of 0.06% (w/v), urine samples were still 
susceptible to bacterial growth, suggesting that higher concentrations or different preservatives are 
required to maintain sample stability. This has implications for sample handling and data 
interpretation, as the currently recommended preservative for urine samples is sodium azide at a 
final concentration of 0.05% (w/v) (5.2 mM), a concentration shown in this study and by others 
found to be insufficient for maintaining sample stability [19,32]. In contrast, samples kept at 25°C 
or 30°C for 48 hours with a concentration of at least 100 mM sodium borate, retained their original 
metabolic profile indicating that this concentration of borate is required and sufficient to maintain 
the stability of the sample for that period of time.  
A previous study has investigated the addition of up to 30.73 mM borate to human urine 
samples and found that while borate can cause alteration to the metabolic profile, they are minor 
when compared with individual variations between samples or changes due to bacterial 
contamination and do not influence the outcome of multivariate analysis [12]. In our own study, we 
found the following consequences as a result of adding borate to urine samples. The urine samples 
collected had a pH range of 6.8-7.2. For example, after the addition of 100 mM borate and 
phosphate buffer to a urine sample of pH 6.92, the pH changes to 7.22. The same urine with just 
phosphate buffer added has a pH of 7.29 indicating that with the addition of 100 mM borate, it 
changes the pH of the buffered NMR sample by 0.07 units, which is less than what is caused by the 
variability in the urine samples alone. However, investigating the reduction of a signal to noise ratio 
associated with the addition of sodium borate to the urine samples would be beneficial in future 
studies to further prove that 100 mM of sodium borate is sufficient to maintain the stability of urine. 
Secondly, borate reacts with metabolites containing hydroxyl groups or carboxylates to form 
esters or anhydride adducts. This causes line broadening for some metabolites and additional signals 
or signal shifts for others (Figure S2.4). The changes in signal shape or position due to borate cause 
subtle changes in metabolic profiles that are detectable with multivariate analysis but have only 
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minor consequences. A PCA of urine samples of three volunteers with and without borate in Figure 
2.6 shows that the change in metabolite profile caused by borate addition is less than the difference 
between samples due to gender or differences between the volunteers. Therefore, the effect of 
borate addition on metabonomic analysis was only minor and tolerable, in agreement with the 
findings by Smith et al. [12].  
The fact that a minimum concentration of 100 mM sodium borate is required to ensure 
sample stability also has implications for the interpretation of clinical studies involving human 
urine. If the study design involves both (a) collection human urine under conditions where 
compliance with appropriate urine storage cannot be guaranteed (e.g. 24-hour urine collection by 
participants at home) and (b) the preservative used was either sodium azide or sodium borate at a 
concentration of less than 100 mM, then the stability of the urine samples cannot be taken for 
granted. Consequently, the observation of acetate, ethanol, formate (or any of the other metabolites 
reported above) as significant biomarkers in these studies should be regarded with caution, as they 
might be rather a reflection of insufficient sample stability than an indication of biological change 
in a study cohort. Nonetheless, this current study has shown that a final concentration of 100 mM 
sodium borate is sufficient to provide sample stability and to maintain the quality of data collected 
for metabonomics studies, in cases where samples might have been kept at room temperature for a 
period of time before they were stored frozen.  
Previous similar stability studies have used a small number of subjects and provided 
significant results, indicating that sample stability is affected by temperature and absence of 
preservatives [11-12, 24]. Even though the current study only involved the collection of urine 
samples from two volunteers, a total of 99 samples were collected from them for all the studies 
mentioned above including technical and biological replicates (Table S2.1). These replicates 
provided similar metabolic changes when the samples were left at room temperature with the 
absence or without adequate preservatives. Therefore even with just two subjects in the current 
study, it is evidential that these changes are still significant. While increasing the number of 
subjects would have provided more variation in the composition of urine samples, the two subjects 
in this study were of different gender, had markedly different ages, different ethnic backgrounds 
and lifestyles, and were thus quite disparate.   
 In summary, it has been shown that the recommended standard concentration of 0.06% 
sodium azide is insufficient for optimal sample stability if samples were collected under non-
optimal collection conditions (e.g. collected at home or there were long delays before the samples 
reached the clinic or laboratory). Similarly, the usual concentrations of sodium borate used in 
previous studies have been proven to be insufficient and that a minimum final concentration of 100 
mM is required for sample stability. For optimal sample stability, the following protocol for 
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collection and storage of urine samples should be followed if there is a potential for urine samples 
to be left at room temperature for an extended period of time and that contamination is highly like 
to occur: (1) Urine samples should be collected in containers containing enough solid sodium borate 
to ensure a minimum concentration of 100 mM in the final sample solution. (2) The samples should 
be stored as soon as possible at a maximum temperature of -20°C to minimize bacterial growth, and 
(3) NMR spectra of urine samples should be recorded within 24 hours after thawing the sample. 
This way, even if patients do not comply with storage instructions before delivering samples to the 
clinic, or if the samples are left at room temperature for more than 24 hours, an accurate metabolic 
fingerprint can still be recorded.  
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Materials and Methods 
 
Ethics Statement – Sample Collection 
 Urine samples were provided with written informed consent by a healthy female and male 
adult volunteer, aged 24 and 37 years respectively over a period of 3 years, under ethics approval 
No. 2009001572 of the University of Queensland Medical Research Ethics Committee, which 
specifically approved this study. Midstream morning urine samples were collected in sterile 
collection jars and immediately prepared for NMR measurements or storage. In addition, urine 
samples were also collected from a 24 year old male adult volunteer for the borate experiment in 
Figure 2.6.  
 
Materials 
Deuterium oxide (D2O) was from Cambridge Isotope Laboratories Inc 
(Andover, MA, USA). 2-trimethylsilyl-
2
H4-propionate (TSP), monosodium phosphate 
monohydrate, disodium phosphate octohydrate, sodium azide, sodium tetraborate decahydrate and 
sodium fluoride were from Sigma Aldrich (Castle Hill, NSW, Australia).  
 
NMR Sample Preparation 
 
48 Hour Experiment (Experiment 1) 
For the first experiment, two samples each were collected from both volunteers (Figure 
2.1A). Each urine sample was aliquoted into four Eppendorf tubes (2 technical replicates for each 
temperature) and centrifuged at 13000×g for 10 minutes. A final concentration of either 
0.06% (w/v) (9.2 mM) sodium azide, sodium tetraborate (6.3 mM borate) or sodium fluoride 
(14.3 mM) was added to the samples receiving preservation treatment after centrifugation. In 
addition, untreated samples were also prepared as controls. From each Eppendorf tube two NMR 
samples (= two technical replicates for each temperature) were prepared by aliquotting 445 µl of 
each urine sample into a 5 mm NMR tube together with 55 µl of 0.1 M sodium phosphate buffer 
(pH 7.2), 49 µl D2O and 1 µl of 0.1% (w/v) TSP. In total, n=32 samples were analyzed in 
experiment 1 (Table S2.1). NMR spectra were measured immediately at both 25°C and 30°C 
(0 hours). Samples were then stored in water-baths at 25°C and 30°C respectively for a total of 48 
hours, and NMR spectra were recorded after  24 and 48 hours.  
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72 Hour Experiment (Experiment 2) 
In the second experiment, two samples each were collected from both volunteers to mimic 
how a urine sample is possibly handled in a clinical setting (Figure 1B). Samples were aliquoted 
and prepared similarly to the first experiment (n=32), but after NMR spectra were recorded at 
24 hours, samples were stored at -20°C for 24 hours (thus simulating a sample left left at room 
temperature in a patient’s home and frozen upon receipt in the clinic) before being placed back into 
the water-baths for a further 24 hours (simulating the waiting time in an unthermostatted NMR 
sample changer). 1D NMR spectra were recorded at the end of each 24 hour storage period. In total, 
these samples were monitored for 72 hours.  
 
24 Hour Experiment (Experiment 3) 
 In this experiment, a total of 8 samples each were collected from the male and female 
volunteer over a period of time (Figure 2.1C). Samples were collected and prepared similarly to the 
first two studies. For the samples monitored at 25°C, NMR spectra were recorded immediately 
every half hour for 24 hours, while the 30°C samples were stored at -20°C and measured the next 
day.  
 
Borate as Preservative (Experiment 4) 
To test the suitability of sodium tetraborate as preservative, two separate experiments were 
conducted to test the stability of male urine samples for an extended period of 48 hours. In 
experiment 4 (n = 3) we tested the highest possible concentration of sodium borate, of 2.5% (w/v) 
sodium tetraborate (262 mM borate). Urine samples form the male volunteer were centrifuged at 
13000×g for 10 min and aliquotted into tubes containing enough solid sodium tetraborate to yield 
the highest possible concentration. NMR spectra were recorded every half hour for 48 hours at 
25°C and at 30°C. The 25°C samples were measured immediately, while the 30°C samples were 
stored at -20°C, and NMR spectra were recorded in a similar fashion two days later.  
 
Borate Concentrations Experiments (Experiments 4 and 5) 
 To determine the minimum borate concentration required to maintain the stability of urine 
samples, we used urine sample from both the male and female volunteer. Urine samples were 
centrifuged at 13000×g for 10 minutes and aliquoted into tubes containing sodium tetraborate 
yielding final borate concentrations of 10 mM, 20 mM, 30 mM, 50 mM, 100 mM, 150mM or 
200 mM, or no sodium borate at all (n=16). Samples were prepared the same way as in 
experiment 1. Samples were then measured immediately (0 hour) and after 48 hours storage at 25°C 
and 30°C, respectively.  
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NMR Spectroscopy 
All NMR spectra were measured on a Bruker AV500 NMR spectrometer 
(Bruker Biospin, Germany) equipped with a 5 mm self-shielded z-gradient triple resonance probe. 
Proton 1D NOESY spectra were recorded using the standard noesypr1d pulse sequence with 
128 scans and 32k data points over a spectral width of 14 ppm. The carrier frequency was set to the 
water resonance which was suppressed by low-intensity continuous wave irradiation during the 
mixing time of 100 ms and the relaxation delay of 2.3 s. The spectra were measured at probe 
temperatures of 298 K (25°C) or 303 K (30°C), respectively. For experiments 1, 2 and 5, spectra 
were recorded at 0 hours storage time and then after every 24 hours of storage. For experiments 3 
and 4, 1D spectra were recorded every half hour for 24 and 48 hours, respectively. 
 
NMR Analysis 
Data Processing 
Prior to analysis, spectra were Fourier transformed, manually phased and baseline corrected, 
and chemical shifts were referenced to TSP using Topspin (Bruker Biospin, Germany). 1D spectra 
of samples were compared to each other to identify any significant differences. The signal intensity 
as a function of time was plotted for each metabolite whose concentration markedly changed over 
the time period of the respective experiment.   
 
Principal Components Analysis 
PCA was performed on untreated and samples treated with 100 mM sodium tetraborate at 
both 25°C and 30°C from both volunteers to evaluate the metabolic differences in the NMR spectra 
over time and effect of sodium tetraborate on the samples. In addition, urine samples from a third 
male volunteer were also added to the analysis. 1D NMR spectra were measured as described above 
at 25°C, divided in the program Amix (Bruker Biospin, Germany) into integral regions of 0.04 ppm 
width (called buckets) between the range of δ= 10 – 0.25 ppm. The regions from δ=4.7 – 5.15 ppm 
and δ= 5.2 – 6.3 ppm were excluded to prevent variations in the water and urea signals from 
affecting the analysis, resulting in 245 buckets. PCA was performed with SIMCA P+ 12.0.1 
(Umetrics, Sweden) using the data reduced spectra with Pareto scaling. Classification was 
performed by assigning different colour codes to each group of spectra to determine whether there 
are systematic differences between them.  
 
Identification of Metabolites 
Metabolites present in the 1D spectra were identified and confirmed by comparing their 
chemical shifts and coupling patterns to data deposited in the Biological Magnetic Resonance Data 
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Bank (http://www.bmrb.wisc.edu) and the Human Metabolome Database (http://www.hmdb.ca). In 
addition, metabolites were also identified with Chenomx NMR Suite 7.1 (Chenomx Inc, Edmonton, 
Alberta, Canada). 
 
Microbiology 
A male urine sample prepared with 0.06% (w/v) (9.2 mM) sodium azide was streaked onto 
LB agar plates (3 replicates) and incubated overnight at 37°C to investigate whether bacterial 
contamination was present. For comparison, LB agar plates streaked with the same urine samples 
that were left untreated and also unstreaked control plates were incubated overnight.   
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Supplementary Information 
 
*Table S2.1: Summary of the number of urine samples collected for 
the study (Experiments 1 - 5) 
Experiment No. of samples 
collected from 
subjects 
No. of 
aliquots 
Total no. of 
samples 
1 Male - 2 4 treatments 
x 2 technical 
replicates 
16 
Female - 2 16 
2 Male  - 2 16 
Female - 2 16 
3 Male – 8 None 8 
Female - 8 8 
4 Male - 3 3 
5 Male - 1 8 treatments 8 
Female - 1 8 
Grand total no. of samples 99 
*1 male and 1 female subject were recruited for this study however, their urine samples were collected over different occasions as shown in the table 
above. Total number of samples collected was 99. 
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^Table S2.2: Summary of results of male and female urine samples under different room temperatures and preservative treatments 
(Experiment 3). 
MALE FEMALE 
Untreated 25 °C Fold 
Change 
30 °C Fold 
Change 
Untreated  25 °C Fold 
Change 
30 °C Fold 
Change 
Acetate *14 hr ↑ 3.8 6.5hr ↑ 21.3 Acetate  18hr ↑ 6.87 13hr ↑ 66.46 
Ethanol - - - - Ethanol  - - 18.5hr ↑ 10.87 
Succinate - - 15 hr ↑ 6.78 Succinate  - - 17hr ↑ 6.49 
Trimethylamine - - 18.5hr ↑ 35.33 Trimethylamine 20hr ↑ 13.38 17.5hr ↑ 19.75 
Trimethylamine-
oxide 
- - 17.5hr ↓ 10.92 Trimethylamine-
oxide 
- - 18hr ↑ 89.22 
3.79 ppm - - 18hr ↓ 4.25 3.79 ppm  - - - - 
Formate 11.5hr ↑ 2.73 6hr ↑ 11.3 Formate  18hr ↑ 4.04 14.5hr ↑ 24.98 
Lactate - - - - Lactate  - - - - 
0.06% Sodium 
Azide 
25 °C Fold 
Change 
30 °C Fold 
Change 
0.06% Sodium 
Azide 
25 °C Fold 
Change 
30 °C Fold 
Change 
Acetate - - 16hr ↑ 3.70 Acetate  - - - - 
Ethanol - - - - Ethanol  - - - - 
Succinate - - 16.5hr ↑ 2 Succinate  - - - - 
Trimethylamine - - - - Trimethylamine - - - - 
Trimethylamine-
oxide 
- - - - Trimethylamine-
oxide 
- - - - 
3.79 ppm - - - - 3.79 ppm  - - - - 
Formate - - 18hr ↑ 2.5 Formate  - - - - 
Lactate - - 16.5hr ↑ 3.08 Lactate  - - - - 
0.06% Sodium 
Borate 
25 °C Fold 
Change 
30 °C Fold 
Change 
0.06% Sodium 
Borate 
25 °C Fold 
Change 
30 °C Fold 
Change 
Acetate - - 15hr ↑ 3.26 Acetate  - - - - 
Ethanol - - - - Ethanol  - - - - 
Succinate - - - - Succinate  - - - - 
Trimethylamine - - - - Trimethylamine - - - - 
Trimethylamine-
oxide 
- - - - Trimethylamine-
oxide 
- - - - 
3.79 ppm - - - - 3.79 ppm  - - - - 
Formate - - - - Formate  - - - - 
Lactate - - - - Lactate  - - - - 
0.06% Sodium 
Fluoride 
25 °C Fold 
Change 
30 °C Fold 
Change 
0.06% Sodium 
Fluoride 
25 °C Fold 
Change 
30 °C Fold 
Change 
Acetate 15hr ↑ 19.04 12hr ↑ 32.53 Acetate  20.5hr ↑ 10.02 16hr ↑ 3.36 
Ethanol - - - - Ethanol  - - - - 
Succinate 21hr ↑ 5.32 15hr ↑ 9.91 Succinate  - - - - 
Trimethylamine 20.5hr ↑ 8.25 16.5hr ↑ 27.87 Trimethylamine - - - - 
Trimethylamine-
oxide 
- - - - Trimethylamine-
oxide 
- - - - 
3.79 ppm - - - - 3.79 ppm  - - - - 
Formate 19hr ↑ 7.04 13.5hr ↑ 16.78 Formate  - - 19.5hr↑ 2 
Lactate - - 17hr ↑ 2 Lactate  - - - - 
 
 
Table S2.2. Metabolites that were observed to be altered in the respective male and female metabolic profiles are listed 
in this table. ↑ indicates an increase in the levels of particular metabolite, ↓ indicates a decrease, and –indicates no 
change. The quantity of change is measure by the fold change in the signal intensity as shown. Measurements are based 
on the intensity of the NMR signal of the corresponding metabolites. 
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Figure S2.1. Overlay of 0hr (blue) and 48hr (red) 1D NMR spectrum of untreated male sample at 25°C. A. 
Spectrum from 0 – 2 ppm showing ethanol and acetate signals increasing after 48 hours, B. 2 – 4.5 ppm showing 
increase in acetate, succinate and TMA signals and decrease in TMAO signal and C. 6.5 – 8.5 ppm an increase in 
formate signal after 48 hours storage at 25°C. 
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Figure S2.2. LB agar plates streaked with male urine incubated at 37°C. Top row: control plates (no sample 
added), middle row: plates streaked with male urine sample (untreated) and bottom row: plates streaked with male urine 
sample containing 0.06% (w/v) sodium azide. White bacterial colonies observed growing on agar plates containing 
untreated and 0.06% (w/v) sodium azide urine samples after 24 hours in the 37°C incubator. The number of colonies 
observed was much lesser in the sodium azide plates compared to the untreated ones but it still proves that bacteria were 
growing despite the presence of 0.06% (w/v) sodium azide in the male urine sample.  
 
 
Figure S2.3. Metabolite changes in male urine samples after addition of 2.5% (w/v) sodium tetraborate (262 mM 
borate) during 48 hours storage A. at 25°C and B. at 30°C. Both samples remained stable for 48 hours storage at 
25°C and 30°C after the addition of the maximum possible concentration of sodium tetraborate. Acetate: filled red 
circles, formate: open green diamonds, succinate: filled orange triangles, TMA: filled blue squares and TMAO: open 
blue squares.  Each graph represents urine samples collected from the male volunteer on different occasions. * The 
acetate signals are considered to be insignificant even though it is increasing in these graphs because the signal is being 
blown up. When compared to the intensities of acetate in the other studies, the intensities are considered to be smaller.  
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Figure S2.4. Chemical shifts of NMR signals with the addition of 100 mM borate at 25 and 30°C. A and B – 
lactate, C and D – citrate, E and F – mannitol and G – J – methylmallonate. Signals of respective metabolite represented 
by arrows or black lines. Change in lactate signals (doublet) is due to ageing process however considered to be 
insignificant as the change in intensity is smaller compared to the intensity of lactate signals of other concentrations of 
borate. 
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2.9 Additional Work on Chapter 2 
2.9.1. Additional Figures to the work presented in the manuscript 
The following figures were not included in the manuscript, but provide additional useful 
information: 
Figures 2.7 and 2.8: The stack plots show the change in the intensities of acetate, formate, TMA and 
ethanol. Signals of these metabolites start to increase when untreated and 0.06% sodium fluoride 
urine samples were stored at 25°C and 30°C during the 24 hour study.   
Figure 2.9: The overlay between 0 hour (red) and 24 hour (blue) untreated samples at 25°C showed 
metabolite such as acetate, formate, ethanol, TMA and TMAO changing their signal intensities after 
24 hours.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Stack plots of urine samples with 0.06% sodium fluoride measured at 25°C and 30°C over a period of 
24 hours. Acetate appeared in the (a) sample stored at 25°C after 20.5 hours and after 16 hours in the (b) sample stored 
at 30°C after 13 hours. (c) Formate increased only in the sample stored at 30°C after 19.5 hours. 
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25°C ACETATE 
20.5hr 
(a) (b) 
30°C ACETATE 
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Figure 2.8: Stack plots of untreated urine samples measured at 25°C and 30°C over a period of 24 hours. Acetate 
(a) and formate (c) appeared in the sample stored at 25°C after 18 hours. (b) Acetate increased in the sample stored at 
30°C after 13 hours. (d) Formate appeared in the sample stored at 30°C after 14.5 hours. (e) Trimethylamine appeared 
in the sample stored at 25°C after 20 hours and after 17.5 hours in the (f) sample stored at 30°C. (g) Ethanol signals 
appeared after 18.5 hours only in the sample stored at 30°C. 
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Figure 2.9: Overlays of a 0hr (red spectrum) with a 24hr (blue spectrum) untreated male sample stored at 25°C 
A. between 0.9 – 2 ppm, B. 2 – 4 ppm and C. 6.5 – 8.5 ppm showing changes in intensities of metabolites after 24 
hours of storage.  
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2.9.2. Ageing effects of urine samples stored at -20°C 
 Previously, it has been shown in the manuscript that metabolic profiles of urine samples 
are susceptible to changes when they are left at room temperature without adequate preservatives. 
In addition to the work presented in the manuscript, we have also investigated a few other effects 
that were not included in the manuscript. One of those studies investigated the effect of storage 
at -20°C for 24 hours with and without preservatives on the metabolic profile of the urine sample.  
Methods 
 First morning urine samples were collected from a healthy 23 year old female volunteer 
on four different occasions and aliquoted into different tubes with or without different preservatives 
added (Preparation was similar to those samples prepared in the manuscript). NMR spectra of the 
samples were recorded at 0 hr, the samples were then stored at -20°C for 24 hours, after which a 
second set of NMR spectra, was recorded (probe at 25C) to investigate any changes in the 
metabolic profile of the urine samples.  
Results 
 A shift in the position and changes in the intensities of several signals were observed in 
the -20°C untreated sample and the sample containing 0.06% sodium fluoride after 24 hours (Figure 
2.10 a and d).  The metabolic profiles of the samples containing 0.06% sodium azide or 0.06% 
sodium borate remained stable, without any appearance of additional metabolites during the 24 hour 
period of -20°C storage. These results showed that preservatives such as sodium azide and sodium 
borate should also be added to inhibit bacterial growth in urine samples that are stored at -20°C. 
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Figure 2.10: Overlay spectra of 
0 hour (red) and 24 hours 
(blue) urine samples. (a) An 
unknown metabolite at 2.16 ppm 
decreased significantly after 24 
hours in the untreated sample. 
The urine samples remained 
stable in both the (b) 0.06% 
sodium azide and (c) 0.06% 
sodium borate samples. (d) The 
signals were observed to have 
shifted and there were changes 
to the intensities of the signals 
after 24 hours in the sample that 
contained 0.06% sodium 
fluoride.  
Untreated 
Red – 0hr  
Blue – 24hr 
Unknown metabolite 
at 2.16ppm 
decreased 
significantly after 24 
hours 
0.02% Sodium Azide  
0.02% Sodium Borate 
0.06% Sodium 
Fluoride 
Shifts in signals 
and changes to 
signal intensities 
after 24 hours 
(d) 
(c) 
(a) 
(b)
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2.9.3. The ideal pH for phosphate buffers to maintain stability of urine samples  
 As is the case with several other metabolites, the chemical shifts of the creatine and 
creatinine signals are sensitive to pH changes in urine and pH-related changes in the position of 
these signals will thus affect the accuracy of measuring these metabolites in samples. Phosphate 
buffer is usually added to urine samples to maintain a stable pH in metabonomic studies. However, 
different pH values (between 6-7.4) and concentrations of phosphate buffers have been used in 
various published metabonomic studies that used urine samples (Gavaghan et al., 2000; Lauridsen 
et al., 2007; Parsons et al., 2007; Robertson et al., 2000). For this reason, this experiment 
determined the ideal pH of phosphate buffer to guarantee the stability of key signals such as 
creatine and creatinine in human urine samples by titrating a human urine sample and following the 
changes in the chemical shift of creatine and creatinine. 
 
Methods  
A first morning urine sample was collected from a 23 year old healthy female volunteer and 
the original pH was recorded. A 1D spectrum of the sample was measured. Then 1 l of sodium 
hydroxide or 1 l of hydrochloric acid were added to the sample at a time, the new resulting pH 
recorded (range of pH 6.2 – 8.35), and the sample remeasured on the NMR spectrometer after each 
titration step. 
 
Results 
 On an average, the chemical shifts of all four signals of creatine and creatinine remained 
fairly constant in the ranges of pH 7.2 – 7.4 (Figure 2.11). Therefore, it can be concluded that using 
a phosphate buffer at pH 7.4 is best for maintaining the signals of creatine and creatinine stable in 
human urine samples. Accordingly, most metabonomic studies involving urine samples either use 
phosphate buffer at pH 7, 7.2 or 7.4.   
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Figure 2.11: Plots of the shifts in the creatine and creatinine signals for pH 6 – 8.4 in human urine samples. The 
(a) creatine methylene signal stabilized between pH 6.8 – 7.45 while the (b) creatine methyl signal stabilized between 
pH 7.25 – 7.7. The (c) creatinine methyl signal stabilized between pH 7.25 -7.5 while the (d) creatinine methylene 
signal stabilized between pH 7.25 – 7.7.  
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Objective: Growth hormone (GH) is a protein hormone with important roles in growth and metabolism. The
objective of this studywas to investigate themetabolismof a human subjectwith severe GHdeficiency (GHD) due
to a PIT-1 genemutation and themetabolic effects of GH therapy usingNuclearMagnetic Resonance (NMR)-based
metabonomics. NMR-basedmetabonomics is a platform that allows themetabolic profile of biological fluids such
as urine to be recorded, and any alterations in the profile modulated by GH can potentially be detected.
Design:Urine sampleswere collected from a female subjectwith severeGHDbefore, during and after GH therapy,
and from healthy age- and sex-matched controls and analysed with NMR-based metabonomics.
Setting: The samples were collected at a hospital and the study was performed at a research facility.
Participants: We studied a 17 year old female adolescent with severe GHD secondary to PIT-1 gene mutation
whohad reachedfinal adult height andwhohad ceasedGH therapy for over 3 years. The subjectwas subsequently
followed for 5 years with and without GH therapy. Twelve healthy age-matched female subjects acted as control
subjects.
Intervention: The GH-deficient subject re-commenced GH therapy at a dose of 1 mg/day to normalise serum IGF-1
levels.
Main outcome measures: Urine metabolic profiles were recorded using NMR spectroscopy and analysed with
multivariate statistics to distinguish the profiles at different time points and identify significant metabolites
affected by GH therapy.
Results: NMR-based metabonomics revealed that the metabolic profile of the GH-deficient subject altered with
GH therapy and that her profilewas different fromhealthy controls before, and duringwithdrawal of GH therapy.
Conclusion: This study illustrates the potential use of NMR-based metabonomics for monitoring the effects of
GH therapy on metabolism by profiling the urine of GH-deficient subjects. Further controlled studies in larger
numbers of GH-deficient subjects are required to determine the clinical benefits of NMR-based metabonomics
in subjects receiving GH therapy.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Growth hormone (GH) is an anabolic hormone consisting of a
191-amino acid, single-chain protein that plays an important role in
growth, cell reproduction and regeneration [1]. Somatotroph cells
found in the anterior pituitary gland are responsible for the synthesis,
secretion and storage of GH [2]. Factors that stimulate the secretion
and release of GH include the presence of the peptide hormone ghrelin,
increased secretion of sex hormones during puberty, deep slow-wave
sleep, fasting and vigorous exercise [3]. In contrast, GH release is
inhibited when there is a high circulating concentration of GH and
insulin-like growth factor-1 (IGF-1) which works as negative feedback
on the pituitary and hypothalamus [4].
GH plays a major role in linear body growth and organ growth
during childhood. This is achieved by regulation of bone growth
through induction of chondrocyte proliferation in cartilage and oste-
oblast proliferation in bone [5]. The other major function of GH in
the body is the regulation of metabolism. GH stimulates lipolysis
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and ketogenesis to stimulate the breakdown of triglycerides and in-
creases levels of free fatty acids (FFA) and ketone bodies in the
blood [6,7]. GH has an anabolic effect in skeletal muscles increasing
amino acid uptake, protein synthesis and decreasing protein oxida-
tion [6,7]. In addition, GH is also involved in maintaining blood glu-
cose levels by inhibiting glucose uptake in peripheral tissues and
decreasing glucose oxidation which in turn enhances gluconeogene-
sis in the liver [6–10]. The actions of GH on target tissues are either
direct through the GH receptor or through induction of IGF-I.
Congenital GHD in children can arise from genetic conditions
that interfere with pituitary development and if left untreated results in
severe short stature [11]. The effects of GHD (GHD) on growth, body com-
position andmetabolism canbe treatedwith replacement therapy in chil-
dren and in adolescents, and GH treatment in adults with GHD has been
advocated for general well-being and prevention of osteoporosis and car-
diovascular disease [12]. In adolescents who have reached final height or
in adult subjects with GHD withdrawal of GH therapy leads to adverse
changes on body composition and increases cardiovascular disease and
metabolic disease risk factors [13,14]. GH therapy in adolescents and
adults with GHD reduces fat mass, increases lean mass and bone density,
improves lipid profile and psychosocial well-being [15–17].
Pituitary-specific positive transcription factor (PIT)-1 (POU1F1) is
important for normal anterior pituitary gland development. A defect
or mutation of PIT-1 will result in the failure of GH production and
other hormones [18]. PIT-1 belongs to the POU homeodomain family
of transcription factors. The PIT-1 gene is located on chromosome
3p11-12, contains 6 exons and encodes a protein consisting of 291
amino acids [19–21]. PIT-1 regulates the gene expression of GH, prolactin
(PRL) and thyroid stimulating hormone (TSH) and is responsible for the
development of somatotrophs, lactotrophs and thyrotrophs [18–21].
Studies in humans with GH, PRL and TSH deficiencies or combined pitui-
tary hormone deficiency (CPHD) where production of GH is impaired,
have been shown to harbour PIT-1 mutations and present with severe
growth failure during childhood with hypothyroidism [22–24].
Nuclear Magnetic Resonance (NMR)-based metabonomics uses
NMR spectroscopy to measure metabolite concentrations in biofluids
such as urine and plasma. Metabonomics provides both qualitative
and quantitative analysis of the dynamic multiparametric metabolic
response of living systems to pathophysiological stimuli or genetic
modifications [25]. This means any abnormality resulting from dis-
ease or other metabolic insults will be reflected in altered biofluid
compositions. Thus, identification of significantly different metabo-
lites in these altered biofluids could potentially provide a clearer
picture of the metabolic processes involved in a particular disease
or toxic state. Metabonomics describes the ultimate end point of po-
tential changes suggested by genomics and proteomics [26].
Metabonomics has been utilised effectively in both animal and
human clinical studies and has aided in the understanding of physiolog-
ical variations, disease progression and drug toxicity by analysing
biofluid spectral patterns [27–35]. In particular, we showed that GHD
mice with a truncation of the intracellular domain of the GH receptor
that leads to impaired STAT5 signalling provided insights into the meta-
bolic pathways that were associated with severe GHD [33]. With ad-
vancements in instrumentation and software for studies involving
clinical metabonomics, an accurate snapshot of a subject's health status
can be obtained at any particular point in time by investigatingmetabolic
fingerprints of body fluids or tissues collected from subjects. Ultimately,
the aim is to utilise metabonomics as a clinical tool to help predict the
health status and disease risk in an individual in a personalised manner.
In addition, metabonomics data can be used to monitor and predict the
efficacy of a particular therapy in a patient. This means that
metabonomics plays an important role in personalising all three areas
of medical patient management: diagnosis, prognosis and theranosis.
In the present study, we investigated the effects of GH therapy
on body composition and metabolism in a 17 year old subject with
severe GHD secondary to a PIT-1 gene mutation [36]. The subject,
who had reached final adult height, re-initiated GH therapy after a
3 year period without GH therapy. This presented a unique clinical
research opportunity to use NMR-based metabonomics to examine
the effects of GH therapy on metabolism in a human subject with
GHD compared to age and sex-matched healthy controls.
2. Material and methods
2.1. Subjects
Parents and subjects gave written informed consent and assent
prior to participation in this study. The study was approved by the
Mater Health Services Human Research Ethics Committee and the
University of Queensland Medical Research Ethics Committee.
2.2. The patient
The patient, a 17 year-old female, was born at 42 weeks gestation
to non-consanguineous Caucasian parents of normal stature. Her birth
weightwas 3100 g (10–25th centile), and length at 15 dayswas 46 cm
(b1st centile). She initially presented at 37 days of age with failure-
to-thrive, poor growth and hypotonia. Central hypothyroidism was
diagnosed [T3 0.54 nmol/L (normal range (NR): 1.3–2.8); free T4 2.4
pmol/L (NR:10–23); Thyroid Stimulating Hormone (TSH) 1.77 mU/L
(NR:0.1–5.0)]. Thyroxine hormone therapy was commenced from
6 weeks of age. Inadequate catch-up growth prompted investigation
of her GH axis by insulin-arginine and GH-Releasing Hormone (GHRH)
stimulation testing, which confirmed the patient had severe GHD with
a peak GH of b1 μg/L and 3.6 μg/L respectively. Magnetic Resonance
Imaging (MRI) of her hypothalamus and pituitary gland confirmed
the presence of a hypoplastic pituitary gland. GH therapy was com-
menced at 6 months of age and continued to near final adult height
with excellent catch-up growth observed (Fig. 1).
The cause of the patient's GH, TSH, and prolactin deficiencies was
confirmed by PIT-1 gene mutation testing using Genomic DNA PCR
analysis on peripheral blood leucocytes. The patient was demonstrated
to be a compound heterozygotewith previously describedmutations in
the PIT1 gene including a (G>T) mutation at nucleotide 428 (Exon 3)
resulting in an amino acid substitution of arginine 143 to lysine
inherited from her mother plus a (T>A) mutation at nucleotide 581
(Exon 4) resulting in an amino acid substitution of leucine 194 to
glutamine inherited from her father [11].
GH therapywas continued until the age of 13 years 7 months when
nearfinal heightwas reached and her bone agewas 13.5 years. Puberty
and menarche progressed unremarkably. After cessation of GH treat-
ment the subject suffered from chronic lethargy which was attributed
to her severe GH-deficient state as evidenced by very low IGF-1 levels
(Table 1). Thus, at 17 years of age, after having been without GH
therapy for more than 3 years, a 12-month trial of rhGH (SciTropin™)
therapy was commenced (GH supplies kindly provided by SciGen,
Australia) — initially at 0.5 mg daily in the first three months and
thereafter at a dose of 1.0 mg daily. These symptoms improved signif-
icantly on recommencement of GH therapy.
Prior to the commencement of rhGH therapy, the subject was
assessed at 17 years age and subsequently reviewed every 3 months
for a year during therapy and then annually over the subsequent
5 years. As part of the study, the subject voluntarily withdrew GH
treatment for a 2 month period during the 4th year after which
blood and urine samples were obtained and further samples collected
after a year of further GH therapy (Table 1). Throughout the study pe-
riod she received adequate thyroid hormone replacement and
remained clinically and biochemically euthyroid.
2.2.1. Auxology
Weight (electronic scales to the nearest 10 g), height (using a
Harpenden stadiometer to the nearest millimetre), and waist
30 S. Abd Rahman et al. / Growth Hormone & IGF Research 23 (2013) 29–36
circumference (immediately above the iliac crest, WC4: National
Institute of Health, NIH and National Health and Nutrition Examina-
tion Survey III, NHANES III) were measured at each of the assessment
intervals. Body Mass Index (BMI) was calculated using the standard
formula, weight (kg)/height (m).
2.2.2. Biochemical parameters
Free T4 andTSH levelsweremeasuredusing an enzyme immunoassay
(AXSYM & Architect i2000SR, Abbott Australasia, Lane Cove, Australia).
IGF-I was measured using a competitive binding radioimmunassay
(Mater Health Services Laboratory, South Brisbane, Australia). IGFBP3
Fig. 1. Height chart (0–21 years) showing growth of GHD subject correlated with commencement and cessation of GH therapy while on T4 (Father — father's height, Mother —
mother's height, MPH — mid parental height). Lower right inset shows height chart from 0 to 4 years with improved growth of subject with GHD after commencement of thyroxine
and GH therapy. Percentile lines for the 99.6th, 98th, 91st, 75th, 50th, 25th, 9th, 2nd, and 0.4th percentile (from top to bottom, respectively) are indicated in both sections of the figure.
Table 1
Auxology, biochemical parameters and body composition of GH-deficient subject over a period of 5 years on and off GH therapy.
0 months 1 months 3 months 6 months 9 months 12 months 24 months 36 months 47 months 48 months 60 months
Growth hormone dose (1 mg/day) 0 0.5 1 1 1 1 1 1 0 0 1
Anthropometry
Weight (kg) 62 61.5 60.9 60.8 55.1 53.2 55.3 55.8 54.2 52.4 56.8
Height (cm) 158 158 158 158 158 158.3 158.7 158.9 158 158 159
BMI (kg/m2) 24.8 24.6 24.4 24.4 22.1 21.2 22 22.1 21.7 21 22.5
Waist circumference (cm) 97 96 94 90 88 84 83.5 83.5 73 74 81
Biochemical parameters
IGF-1 (nmol/L) NR 20-55 7.7 16 41 33 ND 48 33 27 9.4 b3.5 40
IGFBP3 (nmol/L) NR 75-140 56 110 179 145 ND 214 151 ND ND ND ND
Prolactin (mIU/L) NR 80-800 b11
TSH (mU/L) NR 0.1-5.0 b0.03 b0.03 b0.01 b0.01 b0.01 b0.01 b0.01 b0.01 b0.01
Free T4 (pmol/L) NR 9-25 21.0 14.4 21.5 20.9 16.3 23.6 19.8 21.6 18.5
Body composition (BIA and DXA)
BIA
Fat free mass (FFM) (kg) 40.6 42.1 41.7 39.0 39.5 38.1 36.3 39.6
Fat mass (kg) 20.1 18.8 18.9 16.1 14.0 16.1 16.1 17.2
% total body fat (%) 33.1 30.9 31.2 29.3 26.2 29.6 30.6 30.2
Whole body DXA
% fat (total) 45.0 36.1 37.7 39.9
% fat (legs) 45.2 36.5 39.2 43.0
% fat (trunk) 49.4 38.6 39.3 41.4
Whole body BMD (g/cm2) 1.22 1.23 1.25 1.29
Whole body BMD (Z score) 1.30 1.50 2.0 2.5
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wasmeasured using an IGFBP-3 immunoradiometric assay (Diagnostic
Systems Laboratories, Webster, USA) and Immulite 2000 analyser
(Bio-Mediq DPC/Siemens Medical Solutions Diagnostics, Tarrytown,
USA). Prolactin was measured using Immulite 2000 (Bio-Mediq DPC/
Siemens Medical Solutions Diagnostics, Tarrytown, USA).
2.2.3. Body composition
Total body composition by Dual Energy X-ray Absorptiometry
(LUNARProdigy, GEMedical Systems, Diegem, Belgium)wasperformed
at baseline and at 12, 24 and 60 months after recommencement of rhGH
therapy (Table 1). We also assessed body composition by bioelectrical
impendence analysis (BIA) using the BodyStat 1500® and calculated
fat freemass (FFM) and total body fat% using published algorithms val-
idated in adolescent females followed prospectively [37].
2.2.4. Urine metabonomic profile
2.2.4.1. Normal control subjects. First morning urine samples were col-
lected from 12 healthy female adolescents and young adults between
17 and 21 years of age. These adolescents and young adult females
were healthy, of normal height, weight and BMI, had no serious med-
ical history and were not taking any medications.
2.2.5. Sample collection of GHD subject
First morning urine samples were collected from the subject be-
fore starting GH therapy, and regularly over a total time period of
5 years, as described above. For each time point, one sample was col-
lected per day over a period of two to three days (Table 1).
2.2.6. Urine sample treatment and preparation
Samples were collected in standard plastic container jars containing
0.05% (w/v) sodium azide, immediately frozen, and transported back
to the laboratory for storage in a -20 °C freezer until analysis was
performed. Before analysis, samples were thawed at room tempera-
ture. Sample preparation included the addition of 55 μl sterile filtered
(0.22 μm) 1 mol/L sodium phosphate buffer (pH 7.4) to 445 μl of each
sample to keep the sample pH constant. All sampleswere supplemented
with 49 μl of D2O as lock substance, as well as 1 μl of 35.92 mM
2-trimethylsilyl-2H4-propionate (TSP) in D2O for chemical shift
referencing.
2.3. NMR spectroscopy
NMR spectra of the urine samples were recorded on a Bruker
AV500 NMR spectrometer (Bruker Biospin, Germany) equipped with
a 5 mm self-shielded z-gradient triple resonance probe. All spectra
were recorded at 298 k with 256 scans and 32 k data point resolution
over a spectral width of 10 ppm, and the carrier frequency was set
to the water resonance. Proton 1D spectra were measured using the
noesypr1d pulse sequence. Low-power continuous irradiation of the
water resonance during the NOESY mixing time of 100 ms and the
relaxation delay of 2.3 s were used to ensure solvent suppression of
thewater signal. The various samplesweremeasured in several batches
during the 5 years of the study.
2.4. Data processing
Prior to analysis, all spectra recorded were Fourier transformed
to 32 k data points, manually phased and baseline corrected, and
chemical shifts were referenced to TSP using Topspin (Bruker, Biospin,
Germany).
2.5. Data reduction
Prior to performing multivariate statistical analysis, the 1D spectra
were divided in the program Amix (Bruker Biospin, Germany) into
integral regions of 0.04 ppm width (called buckets) between the range
of δ=10–0.2 ppm. The regions from δ=4.6–5.0 ppm and δ=5.5–
6.5 ppm were excluded to prevent variations in the water and urea
signals from affecting the analysis. In addition, the regions from δ=
1.15–1.20 ppm, δ=3.55–3.75 ppm, δ=1.90–1.95 ppm and δ=8.35–
8.55 ppm, containing signals of ethanol, acetate and formate were
excluded from the analysis, as these signals typically arise as a result
from sample ageing e.g. due to bacterial contamination when samples
were stored at room temperature without added preservatives such as
sodium azide or sodium tetraborate. NMR signals were integrated for
each region and normalised to total spectral intensity in all integral
regions.
2.6. Principal Components Analysis (PCA)
Unsupervised PCA was performed with SIMCA P+12 (Umetrics,
Sweden) using the data reduced spectra (245 buckets) with pareto
scaling, and the analysis yielded 5 latent components (R2X: 0.727,
Q2X: 0.228). The scores plots of PCs 1 to 5 were inspected for inherent
differences between the sample groups, and PC1 versus PC2 provided
the best separation between the groups. Buckets that showed the
strongest influence were indentified in the loadings plot of PC1 versus
PC2 to allow identification of the associated metabolites.
2.7. Partial Least Squares (PLS) analysis
To extract more information, supervised PLS was carried out in
Simca P+(Umetrics) using the same data set and parameters used
for PCA. Group identity and age of each sample (Table S1) were
used as Y table (with univariate scaling) in the analysis, (0=being
without GH therapy; 1=during GH therapy). The “during GH therapy”
assignment was also used for the healthy control samples, as it was
assumed that the metabolic profile of the patient during therapy was
closer to a ‘normal’metabolic profile than during timeswithout therapy.
The PLS analysis yielded 3 latent components (R2X: 0.394, Q2: 0.258,
R2Y: 0.715). PLS was validated by running a cross-validated permuta-
tion analysis, based on 200 permutations, to show that the estimated
R2 and Q2 for all permuted models were lower than the corresponding
values for the original model. The scores plots of t1 to t3were examined
and t1 versus t2 provided the best separation between the groups.
2.7.1. Metabolite identification
The metabolites present in the 1D NMR spectra were identified by
comparing their chemical shifts and coupling patterns to data deposited
in the Biological Magnetic Resonance Data Bank (http://www.bmrb.
wisc.edu) and the Human Metabolome Database (http://www.hmdb.
ca). In addition, metabolites were also identified with Chenomx NMR
Suite 7.1 (Chenomx Inc, Edmonton, Alberta, Canada).
2.7.2. Determination of citrate concentration
The concentration of citrate in the samples was determined in two
different ways. First the absolute citrate concentration was calculated
by comparing the integral of the non-overlapped citrate signal at
2.54 ppm with that of the TSP signal, which was present at 65.3 μM
concentration in each sample. As the absolute citrate concentration
varied greatly, especially in control urine samples, due to differences
in urine concentration, depending on the fluid intake of the respective
subject, we also used the combined signal intensity in the 2.54 and
2.58 ppm buckets of the bucket table after probabilistic quotient
normalisation [38]. Probabilistic quotient normalisation can compen-
sate for the fact that the total intensity of a spectrum may vary be-
cause of large concentration changes of one or a few metabolites, or
because the number of metabolites may change due to diet and gut
microflora.
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3. Results
3.1. Clinical changes of GHD subject during GH therapy
As expected, recommencement of GH therapy in the subject with
PIT-1 mutation led to clinical improvement in her chronic lethargy and
general well-being, which was associated with significant changes in
body composition. This included decreasedweight,waist circumference,
BMI, total body fat (as assessed by DXA and bioelectrical impedance)
and increased whole body bone mineral density (BMD) and normal-
isation of IGF-1 levels over time (Table 1).
3.2. NMR metabolic profiles of GHD Subject prior to and during
GH therapy
NMR spectra of all samples collected from the GHD subject prior to
and during GH therapy (Fig. S1) were analysed with the multivariate
statistical methods PCA and PLS. The PCA scores plot of PC1 vs. PC2
showed clear separation between the urine samples at different
time points before, during and after the subject received GH therapy
(Fig. 2a), indicating that her metabolic profile changed with the
progression of therapy. Before the commencement of the GH therapy
(represented by black squares on the scores plot), she had higher
levels of creatine, creatinine, lactate, and trimethylamine-N-oxide
(TMAO) as shown in the loadings plot (Fig. 2b). During the course
of GH therapy, her metabolic profile was mainly characterised by
higher levels of urinary citrate, dimethyamine (DMA) and alanine.
3.3. Metabolic profiles of GHD subject compared to healthy controls
When all urine samples of the subject were compared with those
from sex- and age-matched healthy adolescents and young female
adults, PLS showed that the metabolic profile of the subject while
on GH therapy was similar to those of the healthy controls and clus-
tering away from the samples obtained when the subject was not
on GH therapy (Fig. 2c). The metabolic profile of the GHD subject
was characterised by higher levels of citrate, mannitol, alanine and
DMA,whereas thehealthy controls had higher urinary levels of creatine,
creatinine, TMAO, and aceteoacetate (Fig. 2d). Permutation analysis
(Fig. S2) indicated that the PLS analysis was valid with R2 and Q2
values for all permuted models being lower than the corresponding
Fig. 2.Multivariate statistical analysis of 1D NMR spectra of urine samples from the GH-deficient female subject collected over a period of 5 years. Black squares— before treatment;
red circles — during GH therapy; blue diamonds — 8 weeks after taken off GH therapy; green triangles — a year after recommencement of GH therapy; purple inverted triangles —
healthy controls. (a) PCA scores plot showing separation of samples according to time points and (b) loadings plot showingwhich metabolites were influencing the sample clustering
observed in (a) (N=22, kx=201, Pareto scaling in X, Number of latent components: 5, R2X=0.727, Q2X=0.206). (c) PLS scores plot of urine samples of GH-deficient female subject
comparedwith 12 sex and agematched healthy adolescents and young adults showing separation of samples according to therapy status and time points and (d) loadings plot showing
whichmetaboliteswere influencing the sample clustering observed in (c) (N=34, kx=192, Pareto scaling of X and univariate scaling of Y, Number of latent components: 3, R2X=0.394,
Q2=0.258, R2Y=0.715).
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values for the original model, and the Q2 regression line intersecting
the vertical axis below zero.
4. Discussion
The aims of this studywere to determine the clinical andmetabolic
profiles of a female adolescent with a genetically proven cause of
severe GHD (PIT-1 mutation) and determine the effects of GH therapy
on metabolism. 1D NMR spectra of the subject's urine were recorded
and analysed with PCA and PLS to investigate how samples changed
over a period of time and how they compared to healthy controls.
To our knowledge no similar studies have been previously performed
in human subjects with GHD examining the effects of GH therapy
on urine metabonomics and correlating these changes to the clinical
effects of GH.
As expected, during the course of GH therapy the GH-deficient
subject's total body weight and fat decreased and fat free mass in-
creased, which was reflected in improvements in waist circumference
and body composition (Table 1). These effects on fat mass in patients
with GHD during GH therapy have been ascribed to increased lipolysis
and lipid oxidation [8,39–41], while increased normalisation of IGF-1
levels, as seen in our subject, and improvements in lean muscle mass
with GH therapy have been previously described in GH-deficient adult
subjects treatedwith rGH [42,43]. Interestingly, before recommencement
of GH treatment the subject had higher urinary creatine and creatinine
levels than during GH treatment, possibly indicating an increased protein
turnover due to muscle mass breakdown. These compounds were simi-
larly found to be increased in ametabonomic study of urine frommutant
GH-deficient mice with truncations of the intracellular domain of the
GH receptor [33]. This is also consistentwith the known anabolic effects
of GH on lean body mass and skeletal muscle mass due to an increase
in protein synthesis [6,7,44]. An increase in alanine and lactate levels
observed during GH therapy alsomirrors a study inwhichblood alanine
and lactate concentration increased after GH administration in healthy
adults [6]. This may indicate that GH has an effect on hepatic uptake
of alanine and hepatic clearance of gluconeogenic precursors respec-
tively [6,9].
Additionally, before GH therapy, the subject's metabolic profiles
did not show any evidence of citrate excretion. During GH therapy
(red circles on PCA and PLS scores plots) the subject's urinary citrate
levels normalised and this is evidenced by the increase in citrate and
DMA levels being the major factor causing the clustering of this group
away from the samples when the subject was not on GH therapy. Low
citrate levels were also observed in the mutant GHD mice mentioned
earlier and together with the increased levels of creatine and creati-
nine, indicate that lipid and choline metabolism was altered in the
GH-deficient mutant mice [33].
GH also stimulates the breakdown of triglycerides and increases
levels of FFAs and ketone bodies in the blood via stimulation of lipol-
ysis and ketogenesis [6,7]. With higher levels of circulating FFAs,
these undergo β-oxidation to produce acetyl-CoA which enters the
Tricarboxylic Acid (TCA) cycle. Thus, the increased citrate levels in
our study may also reflect this GH-dependent increase of lipolysis
and β-oxidation (Fig. 3). These results are in concordance with stud-
ies in rats administered human rGH that showed increased citrate
synthase activity in skeletal muscle [45,46]. In human studies where
GH was administered to healthy adults, an increase in muscle mito-
chondrial ATP production and citrate synthase activity has also been
observed providing further corroborative evidence for a GH-dependent
increase in urinary citrate levels in the GH-deficient subject during
GH therapy in our study [47,48].
Urine samples collected 8 weeks after the subject voluntarily
interrupted GH therapy (blue diamonds) showed the metabolic pro-
file reverting back to the baseline GH-deficient profile, clustering
away from data points of samples during GH therapy. In contrast,
the metabolic profiles of the subject during GH therapy were not
statistically significantly different to the profiles of the healthy con-
trols. This indicated on one hand that the normalising metabolic
changes induced by GH-therapy in our GH-deficient subject were de-
tectable using NMR metabonomics, and confirmed on the other hand
that the normalising effects of GH therapy do not continue after ther-
apy cessation. In addition, though despite apparent adequate GH re-
placement the metabolic profiles of the subject do not completely
match the metabolic profiles of the healthy controls.
These results suggest that the progression of GH therapy on metab-
olism in GHD patients can be tracked with NMR-based metabonomics.
In addition, this study confirms that metabonomics can potentially
be used to aid with the monitoring of efficacy and compliance of GH
therapy in subjects with GHD.
One limitation of our study was highlighted when the subject
recommenced GH therapy and two samples (green triangles) were
collected after 12 months. These samples clustered away from other
samples due to higher levels of mannitol and hippurate. Mannitol is
commonly found in sweeteners and confectionaries, and hippurate
is a conjugate of glycine and benzoate, a common food preserving
agent. The conjugation of benzoate and glycine to hippurate can ei-
ther occur in the liver [49] or in the microbial gut microflora [50]. In
both cases, hippurate enters the blood stream and is eventually ex-
creted in urine. Thus, it is likely that these metabolites were the result
of the subject's diet and/or changes in gut microbiota rather than the
effects of GH therapy. To determine whether the levels of hippurate
and mannitol in these samples may have masked alteration of other
metabolites by GH therapy, we analysed the urinary citrate levels in
these two samples and found them to be similar to when the subject
was previously on GH therapy and to the healthy control cohort (Fig.
S3). This indicated that the subject's metabolic status was similar
while on GH therapy despite the spike in mannitol and hippurate
in the two samples mentioned above. Therefore, the presence of
confoundingmetabolites due to dietary and/or changes in gutmicrobiota
Fig. 3.Metabolic pathway of possible effects of GH on lipolysis and the TCA cycle. With
an increase in free fatty acids in the bloodstream due to GH, FFA undergo β-oxidisation
into acetyl-CoA which enters the TCA cycle and thus causing an increase in the levels of
citrate evidenced by levels of excreted citrate in the urine samples of the GHD subject
after commencement of GH therapy.
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needs tobe taken into consideration in the interpretation ofmetabonomic
studies.
5. Conclusion
This study showed that NMR-based urinary metabonomics was
able to provide metabolic fingerprints of a GH-deficient subject and
track her metabolic profiles during 5 years of GH therapy. Detection
of urinary metabolites related to GHD provided a clearer picture of
the impact GH therapy has on metabolism. Our study indicated that
metabonomics was able to differentiate the metabolic profiles of
healthy controls from a GH-deficient subject. This provides evidence
that urinary metabonomics could potentially be used as an adjunct
tool for the assessment of the effects of GHD and its treatment on
metabolism in humans. A study with larger number of GH-deficient and
control subjects would be required to validate the current observations.
Nonetheless, this study demonstrates that NMR-based metabonomics
has the capability to be utilised as a platform to identify the effects of
GH treatment on metabolism.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ghir.2012.12.001.
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Figure S1: Comparison of NMR spectra of representative urine samples with metabolites of interest annotated. 
From top to bottom: baseline sample (black), sample during interruption of GH therapy (blue), sample at 22.01 years 
age (green), sample during GH therapy (red), sample of healthy control subject (purple). 
 
 
Figure S2: Validation plots with 200 permutations of the PLS analysis, presented in Fig. 2 (c) and (d). Validation 
with (a) age and (b) GH therapy showed that the R
2
 and Q
2
 values for all permuted models are lower than the 
corresponding values for the original model and that the Q
2
 regression line is intersecting the vertical axis below zero. 
Green triangles — R2, blue squares — Q2. 
 
102 
 
 
Figure S3: Citrate concentration in urine samples of the subject during withdrawal of GH therapy (GHT 
interruption), at 22.01 years age (22.01 years), during GH therapy, and in urine samples of healthy control 
subjects. Absolute citrate concentration in mMol/L (left axis, grey bars) and relative citrate concentration (right axis, 
white bars) as estimated from the probabilistic quotient normalised (PQN) bucket table are shown. Bar heights show the 
average of all samples from a given type, and error bars depict standard error of measurement. Significant differences in 
citrate concentration are indicated by * (p < 0.05) and *** (p < 0.001). The citrate concentration in the 22.01 year 
samples appeared similar to samples on GH therapy, indicating that the metabolic profiles of the subject were similar 
while on GH therapy despite those two samples being separated from the rest of the samples because of high levels of 
mannitol and hippurate as seen in the PCA plots. 
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Table S1: Timeline of urine samples collected from GHD and healthy control subjects 
No Type of sample
+ Ytable for PLSDA 
Age (years) Identity  
ON GH/NO GH* 
1 
Baseline(No GH) 
Day 1 0 17.05 Black square 
2 Day 2 0 17.06 Black square 
3 Day 3 0 17.06 Black square 
4 
Therapy Week 2 
Day 1 1 17.1 Red circle 
5 Day 2 1 17.11 Red circle 
6 
Therapy Week 5 
Day 1 1 17.17 Red circle 
7 Day 2 1 17.17 Red circle 
8 
Therapy Week 13 
Day 1 1 17.33 Red circle 
9 Day 2 1 17.33 Red circle 
10 
Therapy Week 28 
Day 1 1 17.6 Red circle 
11 Day 2 1 17.61 Red circle 
12 
Therapy Week 39 
Day 1 1 17.82 Red circle 
13 Day 2 1 17.82 Red circle 
14 Therapy 1 year Week 2  1 18.11 Red circle 
15 Therapy 1 year Week 4  1 18.16 Red circle 
16 Therapy 2 year Week 2   1 18.89 Red circle 
17 Therapy 2 years Week 3   1 19.13 Red circle 
18 Therapy 2 years Week 7   1 19.21 Red circle 
19 
No GH 8 weeks 
Day 1 0 21.26 Blue diamond 
20 Day 2 0 21.37 Blue diamond 
21 
Therapy 60 months 
Day 1 1 22.01 Green triangle 
22 Day 2 1 22.01 Green triangle 
23 Healthy control 1   1 20.16 Purple inverted triangle 
24 Healthy control 2   1 21.21 Purple inverted triangle 
25 Healthy control 3   1 21.5 Purple inverted triangle 
26 Healthy control 4   1 21.33 Purple inverted triangle 
27 Healthy control 5   1 17.76 Purple inverted triangle 
28 Healthy control 6   1 19.82 Purple inverted triangle 
29 Healthy control 7   1 17.08 Purple inverted triangle 
30 Healthy control 8   1 21.3 Purple inverted triangle 
31 Healthy control 9   1 17.54 Purple inverted triangle 
32 Healthy control 10   1 18.27 Purple inverted triangle 
33 Healthy control 11   1 16.87 Purple inverted triangle 
34 Healthy control 12   1 17.27 Purple inverted triangle 
*0 – no GH therapy, 1 – on GH therapy and healthy controls  
+no urine samples collected at 36 months 
 
104 
 
Table S2. Identified metabolites with corresponding loadings coefficients in both PCA and PLS 
components.  
Metabolite 1H chemical shifts [ppm] multiplicity^ 
Increase (+) or decrease (-) while 
on GH therapy 
  
creatine 3.94s; 3.04s -- 
creatinine 4.06s; 3.06s -- 
lactate 1.34d - 
TMAO 3.26s - 
citrate 2.7d; 2.54d +++ 
DMA 2.74s ++ 
alanine 1.5d ; 3.76m + 
acetoacetate 3.42s - 
mannitol 3.74m, 3.78m, 3.82m, 3.86m, 3.9m ++* 
hippurate 7.86d; 7.62t; 7.54t; 3.98d ++* 
^chemical shifts in ppm denote the position of a signal in the NMR spectra, the multiplicity describes the coupling pattern of a NMR signal, 
s: singlet, d: doublet, t: triplet, m: multiplet. These data were used for metabolite identification.  
*these metabolites were only found to be increasing in the two samples (green triangles in Figure 2) collected after a year on GH therapy 
when the subject recommenced therapy.  
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3.1 Additional Work 
3.1.1 Comment on Chapter 3 
 While chapter 2 discussed finding the optimal procedure for urine sample collection as part 
of method development for metabonomic studies, chapter 3 importantly deals with applying the 
technique of metabonomics in a clinical setting with a small subset of samples. This is to ascertain 
that metabonomics has the capabilities to perform accurate and robust analysis on clinical samples 
and provide useful information before such a technique is applied on a larger cohort of samples as 
done in chapter 5 and 6.  
Sodium azide was used both in the growth hormone and in the KOALA obesity studies as 
samples were collected and transported on ice within a few hours before the clinic visit and 
immediately frozen at -20°C with a final concentration of 0.05% sodium azide which is sufficient to 
maintain the stability of these samples. As mentioned in Chapter 2, a final concentration of 100 mM 
sodium borate is only required if the samples are collected in non-optimal conditions with the 
potential for overnight room temperature storage.   
3.1.2 O2PLS Analysis of Metabonomic and Clinical Data 
Bidirectional orthogonal projections to latent structures (O2PLS) analysis enables two types 
of datasets to be analysed together e.g. metabonomics versus clinical dataset collected from the 
same group of samples. O2PLS is a regression and prediction method where the PLS is 
decomposed into components correlated to Y and components unique in X but uncorrelated or 
orthogonal to Y and vice versa. Analysis was performed with the metabonomic data set as the X-
variables and compared with the clinical datasets (Table 3.1) set as multiple Y-variables. As the Y 
data did not contain class identity information of the samples, the O2PLS analysis was effectively 
run as an unsupervised analysis that is able to separate variation common to both metabonomic and 
clinical data from variation unique to either, thus improving the model visualization and 
interpretation. This methodology is conceptually similar to the data analysis approach used in 
Chapter 6 to correlate the multiple data matrices of the KOALA project. 
Inspection of the O2PLS model in the first 3 components (Figure 3.1) showed that when the 
subject was on GH therapy, the levels of IGF1, IGFBP3 and citrate (denoted by 2.7, 2.54 and 2.58 
ppm) were higher along t2, and the levels of FT4 (free thyroxine) were lower.  IGF-1 and IGFBP-3 
levels reflect the GH status and as expected was higher in the subject during GH therapy, while the 
lower Ft4 levels is consistent with a previously demonstrated effect of GH on increased peripheral 
conversion of T4 to T3  (Gacs and Banos., 1981).  
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Figure 3.1: O2PLS (pareto scaling) of urine samples of GHD female subject compared with clinical data recorded 
over a period of 5 years. Black squares – before treatment, red circles – during GH therapy, blue diamonds – 8 weeks 
after taken off GH therapy and green triangles – back on GH therapy in 2011. (a) Scores and (b) loadings plot of t1 vs. 
t2 and (c) scores and (d) loadings plot of t2 vs. t3 indicates that citrate levels increased with GH therapy along with 
higher IGF-1 and IGF-BP3 levels along t2 (n: 22, A: 4+2+0, R
2
X: 0.745, R
2
Y: 0.871, Q
2
: 0.448).   
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3.1.3 Univariate Analysis of Metabolite Data 
As it was anticipated that the multivariate data analysis of the metabonomic data is more 
conservative than univariate data analysis, we have also performed univariate data analysis of 
several metabolites. Ten different metabolites were selected and the intensity of these metabolites in 
each of the four study groups (control group, GH therapy. GHT interruption, and 22.01-year 
samples) was calculated as the sum of bucket intensities for each metabolite. This analysis is similar 
to the analysis in Figure 3.S3 and the results are depicted in Figure 3.2. The results confirmed the 
conclusions drawn in Figure S3. The citrate concentration in the samples taken from 22.01 years 
age appeared similar to samples on GH therapy (Figure 3.2a), indicating that the metabolic profiles 
of the subject were similar while on GH therapy despite those two samples being separated from the 
rest of the samples because of high levels of alanine, mannitol and hippurate (Figure 3.2g, i, j). In 
addition, the concentrations of creatine and creatinine decreased when subject was on GH therapy 
and at age 22.01 years as compared to when she was off the therapy which corresponds to the 
weight loss the subject had over the 5 years with a decrease in the amount of FFM and FM when the 
subject was on GHT (Figure 3.2b and c).  Performing univariate analysis not only validated the 
multivariate analysis done previously, it also provided more insight into the differences in 
concentrations of the metabolites before and during GHT. 
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Figure 3.2: Concentrations of ten selected metabolites in urine samples of the subject during withdrawal of GH therapy (off GH), at 22.01 years age (2 samples), during 
GH therapy, and in urine samples of healthy control subjects. (a) citrate, (b) creatine, (c) creatinine, (d) lactate, (e) TMAO, (f) DMA, (g) alanine, (h) acetoacetate, (i) mannitol, 
(j) hippurate. Metabolite concentrations are estimated via the sum of all relevant buckets. Bar heights show the average of all samples from a given type, and error bars depict 
standard errors of measurement.  
(a) 
(b) (c) 
(d) (e) (f) 
(g) (h) (i) 
(j) 
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Chapter 4: KOALA Childhood Obesity Nuclear Receptor (NR) Gene 
Expression Study  
4.1 Introduction 
Obesity is a complex multi-factorial disease as a result of genetic, environmental, and 
lifestyle (nutrition and physical activity) factors that influence metabolism and fat and lean body 
mass (Farooqi, 2005).  This includes genetic and hormonal influences on appetite regulated by the 
hypothalamus and the influence of nuclear hormone receptors (NRs) on metabolism, inflammation 
and energy expenditure in metabolic tissues such as adipose tissue, skeletal muscle and liver 
(Bensinger and Tontonoz, 2008; Flier and Maratos-Flier, 1998). However, the exact underlying 
mechanisms how the majority of these genetic influences affect body weight remains unclear.  
Gene expression studies involving PBMCs as a “sentinel” cell to detect systemic disease 
have been extensively used to understand the molecular mechanisms underlying several human 
diseases (Chiappini et al., 2006; Horwitz et al., 1997; Maes et al., 2006). However, studies 
involving gene expression profiles in PBMCs from obese subjects are small in number, including in 
children. Studying gene expression profiles of PBMCs can potentially highlight the insights that can 
be obtained into the underlying mechanisms of obesity and inflammation. 
The NRs superfamily plays a role in regulating the expression of genes that control 
development, reproduction, inflammation, immunity and metabolism 
(Mangelsdorf and Evans, 1995; Mangelsdorf et al., 1995). NRs have been shown to be involved in 
regulating energy, lipid and glucose metabolism and also inflammation in skeletal muscle, adipose 
tissue, liver and immune cells (Auwerx et al., 2003, Peet et al., 1998; Repa et al., 2002, Glass and 
Ogawa, 2006; Joseph et al., 2003; Ogawa et al., 2005, Lau et al., 2008, 2011; Myers et al., 2009; 
Myers et al., 2006; Pearen et al., 2006, Raichur et al., 2010). The studies mentioned above suggest 
that NRs are therapeutic targets for the treatment of obesity, dyslipidemia, diabetes and CVD 
(Smith and Muscat, 2005).  
Although studies utilising PBMCs have demonstrated changes in metabolic and 
inflammatory gene expression in various disease states that affect metabolism, including obesity, no 
studies have investigated changes in NR mRNA gene expression in obese children or adults. 
Therefore, in this study, we hypothesised that the NR gene expression profile from PBMCs of 
overweight and obese children would be different compared to their healthy weight controls; 
moreover we aimed to investigate the effects of a lifestyle intervention program on the expression 
levels of these NRs.     
   As part of the KOALA lifestyle intervention program, fasting peripheral blood samples were 
collected for peripheral blood mononuclear cells (PBMC) to determine gene expression of NRs. 
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Total body fat and fat free mass were assessed by bioelectrical impedance analysis (BIA) using the 
BodyStat© 1500 machine at baseline and at 6 and 12 month assessments (Schaefer et al., 1994). 
An analysis performed by Dr Gary Leong of the overweight and obese cohort indicated there was a 
significant greater improvement in BMI in the Lifestyle Triple P Scouts intervention arm compared 
to the “Care as Usual” arm of the study with significant greater decreases in % total body fat. 
Interestingly, this effect appeared to be gender-specific with a significant decrease in % total body 
fat only in boys but not in girls in the Arm B Scouts Triple P intervention compared to ‘Care as 
Usual” arm A (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Changes in BMI and total body fat of obese children (Arms A and B) after a 12 month lifestyle 
intervention. Red line – Arm A, blue line – Arm B. BMI Z-scores of (a) all obese children (b) male obese children and 
(c) female obese children that was recorded at 0, 6 and 12 months. After 12 months, there was a significant 
improvement in BMI in the obese children in both arms of the study, though a greater decrease in BMI in the Arm B. 
Percentage total body fat by BIA of (d) all obese children indicated that the decrease in significantly greater in Arm B 
lifestyle intervention compared to Arm A “Care as Usual”. Graphs of % total body fat by BIA of (e) male and (f) 
female obese children during 12 month lifestyle intervention showed that the decrease in % total body fat at 12 months, 
is only significant in the males in Arm B and not the females, compared to the “Care as Usual” Arm A. (g) Bar chart of 
percentage fat of obese children from Arms A and B compared with healthy weight controls showed that obese children 
had twice the amount of % total body fat than in the healthy children. Data were collected and figure was prepared by 
Dr Gary M. Leong.  
  
 
111 
 
4.2 Materials and Methods: 
4.2.1 Sample Collection: 
Parents and subjects from the KOALA childhood obesity program gave written informed 
consent and assent prior to participation in this study. The study was approved by the Mater Health 
Services Human Research Ethics Committee and the University of Queensland Medical Research 
Ethics Committee. Serum samples were collected from children participating in the KOALA 
childhood obesity program (Simbert et al., 2010). The KOALA program was a randomised 
controlled trial that included 72 obese children (BMI>95
th
 percentile according to CDC BMI 
centiles) with two different treatment arms. Both groups underwent a baseline paediatric medical 
consultation with lifestyle advice with Group A designated as ‘Care As Usual’ while children and 
parents in Group B undertook a 12-month intensive lifestyle program (Lifestyle Triple P (Positive 
Parenting Program) (West et al., 2010) and attended three family Scouts active weekend camps 
during the first 6 months of the program). Blood samples for PBMCs were collected at baseline and 
also after 12 months. Comparison of the human nuclear receptor (NR) gene expression profiles 
were made between the obese groups A and B at baseline and in a smaller cohort of obese children 
(N=22) after the lifestyle intervention at 12 months and also with 34 sex- and age-matched healthy 
weight children as controls (Group C) at baseline. 
4.2.2 RNA Extraction and cDNA Synthesis: 
PBMCs were isolated from the baseline peripheral blood samples from pre-pubertal age-
matched boys (n= 51, 33 obese and 18 non-obese) and girls (n=55, 39 obese and 16 non-obese) 
after a Ficoll Gradient to separate white and red blood cells, with the white cell pellets resuspended 
in Trizol reagent and stored at -80°C. RNA was extracted from PBMCs samples using Qiagen 
RNeasy column (QIAGEN) as per the manufacturer’s protocol. Once the RNA samples were 
quantified using a Nanodrop Spectrophotometer, reverse transcription using Superscript III was 
performed from 0.5 μg of total RNA with random hexamers in each cDNA synthesis reaction 
(Invitrogen, Carlsbad, CA). In addition, RNA was extracted from PBMCs from 11 boys who had 12 
month serum samples collected, which was quantified and cDNA were synthesized. Unfortunately 
for unknown technical reasons the female PBMC samples that were harvested after 12 months and 
underwent qRT-PCR were unsuitable for TLDA analysis, as only very low NR expression was 
detectable from these samples. Thus, no further analysis was possible with the 12 month female 
samples. 
4.2.3 Quantitative RT-PCR: 
ABI human NR panels (cat #4379961) that assay the expression of all 48 human NRs with 
16 internal control genes spanning a broad Ct range (with three technical replicates per gene) were 
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used, and NR mRNA gene expression was performed using quantitative PCR coupled to the ABI 
Taqman Low density Array (TLDA) platform (Applied Biosystems ABI 7900 DNA thermocycler) 
that allows high throughput expression analysis of hundreds of genes from multiple samples in hour 
time frames with greater sensitivity than a conventional microarray approach.  
In addition, manual quantitative RT-PCRs were performed on a total of 33 male serum 
samples (11 from each cohort of baseline, 12 months and control) on a subset of NR genes, (PXR, 
THRα and THRβ with PGK1 as the endogenous control) that were differentially expressed in the 
baseline male samples as shown in the TLDA analysis.  
4.2.4 Statistical Analysis:  
Significant changes in expression relative to age- and sex-matched controls were analysed 
using the ABI/integromics ‘StatMiner’ software package. Differentially expressed genes were 
identified by Linear models (contained in the LIMMA package for Bioconductor R embedded in 
Statminer). Significance was assigned by the application of empirical Bayesian statistics. The 
empirical Bayesian statistic is described as equivalent to shrinkage of the estimated sample 
variances towards a pooled estimate, resulting in far more stable inference when the number of 
arrays is small. It returns the log-odds that a gene is differentially expressed. A higher score 
represents a more significant result. Analysis included the corresponding P-values of differential 
expression. Subsequently, a more stringent/conservative data filtering approach was used to control 
for false discovery rate by employing a Benjamini-Hochberg correction to p values and further 
refine the subset of differentially expressed genes. The Statminer statistical package was used to 
compute the appropriate (and most stable) combination of internal control genes (GUSB, HPRT1 
and PGK1) with which to normalise the expression data. The calculated fold differences (relative 
quantification) between the target (obese cohort) and the calibrator (healthy weight cohort) are 
considered valid when the Ct values of the gene in the target and calibrator samples are less than 35 
cycles.  
4.3 Results  
 To determine the NR gene expression profiles through the use of TLDA analysis, mRNA 
was extracted from PBMCs collected from overweight and obese children from the KOALA 
childhood obesity program and a cohort of non-obese healthy controls.  The effects of a lifestyle 
intervention program on the expression levels of these NRs were also examined in a small sub-set 
of the cohort. Statistical analysis was performed to obtain the relative expression (RE) and relative 
quantification (RQ) levels of these NRs.  RE is a qualitative study used to check which receptors 
are expressed in the respective cohort while RQ shows which receptors are differential expressed 
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between the obese and non-obese groups, i.e. up-regulated or down-regulated with an actual fold 
change. 
4.3.1 Relative Quantification and Expression of Obese versus Healthy Weight Children 
Statminer analysis revealed that 32 out of the 48 human NR genes were expressed in the 
PBMCs of the childhood cohort (obese versus healthy weight children) (Tables S4.1-S4.3 and 
Figures 4.3, 4.5 and 4.7). This includes several NRs that have known roles in obesity, diabetes and 
metabolism including glucocorticoid receptor (GR), thyroid hormone receptors, PPARs and various 
orphan and adopted NRs such as Liver X-activated receptors (LXRs), Nurr77/NOR1, RORα, Rev-
erbs and ERRβ/ERRγ (Evans et al., 2004, Raichur et al., 2010, Muscat et al., 2002, 
Maxwell et al., 2005, Pearen et al., 2008, Lau et al., 2008, Ramakrishnan et al., 2009, 
Raichur et al., 2007). 
4.3.1.1 Male Cohort 
Three out of those 32 NR genes were differentially expressed in the obese versus healthy 
weight males after normalisation to internal controls GUSB, HPRT1 and PGK1 median 
(all P<0.05) (Table 4.1). The expression of Pregnane X Receptor (PXR) was significantly increased 
by 2.2-fold while the expression of Thyroid Hormone Receptor α (TRα) was decreased in the obese 
boys when compared to the healthy weight counterparts (Figure 4.2). The expression of Thyroid 
Hormone Receptor β (TRβ) was up-regulated in the obese males by 2.4-fold. 
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Figure 4.2: Relative quantification (log10), i.e. calculated fold differences of nuclear receptor genes of obese male 
children (n = 33) vs. male healthy weight control children (n = 18). Data are derived from Table 4.1, expressed as 
fold changes normalised to the mean/median of the most stable Genorm selected controls (GUSB, HPRT1 and PGK1) 
with the least expression variation. Data are presented as valid when the Ct values of the gene in the 
calibration/reference and target samples (control and obese samples respectively) are less than 35 cycles. Moreover, 
fold differences are flagged as target not detected, calibrator not detected, and no detection when the Ct value of the 
gene(s) in the target, calibrator and/or both samples are ≥35 cycles (than the threshold limit). Hence, the reported 
quantitative ‘fold change of a gene that is not expressed in some of the biological conditions may not be reliable” [Jun 
et al., 2010]; however, it does reflect a quantitative difference. The Applied Biosystems SDS software utilized with the 
ABI7900 instrument assigns Ct values beyond the arbitrarily set threshold (Ct 35) up to a maximum Ct 40, which are 
utilized to calculate expression (in the calibrator and target not detected genes). Significance is assigned after 
application of the empirical Bayes statistic, and Benjamini-Hochberg false detection rate analysis and adjusted P values 
are considered for the final assignments (*, P < 0.05; **, P < 0.01). PXR and TRβ significantly increased while THRα 
was down regulated in the obese cohort. 
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Table 4.1. Analysis of human NR gene expression in male obese children vs. male healthy weight control children* 
Detector (NR) 
 
P values Adjusted P values (FDR) Linear RQ Log 10 RQ Ct status 
AR 0.384743689 0.678455464 0.544151932 -0.264279825 Valid 
ESR1 0.726583526 0.830381173 1.493549545 0.174219634 Valid 
ESR2 0.756780683 0.844778437 1.017876979 7.70E-03 Valid 
ESRα 0.596454466 0.810106512 1.336003265 0.12580752 Valid 
ESRβ 9.52E-02 0.351610031 0.733149631 -0.134807379 no_detection 
ESRγ 5.14E-02 0.296285963 0.220518613 -0.656554749 no_detection 
HNF4α 7.37E-02 0.321600644 0.64624266 -0.189604377 no_detection 
HNF4γ 0.395765687 0.678455464 2.212068557 0.344798583 no_detection 
DAX 1.44E-02 0.296285963 0.494807091 -0.305564085 no_detection 
SHP 0.116755929 0.400306041 1.170304321 0.068298809 no_detection 
REV-ERBα 0.928353873 0.976089353 1.414656378 0.150650962 Valid 
REV-ERBβ 0.726583526 0.830381173 1.261367527 0.100841646 Valid 
LXRβ 0.303460874 0.662096452 0.884807373 -5.32E-02 Valid 
LXRα 0.960159524 0.976089353 1.285388027 0.10903425 Valid 
FXRα 5.64E-02 0.296285963 0.451606881 -0.345239449 no_detection 
PXR 1.22E-02 0.296285963 2.224159511 0.347165931 Valid 
CAR 0.061726242 0.296285963 1.044549607 1.89E-02 no_detection 
TR2 0.234482607 0.625286952 2.035097742 0.308585272 Valid 
TR4 0.294168283 0.662096452 1.221699027 8.70E-02 Valid 
TLX 0.478114591 0.732008655 1.761783218 0.245952469 no_detection 
PNR 0.080400161 0.321600644 0.962319923 -1.67E-02 no_detection 
COUP-TF1 4.68E-02 0.296285963 0.693412417 -0.159008386 no_detection 
COUP-TF2 0.226711931 0.625286952 0.883446394 -5.38E-02 no_detection 
EAR2 0.596454466 0.810106512 1.065270879 2.75E-02 Valid 
GR 0.50325595 0.732008655 1.136008676 5.54E-02 Valid 
MR 0.342562343 0.678455464 1.421579103 0.152771031 Valid 
NUR77 0.395765687 0.678455464 0.785582807 -0.10480803 Valid 
NURR1 0.234482607 0.625286952 0.653148354 -0.184988163 Valid 
NOR1 0.395765687 0.678455464 0.755532862 -0.121746641 Valid 
SF-1 0.624457103 0.810106512 1.709627657 0.232901535 Valid 
LRH-1 0.653012888 0.821522706 0.646316891 -0.189554494 no_detection 
GCNF 0.197468432 0.625286952 0.585550182 -0.232435879 Valid 
PGR 0.490598699 0.732008655 14.88183823 1.172656579 calibrator_not_detected 
PPARα 0.896662289 0.976089353 1.052483648 2.22E-02 Valid 
PPARδ 0.944245588 0.976089353 1.007532443 3.26E-03 Valid 
PPARγ 0.624457103 0.810106512 1.074773437 3.13E-02 Valid 
RARα 0.418374203 0.692481439 0.851413892 -6.99E-02 Valid 
RARβ 3.33E-02 0.296285963 0.578262427 -0.237875025 no_detection 
RARγ 0.465806174 0.732008655 1.139663743 5.68E-02 Valid 
RORα 0.667487199 0.821522706 3.383332637 0.529344698 Valid 
RORβ 0.976089353 0.976089353 1.033586057 1.43E-02 calibrator_not_detected 
RORγ 5.64E-02 0.296285963 1.094787079 3.93E-02 Valid 
RXRα 0.342562343 0.678455464 1.197446871 7.83E-02 Valid 
RXRβ 0.276160902 0.662096452 1.187886325 7.48E-02 Valid 
RXRγ 0.250585602 0.633058363 1.37865436 0.139455399 no_detection 
TRα 4.25E-02 0.296285963 0.863334452 -6.38E-02 Valid 
TRβ 2.87E-02 0.296285963 2.408171014 0.381687325 calibrator_not_detected 
VDR 0.711639454 0.830381173 1.047383024 0.020105531 Valid 
*Table displays the P values and adjusted P values of target genes before and after the application of False Discovery 
Rate (FDR) for multiple comparisons, respectively. The relative quantification (RQ) linear and log10 denotes the 
calculated fold differences [between target (male obese) and the calibrator/reference (male healthy weight controls) in a 
linear and log scale, respectively], normalised against the mean of the Genorm selected controls, GUSB, HPRT1 and 
PGK1. Bold red indicates genes differentially expressed in a significant manner. 
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Figure 4.3: Relative expression of Nuclear Receptor mRNA expression in pre-pubertal male obese (n = 33) 
[black] and healthy weight children (n = 18) [white] normalised against the median of GUSB, HPRT1 and PGK1. 
Genes that were not detected in ≥50% of samples were treated as not detected, given a value of zero and not added to 
this graph. Error bars represent standard error of the mean (SEM).  
 
4.3.1.2 Female Cohort 
Two out of the 32 NR genes (Table 4.2) were differentially expressed in the obese versus healthy 
non-obese females after normalisation to internal controls B2M, GAPDH and PGK1 median 
(all P<0.05). The expression of Retinoid X Receptor α (RXRα) was significantly increased by 1.57-
fold in the obese females when compared to the healthy non-obese control children (Figure 4.4). 
Germ Cell Nuclear Factor (GCNF) expression was increased by 1.76-fold in the obese cohort.  
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Figure 4.4. Relative quantification (log10), i.e. calculated fold differences of nuclear receptor genes of obese 
female children (n = 38) vs. female healthy weight control children (n = 16). Data are derived from Table 4.2, 
expressed as fold changes normalised to the mean/median of the most stable Genorm selected controls (B2M, GAPDH 
and PGK1) with the least expression variation. Data are presented as valid when the Ct values of the gene in the 
calibration/reference and target samples (control and obese samples respectively) are less than 35 cycles. Moreover, 
fold differences are flagged as target not detected, calibrator not detected, and no detection when the Ct value of the 
gene(s) in the target, calibrator, and/or both samples are 35 cycles or greater (than the threshold limit). Hence, the 
reported quantitative ‘fold change of a gene that is not expressed in some of the biological conditions may not be 
reliable” [Jun et al., 2010]; however, it does reflect a quantitative difference. The Applied Biosystems SDS software 
utilized with the ABI7900 instrument assigns Ct values beyond the arbitrarily set threshold (Ct 35) up to a maximum Ct 
40, which are utilized to calculate expression (in the calibrator and target not detected genes). Significance is assigned 
after application of the empirical Bayes statistic, and Benjamini-Hochberg false detection rate analysis and adjusted P 
values are considered for the final assignments (*, P < 0.05; **, P < 0.01). RXRα was significantly up-regulated 1.57-
fold in the obese cohort when compared to their healthy weight counterparts while GCNF was up-regulated in the obese 
cohort 1.75-fold. 
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Table 4.2. Analysis of human NR gene expression in female obese children vs. female healthy weight control children* 
 
Detector (NR) 
 
P values Adjusted P values (FDR) Linear RQ Log 10 RQ Ct status 
AR 0.948286014 0.989515841 1.533642371 0.185724099 Valid 
ESR1 0.270197279 0.944063297 1.756873673 0.244740535 Valid 
ESR2 0.874838609 0.954369392 1.140971249 5.73E-02 Valid 
ESRα 5.06E-02 0.809244008 1.517277648 0.18106506 Valid 
ESRβ 0.676712976 0.944063297 1.07236352 3.03E-02 no_detection 
ESRγ 0.831241806 0.944063297 0.733543437 -0.134574164 no_detection 
HNF4α 0.452944633 0.944063297 0.954372526 -2.03E-02 no_detection 
HNF4γ 0.546997708 0.944063297 0.631775225 -0.199437409 no_detection 
DAX 0.717831062 0.944063297 1.205731945 8.13E-02 no_detection 
SHP 0.717831062 0.944063297 1.045331768 1.93E-02 no_detection 
REV-ERBα 0.475565816 0.944063297 1.269782195 0.103729233 Valid 
REV-ERBβ 0.08315429 0.944063297 0.675481759 -0.170386374 Valid 
LXRβ 0.84572337 0.944063297 0.993192219 -2.97E-03 Valid 
LXRα 0.623371513 0.944063297 1.178935173 7.15E-02 Valid 
FXRα 0.77393307 0.944063297 1.003663209 1.59E-03 no_detection 
PXR 0.270197279 0.944063297 1.577125157 0.197866159 Valid 
CAR 0.663211169 0.944063297 1.499625495 0.175982815 no_detection 
TR2 0.610325484 0.944063297 0.607840865 -0.216210106 Valid 
TR4 0.498793064 0.944063297 1.245907665 9.55E-02 Valid 
TLX 1 1 1.360135017 0.133582022 no_detection 
PNR 0.610325484 0.944063297 1.012527114 5.41E-03 no_detection 
COUP-TF1 0.610325484 0.944063297 1.012527114 5.41E-03 no_detection 
COUP-TF2 0.731728004 0.944063297 1.075653572 3.17E-02 no_detection 
EAR2 0.597402074 0.944063297 1.553461164 0.191300401 Valid 
GR 0.816817317 0.944063297 1.004324353 1.87E-03 Valid 
MR 0.378732795 0.944063297 0.913605681 -3.92E-02 Valid 
NUR77 0.430943939 0.944063297 0.879352968 -0.055836766 Valid 
NURR1 0.10894533 0.944063297 0.53833643 -0.26894623 Valid 
NOR1 0.140688215 0.944063297 0.530796732 -0.27507176 Valid 
SF-1 0.546997708 0.944063297 0.985919915 -6.16E-03 Valid 
LRH-1 0.441865905 0.944063297 0.140988328 -0.850816841 no_detection 
GCNF 2.68E-02 0.6430948 2.029095116 0.307302406 Valid 
PGR 0.977824179 0.998628949 1.301254985 0.114362406 no_detection 
PPARα 0.759783318 0.944063297 1.148923307 6.03E-02 Valid 
PPARδ 0.816817317 0.944063297 1.066191336 0.027835149 Valid 
PPARγ 0.546997708 0.944063297 0.846464966 -7.24E-02 Valid 
RARα 0.441865905 0.944063297 0.995255718 -2.07E-03 Valid 
RARβ 0.610325484 0.944063297 1.012527114 5.41E-03 no_detection 
RARγ 0.948286014 0.989515841 1.193135265 7.67E-02 Valid 
RORα 0.636536803 0.944063297 1.014839971 6.40E-03 Valid 
RORβ 0.690319507 0.944063297 1.177208857 7.09E-02 Valid 
RORγ 0.358987537 0.944063297 1.457346981 0.163562966 Valid 
RXRα 7.41E-03 0.355754908 1.590295646 0.20147787 Valid 
RXRβ 0.534733656 0.944063297 1.242169679 9.42E-02 Valid 
RXRγ 0.330608111 0.944063297 0.641106652 -0.193069717 no_detection 
TRα 0.179105471 0.944063297 0.833661107 -7.90E-02 Valid 
TRβ 0.231983696 0.944063297 1.87789858 0.273672134 calibrator_not_detected 
VDR 0.150953817 0.944063297 1.213460927 8.40E-02 Valid 
*Table displays the P values and adjusted P values of target genes before and after the application of False Discovery 
Rate (FDR) for multiple comparisons, respectively. The relative quantification (RQ) linear and log10 denotes the 
calculated fold differences [between target (female obese) and the calibrator/reference (female healthy weight controls) 
in a linear and log scale, respectively], normalised against the mean of the Genorm selected controls, B2M, GAPDH 
and PGK1. Bold red indicates genes differentially expressed in a significant manner. 
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Figure 4.5: Ranked relative expression of Nuclear Receptor mRNA expression in pre-pubertal female obese (n = 
38) [black] and healthy weight (n = 16) [white] children normalised against the median of B2M, GAPDH and 
PGK1. Genes that were not detected in ≥50% of samples were treated as not detected, given a value of zero and not 
added to this graph. Error bars represent standard error of the mean (SEM). 
 
4.3.1.3 Combined Cohort 
When the data from the male and female cohort were combined for analysis, four of out the 
32 NR genes (Table 4.3) were differentially expressed in the obese versus healthy non-obese 
children after normalisation to internal controls GAPDH, PGK1 and UBC median (all P<0.05). The 
expression of Nur77, nuclear receptor related 1 (NURR1) and TRα were significantly down-
regulated 0.79-, 0.56- and 0.81-fold respectively in the obese children when compared to the 
healthy weight control children (Figure 4.6). The expression of RXRα was up-regulated 1.36-fold in 
the obese cohort.  
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Figure 4.6. Relative quantification (log10), i.e. calculated fold differences of nuclear receptor genes of obese 
children (n = 71) vs. healthy weight control children (n = 34). Data are derived from Table 4.3, expressed as fold 
changes normalised to the mean/median of the most stable Genorm selected controls (GAPDH, PGK1 and UBC) with 
the least expression variation. Data are presented as valid when the Ct values of the gene in the calibration/reference 
and target samples (control and obese samples respectively) are less than 35 cycles. Moreover, fold differences are 
flagged as target not detected, calibrator not detected, and no detection when the Ct value of the gene(s) in the target, 
calibrator, and/or both samples are 35 cycles or greater (than the threshold limit). Hence, the reported quantitative ‘fold 
change of a gene that is not expressed in some of the biological conditions may not be reliable” [Jun et al., 2010]; 
however, it does reflect a quantitative difference. The Applied Biosystems SDS software utilized with the ABI7900 
instrument assigns Ct values beyond the arbitrarily set threshold (Ct 35) up to a maximum Ct 40, which are utilized to 
calculate expression (in the calibrator and target not detected genes). Significance is assigned after application of the 
empirical Bayes statistic, and Benjamini-Hochberg false detection rate analysis and adjusted P values are considered for 
the final assignments (*, P < 0.05; **, P < 0.01). Nur77 (0.79-fold), NURR1 (0.56-fold) and TRα (0.81-fold) were 
significantly down-regulated in the obese cohort when compared to their healthy weight counterparts. RXRα was 
significantly up-regulated in the obese cohort by 1.36-fold.  
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Table 4.3. Analysis of human NR gene expression in obese children vs. healthy weight control children* 
Detector (NR) 
 
P values Adjusted P values (FDR) Linear RQ Log 10 RQ Ct status 
AR 0.717062126 0.895264744 0.828074168 -8.19E-02 Valid 
ESR1 0.37138057 0.557070856 1.49976392 0.176022901 Valid 
ESR2 0.827871085 0.9384879 0.977104209 -1.01E-02 no_detection 
ESRα 6.69E-02 0.306421816 1.318416972 0.120052785 Valid 
ESRβ 0.142428167 0.359818528 0.766827141 -0.115302524 no_detection 
ESRγ 8.38E-02 0.306421816 0.370869976 -0.430778323 no_detection 
HNF4α 6.19E-02 0.306421816 0.679747864 -0.167652148 no_detection 
HNF4γ 0.210268676 0.435185497 1.011842823 5.11E-03 no_detection 
DAX 8.13E-02 0.306421816 0.68290204 -0.16564159 no_detection 
SHP 0.183928516 0.420408036 0.935968913 -2.87E-02 no_detection 
REV-ERBα 0.283110224 0.485331813 1.086945107 0.036207612 Valid 
REV-ERBβ 0.367698411 0.557070856 0.869006097 -6.10E-02 Valid 
LXRβ 0.244791842 0.435185497 0.919194608 -0.036592532 Valid 
LXRα 0.453896297 0.640794772 1.111981445 4.61E-02 Valid 
FXRα 0.177188045 0.420408036 0.568060438 -0.245605456 no_detection 
PXR 1.23E-02 0.197477197 1.69864364 0.230102277 no_detection 
CAR 9.97E-02 0.306421816 1.066878734 2.81E-02 no_detection 
TR2 0.860280575 0.9384879 1.057275229 0.024188057 Valid 
TR4 0.108524393 0.306421816 1.184316301 0.073467707 Valid 
TLX 0.646216382 0.844775347 1.31797315 0.119906563 no_detection 
PNR 0.104041394 0.306421816 0.847599435 -7.18E-02 no_detection 
COUP-TF1 7.33E-02 0.306421816 0.726072986 -0.139019721 no_detection 
COUP-TF2 0.233770066 0.435185497 0.841249975 -7.51E-02 no_detection 
EAR2 0.509766718 0.699108642 1.207159071 8.18E-02 Valid 
GR 0.942221836 0.942221836 1.035824315 1.53E-02 Valid 
MR 0.651180996 0.844775347 1.072429767 3.04E-02 Valid 
NUR77 4.80E-02 0.306421816 0.798296535 -9.78E-02 Valid 
NURR1 2.69E-02 0.306421816 0.564918443 -0.248014246 Valid 
NOR1 8.88E-02 0.306421816 0.584325799 -0.233344939 Valid 
SF-1 0.942221836 0.942221836 1.137379772 5.59E-02 no_detection 
LRH-1 0.239236187 0.435185497 0.286538071 -0.542817666 no_detection 
GCNF 0.397791586 0.578605944 0.991002235 -3.93E-03 no_detection 
PGR 0.931241571 0.942221836 3.047873369 0.483996919 no_detection 
PPARα 0.727402605 0.895264744 1.038005713 1.62E-02 Valid 
PPARδ 0.892927156 0.942221836 0.993065847 -3.02E-03 Valid 
PPARγ 0.325300175 0.538427876 0.832760164 -7.95E-02 no_detection 
RARα 0.367698411 0.557070856 0.893241238 -4.90E-02 Valid 
RARβ 6.00E-02 0.306421816 0.661229179 -0.17964799 no_detection 
RARγ 0.85486107 0.9384879 1.087058177 3.63E-02 Valid 
RORα 0.844042824 0.9384879 1.777288512 0.249757934 Valid 
RORβ 0.811771993 0.9384879 1.026365863 1.13E-02 no_detection 
RORγ 0.236491961 0.435185497 1.179687518 7.18E-02 Valid 
RXRα 2.06E-03 0.098687355 1.366264791 0.135534877 Valid 
RXRβ 0.212792165 0.435185497 1.147093214 5.96E-02 Valid 
RXRγ 9.15E-02 0.306421816 0.784093346 -0.105632232 no_detection 
TRα 3.62E-02 0.306421816 0.813979664 -8.94E-02 Valid 
 
TRβ 8.28E-03 0.197477197 1.930074241 0.285574015 no_detection 
VDR 0.136878489 0.359818528 1.093297437 3.87E-02 Valid 
*Table displays the P values and adjusted P values of target genes before and after the application of False Discovery 
Rate (FDR) for multiple comparisons, respectively. The relative quantification (RQ) linear and log10 denotes the 
calculated fold differences [between target (obese) and the calibrator/reference (healthy weight controls) in a linear and 
log scale, respectively], normalised against the mean of the Genorm selected controls, GAPDH, PGK1 and UBC. Bold 
red indicates genes differentially expressed in a significant manner.  
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Figure 4.7: Ranked relative expression of Nuclear Receptor mRNA expression in pre-pubertal obese (n = 71) 
[black] and healthy weight (n = 34) [white] children normalised against the median of GAPDH, PGK1 and UBC. 
Genes that were not detected in ≥50% of samples were treated as not detected, given a value of zero and not added to 
this graph. Error bars represent standard error of the mean (SEM). 
 
Thus overall although we were able to detect a small number of NR transcripts differentially 
expressed between the obese and health non-obese cohorts, these apparently significant changes, 
after undergoing adjustment (FDR) for multiple comparisons did not remain significant.   
 
4.3.2 Manual RT-PCR of Obese Male Children after a 12 Months Lifestyle Intervention 
 Only 11 of the 33 obese male children that attended the 12 month lifestyle intervention 
provided blood samples for PBMC extraction after the intervention. 3 of these 11 children did not 
show any improvements in their BMI or percentage fat (data not shown). Moreover, the PBMC 
RNAs from the female subjects at 12 months (N=12) was unfortunately unsuitable for further 
analysis as well due to concerns about the quality of the RNA extractions.  The failure to obtain a 
larger number of 12 month blood samples for PBMC gene expression analysis in our obese cohort 
thus severely limited the power of the study to investigate the effects of the lifestyle intervention. 
Nevertheless, in order to determine if a change in gene expression was detectable in these 11 
subjects, manual RT-PCR was conducted on these samples and compared with their matching 
baseline samples and 11 healthy non-obese male controls who had available RNA for analysis. The 
relative expression of the 3 NRs (TRα, TRβ and PXR) that were differentially expressed in the 
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baseline male samples was investigated relative to the endogenous control PGK1. PGK1 was 
chosen because it was the common endogenous control that was selected for both cohorts in the 
TLDA analysis.  
 The expression of PXR was further up-regulated in the obese cohort after the 12 month 
lifestyle intervention when compared to the baseline and to the healthy weight controls 
(Figure 4.8a). Expression of TRα on the other hand increased after the 12 month lifestyle 
intervention to expression levels similar to the healthy weight cohort (Figure 4.8b). When compared 
to the baseline cohort, the expression of TRβ decreased after the lifestyle intervention, but was still 
much higher than in the healthy weight cohort, but due to the small numbers of RNA samples 
available for repeat study at 12 months, none of these changes were statistically significant at 12 
months compared to baseline NR expression (Figure 4.8c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: RT-PCR expression of (a) PXR, (b) TRα and (c) TRβ in male obese children before and after a 12 
month lifestyle intervention compared to healthy weight children relative to the endogenous control PGK1 (n = 
11 for each cohort). The expression of PXR after the 12 month lifestyle intervention increased slightly and was higher 
as compared to healthy controls. The expression of TRα in the obese male children was lower at baseline however, after 
the intervention, the expression was similar to their healthy weight counterparts and the expression of TRβ in the obese 
male children after the intervention was lower as compared to their samples at baseline however, their expression was 
still higher as compared to their healthy weight counterparts. Error bars represent standard error of the mean (SEM). 
 
 
4.4 Discussion 
Obesity has become a global epidemic that is resulting in millions of people suffering from 
an array of serious health issues including T2DM and CVD. More importantly, adults are not the 
only ones gaining excessive weight but children as young as 5 years old are now becoming 
overweight and obese, with significant health consequences. Consequently, children are diagnosed 
with secondary diseases associated with obesity at a young age and this increases their mortality 
rates during adulthood (Baker et al., 2007, Ludwig, 2007, Poulsen et al., 2011). Risk for obesity is 
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influenced by a number of environmental factors including sedentary lifestyle and consumption of 
high-calorie nutrient poor foods. Interestingly, genetics and hormones play key roles in modulating 
risk for obesity where mutations in certain genes or the influence of NRs can affect the controls of 
appetite, metabolism, inflammation and energy expenditure (Caprio, 2012). The NR superfamily 
especially is involved in regulating the expression of genes that control metabolic and inflammatory 
pathways involved in risk for obesity. NRs regulate expression of multiple genes involved in 
cholesterol, lipid and glucose metabolism that affects adiposity and induces development of 
secondary diseases such as T2DM and metabolic syndrome (Auwerx et al., 2003; 
Lau et al., 2008, 2011, Myers et al., 2006, 2009; Pearen et al., 2006; Peet et al., 1998; 
Raichur et al., 2010).  
The use of PBMCs in gene expression studies has aided in understanding the molecular 
mechanisms underlying several human diseases. These have included a few limited studies on 
obese subjects where oxidative stress and inflammation related genes were found to be altered 
during weight gain (Arvidsson et al., 2004; Chiappini et al., 2006, Crujeiras et al., 2008; 
Goyenechea et al., 2009; Horwitz et al., 1997; Maes et al., 2006). However, no gene expression 
studies involving PBMCs have been performed to identify whether there is a significant role for 
NRs in children with obesity. Therefore, in this pilot NR gene expression study, PBMCs from 
overweight and obese children were compared to their healthy weight control children to investigate 
the effects of a lifestyle intervention program on the expression levels of these NRs.   
In our study, PBMCs in obese children displayed aberrant expression of NR genes that have 
known functions involved in obesity, diabetes and metabolism. Interestingly, the male obese 
children had aberrant expression of PXR which is sensitive to endocrine “disruptors” as PXR is 
involved in metabolism of environmental toxins especially in the liver and THRβ, which is 
involved in the regulation of growth and metabolism in response to food restriction 
(Kudo et al., 2009, Bryzgalova et al., 2008, Amorim et al., 2009). It has been shown that PXR 
expression is up-regulated in TSOD (Tsumura, Suzuki, obese, diabetes) mice, a model of Type 2 
Diabetes and obesity (Kudo et al., 2009). THRβ selective agonists have recently been shown to be 
useful against diet-induced obesity in rodents (Bryzgalova et al., 2008, Amorim et al., 2009). In 
addition, the expression of several NR genes (COUP-TF1 and RARβ) that are involved in the 
development of obesity and metabolism were down-regulated in the male obese children but their 
expression were below the reliable detection limit and/or PCR failed in >50% of the cohort (data 
not shown). 
In the female obese children, only GCNF and RXRα were differentially up-regulated. This 
could indicate that there is a gender difference in the type of NRs affected with obesity. GCNF is 
  
 
125 
 
known to be involved in neurogenesis and germ cell development. Though interesting, the 
biological significance for the observed up regulation of GCNF expression in these female obese 
children remains unclear so requires further study (Zechel C, 2005).  In regard to RXR function in 
obesity, mice lacking RXRα in adipocytes are resistant to dietary- and chemically-induced obesity 
and have impaired fasting-induced lipolysis, indicating a role for RXRα in adipocyte function and 
differentiation (Imai et al., 2001). Unfortunately, possibly due to technical issues that were beyond 
the study’s control, the level of NR expression in the PBMC RNA from the female cohort was low 
with CT values required for expression detection at 35. Thus, the results from this female 
expression data must be interpreted with this in mind. As no remaining RNA was unfortunately 
available from these female subjects we were unable to repeat these studies.  We nevertheless 
decided to combine the baseline male and female expression data for further study to determine if 
any differential expression in a larger sample size number could be detected. 
When all the samples from both genders were combined, Nur77, NURR1, and TRα were 
observed to be down-regulated in obese children while RXRα remained up-regulated when 
compared to their healthy weight counterparts. As mentioned before, orphan receptors NR4As, 
Nur77 and NURR1 haven been identified to be involved in regulating lipid and glucose metabolism 
(Myers et al., 2009). Interestingly, mice lacking the TRα gene displayed higher energy expenditure 
and fat oxidation and were resistant to diet-induced obesity which is opposite to what we observe in 
this study where TRα was down-regulated in obese children (Pelletier et al., 2008). 
RNA PBMC samples from 11 obese male children were collected after the 12 month 
lifestyle intervention program.  The mRNA expression of the three NRs (PXR, TRα and TRβ) that 
were found to be differentially expressed at baseline in the male cohort was re-investigated by qRT-
PCR and compared to RNA samples obtained at baseline from 11 non-obese healthy males of 
similar age. The expression level of TRα in the obese cohort was similar to the healthy non-obese 
cohort while the expression level of TRβ decreased when compared to its baseline levels.  
However, none of these changes were found to be statistically significant probably due to the small 
number of samples used in this study. Thus a larger cohort would be needed to validate these gene 
expression results following the lifestyle intervention. Samples from the female cohort were 
collected after the 12 months intervention, however, the quality of the RNA obtained from these 
samples were found to be unsatisfactory for further analysis with qRT-PCR. Thus the study was 
only concentrated on the male cohort for effects of lifestyle intervention on the expression levels of 
NRs in obese subjects.  
As NRs modulate a diverse metabolic gene expression program that regulates glucose and 
lipid metabolism and insulin sensitivity, our lack of analysis of downstream change in metabolic 
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gene expression is a limitation of these studies.  If time permitted a more global assessment of gene 
expression using a microarray approach of the PBMCs from this unique childhood cohort would 
have been beneficial. Such studies may potentially reveal insightful changes in metabolic gene 
pathways that predispose obese children to insulin resistance or non-alcoholic steatohepatitis 
(NASH) that changes in NR gene expression in themselves may not necessarily reveal. 
As no previous studies examining NR gene expression in PBMCs from any children (obese 
or non-obese) has previously been published, these studies at least provide the first NR gene 
expression profiles in PBMCs that may potentially be utilised as healthy control data in future 
PBMC gene expression studies in children. 
Overall, these preliminary results failed to detect any significant differentially expressed NR 
transcripts between the obese and non-obese cohorts at baseline or following the lifestyle 
intervention. In retrospect, this suggests that there is no significant difference in NR transcripts or 
that there is a lack of statistical power – a limitation, which potentially a study with a larger cohort 
of children with obesity, perhaps with better defined metabolic complications, may have overcome. 
Nevertheless based on the known critical roles of NRs in metabolism in various obese 
models (human and animal), the hypothesis that NRs play a critical role in the development of 
childhood obesity and its underlying complications remains valid and to be tested in further 
controlled studies. 
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Table S4.1: List of NRs mRNA relative expression of pre-pubertal male children normalised against the median of GUSB, HPRT1 and PGK1. 32 out of 48 NR genes were 
expressed in the obese while 31 were expressed in the healthy weight. * ND – Gene not detected or more than 50% of the samples failed the detection criteria and bolded NRs were 
differentially expressed. 
No 
 
Nuclear 
Receptor Nomenclature 
Relative Expression 
No 
Nuclear 
Receptor Nomenclature 
Relative Expression 
Obese Healthy Weight Obese Healthy Weight 
MEAN SD MEAN SD MEAN SD MEAN SD 
1 AR NR3C4 5.57E-02 4.80E-02 6.70E-02 5.90E-02 25 PPARα NR1C1 3.69E-01 8.85E-02 3.46E-01 1.21E-01 
2 CAR NR1I3 ND ND ND ND 26 PPARδ NR1C2 1.54E+00 4.68E-01 1.52E+00 6.09E-01 
3 COUP-TFI NR2F1 ND ND ND ND 27 PPARγ NR1C3 6.22E+00 3.57E+01 1.22E-02 1.45E-02 
4 COUP-TFII NR2F2 ND ND ND ND 28 PR NR3C3 ND ND ND ND 
5 DAX-1 NR0B1 ND ND ND ND 29 PXR NR1I2 2.65E-02 1.81E-02 1.15E-02 1.08E-02 
6 EAR-2 NR2F6 1.12E-01 5.20E-02 1.03E-01 4.60E-02 30 RARα NR1B1 4.70E+00 2.63E+00 5.67E+00 2.80E+00 
7 ERα NR3B1 9.01E-02 4.19E-02 8.00E-02 5.75E-02 31 RARβ NR1B2 ND ND ND ND 
8 ERβ NR3B2 1.98E-02 1.28E-02 2.08E-02 1.87E-02 32 RARγ NR1B3 9.97E-02 5.34E-02 7.86E-02 3.69E-02 
9 ERRα NR3B3 1.61E-01 7.93E-02 1.35E-01 5.58E-02 33 Rev-ErbAα NR1D1 1.74E+00 6.87E-01 1.82E+00 8.21E-01 
10 ERRβ NR3A1 ND ND ND ND 34 Rev-ErbAβ NR1D2 9.47E-01 3.76E-01 9.81E-01 6.22E-01 
11 ERRγ NR3A2 ND ND ND ND 35 RORα NR1F1 3.06E+00 1.28E+00 2.67E+00 2.00E+00 
12 FXR NR1H4 ND ND ND ND 36 RORβ NR1F2 3.01E-01 1.67E+00 ND ND 
13 GCNF NR6A1 2.73E-02 2.55E-02 2.23E-01 8.12E-01 37 RORγ NR1F3 3.79E-01 3.02E-01 2.43E-01 1.37E-01 
14 GR NR3C1 4.71E+00 1.34E+00 4.41E+00 2.05E+00 38 RXRα NR2B1 5.05E+00 2.25E+00 4.23E+00 2.37E+00 
15 HNF4α NR2A1 ND ND ND ND 39 RXRβ NR2B2 7.85E-01 3.26E-01 6.51E-01 3.62E-01 
16 HNF4γ NR2A2 ND ND ND ND 40 RXRγ NR2B3 ND ND ND ND 
17 LRH-1 NR5A2 ND ND ND ND 41 SF1 NR5A1 3.36E-01 1.61E+00 ND ND 
18 LXRα NR1H2 7.86E-02 3.84E-02 6.60E-02 3.86E-02 42 SHP NR0B2 ND ND ND ND 
19 LXRβ NR1H3 3.68E+00 1.53E+00 4.06E+00 1.25E+00 43 TLX NR2E1 ND ND ND ND 
20 MR NR3C2 3.25E-01 1.13E-01 2.89E-01 1.89E-01 44 TR2 NR2C1 3.93E-01 2.34E-01 2.85E-01 2.55E-01 
21 NOR1 NR4A3 1.77E-01 2.58E-01 3.01E-01 3.37E-01 45 TR4 NR2C2 1.46E+00 4.65E-01 1.21E+00 6.47E-01 
22 Nur77 NR4A1 6.59E-01 3.18E-01 8.86E-01 5.65E-01 46 TRα NR1A1 1.59E+00 5.82E-01 2.06E+00 8.58E-01 
23 NURR1 NR4A2 6.08E-01 6.03E-01 1.23E+00 1.39E+00 47 TRβ NR1A2 1.92E-02 1.36E-02 ND ND 
24 PNR NR2E3 ND ND ND ND 48 VDR NR1I1 1.46E+00 6.09E-01 1.51E+00 7.01E-01 
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No Nuclear Receptor Nomenclature 
Relative Expression 
No Nuclear Receptor Nomenclature 
Relative Expression 
Obese Healthy Weight Obese Healthy Weight 
MEAN SD MEAN SD MEAN SD MEAN SD 
1 AR NR3C4 4.73E-04 4.59E-04 5.65E-04 5.88E-04 25 PPARα NR1C1 ND ND ND ND 
2 CAR NR1I3 ND ND ND ND 26 PPARδ NR1C2 3.03E-03 1.03E-03 2.97E-03 1.23E-03 
3 COUP-TFI NR2F1 ND ND ND ND 27 PPARγ NR1C3 1.25E-02 5.22E-03 1.26E-02 5.17E-03 
4 COUP-TFII NR2F2 ND ND ND ND 28 PR NR3C3 6.70E-05 7.75E-05 6.63E-05 5.40E-05 
5 DAX-1 NR0B1 ND ND ND ND 29 PXR NR1I2 1.81E-04 1.37E-04 1.54E-04 1.65E-04 
6 EAR-2 NR2F6 1.22E-03 8.00E-04 1.13E-03 9.58E-04 30 RARα NR1B1 4.88E-02 1.99E-02 5.51E-02 3.09E-02 
7 ERα NR3B1 8.76E-04 5.46E-04 6.97E-04 4.99E-04 31 RARβ NR1B2 ND ND ND ND 
8 ERβ NR3B2 1.48E-04 1.12E-04 1.40E-04 9.19E-05 32 RARγ NR1B3 7.95E-04 3.87E-04 9.15E-04 8.46E-04 
9 ERRα NR3B3 1.30E-03 7.31E-04 9.83E-04 7.99E-04 33 Rev-ErbAα NR1D1 1.38E-02 5.66E-03 1.72E-02 9.70E-03 
10 ERRβ NR3A1 ND ND ND ND 34 Rev-ErbAβ NR1D2 5.51E-03 3.58E-03 1.00E-02 8.92E-03 
11 ERRγ NR3A2 ND ND ND ND 35 RORα NR1F1 2.08E-02 1.64E-02 2.82E-02 2.67E-02 
12 FXR NR1H4 ND ND ND ND 36 RORβ NR1F2 8.72E-05 8.34E-05 1.41E-04 2.81E-04 
13 GCNF NR6A1 2.37E-03 1.29E-02 1.39E-04 7.63E-05 37 RORγ NR1F3 2.88E-03 2.14E-03 2.42E-03 1.88E-03 
14 GR NR3C1 3.56E-02 1.65E-02 3.66E-02 1.64E-02 38 RXRα NR2B1 5.57E-02 2.05E-02 4.31E-02 3.70E-02 
15 HNF4α NR2A1 ND ND ND ND 39 RXRβ NR2B2 5.96E-03 4.15E-03 5.01E-03 2.49E-03 
16 HNF4γ NR2A2 ND ND ND ND 40 RXRγ NR2B3 ND ND ND ND 
17 LRH-1 NR5A2 ND ND ND ND 41 SF1 NR5A1 5.52E-05 5.59E-05 8.05E-05 8.48E-05 
18 LXRα NR1H2 7.57E-04 3.65E-04 1.01E-03 1.42E-03 42 SHP NR0B2 ND ND ND ND 
19 LXRβ NR1H3 3.52E-02 1.19E-02 3.99E-02 2.77E-02 43 TRα NR1A1 1.29E-02 5.25E-03 1.67E-02 9.07E-03 
20 MR NR3C2 2.89E-03 1.51E-03 3.42E-03 1.85E-03 44 TRβ NR1A2 1.29E-04 1.16E-04 8.65E-05 8.76E-05 
21 NOR1 NR4A3 1.57E-03 2.66E-03 3.23E-03 3.68E-03 45 TLX NR2E1 ND ND ND ND 
22 Nur77 NR4A1 7.15E-03 4.68E-03 8.93E-03 7.50E-03 46 TR2 NR2C1 2.93E-03 1.97E-03 3.42E-03 2.17E-03 
23 NURR1 NR4A2 5.25E-03 5.93E-03 1.32E-02 1.32E-02 47 TR4 NR2C2 1.18E-02 6.34E-03 1.07E-02 6.23E-03 
24 PNR NR2E3 ND ND ND ND 48 VDR NR1I1 1.56E-02 7.48E-03 1.50E-02 1.56E-02 
Table S4.2: List of NRs mRNA relative expression of female pre-pubertal children normalised against the median of B2M, GAPDH and PGK1. 32 out of 48 NR genes were 
expressed in both the obese and healthy weight cohorts. * ND – Gene not detected or more than 50% of the samples failed the detection criteria and bolded NRs were differentially 
expressed. 
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No Nuclear Receptor Nomenclature 
Relative Expression 
No Nuclear Receptor Nomenclature 
Relative Expression 
Obese Healthy Weight Obese Healthy Weight 
MEAN SD MEAN SD MEAN SD MEAN SD 
1 AR NR3C4 1.49E-03 1.27E-03 4.63E-03 4.21E-03 25 PPARα NR1C1 ND ND ND ND 
2 CAR NR1I3 ND ND ND ND 26 PPARδ NR1C2 9.65E-03 2.87E-03 2.62E-02 8.32E-03 
3 COUP-TFI NR2F1 ND ND ND ND 27 PPARγ NR1C3 4.05E-02 1.61E-02 1.13E-01 4.07E-02 
4 COUP-TFII NR2F2 ND ND ND ND 28 PR NR3C3 8.82E-02 7.42E-01 7.52E-04 7.30E-04 
5 DAX-1 NR0B1 ND ND ND ND 29 PXR NR1I2 6.54E-04 5.32E-04 1.06E-03 1.01E-03 
6 EAR-2 NR2F6 3.44E-03 2.32E-03 8.40E-03 4.28E-03 30 RARα NR1B1 1.36E-01 5.58E-02 4.72E-01 2.64E-01 
7 ERα NR3B1 2.62E-03 1.55E-03 6.37E-03 4.74E-03 31 RARβ NR1B2 ND ND ND ND 
8 ERβ NR3B2 4.97E-04 3.63E-04 1.40E-03 1.08E-03 32 RARγ NR1B3 2.64E-03 1.71E-03 6.59E-03 3.23E-03 
9 ERRα NR3B3 4.21E-03 2.40E-03 1.03E-02 8.27E-03 33 Rev-ErbAα NR1D1 2.11E-02 1.16E-02 1.52E-01 8.51E-02 
10 ERRβ NR3A1 ND ND ND ND 34 Rev-ErbAβ NR1D2 4.54E-02 2.18E-02 9.06E-02 8.06E-02 
11 ERRγ NR3A2 ND ND ND ND 35 RORα NR1F1 7.34E-02 4.66E-02 2.48E-01 2.24E-01 
12 FXR NR1H4 ND ND ND ND 36 RORβ NR1F2 4.61E-03 3.66E-02 5.82E-03 2.94E-02 
13 GCNF NR6A1 4.84E-03 3.42E-02 1.25E-02 6.32E-02 37 RORγ NR1F3 1.02E-02 1.09E-02 1.97E-02 1.09E-02 
14 GR NR3C1 1.17E-01 4.31E-02 3.39E-01 1.52E-01 38 RXRα NR2B1 1.52E-01 5.46E-02 3.19E-01 1.43E-01 
15 HNF4α NR2A1 ND ND ND ND 39 RXRβ NR2B2 1.98E-02 1.13E-02 4.56E-02 2.08E-02 
16 HNF4γ NR2A2 ND ND ND ND 40 RXRγ NR2B3 ND ND ND ND 
17 LRH-1 NR5A2 ND ND ND ND 41 SF1 NR5A1 3.88E-03 2.66E-02 6.58E-04 6.98E-04 
18 LXRα NR1H2 1.04E-01 4.29E-02 5.88E-03 4.83E-03 42 SHP NR0B2 ND ND ND ND 
19 LXRβ NR1H3 2.23E-03 1.05E-03 3.29E-01 1.31E-01 43 TRα NR1A1 4.13E-02 1.51E-02 1.64E-01 9.69E-02 
20 MR NR3C2 8.97E-03 4.41E-03 2.51E-02 1.35E-02 44 TRβ NR1A2 4.61E-04 3.69E-04 ND ND 
21 NOR1 NR4A3 4.53E-03 6.24E-03 3.02E-02 3.96E-02 45 TLX NR2E1 ND ND ND ND 
22 Nur77 NR4A1 1.97E-02 1.11E-02 7.14E-02 4.13E-02 46 TR2 NR2C1 9.74E-03 6.16E-03 2.69E-02 2.09E-02 
23 NURR1 NR4A2 1.61E-02 1.67E-02 1.24E-01 1.66E-01 47 TR4 NR2C2 3.81E-02 1.67E-02 9.11E-02 4.72E-02 
24 PNR NR2E3 ND ND ND ND 48 VDR NR1I1 4.33E-02 1.76E-02 1.19E-01 6.29E-02 
Table S4.3: List of NRs mRNA relative expression of male and female pre-pubertal children (pooled data) normalised against the median of GAPDH, PGK1 and UBC. 32 
out of 48 NR genes were expressed in the obese while 31 were expressed in the healthy weight. * ND – Gene not detected or more than 50% of the samples failed the detection 
criteria and bolded NRs were differentially expressed. 
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Chapter 5: Analysis of the KOALA Childhood Obesity Cohort with NMR-based 
Metabonomics  
5.1 Introduction 
In the previous chapter, NR gene expression provided insights on the metabolic effects of 
childhood obesity by analysing the PBMCs from blood samples collected in the KOALA childhood 
obesity study. Analysing the same metabolic effects in the KOALA study with a different 
analytical platform and from a different type of sample can potentially provide additional 
information that could be useful in improving our understanding of metabolic changes in children 
with obesity.  
Metabonomics is the study of the metabolite composition of biological fluids and tissues 
that provides an overall view of the whole biological system, with the data being interpreted by 
chemometric techniques. NMR-based metabonomics has previously been utilised to analysed data 
for clinical research and diagnostic applications and the types of biological fluids analysed included 
urine, saliva, plasma and serum, which can all be obtained relatively easily and non-invasively, 
require little or no preparation, and utilize small sample sizes, thus making metabonomic studies 
ideally suited for studies in children (Griffin et al., 2001; Holmes et al., 1994; Holmes et al., 2001; 
Robertson et al., 2002, Lindon, 2004). Thus, in this study urine samples collected at baseline and 
after the 12 months lifestyle intervention from the KOALA study were analysed using NMR-based 
metabonomics to determine the urinary metabolic profiles of obese children when compared with 
their healthy counterparts and to determine whether there were any interesting correlations between 
obesity and metabolism. In addition, multivariate analysis was also performed on the baseline NR 
gene expression and clinical data to extract further correlations.  
5.2 Materials and Methods 
5.2.1. Sample Collection 
First morning urine samples were collected at baseline and also after 12 months from 
overweight and obese (OB) children in Arms A and B of the KOALA study. In addition, samples 
were collected at baseline from healthy weight (HW) children in Arm C. Comparisons of the 
metabolic profiles were made between OB children in Arms A and B and HW children in Arm C. 
Urine samples were collected during this study at home in standard plastic containers on the day of 
clinic visit, and parents were instructed to keep containers on ice during transport to the clinic at the 
Mater Children’s Hospital. Sodium azide was added as preservative to a final concentration of 
0.05% to each urine sample container upon arrival in the clinic and all samples were immediately 
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frozen before being transported to the laboratory on ice and stored in a -20°C freezer until 
measurements were performed. No borate was added to these samples before collection as they 
were collected and transported on ice within a few hours before the clinic visit and samples were 
immediately frozen after the addition of final concentration of 0.05% sodium azide which is 
sufficient to maintain the stability of these samples. Following on from the results of our stability 
study (Chapter 2), sodium borate was not used in these samples as the samples were processed on 
ice in a relatively rapid fashion and not left out at room temperatures for extended periods of time.  
5.2.2 Sample Preparation 
Before analysis, samples were thawed at room temperature. Sample preparation included the 
addition of 55 μl sterile filtered (0.22 μm) 1 mol/L sodium phosphate buffer (pH 7.4) to 445 μl of 
each sample to keep the sample pH constant. All samples were supplemented with 49 μl D2O as 
lock substance, as well as 1 μl of 93 mM 2-trimethylsilyl-2H4-propionate (TSP) in D2O for chemical 
shift referencing.  
5.2.3 NMR Spectroscopy 
NMR spectra of the urine samples were recorded on a Bruker AV500 NMR spectrometer 
(Bruker Biospin, Germany) equipped with a 5 mm self-shielded z-gradient triple resonance probe 
located at the Institute for Molecular Bioscience at The University of Queensland. All spectra were 
recorded at 298 K with 256 scans and 32k data points resolution over a spectral width of 10 ppm, 
and the carrier frequency was set to the water resonance. Proton 1D spectra were measured using 
the noesypr1d pulse sequence. Low-power continuous irradiation of the water resonance during the 
NOESY mixing time of 100 ms and the relaxation delay of 2.3 s were used to ensure solvent 
suppression of the water signal. The various samples were measured in batches over a period of 
time (1.5 years), as not all samples were received at the same time. Tuning and matching was 
performed manually on every sample. All samples were automatically shimmed, and measured 
manually due to the small number of samples received during each delivery over a period of two 
years.   
5.2.3.1 Data Processing 
Prior to analysis, all spectra recorded were, Fourier transformed to 32k data points, manually 
phased and baseline corrected, and chemical shifts were referenced to TSP using Topspin (Version 
3.0) (Bruker, Biospin, Germany).  
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5.2.3.2 Data Reduction 
Prior to performing multivariate statistical analysis, the 1D spectra were divided in the 
program Amix (Bruker Biospin, Germany) into integral regions of 0.04 ppm width (called buckets) 
between the range of δ= 10 – 0.2 ppm. The regions from δ=4.6 – 5.0 ppm and δ= 5.5 – 6.5 ppm 
were excluded to prevent variations in the water and urea signals from affecting the analysis, 
resulting in 245 buckets. 
5.2.4 Principal Components Analysis (PCA) 
PCA was performed with SIMCA P+ 12.0.1 (Umetrics, Sweden) using the data reduced 
spectra with Pareto scaling. The number of principle components (PC) in each PCA varied 
according to the number of spectra or type of cohort being analysed (refer to individual PCAs in the 
result section for respective number of PCs and further information about parameters used).  
Classification was performed by assigning different colour codes to each arm to distinguish 
between groups being compared during PCA. The 2D scores plot along the principal components 
that provided the best separation between the groups was selected. The loadings plot of the selected 
principle components was examined and buckets that showed the strongest influence over group 
separation were identified to allow identification of the associated metabolites. 
5.2.5 Partial Least Squares (PLS) Analysis 
To extract more information, supervised PLS was carried out in Simca P+ 12.0.1 using the 
same data reduced spectra and parameters used for PCA. The method of carrying out this analysis 
was generally similar to PCA. In addition, Y tables containing the group identity of each sample 
were included in this analysis.  For example, in a bucket table with two different arms, each sample 
was assigned either 0 or 1 in the Y table (e.g. 0 for OB and 1 for HW). Samples were colour coded 
according to gender or arm. 
5.2.6 Orthogonal-PLS (OPLS/O2PLS) 
Using OPLS, we are able to rotate projections so that the model focuses more on the effect 
of interest, thus improving the model visualization and interpretation. While OPLS performs only a 
one-directional correlation of X with Y, in O2PLS this correlation is bidirectional and also correlates 
Y with X. In addition, O2PLS is useful for integration of more than one types of dataset e.g. 
metabonomics, transcriptomics and proteomics. In this study, O2PLS was performed on the three 
type of datasets collected and analysed from the KOALA program.  
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5.2.7 Metabolite Identification  
The metabolites present in the 1D NMR spectra were identified by comparing their chemical 
shifts and coupling patterns to data deposited in the Biological Magnetic Resonance Data Bank 
(http://www.bmrb.wisc.edu) and the Human Metabolome Database (http://www.hmdb.ca) (Markley 
et al., 2006, Eldon et al., 2008, Wishart et al, 2007, 2009, 2013) . In addition, metabolites were also 
identified with Chenomx NMR Suite 7.1 (Chenomx Inc, Edmonton, Alberta, Canada). 
5.2.8 Pathway Analysis  
Metabolites found to be differential in the obese cohort by the multivariate analysis 
(PCA/OPLS) in Figure 5.1 and Table 5.1, were chosen and used to perform pathway analysis using 
MetaboAnalyst 2.0 (Xie et al., 2009, 2012). Metabolic pathway analysis, which combines pathway 
enrichment analysis and topology analysis, was performed by using MetaboAnalyst 2.0. Lists of 
those identified metabolites which significantly changed in urine were entered. The Homo-sapiens 
library was selected for metabolic pathway analysis. The algorithms used for over-representation 
and pathway topology analyses were the hypergeometric test and relative betweenness centrality, 
respectively. Pathways were considered significant when the P values calculated from the 
enrichment analysis were less than 0.05. 
5.3 Results 
5.3.1 Metabolite Identification 
A total of 35 metabolites were identified with Chenomx and also by consulting the public 
NMR databases (Figure 5.1). Some of these metabolites were influencing the PCA and/or OPLS 
analysis, thus in addition to the metabolites chemical shifts, the changes in metabolite levels 
(increase/decrease) were denoted in Table 5.1.  
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Figure 5.1: Representative 500 MHz 
1
H NMR spectra of a urine sample obtained from an obese subject: (a) 
aromatic region of the spectrum and (b) aliphatic region of the spectrum. Signals of some of the metabolites found 
to be differential in the obese cohort by the multivariate analysis (PCA/OPLS) are labelled red. 
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Table 5.1: Identified metabolites with significant loadings coefficients in PCA/OPLS loadings plot 
Metabolite 1H chemical shift [ppm] multiplicity 
Increase(+)/decrease(-) in 
OB cohort* 
2-hydroxyisobutyrate 1.34s ND 
3-aminoisobutyrate 3.10m; 3.02m; 2.58m; 1.18d ND 
3-hydroxyisovalerate 2.34s; 1.26s ND 
3-indoxylsulfate 7.7d; 7.5d; 7.34s; 7.3t; 7.22t ND 
alanine 3.78d; 1.46d ND 
betaine 3.9s; 3.22s ND 
carnitine 4.56s; 3.46t; 3.42t; 3.22s; 2.46q; 2.42q + 
citrate 2.7d; 2.54d - 
creatine 3.94s; 3.04s + 
creatine phosphate 3.94s; 3.04s + 
creatinine 4.06s; 3.06s + 
DMA 2.72s - 
formate 8.46s ND 
glutamate 3.74q; 2.38t; 2.3t; 2.1m; 2.02m ND 
glutamine 7.58s; 6.86s; 3.78t; 2.46m; 2.42m; 2.18m; 2.1m ND 
glycine 3.58s + 
glycolate 3.98s ND 
guanidoacetate 3.82s + 
hippurate 8.54s; 7.82d; 7.62t; 7.54t; 3.98d - 
imidazole 8.34s; 7.34s ND 
isoleucine 3.66d; 1.98m; 1.46m; 1.26m; 1.02d; 0.9d ND 
lactate 4.1d; 1.34d ND 
leucine 3.7m; 1.74m; 1.70m; 1.66m; 0.94d; 0.9d ND 
mannitol 3.86dd; 3.78d; 3.74m; 3.66q + 
methylsuccinate 2.62m; 2.5q; 2.1q; 1.06d ND 
phenylalanine 7.42t; 7.38t; 7.34d; 3.98q; 3.26q; 3.1q ND 
proline 
4.14q; 3.42m; 3.33m; 2.38m; 2.06m; 2.02m; 
1.98m ND 
sarcosine 3.62s; 2.74s + 
succinate 2.42s - 
taurine 3.46t; 3.26t ND 
TMA 2.86s ND 
TMAO 3.26s - 
tyrosine 7.18d; 6.94d; 3.94q; 3.18q; 3.06q ND 
valine 3.62d; 2.26m; 1.06d; 0.98d ND 
π-methylhistidine 7.9s; 7.1s; 3.94m; 3.7s; 3.3m; 3.22m ND 
*based on PCA/OPLS loadings plot (ND – not detected in loadings plot as correlated with obese cohort) 
^s – singlet, d – doublet,  t – triplet, q – quadruplet, m – multiplet  
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5.3.2 KOALA Metabonomics (Baseline) 
OB children attending the KOALA lifestyle intervention program were divided into two 
cohorts; Arm A and Arm B, as outlined in detail previously in Chapter 4. Urine samples were 
collected from these OB children and their healthy weight counterparts at the start of the lifestyle 
intervention program to acquire the metabolic profiles of these children and observe for any 
differences between the two cohorts. Samples were processed and measured using NMR 
spectroscopy and the obtained 1D spectra were analysed using multivariate statistical methods 
(PCA and OPLS with Pareto scaling). Table 5.2 shows an overview of multivariate analyses 
performed on the datasets obtained from the KOALA childhood obesity cohorts.  Only PCA and/or 
OPLS analysis are discussed in this chapter as OPLS provided a clearer separation than the 
corresponding PLS models.  
 
M – model no., n – number of samples, k - number of variables, A - no. of components 
Model Analysis Scaling Y -table Objective n k A R 2X R 2Y Q 2 CV-ANOVA p
M1 PCA pareto A/B A vs. B 72 276 2 0.263 - 0.0164 -
M2 PLS pareto A/B A vs. B 61 276 2 0.16 0.484 -0.21 1
M3 OPLS pareto A/B A vs. B 61 276 1+1+0 0.16 0.484 -0.869 1
M4 PCA pareto A/C A vs. C 61 195 7 0.584 - 0.0344 -
M5 PLS pareto A/C A vs. C 63 195 2 0.185 0.377 -0.21 1
M6 OPLS pareto A/C A vs. C 63 195 1+1+0 0.185 0.377 -0.737 1
M7 PCA pareto B/C B vs. C 62 195 12 0.768 - -0.0557 -
M8 PLS pareto B/C B vs. C 57 195 2 0.129 0.576 -0.21 1
M9 OPLS pareto B/C B vs. C 57 195 1+1+0 0.129 0.576 0.0114 0.51
M10 PCA pareto A/B/C AB vs. C 99 195 15 0.787 - 0.121 -
M11 PLS pareto A/B/C AB vs. C 90 195 2 0.172 0.291 -0.21 1
M12 OPLS pareto A/B/C AB vs. C 90 195 1+1+0 0.172 0.291 -0.256 1
M13 PCA pareto LW/HW LW vs. HW 43 228 8 0.694 - 0.0285 -
M14 PLS pareto LW/HW LW vs. HW 43 228 2 0.189 0.589 -0.21 1
M15 OPLS pareto LW/HW LW vs. HW 43 228 1+0+0 0.189 0.589 -0.29 1
M16 PCA pareto GW/HW GW vs. HW 41 197 6 0.606 - 0.0501 -
M17 PLS pareto GW/HW GW vs. HW 41 197 2 0.472 0.944 -0.166 1
M18 OPLS pareto GW/HW GW vs. HW 41 197 1+5+0 0.472 0.944 0.153 0.94
M19 PCA pareto LW/GW GW vs.LW 33 197 6 0.599 - -0.101 -
M20 PLS pareto LW/GW GW vs.LW 33 197 2 0.207 0.573 -0.21 1
M21 OPLS pareto LW/GW GW vs.LW 33 197 1+1+0 0.207 0.573 -0.478 1
M22 PCA univariate OB/HW Male 42 32 3 0.426 - 0.277 -
M23 PLS univariate OB/HW Male 42 32 2 0.233 0.883 0.685 2.76E-04
M24 OPLS univariate OB/HW Male 42 32 1+1+0 0.233 0.833 0.565 2.64E-08
M25 PCA univariate OB/HW Female 46 36 3 0.583 - 0.306 -
M26 PLS univariate OB/HW Female - - - - - - -
M27 OPLS univariate OB/HW Female - - - - - - -
M28 PCA univariate OB/HW Combination 86 32 0.422 - - 0.259 -
M29 PLS univariate OB/HW Combination - - - - - - -
M30 OPLS univariate OB/HW Combination - - - - - - -
M31 PCA univariate OB/HW Male 33 227 2 0.36 - 0.119 -
M32 PLS univariate OB/HW Male 33 227 2 0.229 0.668 -0.21 1
M33 OPLS univariate OB/HW Male 33 227 1+2+0 0.316 0.791 -0.474 1
M34 PCA univariate OB/HW Female 37 227 2 0.397 - 0.152 -
M35 PLS univariate OB/HW Female 37 227 2 0.367 0.433 -0.21 1
M36 OPLS univariate OB/HW Female 37 227 1+2+0 0.425 0.274 -0.499 1
M37 PCA univariate OB/HW Combination 67 227 3 0.444 - 0.19 -
M38 PLS univariate OB/HW Combination 67 227 2 0.217 0.268 -0.229 1
M39 OPLS univariate OB/HW Combination 67 227 1+1+0 0.217 0.268 -0.229 1
Metabonomics
Clinical
Nuclear Receptor
Table 2: Overview of multivariate analyses performed with metabonomics, nuclear receptor and clinical data collected from the KOALA 
childhood obesity program
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5.3.2.1 Arms A vs. B 
Firstly, unsupervised PCA (M1) was performed for samples from Arm A and Arm B at 
baseline, and the analysis yielded 2 latent components (n: 72, R
2
X: 0.262, Q
2
:0.0164) (Figures 5.2A 
and B). PCA did not show any form of patterns or clustering between the two arms. Supervised 
OPLS (M3) with Pareto scaling showed separation between the two cohorts along t1, with 
mannitol, creatinine and glutamine, glutamate, citrate, DMA and carnitine urinary levels higher in 
obese children in arm B (Figures 5.2C and D,). However, the OPLS analysis was not considered to 
be statistically significant due to a negative value for Q
2
 and a CV-ANOVA p-value of 1 (n: 61, no. 
of latent components: 1+1+0, R2X: 0.16, R2Y: 0.484, Q2: -0.869). No gender differences were 
observed in both types of analysis. S-plots of the OPLS analysis can be found in Appendix B, 
Figure M3. 
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Figure 5.2: PCA (M1) and OPLS (M3) (Pareto scaled) of baseline urine samples of obese children from Arms A 
and B (closed black squares – Arm A males, opened black squares – Arm A females, closed red circles – Arm B 
males and opened red circles – Arm B females).  A. Scores and B. loadings plot of PCA showed no separation 
between the two groups at baseline (n: 72, no. of components: 2, R
2
X: 0.262, Q
2
: 0.0164). C. Scores and D. loadings 
plots of OPLS analysis indicated a separation between the 2 obese groups however, the separation was not considered to 
be significant and had a very negative value for Q
2 
(n: 61, no. of components: 1+1+0, R
2
X: 0.16, R
2
Y: 0.484, Q
2
: -
0.869).  
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5.3.2.2 Arm A (“Care as usual”) vs. Healthy Weight 
Next, OB samples from Arm A were compared with the HW cohort. PCA (M4) yielded 7 
latent components but did not show any separation between the two cohorts (n: 61, R
2
X: 0.584, Q
2
: 
0.0344) (Figures 5.3A and B), but with the samples identities added, an OPLS (M6) showed a 
noticeable separation between the OB and HW cohorts along t1 (n: 63, no. of latent components: 
1+1+0, R
2
X: 0.185, R
2
Y: 0.373, Q
2
: -0.737) (Figure 5.3C). The loadings and S-plots showed 
elevated urinary levels of creatine, creatinine, mannitol, isoleucine, creatine phosphate, π-
methylhistidine and lower levels of citrate, glutamine and 3-aminoisobutyrate in the OB cohort of 
Arm A compared to the HW cohort (Figure 5.3D, Appendix B, Figure M6). No gender differences 
were observed in both types of analysis. However, the OPLS analysis was not considered to be 
statistically significant due to a negative value for Q
2
 and a CV-ANOVA p-value of 1. 
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Figure 5.3: PCA (M4) and OPLS (M6) (Pareto scaled) of baseline urine samples of obese children from Arm A 
compared to healthy weight children (closed black squares – Arm A males, opened black squares – Arm A 
females, closed blue triangles – healthy weight males and opened blue triangles – healthy weight females).  A. 
Scores and B. loadings plot of PCA showed no separation between the two groups at baseline (n: 61, no. of 
components: 7, R
2
X: 0.584, Q
2
: 0.0344). C. Scores plots of OPLS analysis indicated a separation between Group A and 
their healthy weight counterparts along t1 and but had a negative value for Q
2
 and therefore was not significant (n: 63, 
no. of components: 1+1+0, R
2
X: 0.185, R
2
Y: 0.373, Q
2
: -0.737). D.  The loadings plot indicated that the obese cohort has 
elevated urinary levels of creatine, creatinine, mannitol, isoleucine, creatine phosphate, π-methylhistidine and lower 
levels of citrate, glutamine and 3-aminoisobutyrate. 
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5.3.2.3 Arm B (lifestyle intervention) vs. Healthy Weight 
No separation or clustering patterns were observed between the OB samples in Arm B and 
the HW cohort in the PCA (M7) analysis (n: 62, no. of latent components: 12, R
2
X: 0.768, 
Q
2
: -0.0557) (Figure 5.4A and B). A noticeable separation between OB children from arm B and the 
HW cohort was observed in OPLS (M9) analysis along t1 (Figure 5.4C) with elevated urinary levels 
of creatinine, carnitine, glutamate, π-methylhistidine and decreased levels of citrate, hippurate, 
phenylalanine and succinate in the OB subjects in Arm B (Figure 5.4D, Appendix B, Figure M9) (n: 
57, no. of latent components: 1+1+0, R
2
X: 0.129, R
2
Y: 0.576, Q
2
: 0.0114, CV-ANOVA p-value: 
0.51). No gender differences were observed in both types of analysis. 
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Figure 5.4 PCA (M7) and OPLS (M9) (Pareto scaled) of baseline urine samples of obese children from Arm B 
compared to healthy weight children (closed black squares – Arm B males, opened black squares – Arm  B 
females, closed blue triangles – healthy weight males and opened blue triangles – healthy weight females).  A. 
Scores and B. loadings plot of PCA did not show any separation between the two groups at baseline (n: 62, no. of 
components: 12, R
2
X: 0.768, Q
2
: -0.0557). C. Scores and D. loadings plots of OPLS analysis indicated a separation 
between Group B and their healthy weight counterparts along t1 (n: 57, no. of components: 1+1+0, R
2
X: 0.129, R
2
Y: 
0.576, Q
2
: 0.0114).  The metabolites elevated in Arm B were creatinine, carnitine, glutamate, π-methylhistidine, 
hippurate, phenylalanine and decreased levels of citrate and succinate.  
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5.3.2.4 Arms A and B vs. Healthy Weight 
OB samples from both arms were combined and compared with the HW cohort. No 
separation was observed when PCA was performed (M10, n: 99, no. of latent components: 15, R
2
X: 
0.787, Q
2
: 0.121) (Figure 5.5A and B). OPLS analysis (M12) indicated a preferential clustering 
along t1 (Figure 5.5C) with elevated urinary levels of creatinine, mannitol, glutamate, betaine and 
hippurate together with lower levels of citrate, glycine, 3-aminoisobutyrate and succinate in the OB 
cohort (Figure 5.5D, Appendix B, Figure M12) (n: 90, no. of latent components: 1+1+0, R
2
X: 0.172, 
R
2
Y: 0.291, Q
2
: -0.256, CV-ANOVA p-value: 1). The OB cohort was more spread out while the 
HW cohort was more concentrate on the right side of the scores plot. However, this separation was 
not considered to be significant with a negative Q
2
 value. No gender differences were observed in 
both types of analysis. 
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Figure 5.5: PCA (M10) and OPLS (M12) (Pareto scaled) of baseline clinical data of pre-pubertal obese children 
vs. healthy weight counterparts (closed black squares – males from Arm A, opened black squares – males from 
Arm B, closed red circles – females from Arm A, opened red circles from Arm B, closed blue triangles – healthy 
weight males and opened blue triangles – healthy weight females). A. Scores and B. loadings plot of PCA did not 
show any separation between the groups at baseline (n: 99, no. of components: 15, R
2
X: 0.787, Q
2
: 0.121). C. Scores 
and D. loadings plots of OPLS analysis indicated a separation between the obese cohort and their healthy weight 
counterparts along t1 and however the separation was not considered to be significant  (n: 90, no. of components: 
1+1+0, R
2
X: 0.172, R
2
Y: 0.291, Q
2
: -0.256).  
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5.3.3 Metabonomics (After 12 Months Lifestyle Intervention) 
After the 12 months lifestyle intervention, more than 50% of the entire OB cohort from both 
arms had dropped out of the study. Therefore, to compensate for the low number of OB subjects left 
in this study, the entire OB cohort (Arms A and B together) was divided into two new cohorts; lost 
weight (LW) [n = 13] and gained weight (GW) [n = 16] for further multivariate analysis. A 10% 
loss in weight was considered as a significant weight lost after the 12 months regardless if they have 
had the lifestyle intervention (Arm B) or not (Arm A). 
5.3.3.1 Lost Weight vs. Healthy Weight 
Samples from the LW cohort were first compared with the HW cohort to see if the weight 
loss altered the metabolic profiles of these LW subjects to be more similar to their HW 
counterparts. PCA (M13) analysis did not show any separation between the two cohorts (n: 43, no. 
of latent components: 8, R
2
X: 0.694, Q
2
: 0.0285) (Figures 5.6A and B). Supervised OPLS (M15) 
provided a noticeable separation along t1 (Figure 5.6C) with elevated urinary levels of creatine, 
creatine phosphate, creatinine, π-methylhistidine, mannitol and decreased levels of citrate, 
succinate, 3-aminoisobutyrate and hippurate in the LW cohort (Figure 5.6D, Appendix B, Figure 
M15). However with a negative Q
2
 value, the separation was not significant (n: 43, no. of latent 
components: 1+1+0, R
2
X: 0.189, R
2
Y: 0.589, Q
2
: -0.29, CV-ANOVA p-value: 1).  
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Figure 5.6: PCA (M13) and OPLS (M15) (Pareto scaled) of 12 months urine samples of obese children that lost 
weight vs. baseline healthy weight counterparts (closed black squares – lost weight after 12 months and closed 
red circles – healthy weight children). A. Scores and B. loadings plot of PCA did not show any separation between 
the groups at baseline (n: 43, no. of components: 8, R
2
X: 0.694, Q
2
: 0.0285). C. Scores and D. loadings plots of OPLS 
analysis indicated a separation between the cohort that lost weight and the healthy weight children along t1 however 
with a negative Q
2
 value, the separation was not significant (n:43 , no. of components: 1+1+0, R
2
X: 0.189, R
2
Y: 0.589, 
Q
2
: -0.29). The cohort that lost weight had elevated urinary levels of creatine, creatine phosphate, creatinine, π-
methylhistidine, mannitol and decreased levels of citrate, succinate, 3-aminoisobutyrate and hippurate. 
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5.3.3.2 Gained Weight vs. Healthy Weight 
Samples from those subjects that gained weight were compared to the HW cohort and PCA 
(M16) did not show any separation between the two cohorts (n: 41, no. of latent components: 6, 
R
2
X: 0.606, Q
2
: 0.0501) (Figures 5.7A and B). OPLS (M18, n: 41, no. of latent components: 1+5+0, 
R
2
X: 0.472, R
2
Y: 0.944, Q
2
: 0.153, CV-ANOVA p-value: 0.94) analysis provided a noticeable 
separation between the two cohorts along t1 (Figure 5.7C) with elevated urinary levels of creatine, 
creatine phosphate, creatinine, π-methylhistidine, betaine, mannitol, tyrosine, 3-indoxylsulfate and 
decreased levels of citrate, succinate and proline in the GW cohort (Figure 5.7D, Appendix B, 
Figure M18) .  
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Figure 5.7: PCA (M16) and OPLS (M18) (Pareto scaled) of 12 months urine samples of obese children that 
gained weight vs. baseline healthy weight counterparts (closed black squares – gained weight after 12 months 
and closed red circles – healthy weight children). A. Scores and B. loadings plot of PCA did not show any separation 
between the groups at baseline (n: 41, no. of components: 6, R
2
X: 0.606, Q
2
: 0.0501). C. Scores and D. loadings plots of 
OPLS analysis indicated a separation between the cohort that gained weight and  the healthy weight children along t1 
but had a p-value of 0.94 and therefore was not significant  (n:41 , no. of components: 1+5+0, R
2
X: 0.472, R
2
Y: 0.944, 
Q
2
: 0.153). The cohort that gained weight had elevated urinary levels of creatine, creatine phosphate, creatinine, π-
methylhistidine, betaine, mannitol, tyrosine, 3-indoxylsulfate and decreased levels of citrate, succinate and proline 
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5.3.3.3 Gained Weight vs. Lost Weight 
To investigate if the metabolic profiles of those that lost weight differ from those that gained 
weight after the 12 months lifestyle intervention program, comparison was performed between the 
GW cohort and LW cohort. PCA (M19) did not show any form of separation between the two 
cohorts (n: 33, no. of latent components: 6, R
2
X: 0.599, Q
2
: -0.101) (Figures 5.8A and B). OPLS 
(M21) analysis showed a noticeable separation along t1 (Figure 5.8C) with elevated urinary levels 
of TMAO, citrate, creatinine, leucine, phenylalanine and decreased levels of creatine, creatine 
phosphate, π-methylhistidine, mannitol and hippurate in the GW cohort (Figure 5.8D, Appendix B, 
Figure M21), but was not significant due to a negative Q
2
 value (n: 33, no. of latent components: 
1+1+0, R
2
X: 0.207, R
2
Y: 0.573, Q
2
: -0.478, CV-ANOVA p-value: 1).  
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Figure 5.8: PCA (M19) and OPLS (M21) (Pareto scaled) of 12 months urine samples of obese children that lost 
weight vs. those that gained weight (closed black squares – gained weight after 12 months and closed red circles – 
lost weight after 12 months). A. Scores and B. loadings plot of PCA did not show any separation between the groups 
(n: 33, no. of components: 6, R
2
X: 0.599, Q
2
: -0.101). C. Scores and D. loadings plots of OPLS analysis indicated a 
separation between the cohort that gained weight and the cohort that lost weight after 12 months along t1 however was 
not significant (n:33 , no. of components: 1+1+0, R
2
X: 0.207, R
2
Y: 0.573, Q
2
: -0.478). The cohort that gained weight 
had elevated urinary levels of TMAO, citrate, creatinine, leucine, phenylalanine and decreased levels of creatine, 
creatine phosphate, π-methylhistidine, mannitol and hippurate. 
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5.3.4 Clinical Data (Baseline) 
In addition to urine samples, clinical data were also collected from the OB and HW children 
during the course of the study. A detailed clinical data table can be found in Appendix A. Therefore, 
a similar multivariate statistical analysis (PCA and OPLS with UV scaling) was performed on the 
clinical data by looking at the cohorts based on their genders.  
5.3.4.1 Males 
OB samples from both arms were compared to the HW cohort.  PCA (M22) showed a 
separation along t1 with the HW cohort clustering away from the OB samples (Figure 5.9A) (n: 42, 
no. of latent components: 3, R
2
X: 0.426, Q
2
: 0.277) with higher levels of % body water, IGF-1 and 
Vitamin D in the HW cohort of these male subjects (Figure 5.9B). Further analysis with OPLS 
(M24) provided a clearer separation between the male HW cohort and the OB cohort along t1 (n: 
42, no. of latent components: 1+1+0, R
2
X: 0.233, R
2
Y: 0.833, Q
2
: 0.565, CV-ANOVA p-value: 
2.64E-008) (Figure 5.9C). HW males had higher levels of % body water while OB males as 
expected had a higher body fat mass (FM) (% fat), weight and BMI, C-peptide and higher insulin 
resistance (as measured by HOMA-IR) (Figure 5.9D, Appendix B, Figure M24).   
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Figure 5.9: PCA (M22) and OPLS (M24) (UV scaled) of baseline clinical data of pre-pubertal obese male 
children vs. healthy weight counterparts. A. Scores plot of the PCA (closed black squares – males from Group A, 
opened black squares – males from Group B, and closed blue triangles – healthy weight males) showing separation 
between the obese male cohort and the healthy weight cohort along PC1. B. Loadings plot indicates that % body water 
levels are higher in the healthy weight males while the weight, BMI, waist circumference, % fat, amount of body fat, fat 
mass, HOMA-IR and C-peptide levels were elevated in the obese male cohort (n: 42, no. of components: 3, R
2
X : 0.426, 
Q
2
: 0.227). C. Scores of OPLS showing a better separation between the obese and healthy weight males and also a 
clearer D. loadings plot (n: 42, no. of components: 1+1+0, R
2
X: 0.233, R
2
Y: 0.833, Q
2
: 0.565). 
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5.3.4.2 Females 
PCA (M25) between female OB cohort of both arms and HW cohort showed a separation 
along t1 (n: 46, no. of latent component: 3, R
2
X: 0.583, Q
2
: 0.306) (Figure 5.10A). The HW cohort 
had elevated levels of % body water, HDL and AST while the OB cohort as expected had elevated 
levels of weight, BMI, body at mass (%fat),, C-peptide, triglyceride and insulin resistance (HOMA-
IR)  (Figure 5.10B). 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: PCA (M25) (UV scaled) of baseline clinical data of pre-pubertal obese female children vs. healthy 
weight counterparts. A. Scores plot of the PCA (closed red circles – females from Group A, opened red circles from 
Group B and opened blue triangles – healthy weight females) showing separation between the obese female cohort and 
the healthy weight cohort along PC1. B. Loadings plot indicates that % body water and HDL levels are higher in the 
healthy weight males while the weight, BMI, waist circumference, % fat, body fat, fat mass, triglyceride (TG), HOMA-
IR and C-peptide levels were elevated in the obese female cohort (n: 46, no. of components: 3, R
2
X : 0.583, Q
2
: 0.306).  
 
5.3.4.3 Combined Cohorts 
When the entire OB cohort was combined (both males and females) and compared with the 
HW cohort, PCA (M28) showed separation along t1 with the HW cohort having elevated levels of 
% body water and HDL (n: 86, no. of latent components: 3, R
2
X: 0.422, Q
2
: 0.259)(Figures 5.11A 
and B). The OB cohort had higher weight, BMI, waist circumference, C-peptide, body fat mass (% 
fat, ) and insulin resistance (HOMA-IR).  
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Figure 5.11: PCA (M28) (UV scaled) of baseline clinical data of pre-pubertal obese children vs. healthy weight 
counterparts. A. Scores plot of the PCA (closed black squares – males from Group A, opened black squares – males 
from Group B, closed red circles – females from Group A, opened red circles – females from Group B, closed blue 
triangles – healthy weight males and opened blue triangles – healthy weight females) showing separation between the 
obese cohort and the healthy weight cohort along t1 indicating that the separation is not based on gender. B. Loadings 
plot indicates that % body water and HDL levels are higher in the healthy weight cohort while the weight, BMI, waist 
circumference, % fat, amount of body fat, fat mass, HOMA-IR and C-peptide levels were elevated in the obese cohort 
(n: 86, no. of components: 3, R
2
X : 0.422, Q
2
: 0.259).  
 
5.3.5 Nuclear Receptors (Baseline) 
Relative expression data collected from the gene expression study in chapter 4 was analysed 
again using multivariate statistical analysis (PCA and OPLS with UV scaling) to check if more 
information can be extracted with regards to the effects of obesity on NR expression.  
5.3.5.1 Males 
PCA (M31) showed no separation between the OB cohort of both arms with the HW cohort 
(n: 33, no. of latent components: 2, R
2
X: 0.36, Q
2
:0.119) (Figures 5.12A and B).  OPLS (M33) 
analysis provided a noticeable separation between the OB and HW cohort along t1 (Figure 5.12C) 
(n: 33, no. of latent components: 1+2+0, R
2
X: 0.316, R
2
Y: 0.791, Q
2
: -0.474, CV-ANOVA p-value: 
1). These obese male children had an elevated expression of PXR and a decreased expression of 
NUR77 (Figure 5.12D, Appendix B, Figure M33), however due to a negative Q
2
 value, it was not 
significant. 
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Figure 5.12: PCA (M31) and OPLS (M33) (UV scaled) of baseline NR relative expression data of pre-pubertal 
obese male children vs. healthy weight counterparts. A. Scores and B. loadings plot of the PCA (closed black 
squares – obese males and opened black squares – healthy weight males) showing no separation between the two 
cohorts. (n: 33, A: 2, R
2
X: 0.36, Q
2
: 0.119). C. Scores of OPLS showing a noticeable separation between the obese and 
healthy weight males and also a clearer D. loadings plot with elevated levels of PXR in the obese male children 
however it was not significant due to a negative Q
2 
value (n: 33, A: 1+2+0, R
2
X: 0.316, R
2
Y: 0.791, Q
2
: -0.474).  
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5.3.5.2 Females 
Again no separation was observed in the PCA (M34) between female OB subjects and the 
HW cohort (n: 37, no. of latent component: 2, R
2
X: 0.397, Q
2
: 0.152) (Figures 5.13A and B). A 
clearer separation was observed in the OPLS (M36) analysis along t1 (Figure 5.13C) (n: 37, no. of 
latent components: 1+2+0, R
2
X: 0.425, R
2
Y: 0.274, Q
2
: -0.499, CV-ANOVA p-value: 1). These OB 
female children had elevated expression levels of GCNF, RXRα and VDR and reduced expression 
levels of SF-1, TRα LXRα (Figure 5.13D, Appendix B, Figure M36).  
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Figure 5.13: PCA (M34) and OPLS (M36) (UV scaled) of baseline NR relative expression data of pre-pubertal 
obese female children vs. healthy weight counterparts. A. Scores and B. loadings plot of the PCA (closed red circles 
– obese females and opened red circles – healthy weight females) showing no separation between the two cohorts. (n: 
37, A: 2, R
2
X: 0.397, Q
2
: 0.152). C. Scores of OPLS showing a separation between the obese and healthy weight 
females along t1 and also a clearer D. loadings plot with elevated levels of GCNF and VDR and reduced expression 
levels of SF-1, TRα LXRα in the obese female children however, with a negative Q2 value it was not significant (n: 37, 
A: 1+2+0, R
2
X: 0.425, R
2
Y: 0.274, Q
2
: -0.499). 
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5.3.5.3 Combined Cohorts 
When all of the female OB subjects from both arms were combined and compared with the 
HW cohort, PCA (M37) did not show any separation between the two cohorts (Figures 5.14A and 
B) (n: 67, no. of latent components: 3, R
2
X: 0.444, Q
2
: 0.19). However, with OPLS (M39) analysis, 
a slight separation along t1 was observed (Figure 5.14C) with elevated expression levels of NUR77 
in the HW cohort and elevated expression levels of TR2, ESSRα, VDR, RXRα, RARα, RXRβ, SF-
1, GCNF and PPARγ in the OB cohort (n: 67, no. of latent components: 1+1+0, R2X: 0.217, R2Y: 
0.268, Q
2
: -0.229, CV-ANOVA p-value: 1) (Figure 5.14D, Appendix B, Figure M39).  
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Figure 5.14: PCA (M37) and OPLS (M39) (UV scaling) of baseline NR relative expression data of pre-pubertal 
obese children vs. healthy weight counterparts. A. Scores and B. loadings plot of the PCA (closed black squares – 
obese males, opened black squares – healthy weight males, closed red circles – obese females and opened red circles – 
healthy weight females) showing no separation between the cohorts. (n: 67, A: 3, R
2
X: 0.444, Q
2
: 0.19). C. Scores of 
OPLS showing a noticeable separation between the obese and healthy weight children along t1 and D. loadings plot 
showed elevated levels of TR2, ESSRα, VDR,RXRα, RARα, RXRβ, SF-1, GCNF and PPARγ in the obese children 
(n:63, A: 1+1+0, R
2
X: 0.217, R
2
Y: 0.268, Q
2
: -0.229). 
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5.3.6 MetaboAnalyst Pathway Analysis  
Metabolic pathway analysis using MetaboAnalyst 2.0 (Xie et al., 2009, 2012) was used to 
better understand the metabolic changes that occurred in children with obesity from the KOALA 
childhood obesity study. The list of metabolites from Figure 5.1 and Table 5.1 showed a change in 
their levels was used as input to this pathway analysis and several enriched pathways (P<0.05) were 
detected (Figure 5.15) using the Homo sapiens library. The identified metabolic pathways included: 
Arginine and proline metabolism, glycine, serine and threonine metabolism, methane metabolism, 
alanine, aspartate and glutamate metabolism, citrate cycle (TCA cycle), nitrogen metabolism, 
phenylalanine metabolism, D-glutamine and D-glutamate metabolism, glyoxylate and dicarboxylate 
metabolism, aminoacyl-tRNA biosynthesis and purine metabolism.  
 
 
 
 
 
 
 
Figure 5.15: Metabolic pathway analysis: The metabolic pathways are represented as circles according to their scores 
from enrichment (vertical axis) and topology analyses (pathway impact, horizontal axis) using MetaboAnalyst 2.0 The 
color of each metabolic pathway is related to the P value obtained from the enrichment analysis. The size of the circle 
represents the fold enrichment score i.e. –ln(P).. The analysis was generated using the Homo sapiens library. Pathways 
were annotated by numbering when the P values calculated from the enrichment analysis were <0.05. The annotated 
pathways include: 1, Arginine and proline metabolism; 2, Glycine, serine and threonine metabolism; 3, Methane 
metabolism; 4, Alanine, aspartate and glutamate metabolism; 5, Citrate cycle (TCA cycle); 6, Nitrogen metabolism; 7, 
Phenylalanine metabolism; 8 D-Glutamine and D-glutamate metabolism; 9, Glyoxylate and dicarboxylate metabolism; 
10, Aminoacyl-tRNA biosynthesis; 11, Purine metabolism. 
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5.4 Discussion 
It is of great importance that the pathophysiological process of obesity is elucidated and to 
look beyond the mere categorisation of obesity by BMI [a child is considered overweight with a 
BMI of 85-95
th
 percentile and obese above 95
th
 percentile for age and sex (Jonsson et al., 2004)]. It 
is therefore crucial to investigate other physiological changes in the body that are connected to 
obesity including metabolism. Metabonomics has been widely used to profile many diseases, 
including diabetes and heart disease (Ellis et al., 2007), and is therefore potentially useful in 
exploring systemic metabolic changes and biomarker candidates for obesity and its related diseases. 
Therefore in this study, urine samples collected from the KOALA childhood obesity study were 
profiled using NMR-based metabonomics to investigate the differences between obese (OB) and 
healthy weight (HW) children and potentially identify obesity and its related diseases-associated 
metabolites. In addition, clinical and NR gene expression data were also analysed using multivariate 
analysis similar to those of the urine samples to extract more useful information that can be 
correlated with obesity. In a representative 1D NMR spectrum of an OB subject 35 metabolites 
were identified, however, not all of them were responsible for the separation between the OB and 
HW cohorts in the multivariate analysis.  
5.4.1 Obese vs. Healthy Weight Children at Baseline 
At the start of the KOALA program, the obese cohort was randomised into two different 
treatment arms with no discernable significant clinical differences. As expected, PCA did not 
provide any form of separation between the two groups and even though OPLS analysis did provide 
a clear separation between the two arms, it was not considered to be valid as it was not significant 
with a negative Q
2
 value. However, when both OB arms were compared to the healthy weight (HW) 
cohort respectively and together, urinary levels of creatine, creatine phosphate, creatinine, carnitine, 
glutamate, π-methylhistidine, isoleucine, betaine and mannitol were elevated while levels of citrate, 
sarcosine, glycine, succinate, phenylalanine and hipppurate were lower. These analyses were 
unfortunately not significant with either with negative Q
2 
values and/or high C-ANOVA p-values. 
However, it is still worth discussing speculative reasons as to why these metabolites are causing the 
separation between the OB and HW cohorts.  
Creatine is usually synthesized in the kidney and liver from glycine and L-arginine and is 
transported in blood to supply energy (ATP) to primarily the skeletal muscles and brain 
(Figure 5.16) (Walker, 1961). It can then be reversibly phosphorylated to creatine phosphate as an 
energy reserve. Men usually have higher levels of creatine or creatine phosphate as compared to 
women as they have more muscle mass. In addition to creatine being naturally synthesized in the 
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body, foods rich in meat also provide creatine in dietary form. On the other hand, creatinine which 
is produced at a fairly constant rate proportional to muscle mass, is the by-product of creatine in 
muscle or energy metabolism and is excreted in urine. However, there have been studies showing 
that creatinine levels differ over a 24 hour period between obese individuals due to hypertrophy in 
skeletal and cardiac muscles to support the larger fat mass as compared to a lean individual 
(Konishi, 1964). The increase of creatine, creatine phosphate and creatinine levels seen in the OB 
cohorts in both arms could potentially therefore be due to the obese subjects having more muscle 
mass as compared to a lean individual which is reflected in the clinical data (Appendix A). In 
addition, subjects in the OB cohort are more likely to consume a diet rich in meats and potentially 
contributing to the increase in these metabolite levels. Due to an increase in the creatine 
metabolism, the levels of glycine were expected to decrease as it was being converted in the 
process.  
 
 
 
 
 
 
 
 
 
 
Figure 5.16: Outline on how creatine is synthesized in the human body. 
Fatty acids are usually β-oxidised to acetyl CoA which in turns enters the citric acid cycle to 
produce energy in the body. Carnitine is involved in fatty acid metabolism and thus associated with 
obesity because it helps to transport long chain acyl groups of fatty acids from the cytosol into the 
mitochondria where β-oxidation can take place (Cha, 2008). Lower carnitine levels in liver and 
blood samples have been associated with obesity (Kim et al., 2010, 2011) however, what is being 
observed in the urine samples in the current study is opposite. It is plausible that the higher level of 
carnitine being excreted in the urine is indicative that the metabolite is not being circulated and 
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maintained in the body which is consistent with the previous studies. Excess lipids are then stored 
in adipose tissues as triglycerides as shown in the clinical data of the OB cohort. While carnitine 
helps to catabolise fatty acids to produce energy, any excess lipids are usually stored in adipose 
tissues as triglycerides and in the baseline clinical analysis, the OB cohort had elevated plasma 
levels of triglycerides as compared to the HW cohort. Besides being found naturally in beets, 
betaine is also involved in fatty acid metabolism with regards to carnitine production (Kim et al., 
2011). Therefore, an increase in betaine is associated with the increase in carnitine levels in the OB 
cohort. Isoleucine is a type of branched chain amino acid (BCAA) that is involved in metabolism 
and one of them is to improve glucose metabolism and oxidation (Doi et al., 2007). BCAAs 
together with phenylalanine have also been shown to be potential biomarkers for predicting diabetes 
(Wang et al., 2011). Phenylalanine is an amino acid that has been shown to be decreased in mice 
fed a high fat diet (Klien et al., 2011), and therefore mirrors the decreased levels of urinary 
phenylalanine in our OB cohort. A metabolomics study where plasma samples from obese and 
insulin resistant patients were analysed against lean and insulin sensitive controls using PCA, 
revealed that BCAAs, aromatic amino acids (namely Phe and Tyr), C3 and C5 acylcarinitines, as 
well as glutamine, glutamate and alanine were linked with insulin sensitivity based on the HOMA 
score (Newgard et al., 2009). Another study showed the association of BCAA-related metabolites 
with coronary artery disease even after excluding Type 2 diabetes and other clinical variables (Shah 
et al., 2010) indicating that BCAAs are indeed involved in the process of insulin sensitivity.  
The diet of an individual will determine if that individual is at risk of being or are already 
over-weight or obese especially if a balance diet is not maintained on a daily basis. Therefore, what 
is consumed daily will have an impact on the metabolism of any individual. Mannitol is a type of 
sugar alcohol that is commonly found in candies, chewing gum and dried fruits (Kearsley and Dies, 
2006). Therefore, an increase in urinary mannitol levels in the OB cohort is more likely due to a 
dietary source than a metabolic disturbance in the body. However, mannitol can also be synthesis 
by bacteria through the conversion of fructose and glucose molecules, and it is thus possible that 
intestinal bacteria synthesized increase level of mannitol provided the subject consumed a high 
sugar diet which is usually common in OB subjects. Further studies need to be performed in order 
to confirm these conclusions. Likewise, glutamate is mainly present in monosodium glutamate 
(MSG) which is commonly found in many foods especially fast food therefore, it is likely that these 
OB subject have consumed more foods rich with MSG thus increasing their urinary glutamate level 
(Hermanussen et al., 2006). π-methylhistidine and glutamine are commonly found in meats 
especially poultry and therefore, a diet rich in meats will lead to an increase in the metabolite level 
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in the urine. In addition, π-methylhistidine has been shown to be elevated in obese adults when 
compared to healthy controls (Tuma et al., 2005). 
As mentioned before in Chapter 3, hippurate is a conjugate of glycine and benzoate, a 
common food preserving agent and the conjugation can occur in the liver (Gatley et al., 1977) or in 
the microbial gut microflora (Williams et al., 2002). Hippurate then enters the blood stream and is 
eventually excreted in urine. It is possible that because benzoate is usually present in fruits, 
vegetables, tea and coffee, children in the OB cohort are least likely to consume a lot of those types 
of foods as a lot of children in general are not fond of eating their greens and may be too young to 
be consuming caffeine. While the diet of the OB cohort could be a contributing factor to the lower 
urinary hippurate levels, more importantly urinary hippurate is another marker of gut microbiota 
activity and there have been studies suggesting that alterations to the metabolism of microbial gut 
microflora have been associated with obesity (Backhed et al., 2004, Waldram et al., 2009, Calvani 
et al., 2010). In these studies, levels of hippurate were found to be lower in obese individuals or 
animals and were consistent with the results we see in our study. Therefore, it is possible that 
microbial gut microflora play a more prominent role in the decrease of hippurate levels than the 
lack of consumption of benzoate rich foods in these OB subjects.   
As the carnitine levels were elevated in the OB cohort, it was expected that metabolites 
involved in the citric acid cycle would also increase. However, it was shown in this study that the 
citrate levels in the OB cohort was lower when compared to the HW cohort. This result was similar 
to the lower citrate levels in the GH-deficient patient discussed in Chapter 3, indicating that obesity 
as well had caused metabolic alterations to the lipid and choline metabolism (Schirra et al., 2008). 
Likewise sarcosine and succinate levels were previously reported to be elevated in obese subjects 
(Li et al., 2008, Duggan et al., 2011, Rubio-Aliaga et al., 2011) but in our study, both of these 
metabolites were decreased in the OB cohort. 
When these above mentioned metabolites were collated and used as inputs for pathway 
analysis in MetaboAnalyst 2.0, it generated similar metabolite pathways like arginine and proline 
metabolism and also glycine, serine and threonine metabolism etc. that show some of the potential 
effects of childhood obesity on whole body metabolism.  
In the clinical analysis, results showed that in addition to the usual weight and BMI being an 
indicator of obesity, fat mass (FM) as % fat, waist circumference, C-peptide, triglycerides and 
insulin resistance levels were found to be higher while % body water and HDL levels were lower in 
the OB cohort. While these obese children have yet to develop secondary diseases, factors such as 
presence of insulin resistance are indicative that these children are at higher risk of developing 
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T2DM, while low HDL and high triglyceride levels are risk factors for CVD. Therefore, these 
additional factors can be tested for and used in parallel with weight and BMI as indicators for 
children who are overweight and/or obese and at risk of developing associated diseases such as 
T2DM and CVD.   
The NR gene expression data analysed with PCA and OPLS mirrored the results observed 
and discussed in Chapter 4. In addition, to the already discussed NR genes (PXR, TRα, TRβ, 
GCNF, RXRα, NUR77), VDR expression levels were found to be elevated in the female OB cohort 
and TR2, ESSRα, VDR, RARα, RXRβ, SF-1, and PPARγ expression levels were elevated in the 
combined OB cohort. PPAR-γ is involved in controlling the differentiation of adipocytes (Barak et 
al., 1999; Tontonoz et al., 1994) while TR2 is a mediator of preadipocyte proliferation (Gupta et al., 
2007). ESSRα is involved in fatty acid metabolism (Luo et al., 2010), and VDR has been associated 
with patients with T2DM that are obese (Ye et al., 2001). SF-1 is usually a regulator of 
reproduction and is involved in sexual development (Jameson, 2004). However, a recent study 
showed that SF-1 knocked out mice were susceptible to obesity when they were on a high fat diet, 
and that they developed leptin resistance (Kim et al., 2011).  
While the above mentioned metabolites/NRs/clinical factors have been shown in the 
analysis to be altered in the OB cohort, most of the models generated in these analyses were weak 
and not significant, possibly due to the small number of subjects in this study. Most of these 
analyses were not significant according to the significance rules in Simca P+ 12.0.1 (component is 
significant when Q
2
 > 0.05 for OPLS models with 100 observations/samples or less, and all analysis 
had less than 100 observations/samples) and had negative Q
2
 values even though a clear separation 
was observed between the different arms or cohorts. Overall, these altered metabolites, though 
potentially shedding some light on the disturbances that may occur in metabolism due to obesity, 
require further larger more detailed studies before potentially providing a greater understanding of 
the pathophysiological process that occurs in childhood obesity.  
5.4.2 Obese vs. Healthy Weight Children after 12 Months Lifestyle Intervention 
Due to a high-dropout rate of children in the KOALA study after the 12 months lifestyle 
intervention, it was unfortunately not possible to continue with the aim of determining if the 
intervention had any impact on the metabolic profiles of the intervention cohort in arm B.  
Therefore, the study was altered in such a way that the analysis was conducted based on those OB 
subjects that have lost or gained weight after 12 months and compared with the baseline HW 
cohort. Separation was observed when those subjects that lost weight (defined as a 10% total weight 
loss from baseline) in the OB cohort were compared to the HW cohort. Even those OB subjects who 
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lost weight, were still considerably heavier than their healthy counterparts. All of the metabolites 
mentioned above in the baseline analysis were elevated in the cohort that lost weight. As expected, 
the metabolic profiles of the subjects that gained weight after 12 months were still different 
compared to the HW cohort, and they presented similar results as seen in the baseline analysis. 
When the subjects that lost weight were compared with the subjects that gained weight, after 
the lifestyle intervention, separation was observed, with elevated levels of creatinine, TMAO, 
citrate and phenylalanine (in the subjects that gained weight) but lower levels of hippurate, π-
methylhistidine, mannitol, creatine and creatine phosphate levels. While they are still obese, the 
metabolic profiles of these subjects that lost weight were probably more ‘normal’ compared to those 
subjects that gained weight. Therefore, metabolites that were previously elevated in the OB subjects 
in the baseline cohort had decreased.  
5.4.3. Limitations and Future Outlook 
The main limitation of this study was the small sample numbers of OB subjects after the 
lifestyle intervention, which made it difficult to obtain multivariate models that were strong and 
significant. Therefore, for any future obesity NMR-based metabonomic studies, a much better 
planned clinical study needs to be executed. A larger sample number is crucial in obtaining accurate 
and significant metabolic fingerprints especially when investigating such a complex disease such as 
obesity. A similar study  where 65 plasma samples were collected determined the metabolic 
fingerprint of childhood obesity using GC/MS data which was performed using ULDA 
(uncorrelated linear discriminant analysis) and CCA (canonical correlation analysis, with the ability 
to determine new variables with optimal discriminatory ability and small redundancy (Zeng et al., 
2010). Therefore, other types of multivariate analysis could be performed to determine if these 
analyses can obtain a clearer picture of separation between the obese vs non-obese cohorts and if 
possible, samples should be measured using different analytical platforms (e.g. both NMR and MS) 
to extract more metabolites correlated with obesity. Recently, full resolution analysis is preferred in 
contemporary metabonomics analysis (Agnolet et al., 2010, Kim et al., 2013). However, given the 
statistical weakness of our data at a resolution of 0.04 ppm bucketing (which usually yields 
statistically relatively robust results when compared to higher resolution bucketing due to the lower 
number of variables being considered), it is unlikely that our data would provide further 
discriminatory  information at higher resolutions.  
Even though some of the multivariate models we utilised in these studies were considered 
weak, it is still beneficial to bring these data together and analyse them as a multi-model network 
with the aim that the models will be stronger, such that potentially more useful information can be 
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extracted and correlated with obesity and its related diseases. At the same time, metabolites or 
factors that were found to be insignificant might become significant after combining the three types 
of baseline datasets together. While this was not the case in these studies, the bioinformatics and 
statistical analytical process utilised in these studies to unravel potential metabolites and their 
involvement with obesity and associated clinical factors was undertaken rigorously using the latest 
statistical tools available at the time. The metabolites that in this thesis were found to be altered in 
obese children, although not statistically significantly altered, do link up and make metabolic sense 
and mirror other studies. Unfortunately, based on the cohort size and phenotypes we observed, no 
differences between the obese and non-obese cohorts was observable suggesting studies with larger 
numbers of subjects with greater clinical and metabolic differences may be required for significant 
findings to be observable in any future metabolomics studies.  
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Chapter 6: Integration of KOALA Childhood Obesity Data 
6.1 Introduction 
In the previous chapter, metabonomics, NR gene expression and clinical data were analysed 
separately with PLS and OPLS to profile the effects of childhood obesity on metabolism. Results 
from analysing the clinical and NR gene expression data did reveal some variables that were 
noticeably correlated with obesity with the corresponding components showing positive R
2
X, R
2
Y 
and Q
2
 values. Overall, the metabonomics models were though relatively weak, and most models 
did not show any significance. Nonetheless, studying the effects of obesity on metabolism as an 
integrated system which consists of the genetic, metabolic and clinical data has the potential to 
provide a higher level of understanding the interplay between these datasets. Datasets that 
previously provided little or no biological sense when analysed individually might potentially 
provide more insights and yield significant components that are correlated with metabolism and 
obesity when analysed together.  
There are several statistical tools that can be used to integrate the datasets, but in the context 
of this project, O2PLS analysis was chosen because it has the capacity to integrate data from two or 
more different sources or analytical platforms (e.g. metabonomics and clinical data) (Trygg; 2002, 
Trygg and Wold; 2003), which opens the door to the integration of metabolomics, nuclear receptor 
gene expression and clinical data that we want to achieve. O2PLS analysis can identify common 
trends between the two datasets. In addition, correlated (joined) information from the datasets can 
be extracted and separated from systemic variation that is unique to each dataset. This in turn can 
improve the biological interpretation of multiple data sets, as both joint and unique contributions 
can be interpreted. Thus O2PLS is likely to provide additional information to the overall 
understanding of childhood obesity and its effects on metabolism which, as discussed previously, is 
a complex biological process. O2PLS analysis in this chapter was effectively run as an 
unsupervised analysis, because any group identity (e.g. obese or non-obese) was not included in the 
data during analysis. The state of obesity and gender were only used as marker labels without 
influencing the analysis in any way.  
Integration of the datasets was performed in a three-step process as follows: 
1. Each individual data matrix was normalised, scaled and block scaled with the sum of 
squares so that data from each dataset have the same weight relative to the other.  
2. Pair-wise O2PLS analysis was performed by combining two datasets and analysing them 
together. The combinations were: 
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a. Metabonomics vs. clinical  
b. Metabonomics vs. NR gene expression  
c. Clinical vs. NR gene expression  
3.  The best model generated from each type of pair-wise O2PLS analysis was chosen and the 
joint components from this model were integrated with the respective third block of data in 
another round of O2PLS (e.g. best model from NR gene expression vs. clinical O2PLS 
analysis was integrated with the metabonomics block of data). 
a. Metabonomics & Clinical vs. NR 
b. Metabonomics & NR vs. Clinical 
c. Clinical & NR vs. Metabonomics 
A schematic overview of the entire pairwise and integration process is shown in Figure 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Outline of the bootstrapping analysis performed on the three types of datasets. 
 
Z 
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6.2 Materials and Methods 
6.2.1 General Notation 
To create a new bucket table containing all project data (Appendix A & bucket excel tables), 
the bucket table of the OB baseline cohort (Arms A and B) and the HW cohort (Arm C) that was 
created in the metabonomic analysis (Chapter 5) was collated with the baseline NR relative 
expression levels from the NR gene expression study (Chapter 4), and with the clinical data that 
were collected by the GPs during the KOALA study. A ‘bootstrapping’ method was applied to 
analyse the combined datasets together to investigate what is common among them (Figure 6.1). 
The NR gene expression data set will be referred to as N matrix, the clinical data will be referred to 
as C matrix and the metabonomic data as M matrix throughout the rest of this thesis.  
6.2.2 Pre-processing of individual data matrices 
6.2.2.1 Metabonomics  
The entire metabonomics (M) matrix was mean centred by subtracting the mean of each 
column to ensure that the arithmetic mean of each variable over all observations is set to zero. Each 
cell in a column was then divided by the square root of the standard deviations of each column 
(Pareto scaling). Lastly, each cell in the dataset was divided by the sum of squares of the entire 
matrix to give the matrix equal weights with the N and C matrices.  
 
6.2.2.2 Clinical 
The clinical (C) matrix was processed similarly to the M matrix, but each cell in a mean-
centred column was divided by the respective standard deviation of that column (univariate scaling) 
to ensure that the variances of all the variables were equal.  
 
6.2.2.3 Nuclear Receptor 
The NR gene expression (N) matrix had already been normalised and scaled with GeNorm 
in Statminer as previously mentioned (Chapter 4). Therefore, each cell in the matrix just had to be 
divided by the sum of squares of the entire matrix to give the dataset equal weights when compared 
with the M and C matrices.  
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6.2.3 Pairwise Analysis 
Once all three matrices had been normalised, pairwise comparisons were performed between 
these matrices using O2PLS to extract the joint variations between them; (1) matrix N vs. C, (2) N 
vs. M and (3) C vs. M. Samples were labelled according to their obese/healthy weight state and also 
their genders but these data were not used in the O2PLS analysis, thus O2PLS was essentially run 
as unsupervised analysis that was not influenced by these marker variables. None of the matrices 
were scaled in the O2PLS step since they had already been normalised in the pre-processing step. In 
each O2PLS analysis, outliers were removed accordingly, thus each resulting multivariate model 
contained slightly different number of samples (n).  
In order to find out what combination of joint and orthogonal components A + B + C yields 
the best models, analyses were ran with components iterated from 1+0+0 to 3+2+2, and for each 
model Q
2
X and Q
2
Y values were obtained. A maximum of 27 different O2PLS test models needed 
to be calculated, as Simca P+ reports only one Q
2
 value (which is Q
2
X) for each O2PLS analysis, 
and thus each model had to be calculated twice: The Q
2
 value from e.g. matrix N vs. matrix C with 
components 1+0+1 was paired with the Q
2
 value of matrix C vs. matrix N with components 1+1+0. 
The Q
2 
value from the first analysis (N vs. C) was denoted as Q
2
X while the second one (C vs. N) 
was denoted as Q
2
Y. The Q
2
X and Q
2
Y values of all models were plotted together to provide a 
graphical view of the best combination of joint and orthogonal components in each pairwise 
comparison that should then be used as the basis for further integration analysis with a third dataset. 
This process was repeated for all the O2PLS pairwise analysis models. The S-plot (Appendix B) 
from the pairwise analysis provided an insight on metabolite/NR/clinical components (joint 
variables) that were correlated with the obese or healthy weight cohort.  
6.2.4 Addition of Third Dataset 
Once the best combination of joint and orthogonal components was selected, the t and u 
scores (joint variables) from that model were selected and added as a new matrix (designated e.g. 
N+C etc.) onto the third dataset. A second round of O2PLS analysis was performed, this time using 
matrices; (1) N+C vs. M, (2) N+M vs. C and (3) C+M vs. N with similar marker labels (obese and 
healthy weight). Again, O2PLS analysis was performed with latent components ranging from 
1+0+0 to 3+2+2 to obtain the model with the optimum of both Q
2
X and Q
2
Y values (maximum of 
27 different O2PLS models per pairwise comparison) and the S-plot was used in the final model to 
sieve out variables that were correlated between all three data sets, and thus were likely to be 
correlated with obesity.  
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This O2PLS analysis pipeline (section 6.2.2 to 6.2.4) was carried out for three groups of samples; 
(a) males only, (b) females only and (c) the entire cohort. 
6.3 Results 
The overview and statistical figures of merit of the best models of the pairwise and 
integration analysis can be found in Table 1. 
 
M – model no., n – number of samples, k - number of variables, A - no. of components 
6.3.1 Pairwise Analysis 
Pairwise O2PLS analysis was performed on two datasets at a time (e.g. matrix N vs. matrix 
C) to extract the variation that was common between both data sets. To find the model that best 
represents this joint variation between two matrices, the number of latent components was 
systematically varied in a series of O2PLS models, and the best model was chosen based on the 
optimal combination of maximum Q
2
X and Q
2
Y values (Figure 6.2 and Table 6.2). In the following 
steps, only these best models were used for each type of pairwise analysis and discussed in this 
thesis. Selection of aberrant metabolites/NRs/clinical factors is based on loadings plot but more 
importantly were confirmed with corresponding S-plots (Appendix B). Only those metabolites that 
were separated from the centre cluster in the S-plots were considered to be factors influencing the 
scores and loadings plots. 
 
 
Model Analysis Scaling Y -table Objective n k A R
2X R 2Y Q 2X Q 2Y CV-ANOVA p
M1 O2PLS none C/N N vs. C combined 62 261 1+0+0 0.281 0.024 -0.016 -0.0183 1
M2 O2PLS none N/M N vs. M combined 62 261 1+0+0 0.336 0.00891 -0.03 -0.06533 0.94
M3 O2PLS none C/M C vs. M combined 62 261 1+0+0 0.248 0.0148 -0.0243 -0.0446 1
M4 O2PLS none C/N N vs. C male 25 261 2+0+0 0.608 0.156 -0.014 -0.00234 1
M5 O2PLS none N/M N vs. M male 25 261 2+0+0 0.574 0.104 -0.0342 0.00848 1
M6 O2PLS none C/M C vs. M male 25 261 1+0+0 0.386 0.0372 -0.0527 -0.0232 1
M7 O2PLS none C/N N vs. C female 33 261 1+2+1 0.832 0.0835 -0.0767 -0.0341 1
M8 O2PLS none N/M N vs. M female 33 261 1+0+0 0.552 0.0233 -0.035 -0.0591 0.86
M9 O2PLS none C/M C vs. M female 33 261 1+0+0 0.19 0.0439 -0.0306 -0.00351 1
M10 O2PLS none t/u scores /MN+C vs. M combined 62 269 1+0+0 0.104 0.195 -0.232 -0.0417 1
M11 O2PLS none t/u scores /CN+M vs. C combined 62 269 1+0+0 0.196 0.0973 -0.0933 -0.0172 0.77
M12 O2PLS none t/u scores /NC+M vs. N combined 62 269 1+0+0 0.313 0.0521 -0.0193 0.00617 1
M13 O2PLS none t/u scores /MN+C vs. M male 25 269 1+0+1 0.126 0.413 -0.0191 -0.0993 1
M14 O2PLS none t/u scores /CN+M vs. C male 25 269 1+0+0 0.121 0.195 -0.0365 -0.0419 1
M15 O2PLS none t/u scores /NC+M vs. N male 25 269 1+0+0 0.326 0.143 -0.16 -0.0488 1
M16 O2PLS none t/u scores /MN+C vs. M female 33 269 1+0+0 0.122 0.28 -0.174 -906 1
M17 O2PLS none t/u scores /CN+M vs. C female 33 269 1+1+0 1 0.0523 -0.174 -0.00439 1
M18 O2PLS none t/u scores /NC+M vs. N female 33 269 1+2+0 0.841 0.442 0.125 -0.0285 0.98
Table 1: Overview of pairwise and integrated multivariate analyses performed with metabonomics, nuclear receptor and clinical data collected 
from the KOALA childhood obesity program
Pairwise
Integration
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Figure 6.2: Plots of Q
2
X vs. Q
2
Y to determine the best models for each type of pairwise analysis. Q
2
X and Q
2
Y 
values were obtained from components 1+0+0 to 3+2+2 that were generated during O2PLS pairwise analysis.  When 
there was more than 1 possible potential best model, those with * have been selected as the best model based on a more 
positive Q
2
X and Q
2
Y values. Majority of analysis generated components 1+0+0 as the best model except for (D) N vs. 
C (male) [2+0+0], (E) N vs. M (male) [2+0+0] and (G) N vs. C (female) [1+2+1].  
 
 
 
 
 
 
 
 
* 
* 
* 
* 
* 
174 
 
 
Table 6.2: Results from pairwise O2PLS analysis showing Q
2
X and Q
2
Y values and if the analysis was significant 
according to the rules set by SIMCAP+ 12.0.1. 
Type of Pairwise 
O2PLS Analysis 
Best 
Models* 
Q
2
X 
value 
Q
2
Y value Significance Rules Significant 
Nuclear receptor 
vs. Clinical (all) 
1+0+0 
-0.0287 
 
-0.03140 
 
NS 
no 
Nuclear receptors 
vs. Metabonomics 
(all) 
1+0+0 
-0.0300 
 
 
-0.0653 
NS 
no 
Clinical vs. 
Metabonomics (all) 
1+0+0 
-0.0352 
 
 
-0.0857 
 NS 
no 
Nuclear receptor 
vs. Clinical (male) 
2+0+0 
-0.01700 
 
 
-0.01050 
All R1 
no 
Nuclear receptors 
vs. Metabonomics 
(male) 
2+0+0 
-0.0342 
 
 
0.00848 
All R1 
no 
Clinical vs. 
Metabonomics 
(male) 
1+0+0 
-0.0575 
   
 
-0.0595 
 R1 
no 
Nuclear receptor 
vs. Clinical 
(female) 
1+2+1 
-0.0584 
 
 
0.0243 
All NS except unrelated to X - R1 
no 
Nuclear receptors 
vs. Metabonomics 
(female) 
1+0+0 
-0.0350 
 
 
-0.0591 
 R1 
no 
Clinical vs. 
Metabonomics 
(female) 
1+0+0 
-0.09480 
 
 
-0.12100 
NS 
no 
*models are based on (a+b+c) where a – X/Y joint predictive variation, b – the Y-orthogonal variation in X and c – the 
X-unrelated variation in Y. 
^
R1 – a component is significant according to R1 (rule 1) when Q2 > 0.05 for PLS models with 100 
observations/samples or less and all analysis had less than 100 observations/samples.  
#
NS – not significant  
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6.3.1.1 Combined Cohort 
6.3.1.1.1 Nuclear Receptor vs. Clinical Data  
O2PLS analysis between the N matrix and the C matrix generated a total of 27 models, of 
which 1+0+0 was chosen as the best model with the maximum Q
2
X and Q
2
Y values when compared 
to the rest of the models (Figure 6.3A and B, Appendix B Chapter 6 M1) (n: 28 males and 34 
female, R
2
X: 0.281, R
2
Y: 0.024, Q
2
X: -0.016, Q
2
Y: -0.0183, CV-ANOVA p-value: 1). As the best 
model only generated one component, the scores plot was based on t(1) [component] vs. sample 
number. However, it was still possible to observe patterns and clustering between different groups 
in this study (e.g. OB cohort clustering at the top of scores plot while the HW cohort clustered at the 
bottom). Even though the identity of OB, HW and genders were only added as a label and did not 
have any influence on the O2PLS analysis, the scores plot showed clustering between the male and 
female cohorts and also they were separated according to their OB or HW state (Figure 6.3A). In 
this particular model, clustering was based on gender where OB females were associated with 
elevated expression of RARα and LXRβ with decreased GR, RORα, TR4, and MR expression. The 
HW female cohort had elevated VDR and RXRα expression levels. The OB male cohort was 
associated with elevated fat mass, fat weight, BMI, weight, waist circumference, C-peptide, lean 
weight, fat free mass, insulin, insulin resistance, % body fat and lower % body water, AST and 
HDL.  Nonetheless, this analysis was not considered to be significant due to a negative Q
2
 value.  
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Figure 6.3: O2PLS [1+0+0] of baseline nuclear receptor and clinical data of children from the KOALA obesity 
program. (blue triangles – obese females, yellow diamonds – healthy weight females, black dots – obese males 
and red squares – healthy weight males). O2PLS (A) scores and (B) loadings plot of the analysis. OB and HW 
cohorts were separated based on their genders where OB females were associated with elevated expression of RARα 
and LXRβ with decreased GR, RORα, TR4, and MR expression. The HW female cohort had elevated VDR and RXRα 
expression levels. The OB male cohort was associated with elevated fat mass, fat weight, BMI, weight, waist 
circumference, C-peptide, lean weight, fat free mass, insulin, insulin resistance, % body fat and lower % body water, 
AST and HDL. However, this analysis was not significant according to the O2PLS ruling (R
2
X: 0.281, R
2
Y: 0.024, Q
2
X: 
-0.016, Q
2
Y: -0.0183).    
 
 
 
A 
B 
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6.3.1.1.2 Nuclear Receptor vs. Metabonomics Data 
Once again, a total of 27 O2PLS models were generated, and 1+0+0 was chosen as the best 
model. Similar to the pairwise analysis of the N matrix vs. C matrix, the samples were separated to 
their genders, with males having elevated urinary levels of creatinine, creatine, citrate and lower 
levels of unknown metabolites while the female cohort having elevated expression levels of RORα 
and GR together with decreased expression of LXRβ and NUR77 but the analysis was not 
considered to be significant (Figure 6.4A and B, Appendix B Chapter 6 M2) (n: 28 males and 34 
female, R
2
X: 0.336, R
2
Y: 0.00891, Q
2
X: -0.03, Q
2
Y: -0.06533, CV-ANOVA p-value: 0.94).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: O2PLS [1+0+0] of baseline nuclear receptor and metabonomics data of children from the KOALA 
obesity program (blue triangles – obese females, yellow diamonds – healthy weight females, black dots – obese 
males and red squares – healthy weight males). O2PLS (A) scores plot and (B) loadings plot of the analysis. OB and 
HW cohorts were separated to their genders, with males having elevated urinary levels of creatinine, creatine, citrate 
and lower levels of unknown metabolites while the female cohort having elevated expression levels of RORα and GR 
together with decreased expression of LXRβ and NUR77 but this analysis was not significant (R2X: 0.336, R2Y: 
0.00891, Q
2
X: -0.03, Q
2
Y: -0.06533).    
A 
B 
creatinine 
creatinine 
creatine/ creatine 
phosphate/Π-methylhistidine citrate 
citrate 
Π-methylhistidine 
Π-methylhistidine 
sarcosine 
citrate 
unknown 
mannitol 
unknown 3-indoxylsulfate 
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6.3.1.1.3 Clinical vs. Metabonomics Data 
A total of 27 models were generated, and 1+0+0 was the best model chosen (Figure 6.5A 
and B, Appendix B Chapter 6 M3). Samples were observed to be clustering based on gender and 
also the HW males were clustering on the bottom of the scores plot compared to the rest of the 
samples in the analysis. These HW males had higher % body water and AST together with higher 
urinary creatinine, 3-indoxylsufate and some unknowns. Results generated were similar compared 
to the N vs. C and N vs. M pairwise analysis of the combined cohort and were not significant (n: 28 
males and 34 females, R
2
X: 0.248, R
2
Y: 0.0148, Q
2
X: -0.0243, Q
2
Y: -0.0446, CV-ANOVA p-value: 
1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: O2PLS [1+0+0] of baseline clinical and metabonomics data of children from the KOALA obesity 
program (blue triangles – obese females, yellow diamonds – healthy weight females, black dots – obese males and 
red squares – healthy weight males). O2PLS (A) scores plot and (B) loadings plot of the analysis. OB and HW 
cohorts were observed to be clustering based on gender and HW males had higher % body water, AST and HDL 
together with a number of unknown metabolites (3.54 ppm, 3.62 ppm, 3.9 ppm, 6.98 ppm).  However, this analysis was 
not significant according to the O2PLS ruling (R
2
X: 0.248, R
2
Y: 0.0148, Q
2
X: -0.0243, Q
2
Y: -0.0446).    
A 
B 
citrate 
creatinine 
creatinine 
citrate 
unknowns 
leucine 
unknowns 
unknowns 
Creatine/creatine 
phosphate/ π-
methylhistidine 
3-indoxylsulfate 
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6.3.1.2 Male Cohort 
6.3.1.2.1 Nuclear Receptor vs. Clinical Data 
20 models were generated in the N vs. C pairwise analysis for the male cohort, and 2+0+0 
was chosen to be the best model (n: 25, R
2
X: 0.608, R
2
Y: 0.156, Q
2
X: -0.014, Q
2
Y: -0.00234, CV-
ANOVA p-value: 1). A significant separation was observed between the OB cohort and the HW 
cohort in the scores plot (Figure 6.6A, Appendix B Chapter 6 M4). Expression levels of SF-1, PXR, 
LXRβ and PPARγ were elevated in the OB male cohort (Figure 6.6B). In addition, these OB males 
also have higher BMI, weight, waist circumference, fat mass, free fat mass, C-peptide, IGF, % fat, 
dry lean weight and lower % body water, AST and HDL. 
 
 
 
 
 
 
 
 
 
Figure 6.6: O2PLS [2+0+0] of baseline nuclear receptor and clinical data of male children from the KOALA 
obesity program (black dots – obese males and red squares – healthy weight males). O2PLS (A) scores plot and 
(B) loadings plot of the analysis. OB and HW cohorts were significantly separated based on their weights with levels of 
SF-1, PXR, LXRβ and PPARγ elevated in the OB male cohort together with higher BMI, weight, waist circumference, 
fat mass, free fat mass, C-peptide, IGF, % fat, dry lean weight and lower % body water, AST and HDL. (R
2
X: 0.608, 
R
2
Y: 0.156, Q
2
X: -0.014, Q
2
Y: -0.00234).    
 
 
 
 
A B 
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6.3.1.2.2 Nuclear Receptor vs. Metabonomics Data 
2+0+0 was chosen to be the best model from the 24 models generated however, no 
separation was observed between the OB and HW male cohorts despite the O2PLS analysis being 
significant (Figure 6.7A and B, Appendix B Chapter 6 M5) (n: 25, R
2
X: 0.574, R
2
Y: 0.104, Q
2
X: -
0.0342, Q
2
Y: 0.00848, CV-ANOVA p-value: 1).  
 
 
 
 
 
 
 
 
 
Figure 6.7: O2PLS [2+0+0] of baseline nuclear receptor and metabonomics data of male children from the 
KOALA obesity program (black dots – obese males and red squares – healthy weight males). O2PLS (A) scores 
plot and (B) loadings plot of the analysis. OB and HW cohorts were not separated even though this analysis was 
significant according to the O2PLS ruling (R
2
X: 0.574, R
2
Y: 0.104, Q
2
X: -0.0342, Q
2
Y: 0.00848).    
 
6.3.1.2.3 Clinical vs. Metabonomics Data 
1+0+0 was chosen to be the best model out of the 24 models generated (n: 25, R
2
X: 0.386, 
R
2
Y: 0.0372, Q
2
X: -0.0527, Q
2
Y: -0.0232, CV-ANOVA p-value: 1). Although only 1 component 
was generated in this significant model, a pattern was observed with the majority of the HW male 
cohort being in the lower portion of the scores plot as compared to the OB male cohort (HW cohort 
having t(1) values lower than -0.001) (Figure 6.8A, Appendix B Chapter 6 M6). OB male cohort 
had higher weight, BMI, waist circumference, fat mass, fat weight, % fat, C-peptide, triglyceride, 
lean body weight and lower urinary creatinine levels (Figure 6.8B).  
 
A B 
creatinine 
alanine 
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Figure 6.8: O2PLS [1+0+0] of baseline clinical and metabonomics data of male children from the KOALA 
obesity program (black dots – obese males and red squares – healthy weight males). O2PLS (A) scores plot and 
(B) loadings plot of the analysis. OB and HW cohorts were significantly separated with higher BMI, weight, waist 
circumference, fat mass, fat weight, C-peptide, % fat, lean body weight, triglyceride and lower urinary creatinine levels. 
(R
2
X: 0.386, R
2
Y: 0.0372, Q
2
X: -0.0527, Q
2
Y: -0.0232).    
 
 
 
 
 
 
A 
B 
creatinine 
creatinine 
unknown 
Creatine/creatine 
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unknowns 
citrate 
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6.3.1.3 Female Cohort 
6.3.1.3.1 Nuclear Receptor vs. Clinical Data 
Out of the 27 models generated, 1+2+1 (1+1+2 for C vs. N to obtain the clinical loadings 
plot) was chosen to be the best model. No separation was observed in the scores plot and in 
addition, this analysis was not significant (Figure 6.9A – D, Appendix B Chapter 6 M7) (n: 33, R2X: 
0.832, R
2
Y: 0.0835, Q
2
X: -0.0767, Q
2
Y: -0.0341, CV-ANOVA p-value: 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: O2PLS of baseline nuclear receptor and clinical data of female children from the KOALA obesity 
program. (blue triangles – obese females, yellow diamonds – healthy weight females). 1+2+1 O2PLS (A) scores 
plot and (B) loadings plot and 1+1+2 (C) scores plot and (D) loadings plot of the analysis. No separation was observed 
in both scores plot and the analysis performed was not significant (R
2
X: 0.832, R
2
Y: 0.0835, Q
2
X: -0.0767, Q
2
Y: -
0.0341).    
 
A B 
C D 
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6.3.1.3.2 Nuclear Receptor vs. Metabonomics Data 
  With 1+0+0 chosen as the best model out of the 22 models generated, a slight separation 
was observed between the OB and HW female cohort (n: 33, R
2
X: 0.522, R
2
Y: 0.0233, Q
2
X: -0.035, 
Q
2
Y: -0.0591, CV-ANOVA p-value: 0.86). Like in the male cohort (Figure 6.8A), the HW female 
cohort was observed to be located in the lower portion of the scores plot (Figure 6.10A, Appendix B 
Chapter 6 M8). The OB female cohort had elevated expression levels of SF-1, RORA, LXRβ, 
PPARγ, PXR, TRβ and VDR together with higher urinary creatinine, carnitine and lower mannitol 
levels (Figure 6.10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: O2PLS [1+0+0] of baseline nuclear receptor and metabonomics data of female children from the 
KOALA obesity program (blue triangles – obese females, yellow diamonds – healthy weight females). O2PLS (A) 
scores plot and (B) loadings plot of the analysis. OB and HW cohorts were significantly separated with elevated 
expression level of SF-1, RORA, LXRβ, PPARγ, PXR, TRβ and VDR together with higher urinary creatinine, carnitine 
and lower mannitol levels. (R
2
X: 0.522, R
2
Y: 0.0233, Q
2
X: -0.035, Q
2
Y: -0.0591).    
creatinine 
creatinine 
carnitine 
mannitol 
A 
B 
glutamine 
unknowns 
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6.3.1.3.3 Clinical vs. Metabonomics Data 
Out of the 24 models generated, 1+0+0 was chosen to be the best model. but, similar to the 
results in the N vs. C pairwise analysis in the female cohort, no separation was observed in the 
scores plot and in addition, this analysis was not significant (Figure 6.11A and B, Appendix B 
Chapter 6 M9) (n: 33, R
2
X: 0.19, R
2
Y: 0.0439, Q
2
X: -0.0306, Q
2
Y: -0.00351, CV-ANOVA p-value: 
1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: O2PLS [1+0+0] of baseline clinical and metabonomics data of female children from the KOALA 
obesity program (blue triangles – obese females, yellow diamonds – healthy weight females). O2PLS (A) scores 
plot and (B) loadings plot of the analysis. No separation was observed in both scores plot and the analysis performed 
was not significant (R
2
X: 0.19, R
2
Y: 0.0439, Q
2
X: -0.0306, Q
2
Y: -0.00351).    
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6.3.2 Integration of Third Dataset 
The t and u scores from each of the best models were compiled together with the respective 
third matrix (e.g. t and u scores from pairwise analysis N vs. C were combined with the M matrix) 
and O2PLS was ran again with the aim to extract the common denominators between all three data 
sets and to investigate whether the joint variables are correlated with the metabolic effects of 
childhood obesity. Once again, the number of components was systematically varied to find the best 
model for each type of integration, based on the plotted Q
2
X and Q
2
Y values for all the models 
generated (Figure 6.12 and Table 6.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12: Plots of Q
2
X vs. Q
2
Y to determine the best models for each type of integration analysis. Q
2
X and Q
2
Y 
values were obtained from components 1+0+0 to 3+2+2 that was generated during O2PLS integration analysis.  
Majority of analysis generated components 1+0+0 as the best model except for (D) NR+C vs. M (male) [1+0+1], (H) 
NR+M vs. C (female) [1+1+0] and (I) C+M vs. NR (female) [1+2+0].  
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Table 6.3: Results from integration O2PLS analysis showing Q
2
X and Q
2
Y values and if the analysis was 
significant according to the rules set by SIMCAP+ 12.0.1. 
Type of 
Integration 
O2PLS Analysis 
Best 
Models* 
Q2X 
value 
Q2Y 
value 
Significance Rules Significant 
Nuclear receptor + 
Clinical vs. 
Metabonomics (all) 
1+0+0 
-0.232 
 
 
-0.0417 
 
 NS 
No 
Nuclear receptors + 
Metabonomics vs. 
Clinical (all) 
1+0+0 
-0.0933 
 
 
 
-0.0172 
 R1 
No 
Clinical + 
Metabonomics vs. 
Nuclear Receptor 
(all) 
1+0+0 
-0.0193 
 
 
 
0.00617 
 
R1 
No 
Nuclear receptor + 
Clinical vs. 
Metabonomics 
(male) 
1+0+1 
-0.0716 
 
 
 
-0.012 
 
R1 
No 
Nuclear receptors + 
Metabonomics vs. 
Clinical (male) 
1+0+0 
0.00793 
 
-0.0352 
 R1 
No 
Clinical + 
Metabonomics vs. 
Nuclear Receptor 
(male) 
1+0+0 
-0.0357 
 
  
 
-0.0139 
 
 R1 
No 
Nuclear receptor + 
Clinical vs. 
Metabonomics 
(female) 
1+0+0 
-0.174 
 
 
 
-906. 
 
NS  
No 
Nuclear receptors + 
Metabonomics vs. 
Clinical (female) 
1+1+0 
-0.330 
 
 
-0.0493 
 
 R1 
No 
Clinical + 
Metabonomics vs. 
Nuclear Receptor 
(female) 
1+2+0 
0.125 
 
 
 
-0.0285 
 
R1 
No 
*models are based on (a+b+c) where a – X/Y joint predictive variation, b – the Y-orthogonal variation in X and c – the 
X-unrelated variation in Y. 
^
R1 – a component is significant according to R1 (rule 1) when Q2 > 0.05 for PLS models with 100 
observations/samples or less and all analysis had less than 100 observations/samples.  
#
NS – not significant  
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A 
B creatinine 
creatinine 
Creatine/creatine 
phosphate/ Π-
methylhistidine 
hippurate 
citrate proline 
Π-methylhistidine 
3-indoxylsulfate 
6.3.2.1 Combined Cohort 
6.3.2.1.1 Nuclear Receptor + Clinical vs. Metabonomics Data  
9 models were generated in total and 1+0+0 was chosen as the best model according to the 
Q
2
X and Q
2
Y values plotted in Figure 6.12 (n: 28 males and 34 females, R
2
X: 0.104, R
2
Y: 0.195, 
Q
2
X: -0.232, Q
2
Y: -0.0417, CV-ANOVA p-value: 1). Similar to the combined cohort pairwise 
analysis, this analysis did not yield a significant analysis but these samples were clustering 
according to their genders with males having higher urinary creatine, creatine phosphate and 
creatinine levels (Figure 6.13A and B, Appendix B Chapter 6 M10). These male OB subjects also 
have lowered NvCt1 which corresponded to the NRs causing separation in the N vs. C combined 
cohort pairwise analysis which was RARα, RXRα, LXRβ, VDR, GR, TR4, MR and RORα (Figures 
6.3A-B and corresponding N vs. C S-plot in Appendix B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: O2PLS [1+0+0] of t and u scores from the N vs. C pairwise analysis with metabonomics data of 
children from the KOALA obesity program. (blue triangles – obese females, yellow diamonds – healthy weight 
females, black dots – obese males and red squares – healthy weight males). O2PLS (A) scores plot and (B) loadings 
plot of the analysis. OB and HW cohorts were separated based on genders males having higher urinary creatine, 
creatine phosphate and creatinine levels however, this analysis was not significant (R
2
X: 0.104, R
2
Y: 0.195, Q
2
X: -0.232, 
Q
2
Y: -0.0417).    
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6.3.2.1.2 Nuclear Receptor + Metabonomics vs. Clinical Data 
Like the above analysis, 9 models were generated in total and 1+0+0 was chosen as the best 
model (n: 28 males and 34 females, R
2
X: 0.196, R
2
Y: 0.0973, Q
2
X: -0.0933, Q
2
Y: -0.0172, CV-
ANOVA p-value: 0.77). This analysis did not yield a significant analysis, even though samples 
were clustering according to their OB or HW state and also their genders where females had 
elevated levels of PAI-1 (Figure 6.14A and B, Appendix B Chapter 6 M11). In addition, lower 
levels of NvMt1in females corresponded to lower expression of RORα, GR, LXRβ and NUR77 as 
in Figures 4A-B and corresponding N vs. M S-plot in Appendix B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14: O2PLS [1+0+0] of t and u scores from the N vs. M pairwise analysis with clinical data of children 
from the KOALA obesity program. (blue triangles – obese females, yellow diamonds – healthy weight females, 
black dots – obese males and red squares – healthy weight males). O2PLS (A) scores plot and (B) loadings plot of 
the analysis. OB and HW cohorts were separated not only based on their weights but also based on their genders where 
females had elevated levels of PAI-1 however, this analysis was not significant (R
2
X: 0.196, R
2
Y: 0.0973, Q
2
X: -0.0933, 
Q
2
Y: -0.0172).    
 
A 
B 
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6.3.2.1.3 Clinical + Metabonomics vs. Nuclear Receptor Data 
9 models were generated in total and 1+0+0 was chosen as the best model (n: 28 males and 
34 females, R
2
X: 0.313, R
2
Y: 0.0521, Q
2
X: -0.0193, Q
2
Y: 0.00617, CV-ANOVA p-value: 1) and this 
analysis did not yield a significant analysis even though samples were clustering according to their 
genders with elevated expression of GR and decreased expression in LXRβ in females while male 
cohorts had elevated expression of RORα and decreased RARα and RXRα levels (Figure 6.15A and 
B, Appendix B Chapter 6 M12). The male cohorts also had lower levels of CvMt1 and CvMu1 
which corresponded to lower % body water, AST, HDL and creatinine as in Figures 6.5A-B and the 
corresponding C vs. M S-plot in Appendix B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15: O2PLS [1+0+0] of t and u scores from the C vs. M pairwise analysis with nuclear receptor data of 
children from the KOALA obesity program. (blue triangles – obese females, yellow diamonds – healthy weight 
females, black dots – obese males and red squares – healthy weight males). O2PLS (A) scores plot and (B) loadings 
plot of the analysis. OB and HW cohorts were separated not only based on their genders with elevated expression of GR 
and decreased expression in LXRβ in females while male cohort had elevated expression of RORα and decreased 
RARα and RXRα levels but this analysis was not significant with a high p value (R2X: 0.313, R2Y: 0.0521, Q2X: -
0.0193, Q
2
Y: 0.00617).    
A 
B 
190 
 
6.3.2.2 Male Cohort 
6.3.2.2.1 Nuclear Receptor + Clinical vs. Metabonomics Data 
1+0+1 was chosen to be the best model out of the 9 models generated. However, no clear 
separation was observed between the OB and HW male cohort (Figure 6.16A and B, Appendix B 
Chapter 6 M13) (n: 25, R
2
X: 0.126, R
2
Y: 0.413, Q
2
X:-0.0191, Q
2
Y:-0.0993, CV-ANOVA p-value: 
1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: O2PLS [1+0+1] of t and u scores from the N vs. C pairwise analysis with metabonomics data of male 
children from the KOALA obesity program. (black dots – obese males and red squares – healthy weight males). 
O2PLS (A) scores plot and (B) loadings plot of the analysis. OB and HW cohorts were not separated in this analysis 
(R
2
X: 0.126, R
2
Y: 0.413, Q
2
X:-0.0191, Q
2
Y:-0.0993).    
 
 
A 
B creatinine 
creatinine 
creatine 
carnitine 
glycine Π-methylhistidine 
3-indoxylsulfate 
191 
 
6.3.2.2.2 Nuclear Receptor + Metabonomics vs. Clinical Data 
Out of the 9 models generated, 1+0+0 was chosen to be the best model (n: 25, R
2
X: 0.121, 
R
2
Y: 0.195, Q
2
X:-0.0365, Q
2
Y:-0.0419, CV-ANOVA p-value: 1). In this model, the OB and HW 
male cohort was separated from each other with the HW male cohort being in the lower portion of 
the scores plot as compared to the OB cohort (Figure 6.17A, Appendix B Chapter 6 M14). OB male 
cohort had higher BMI, weight, waist circumference, fat weight, fat mass, % fat, C-peptide, 
triglycerides, ALT, insulin, insulin resistance (HOMA), lean body weight, total body weight, fat 
free mass, dry lean weight, % body fat, fasting glucose and lower AST and % body water (Figure 
6.17B). lower levels of NvMt1 and NvMt2 was also associated with the HW males (lower 
expression of SF-1, PXR, RORα, VDR, LXRβ, PPARγ, creatinine, creatine, creatine phosphate, π-
methylhistidine, carnitine and mannitol as shown in Figures 6.7A-B and the corresponding N vs. M 
S-plot in Appendix B).  
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Figure 6.17: O2PLS [1+0+0] of t and u scores from the N vs. M pairwise analysis with clinical data of male 
children from the KOALA obesity program. (black dots – obese males and red squares – healthy weight males). 
O2PLS (A) scores plot and (B) loadings plot of the analysis. OB and HW cohorts were separated with higher BMI, 
weight, waist circumference, fat weight, fat mass, % fat, C-peptide, IGFBP1, triglycerides, ALT, insulin, insulin 
resistance (HOMA), lean body weight, total body weight, fat free mass, dry lean weight, % body fat, fasting glucose 
and lower ALT and % body water (R
2
X: 0.121, R
2
Y: 0.195, Q
2
X:-0.0365, Q
2
Y:-0.0419).    
 
 
 
 
 
 
A 
B 
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6.3.2.2.3 Clinical + Metabonomics vs. Nuclear Receptor Data 
Similar to the results from the N+C vs. M integrated analysis, the best model (1+0+0) 
showed no clear separation in the scores plot (Figure 6.18A and B, Appendix B Chapter 6 M15) (n: 
25, R
2
X: 0.326, R
2
Y: 0.143, Q
2
X:-0.16, Q
2
Y:-0.0488, CV-ANOVA p-value: 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.18: O2PLS [1+0+0] of t and u scores from the C vs. M pairwise analysis with nuclear receptor data of 
male children from the KOALA obesity program. (black dots – obese males and red squares – healthy weight 
males). O2PLS (A) scores plot and (B) loadings plot of the analysis. OB and HW cohorts were not separated in this 
non-significant analysis (R
2
X: 0.326, R
2
Y: 0.143, Q
2
X:-0.16, Q
2
Y:-0.0488).    
6.3.2.3 Female Cohort 
6.3.2.3.1 Nuclear Receptor + Clinical vs. Metabonomics Data 
While the best model (1+0+0) out of the 9 models generated for NR + C vs. M female 
cohort integrated analysis was not significant, a separation was observed in the scores plot with the 
HW female cohort being in the lower portion of the plot (Figure 6.19A, Appendix B Chapter 6 
M16) (n: 33, R
2
X: 0.122, R
2
Y: 0.28, Q
2
X:-0.174, Q
2
Y:-906, CV-ANOVA p-value: 1). The OB 
A 
B 
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female cohort had elevated levels of creatine, creatinine and an unknown metabolite plus a decrease 
in mannitol and citrate (7.98 ppm) (Figure 6.19B). In addition, they also had lowered NvCt1 which 
corresponded to lower expression of SF-1, RORα, LXRβ, VDR, PXR, PPARγ together with low 
levels of TG, Vitamin D, insulin resistance and insulin (Refer to Figure 6.9A-B and the 
corresponding N vs. C S-plot in Appendix B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19: O2PLS [1+0+0] of t and u scores from the N vs. C pairwise analysis with metabonomics data of 
female children from the KOALA obesity program. (blue triangles – obese females, yellow diamonds – healthy 
weight females). O2PLS (A) scores plot and (B) loadings plot of the analysis. OB and HW cohorts were separated even 
though this analysis was not significant with elevated levels of creatine, creatinine and an unknown metabolite (7.98 
ppm) plus a decrease in mannitol and citrate (R
2
X: 0.122, R
2
Y: 0.28, Q
2
X:-0.174, Q
2
Y:-906).    
 
 
 
 
creatine 
unknown 
A 
B 
creatine 
creatinine 
citrate 
mannitol 
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6.3.2.3.2 Nuclear Receptor + Metabonomics vs. Clinical Data 
1+1+0 was chosen to be the best model for this analysis out of the 9 models generated 
(Figure 6.20A and B, Appendix B Chapter 6 M17). No separation was observed between the OB 
and HW female cohort (n: 33, R
2
X: 1, R
2
Y: 0.0523, Q
2
X:-0.174, Q
2
Y:-0.00439, CV-ANOVA p-
value: 1).  
 
 
 
 
 
 
 
 
Figure 6.20: O2PLS [1+1+0] of t and u scores from the N vs. M pairwise analysis with clinical data of female 
children from the KOALA obesity program. (blue triangles – obese females, yellow diamonds – healthy weight 
females). O2PLS (A) scores plot and (B) loadings plot of the analysis. No separation was observed in this non-
significant analysis (R
2
X: 1, R
2
Y: 0.0523, Q
2
X:-0.174, Q
2
Y:-0.00439).    
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6.3.2.3.3 Clinical + Metabonomics vs. Nuclear Receptor Data 
1+2+0 was chosen to be the best model for this analysis out of the 9 models generated 
(Figure 6.21A and B, Appendix B Chapter 6 M18). No separation was observed between the OB 
and HW female cohort (n: 33, R
2
X: 0.841, R
2
Y: 0.442, Q
2
X:0.125, Q
2
Y:-0.0285, CV-ANOVA p-
value: 0.98). 
  
 
 
 
 
 
 
 
 
 
Figure 6.21: O2PLS [1+1+0] of t and u scores from the C vs. M pairwise analysis with nuclear receptor data of 
female children from the KOALA obesity program. (blue triangles – obese females, yellow diamonds – healthy 
weight females). O2PLS (A) scores plot and (B) loadings plot of the analysis. No separation was observed in this non-
significant analysis (R
2
X: 0.841, R
2
Y: 0.442, Q
2
X:0.125, Q
2
Y:-0.0285).    
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6.4 Discussion 
Until recently, most research-based studies usually utilised one type of analytical technology 
such as transcriptomics, proteomics or metabonomics and examined only a specific type of ‘omics’ 
data where it can be interpreted. Recently, to obtain a more holistic perspective, the above 
mentioned technologies were integrated to obtain a better understanding of biological studies. This 
is better known as systems biology where complex data from different analytical platforms and 
technologies can be analysed together by utilising advanced statistical methods to extract 
information across all types of data that can potentially shed insight on the chemical and biological 
processes involved in a biological system and their correlation (des Santos et al., 2010, Ghosh et al., 
2011). 
In chapters 4 and 5, blood and urine samples collected from the KOALA childhood obesity 
program were profiled and analysed with gene expression and metabonomics respectively. Together 
with the clinical data, three different types of data (matrix C, M and N) were collected for this study. 
Therefore, in this chapter, all three datasets were integrated and analysed to extract more 
information on the metabolic effects of childhood obesity. O2PLS analysis was chosen for this 
study as the statistical tool to run multivariate analysis as it has the capability to analyse datasets 
from different analytical platforms to identify the joint variations and also platform specific 
variations to aid in the profiling of childhood obesity. In this study, pairwise analysis was first 
performed on two of the datasets to extract the joint variations before they were integrated with the 
respective third dataset. 
 6.4.1 Pairwise Analysis             
Once the three matrices have been normalised, two of them were paired up and analysed 
using O2PLS at a time. In total 9 different classifications were generated and for each classification, 
a maximum of 27 models were constructed. The Q
2
X and Q
2
Y values from all of these models were 
then plotted and the best model was chosen based on the most positive Q
2
 values. However, 
analyses revealed that most of the models generated were fairly weak with borderline R
2
X, R
2
Y and 
negative Q
2
 values or the analysis was not considered significant by SIMCAP+. Nonetheless, we 
pushed through with the analysis in the hope that the integration of the different datasets would 
make some significant and interesting biological sense with respect to the metabolic effects of 
obesity. All of the combined cohort analyses did not show any significant separation between the 
OB and HW cohort. Therefore, the each cohort was analysed based on their genders instead to 
observe for any patterns between the OB and HW cohort.  
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In the male cohort, only the N vs. C and the C vs. M combinations yielded a noticeable 
separation between the OB and HW cohort. In both analysis, along with the usual weight and BMI 
being the common clinical factors associated with obesity, the waist circumference, fat mass (FM), 
fat free mass (FFM), C-peptides, triglycerides, IGF-1, % fat and dry lean weight were elevated in 
the OB cohort together with lower % body water, AST and HDL levels.  
Waist circumference together with BMI has been used interchangeably as a measure of 
obesity. A study in obese children with waist circumference above the 90
th
 percentile showed that 
they are at higher risk for diabetes and CVD as compared to other obese or overweight children 
(Bassali et al., 2010). The composition of FFM (or dry lean weight) is different in children and 
adults with children having a higher proportion of water and different proportions of minerals and 
protein (Wells et al., 1999). In a study, obese children had greater hydration and reduced FFM 
compared to their healthy weight counterparts with higher water and mineral contents (Haroun et 
al., 2004).  C-peptide is an amino acid protein that is involved in connecting A-chain and B-chain of 
insulin and recently has been used as a measure to distinguish between type 1 (T1DM) and T2DM 
patients. T2DM children had higher levels of C-peptides compared to those with T1DM 
(Ludvigsson et al., 2012). In addition, higher C-peptides levels have been linked with higher BMI 
in women (Jernstrom and Barrett-Conner, 1999, Irwin et al., 2005). IGF-1 is a hormone produced in 
the liver, is stimulated by GH and plays a role in promoting growth in almost every cell. IGF-1 
levels in the body can be affected by BMI, nutritional and exercise status and have been associated 
with obesity where over eating altered IGF-1 activity (Nam et al., 1997). In obese African 
American and Latino adolescents, an increase in IGF-1 levels was mirrored with a lower IGFBP-3 
level (Alderete et al., 2011). Triglycerides (TG) are stored in fat cells and in involved in the 
bidirectional transference of adipose fat and blood glucose from the liver. In addition, TG can be 
found in vegetable oil and animal fats therefore a diet high in those fats will result in a higher TG 
levels in the body. TG has also been shown to block the hormone leptin which is needed to send a 
signal to the brain to indicate satiety (Banks et al., 2004). Higher TG levels have been associated 
with a lower HDL level in premenopausal obese women (Despres et al., 1989). In addition, TG has 
been linked with diseases such as diabetes, heart diseases and stroke (McKeigue et al., 1991). One 
of the characteristics of obesity is dyslipidemia where levels of TG are found to be high and levels 
of HDL low (Poirier et al., 2006). This result in the levels of TG and HDL is mirrored in the current 
study indicating that these OB children are at risk of developing dyslipidemia and in the long run 
potentially, CVD as it is inversely related to the risk of CVD (Rubins et al., 1999). C vs M male: 
lower urinary creatinine levels which is an inverse of what was observed in chapter 5. 
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The N vs. C O2PLS analysis also showed elevated SF-1, PXR, LXRβ and PPARγ 
expression levels in the OB male cohort. PXR has been shown to be up-regulated in TSOD 
(Tsumura, Suzuki, obese, diabetes) mice, a model of Type 2 Diabetes and obesity (Kudo et al., 
2009).  The PPAR family is involved in regulating energy, lipid and glucose metabolism (Auwerx 
et al., 2003) and PPARγ especially is involved in the differentiation of adipocytes (Barak et al., 
1999; Tontonoz et al., 1994). In addition, a study by Odegaard et al. (2007) showed that a 
macrophage-specific deletion of the gene encoding PPAR-γ in BALB/c mice regulated diet-induced 
obesity and insulin sensitivity which contributes to the development of T2DM and metabolic 
syndrome. LXRs on the other hand play a role in regulating the expression of genes involved in 
cholesterol metabolism (Peet et al., 1998; Repa et al., 2002). Studies also found that the activation 
of LXRs results in the suppression of inflammatory gene expression downstream of TLR4, IL-1β 
mediated and TNF-α mediated signalling pathways (Joseph et al., 2003; Ogawa et al., 2005). A 
recent study showed that SF-1 knocked out mice was susceptible to obesity when they were on a 
high fat diet (Kim et al., 2011). In addition these mice had decreased leptin receptor expression 
which eventually led to leptin resistance therefore these mice could not send a signal to the 
hypothalamus to indicate satiety.  
In the N vs M pairwise analysis, the OB female cohort had elevated expression levels of SF-
1, RORA, LXRβ, PPARγ, PXR, TRβ and VDR together with higher urinary creatinine, carnitine 
and lower mannitol levels. It was likely that these obese subjects had more muscle mass as 
compared to a lean individual and were more likely to consume a diet rich in meats, potentially 
contributing to the increase in creatine levels which were ultimately converted to creatinine to be 
excreted in urine causing the increase. As mentioned before, higher levels of urinary carnitine was 
possibly due to the metabolite not being circulated and maintained in the body and in addition, 
excess lipids being stored in adipose tissues as triglycerides this is reflected in the clinical data 
where the OB cohort had elevated levels of triglycerides as compared to the HW cohort. The 
decrease in mannitol level was an opposite of what was observed in the single metabonomics 
analysis previously in chapter 5.  
6.4.2 Integration 
6.4.2.1 Biological Effects 
Out of the three combined cohort models, the N+M vs. C model provided the best separation 
between the OB and HW cohorts and also based on their genders even though the analysis was not 
significant. The OB males had elevated levels of Plasminogen activator inhibitor-1 (PAI-1) which is 
usually produced by the endothelium and inhibits the degradation of blood clots but is also secreted 
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by other tissues such as adipose tissues.  Studies have shown that PAI-1 levels being up-regulated in 
obese subjects and also those who are at risk of CVD (JuhanVague and Alessi, 1997, Loskutoff and 
Samad, 1998). Mice lacking in PAI-1 but on a high fat diet were not obese or insulin resistant when 
compared to their wild type counterparts (Ma et al., 2004). 
Integration of the third respective datasets to the pairwise analyses did not yield a significant 
separation between the OB and HW cohort in the combined cohort analyses therefore, the analyses 
were performed based on genders instead. Even though the pairwise analysis of matrix N vs. M in 
the male cohort did not provide any separation between the OB and HW cohort, the N + M vs. C 
integration analysis showed that in addition to clinical factors that were already extract in the male 
pairwise analysis (N vs. C and C vs. M), levels of alanine amino transferase (ALT), insulin, insulin 
resistance (IR) (HOMA), total body weight and fasting glucose were higher in the OB cohort. 
Aspartate amino transferase/alanine amino transferase (AST/ALT) levels are usually tested to check 
the state of the liver. High ALT/AST levels have been linked with diabetes and reflected an 
underlying IR (Harris, 2005). In addition, obesity is also known as another cause of fatty liver 
disease other than high alcohol consumption cause increase in ALT/AST levels (Loomba et al., 
2008). Increase in fasting glucose and IR have also been positively correlated with increased BMI, 
waist circumference, TG levels and negatively correlated with low levels of HDL (Williams et al., 
2005, Qian et al., 2010).  
6.4.2.2 Limitations 
One of the main limitations in this multi-modal study is the sample number. Whereas the 
total number of baseline plasma and urine samples collected across the KOALA study was 99 urine 
and 104 plasma samples, not all of the children in the study had full clinical data collected. 
Therefore, a total of 62 samples with complete metabonomics, gene expression and clinical data 
was used for the pairwise and integration analysis in Chapters 4, 5 and 6. For the gender-divided 
analyses, the number of samples reduced to 25 males and 33 females. Due to the high dropout rate 
after the 12 months lifestyle intervention, pairwise and integration analysis on these samples was 
not possible and we were constricted to just the baseline samples. Therefore our aims for chapter 6 
had to be slight modified and we focused only on the baseline samples and aimed at profiling the 
effects of metabolism on childhood obesity compared to healthy weight children. Overall, the 
majority of O2PLS models generated were statistically weak. Stronger O2PLS models would 
probably be possible if there were more samples in the analysis which can be added on if more 
urine and plasma samples are collected in future studies.  
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In reality, the joint variation between all three datasets is the same and no matter the order of 
correlation of these three matrices, the same result should be generated i.e. the models generated at 
the end should be three high-level O2PLS models that identify the same variables, and have similar 
characteristics (number of components, figures of merit etc.). However, in this study, the final 
three-way correlation models were not completely identical. Potential asymmetries in the 
implementation of the O2PLS algorithm in SIMCA-P+12 could have led to small imprecisions 
when the analysis was run in a mirrored fashion, as we did to pick the best combination of Q
2
X and 
Q
2
Y. That numerical imbalance could have led to variables being apportioned into the joint and 
orthogonal variation with slightly different weightings, depending on the order in which the 
matrices were integrated. In extreme cases, this could have led to us picking the “wrong” model in 
the first (pairwise) O2PLS round in cases where there are two alternative models with almost 
identical Q
2
X/Q
2
Y values. Furthermore, during model interpretation, the ‘cut-off of variables’ of the 
S-plots selected for this study could have also impacted the variables selected that were influencing 
the separation of the cohorts. It is possible that in one model a particular variable just ‘makes the 
grade’, but in another model does not. In this study, the cut-off point was based on VIP values, 
coefficients which summarize the relationship between the Y and X variables where a VIP value of 
>1 was considered valid. If variables were then also clustering on extreme top and bottom of the S-
plots they were selected as the variables influencing the model.  
Even though the models that did provide significant separation between the OB and HW 
cohorts were considered to be weak, they still shed some insight on clinical, NR and metabolic 
factors that were associated with childhood obesity. This study ultimately provides a stepping stone 
in understanding the metabolic effects of childhood obesity that can be further investigated in future 
studies. If previously childhood obesity was measured by weight and more importantly BMI, this 
study provides evidence that clinical factors such as higher waist circumference, triglycerides, fat 
mass, fat free mass, C-peptide, IGF-1, fasting glucose and lower body water and HDL levels can be 
indications or risk factors of childhood obesity and its secondary diseases such as T2DM and CVD.  
6.4.2.3 Future Studies 
Future multi-model childhood obesity studies should involve an effective and consistent 
sample collection plan where the number of samples need not be compromised during the study. 
The type and contents of datasets collected should also be complete across all samples. In addition, 
the 12 months follow up in this study could possibly be too short to observe for more obvious 
changes in the metabolism of these obese children and probably a study where these children are 
followed through for a couple of years with weight loss, these metabolic changes will be more 
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obvious and significant. In addition, other types of multivariate analysis such as hierarchical PCA 
(HPCA), uncorrelated linear discriminant analysis (ULDA) and canonical correlation analysis 
(CCA) should be utilised to extract more information from the datasets in parallel with the O2PLS 
analysis. A study utilizing ULDA and CCA was able to profile plasma samples collected from 
obese children and measure with GC/MS with strong analyses models (Zeng et al., 2010). While 
NMR spectroscopy is able to detect hundreds of metabolites, there is a limitation with the 
metabolite database available for identification. For future studies, in addition to NMR, urine 
samples can be recorded using a different analytical platform such as mass spectroscopy which has 
a larger metabolite database which can be utilised to identify for metabolites affected by obesity.   
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Chapter 7 General Conclusions 
7.1 Conclusion 
The studies performed for this PhD were based on the hypothesis that metabolic changes 
altered in children with obesity may be detectable at a physiological, biochemical and metabonomic 
(whole-body) level. We chose to examine the expression of NRs in the PBMC transcriptome as a 
surrogate tissue (as it expresses about 80% of the human transcriptome) as opposed to metabolic 
tissues, such as skeletal muscle and adipose tissue that were unobtainable from both a clinical and 
potentially ethical and technical point-of-view. The concept of metabonomics also recommends the 
investigation of biological fluid samples, such as urine, which especially in children can be 
collected relatively non-invasively in an attempt to inform us about metabolic changes in obesity in 
children.  
While the overall findings of NR expression between the healthy weight and obese cohort 
identified only a handful of potentially differentially expressing NR transcripts, none of these were 
statistically significant when corrections for multiple comparisons were undertaken. A thorough 
statistical analysis of the data was undertaken using both multivariate and univariate analysis, 
including assessment of correlation between NR and metabonomics data and clinical measures with 
and without the NR gene expression. This analysis failed to reveal any statistically significant 
differences in metabonomic or gene expression profiling between the obese children and their non-
obese children. Several reasons for this lack of statistical significance could be envisioned. These 
include an inadequate sample number and therefore statistical power. Our studies were based on 
previous published metabonomic and gene expression analyses which suggested nevertheless that 
the sample numbers we utilised would potentially be informative.  Moreover we were careful to 
obtain largely prepubertal children for our studies to avoid the confounding effect of puberty to 
minimise the effect of sex steroids on metabolism and insulin sensitivity.  
Whether as a result of only including largely prepubertal children in this study, who 
therefore had few, if any, obesity-related complications, contributed to a lack of significant 
differences between the obese and non-obese cohort remains also a possibility.  Our original aim 
was to try and identify early distinguishing biomarkers of obesity and its effects of whole body 
metabolism, so hence our strategy to recruit younger pre-adolescent children with obesity.  Whether 
further studies with adolescents with established insulin resistance and other obesity-related 
complications may have yielded more interesting and significant findings remains to be determined.  
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Even though we failed to detect any statistically significant changes in metabonomics and NR gene 
expression in these studies, the metabolites detected as potentially being altered fit with expected 
obesity-related metabolite changes documented in the literature. Furthermore, the analyses allowed 
utilisation with several state-of-the-art bioinformatics statistical approaches that allowed a detailed 
and exhaustive analysis of the available data.  
7.1.1 Urine Stability in NMR-Based Metabonomics Study 
Like any research-based studies, sample collection, storage and handling is crucial for 
NMR-based metabonomic studies. This is especially true in clinical studies where when patients are 
requested to collect samples from home before delivery to the clinic or hospital and may not follow 
protocols to maintain samples in optimal condition i.e. at 4 C
o
 on ice or in the fridge. In addition, 
samples are potentially left overnight at room temperature queued on a sample changer in NMR-
based metabonomic studies. Therefore, it is important that the optimal storage and handling 
methods of samples during metabonomics clinical studies is examined closely to ensure accuracy in 
measurements.  
The aim of the first part of this PhD - the urinary stability study - was to determine the 
optimal storage conditions and handling methods of human urine samples for metabonomics 
analysis. This study showed that samples collected from volunteers left at room temperature are 
susceptible to alterations in metabolic profiles within 24 hours despite the addition of preservatives 
such as sodium azide, sodium borate or sodium fluoride. Changes in metabolite levels were 
indicative of bacterial contamination. Our results showed that this contamination problem was 
resolved by preserving the urine sample in a minimum final concentration of 100mM sodium borate 
upon collection. Furthermore, this study showed that samples should also be stored immediately at 
a temperature at or below -20°C until analysed and NMR spectra should be recorded within 24 
hours after the samples has been thawed to obtain an accurate metabolic fingerprint. Overall, this 
urine stability study importantly demonstrated the optimal storage and handling conditions required 
for accurate urinary metabonomic footprints within a common clinical setting involving patient self-
collection. However, it is important to note that this study applies to cases where the optimal 
condition of samples collected in a study cannot be guaranteed.  The KOALA metabonomics study 
performed in this PhD followed protocols that ensured the samples collected had minimal risk of 
contamination and therefore, the protocols outlined in the stability study in chapter 2 did not need to 
be followed.  
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7.1.2 Effects of Growth Hormone (GH) Therapy on Metabolism of a GH Deficient Patient 
Growth hormone (GH) plays crucial roles in growth and metabolism and effects on body 
composition. Thus, GH therapy is recommended for GH deficient (GHD) patients, especially during 
childhood, to optimise whole body growth and final adult height. In this study, the effects on 
metabolism of GH therapy over a period of 5 years was closely monitored using urinary NMR-
based metabonomics in a female adolescent with severe GH deficiency due to a PIT-1 gene 
mutation.  Metabonomics revealed that the metabolic profiles of this GHD subject altered with GH 
therapy with increases in urinary levels of citrate, dimethylamine and alanine. Furthermore, this 
subject’s metabolic profile was distinguishable and significantly different from age- and sex- 
matched healthy controls before and during withdrawal from GH therapy. This study highlighted 
the potential use of urinary NMR-based metabonomics as an adjunct tool in monitoring effects of 
GH therapy on metabolism in GHD patients, and more generally, this study is a prime example of 
the application of NMR-based metabonomics in theranosis (evaluation of the effectiveness of 
therapy) and personalised medicine. The studies in this chapter while not focused on child obesity 
per se, nevertheless illustrated the potential clinical role of metabonomic studies on hormone-
dependent (in this case growth hormone) regulation of metabolism in relation to effects on body 
composition, including alterations by GH on total fat and lean muscle mass. As such this GH 
clinical study illustrated how successful the application of metabonomics is in potentially yielding 
crucial information pertaining to the alterations of the metabolism of small molecules in an 
organism and/or subject due to a disease. This ‘stepping stone’ reassured us that metabonomics had 
the potential to be utilised to investigate the metabolic alterations that potentially may occur during 
childhood obesity.  
7.1.3 NR Gene Expression and Metabolism of Children with Obesity – the KOALA study 
Obesity is a major world-wide public health issue affecting adults and children and 
adolescents alike, as our society leads more sedentary lifestyles and adopts calorie-dense and low 
nutritious diets. Children with obesity are more susceptible to metabolic diseases associated with an 
increased risk of cardiovascular disease and T2DM and higher morbidity and mortality rates. This 
study aimed to investigate the metabolic changes in children with obesity utilising systems biology 
tools such as gene expression, NMR metabonomics and multivariate analysis. Urine and PBMC 
samples as well as clinical data were collected during a lifestyle intervention from obese and 
healthy weight children from the KOALA childhood obesity study.  
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7.1.3.1 NR Gene Expression of Children with Obesity 
The aim of this study was to determine the NR gene expression profile in PBMCs from 
children with obesity compared to healthy weight control children. As no previous studies have 
examined the NR gene expression in any tissues, including PBMCs, from either healthy or obese 
children, we hypothesised that differential gene expression between the two cohorts may be 
detectable and potentially play a functional role in obesity based on the known critical roles of NRs 
in metabolism and adipogenesis. TLDA analysis revealed aberrant expression of PXR and TRβ in 
the obese male cohort that is involved in regulation of growth, metabolism and obesity, in the obese 
female cohort, there was a differential up-regulation of other NRs such, including GCNF and RXRα 
which have been shown to be involved in adipocyte function and differentiation in mice. When both 
obese cohorts were analysed together, it revealed a down-regulation of Nur77, NURR1 and TRα 
together with up-regulation of RXRα. Nur77 and NURR1 which are known to be involved in 
regulating lipid and glucose metabolism. However, correction for the multiple comparisons made 
with this analysis failed to reveal any significant statistical differences in NR expression between 
the obese and non-obese cohorts, highlighting the inherent challenge of conducting an experiment 
in human clinical studies where perhaps greater phenotypic variation between individuals exists, 
which potentially could require greater sample sizes for statistical power.  
Due to a large dropout in number of subjects after the 12 months lifestyle intervention and 
also the lack of significant differential expression of the 12 month female data, only PBMC samples 
from 11 obese male subjects were analysed manually using RT-PCR and concentrating on the 3 
NRs (PXR, TRα and TRβ) that were differentially expressed in the baseline results. None of these 
NRs were significantly altered after the lifestyle intervention, but based on the small sample number 
this was not surprising. Thus a larger cohort needs to be investigated in order to validate the results 
observed. The small sample numbers especially at the conclusion of the 12 months study limited 
making any definitive conclusions about the effect of a lifestyle program on the NR gene expression 
of these obese children.  
7.1.3.2 Metabonomics and Multi-Model Analysis of Children with Obesity 
In this study, urine samples from both obese and healthy weight children from the KOALA 
childhood obesity study was collected and analysed using NMR metabonomics to determine their 
urinary metabolic profiles. The obese children (OB) in this study were subdivided into two cohorts 
(Arm A – care as usual and Arm B – lifestyle intervention) and compared with their healthy 
counterparts at baseline and also after a 12 months lifestyle intervention. In addition, multivariate 
analysis (PLS/O2PLS) were performed on the NR gene expression and clinical data respectively.  
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7.1.3.2.1 Obese vs. Healthy Weight Children at Baseline 
Both OB arms were compared to the healthy weight (HW) cohort respectively, and results 
showed that urinary levels of creatine, creatine phosphate, creatinine, glycine, carnitine and 
mannitol were elevated while levels of citrate, hipppurate and DMA were lower. These altered 
metabolites have been previously associated with obesity. Results also showed that in addition to 
the usual weight and BMI being an indicator of obesity, fat mass (FM) or % fat, waist 
circumference, C-peptide, triglycerides and insulin resistance levels were found to be higher while 
% body water and HDL levels were lower in the OB cohort. Whether these altered metabolites in 
the OB cohort are directly or indirectly involved in altered metabolism in obesity or secondary to 
other non-obesity related factors remains to be determined in future studies. 
7.1.3.2.2 Obese vs. Healthy Weight Children after 12 Months Lifestyle Intervention 
The post-lifestyle analysis performed was altered because of a high drop-out rate of subjects 
after the 12 months lifestyle intervention. Thus separation between subjects that lost weight in the 
OB cohort was compared to the HW cohort with creatine, creatine phosphate, creatinine and 
mannitol levels elevated. Even with significant weight loss, these obese subjects remained 
overweight or obese as compared to their healthy weight counterparts after 12 months. As expected, 
the metabolic profiles of the subjects that gained weight despite the lifestyle intervention was 
different when compared to the HW cohort as was observed in the baseline analysis. Due to the 
sample size limitation multivariate models obtained were not significant. Therefore, for future 
obesity NMR-based metabonomic studies, a clinical study with larger numbers of subjects and 
follow-up after a lifestyle intervention would be required to determine accurate and significant 
metabolic fingerprints especially when investigating such a complex disease such as obesity. 
Unfortunately, there is no formal algorithm for calculating sample sizes for metabonomic data, as 
power calculations do not apply to multivariate data. The standard method is to estimate sample 
sizes from pilot studies or comparable studies in the literature. Based on comparable studies (Lenz 
et al., 2004, Yan et al., 2008) we had originally estimated that n=43 would be a sufficient cohort 
size. 
7.1.3.2.3 Pairwise and Integration Analysis of Children with Obesity 
The metabonomics, NR gene expression and clinical datasets collected from the KOALA 
childhood obesity program were analysed together via a bootstrapping O2PLS pipeline, consisting 
of pairwise analysis of two datasets followed by integration of the third dataset with O2PLS. Even 
though most of the models generated in both the pairwise and integration analysis were not 
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significant, noticeable separation were still observed in some of the analysis especially when the 
samples were analysed based on gender. In addition to the metabolites/NRs/clinical factors that 
were extracted in the single metabonomics analysis in chapter 5, IGF-1, fat free mass, insulin, 
fasting glucose, lean body weight, total body weight and ALT levels were elevated in the OB cohort 
which are possible indications or risk factors of childhood obesity for secondary diseases such as 
T2DM and CVD.  
One of the main limitations in this multi-modal study was again the small sample number. 
Due to the high dropout rate after the 12 months lifestyle intervention, pairwise and integration 
analyses on these samples were not possible and we were constricted with just the baseline samples. 
Therefore our aims for the multi-modal chapter had to be slightly modified and we only focused on 
the baseline samples and aimed at profiling the effects of metabolism on childhood obesity 
compared to healthy weight children.  
7.1.4 General Conclusions 
7.1.4.1 Cost-Benefits of Project 
At the commencement of this PhD project, it was anticipated that the project would be able 
to provide useful significant insights on the metabolic effects of obesity in children. While 
performing this PhD project unexpected challenges such as large dropout rate in the KOALA study 
compromised its progress, because of smaller sample sizes and study power. This obviously was 
beyond the control of the candidate but had a huge impact on the project. With a larger cohort size 
in any future studies, we anticipate that the quality of the study, together with more advanced and 
robust multi-model analysis that a metabonomics analysis of an obese cohort in children may still 
be able to provide novel insights into the metabolic effects of childhood obesity.  
This entire PhD project has demonstrated the versatility of systems biology in understanding 
the underlying mechanism of childhood obesity and its related effects on metabolism. Before any 
systems biology studies was undertaken, we first established the optimal collection and storage 
methods of human urine samples for NMR-based metabonomics in order to obtain accurate 
metabolic fingerprints. More importantly, tools of systems biology (NMR-based metabonomics, 
gene expression profiling, multivariate analysis) were utilised to profile metabolic changes in 
children and adolescents with childhood obesity and obesity-related diseases (i.e. GH deficiency). 
Integration of datasets using state-of-the-art statistical methods obtained from different analytical 
platforms and biological sources provided insight into possible clinical, gene and metabolic risk 
factors associated with childhood obesity. Future studies need to be performed especially in the 
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metabonomics and multi-model analysis with a larger cohort to validate the results observed during 
these PhD studies.  
7.2 Future Aims 
7.2.1 Urine Stability in NMR-Based Metabonomics Studies 
1. Perform entire study with a larger cohort of subjects from both genders and a wider age 
range to validate results 
2. Examine the effects of freezing conditions and its effect on urine samples for metabonomic 
studies 
3. Assess the reduction of a signal to noise ratio associated with the addition of sodium borate 
to urine samples. 
7.2.2 Effects of GH Therapy on Metabolism of a GHD Patient 
1. Collect more samples from GHD subjects over the course of GH therapy to validate the 
current results in a larger patient cohort 
7.2.3 NR Gene Expression of Children with Obesity 
1. Perform study on more samples to validate results especially 12 months samples 
a. To collect especially more female samples to pool the results with existing data to 
strengthen the female data.  
2. Run TLDA analysis on 12 month samples to obtain expression of all 48 NRs of these 
subjects 
3. Assess global gene expression analysis related to metabolism and obesity using either a 
microarray or next generation sequencing approach, and correlate these changes in PBMCs 
with other metabolic tissues (e.g. adipose tissue, skeletal muscle). 
 
7.2.4 Metabonomics and Multi-modal Analysis of Children with Obesity  
1. Follow subjects on lifestyle intervention program for more than 12 months to map out a 
clearer progression of weight loss or slowed weight gain and its effects on metabolism. 
2. Study requires a much more stringent sample collection and the drop-out rate needs to be 
minimised to obtain a more statistically validated result.  
3. Measure urine and/or plasma samples with mass spectroscopy to obtain a larger dataset that 
can be incorporated into the analysis.  
4. Perform OnPLS on data collected from the KOALA multi-model study. 
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Overall our metabonomic studies in children with obesity failed to identify any highly 
significant metabolic markers that could be used in the clinical situation for assessment of obesity 
and its complications.  In hindsight, perhaps if better-defined inclusion clinical criteria with a 
narrower and more distinct phenotype between the cohorts were undertaken e.g. comparing healthy 
children with children obesity versus children with obesity-related complications, such as insulin 
resistance or non-alcoholic steatohepatitis (NASH) may have increased our likelihood of observing 
significant metabolic changes using this systems biology approach. 
While our lack of significant results therefore do not necessarily support a role at this point for 
further metabonomic studies in childhood obesity per se, based on the increasing literature of 
metabolomics studies in obese and diabetic adults, and specifically until further larger better 
controlled studies are performed in children, we remain optimistic that there is value in using this 
systems biology approach to the study of obesity. Moreover, our observations on the effects of GH 
therapy on human metabolism and metabonomic biomarkers highlight the potential insights from 
metabonomics studies on the roles of hormones, including growth hormone regulation of growth 
and body composition. 
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No ID
Age 
Years
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(M/F)
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(A/B/C)
Obese 
(OB)/Healthy 
Weight (HW)
      Wt     
Kg WT SDS
    Ht       
cm HTSDS BMISDS waist circum WCSDS Fat(%) Fat Wt (kg) Lean(%)
Dry Lean 
Wt (kg) Water (%)
Total Body 
Water (L)
Impedence
5HZ
Impedance 
50Hz Resistance
Reactance 
50Hz
FFM(Schaef
er)
FM(Schaefe
r)
Schaefer%
BF
1 C38 7.65 M C HW 25.8 0.28 127 0.28 0.21 60.75 1.09 17.8 4.6 21.2 4.9 63.2 16.3 719 656 653 61.8 21.4069005 4.39309954 17.0275176
2 C4 10.17 M C HW 46.6 1.24 152 1.25 1.05 77 2.02 18.9 8.8 37.8 9.3 61.2 28.5 568 ND 566 ND 33.5961955 13.0038045 27.9051598
3 C1 6.33 M C HW 24.6 0.86 120.6 0.54 0.93 ND ND 51.2 12.6 ND 12 84.6 20.8 ND ND 646 ND 19.0910846 5.50891538 22.3939649
4 C5 9.00 M C HW 25 -0.97 119.9 -2.38 0.56 57 -0.35 19.2 4.8 20.2 4.7 62 15.5 688 617 614 64.2 21.4889031 3.51109691 14.0443876
5 C3 9.00 M C HW 35.35 1.11 138.5 0.78 0.98 68.5 1.51 19.2 6.8 28.6 35.4 61.6 21.8 645 588 585 51.6 27.5836111 7.76638889 21.9699827
6 C10 9.50 M C HW 26.6 -0.78 132.3 -0.59 -0.72 56 -0.25 20.2 5.4 21.3 5.1 60.7 16.2 715 ND 712 ND 22.5891271 4.01087289 15.0784695
7 C15 10.17 M C HW 31.2 -0.22 138 -0.2 -0.16 63.5 0.58 48.5 31.8 33.7 8 39.2 25.7 725 ND 723 ND 24.1844952 7.01550484 22.4855924
8 C16 7.33 M C HW 25 0.28 120.2 -0.69 0.93 62 1.30 26.8 6.7 18.3 4.2 56.4 14.1 689 ND 686 ND 18.8265005 6.17349951 24.6939981
9 C44 8.87 M C HW 27.8 -0.07 126.9 ND ND ND ND 10.4 2.9 24.9 5.8 68.7 19.1 614 545 541 61 25.5297451 2.2702549 8.16638453
10 C42 11.48 M C HW 35.2 -0.42 137 ND ND ND ND 10.2 3.6 31.6 7.8 67.6 23.8 609 532 528 66.2 31.0621765 4.13782348 11.7551804
11 C30 10.08 M C HW 40.2 1.08 145.5 0.97 0.91 73 1.70 21.4 8.6 31.6 7.5 60 24.1 633 ND 630 ND 28.8489881 11.3510119 28.236348
12 C18 6.58 M C HW 20.6 -0.55 115.3 0.26 -0.81 54.5 -0.17 34.5 7.1 13.5 3.1 50.5 10.4 728 ND 725 ND 16.545506 4.05449402 19.6820098
13 C31 7.42 M C HW 25.4 0.33 124.4 0 0.49 62.2 1.33 31.1 7.9 17.5 4 53.1 13.5 775 ND 771 ND 18.2400052 7.15999481 28.188956
14 C29 6.75 M C HW 25.2 0.77 126.4 1.21 0.22 57.1 0.43 19.8 5 20.2 4.6 61.9 15.6 678 ND 675 ND 20.1252207 5.07477926 20.1380129
15 C25 10.92 M C HW 44 1.78 155.7 1.02 0.43 68 1.19 19.5 8.6 35.4 8.4 61.4 27 635 ND 632 ND 32.506274 11.493726 26.1221046
16 C28 9.17 M C HW 23.4 -0.61 130.6 -0.15 -1.92 53.5 -1.25 17.1 4 19.4 4.6 63.2 14.8 758 ND 756 ND 21.0481931 2.35180688 10.0504567
17 C20 7.08 M C HW 27.8 1.09 129 1.24 0.71 58 0.58 23.4 6.5 21.3 27.8 58.6 16.3 685 ND 682 ND 20.8268573 6.97314272 25.0832472
18 C17 6.83 M C HW 22 -0.17 117.2 -0.6 0.37 57 0.41 ND ND ND ND ND ND 781 713 710 65.3 17.3717315 4.62826854 21.0375843
19 C2 10.25 F C HW 29 -0.86 140.2 0.12 -1.19 55 -0.7680018 16.6 4.8 24.2 5.6 64.1 18.6 764 ND 762 ND 23.8869633 5.11303675 17.6311612
20 C34 9.92 F C HW 29.4 -0.56 135.1 -0.39 0.58 60 0.40851173 22.8 6.7 22.7 5.2 59.5 17.5 695 ND 692 ND 24.0375624 5.36243762 18.2395837
21 C32 6.83 F C HW 23.2 0.25 121.2 0.25 0.24 55 0.02060714 21.1 4.9 18.3 4.1 61.2 14.2 684 ND 681 ND 18.8174244 4.38257562 18.8904122
22 C27 7.50 F C HW 23 0.44 119.7 0.31 0.45 58.2 0.61421301 22.6 5.2 17.8 4 60 13.8 682 ND 680 ND 18.9459684 4.05403162 17.6262244
23 C26 9.75 F C HW 27.4 -0.83 133.1 -0.53 -0.62 ND ND 13.5 3.7 23.7 5.4 66.8 18.3 638 ND 635 ND 24.914089 2.48591102 9.07266797
24 C8 9.75 F C HW 37.7 0.83 138.6 0.32 1.02 70 1.64844046 37.4 14.1 23.6 5.5 48 18.1 711 ND 708 ND 24.4162627 13.2837373 35.2353774
25 C19 6.00 F C HW 24 0.39 127 0.39 -0.36 53.5 -0.3033981 32.5 5.4 18.6 4.1 60.4 14.5 741 ND 738 ND 18.4357588 5.56424119 23.1843383
26 C23 10.25 F C HW 31 -0.77 134 -0.46 0.12 68.9 1.33972262 30 9.3 21.7 5 53.9 16.7 868 ND 866 ND 20.5973672 10.4026328 33.55688
27 C33 6.83 F C HW 21 -0.41 116.1 -0.41 0.11 58.2 0.65858381 30 6.3 14.7 3.2 54.8 11.5 793 ND 790 ND 15.8871559 5.11284409 24.3468766
28 C45 8.87 F C HW 31.2 0.47 133.8 0.25 0.52 ND ND 18.9 5.9 25.3 5.7 62.8 19.6 676 598 594 63.9 25.7718121 5.42818788 17.3980381
29 C11 6.75 F C HW 18.4 -1.36 116.8 -0.62 -1.57 53.6 -0.2807672 26.6 4.9 13.5 3 57.1 10.5 876 ND 875 ND 14.8742354 3.52576457 19.161764
30 C14 6.58 F C HW 25.6 1.08 121.2 0.67 1.1 65.5 1.60299984 24.6 6.3 19.3 4.3 58.6 15 652 ND 649 ND 19.3387406 6.26125937 24.4580444
31 C21 8.50 F C HW 31.6 0.78 133.2 0.49 0.76 62 0.93420583 29.4 9.3 22.3 5 54.7 17.3 691 ND 688 ND 22.6922907 8.9077093 28.1889535
32 C36 6.58 F C HW 24.8 0.81 127 1.5 0.03 59.5 0.82314813 23 5.7 19.1 4.2 60.1 14.9 724 ND 721 ND 19.167374 5.63262598 22.7122015
33 C43 11.48 F C HW 25.6 -2.53 129.3 -2.44 -1.18 ND ND 11.7 3 22.6 5.3 67.6 17.3 785 682 677 81.2 24.008126 1.591874 6.21825782
34 C41 7.02 F C HW 20.8 -0.61 116 -1.04 0.01 ND ND 7.7 1.6 19.2 4.3 71.6 14.9 662 591 587 64.5 19.8237704 0.97622964 4.69341174
CLINICAL MEASUREMENTSHEALTHY WEIGHT DATA
223242
No ID Age Years
Gender 
(M/F) Arm (A/B/C)
Obese 
(OB)/Healthy 
Weight (HW)
Fasting 
glucose Insulin c-peptide HOMA Cholesterol LDL HDL TG CRP ESR VitD HbA1C TSH FT4 AST ALT ALP PAI-1 IGF-1 IGFBP-1 ACTH Cortisol
1 C38 7.65 M C HW 4.5 3 0.25 0.6 4.2 3.1 0.8 0.7 ND 18 125 ND ND ND 34 12 253 ND ND ND ND ND
2 C4 10.17 M C HW 4.8 11 1 2.34666667 3.7 2 1.3 ND <1 4 79 5.7 4.09 12 36 17 248 ND 27 1.2 37 254
3 C1 6.33 M C HW 4.7 3.4 0.44 0.71022222 3.1 1.5 1.5 ND <1 2 103 5.7 1.49 18 32 12 198 ND 11 2.4 7 213
4 C5 9.00 M C HW 3.9 2.1 0.25 0.364 5.1 3.5 1.3 ND <1 8 70 5.2 2.37 13.6 37 29 168 14.4 22 2.4 13 284
5 C3 9.00 M C HW 4.3 2.4 0.27 0.45866667 3.7 2.1 1.4 0.5 <1 2 89 5.3 2.23 13.6 36 ND 244 10.4 21 2.3 17 288
6 C10 9.50 M C HW 4.2 3.1 0.26 0.57866667 4.8 3.2 1.1 1.2 <0.5 2 80 NA 2.7 12.5 38 ND 313 19 26 2.6 10 252
7 C15 10.17 M C HW 4 2 0.21 0.35555556 4.8 2.8 1.7 ND <0.5 2 94 5.7 3.3 13.3 38 ND 346 ND 19 2.6 13 220
8 C16 7.33 M C HW 3.8 4.1 0.22 0.69244444 4.9 2.7 2.1 ND <0.5 7 38 5.6 2.45 12.3 38 ND 303 ND 17 2.6 16 193
9 C44 8.87 M C HW 4.3 3 0.22 0.57333333 6.2 4.4 1.4 0.8 ND 6 72 ND ND ND 44 21 204 ND ND ND ND ND
10 C42 11.48 M C HW 4.6 4.3 0.32 0.87911111 5.8 4 1.3 1 ND 2 85 ND ND ND 38 20 162 ND ND ND ND ND
11 C30 10.08 M C HW 3.9 1.6 0.16 0.27733333 3.6 2.1 1.3 ND <0.05 2 80 5.2 2.38 15.6 32 ND 200 ND 18 3.6 17 327
12 C18 6.58 M C HW 4.8 2.8 0.22 0.59733333 4 2.6 1.2 0.5 ND 5 98 ND ND ND 43 25 208 ND ND ND ND ND
13 C31 7.42 M C HW 4.3 2.8 0.19 0.53511111 3.9 2.5 1.2 0.5 <0.5 2 104 5.2 1.41 15.6 40 29 227 ND 14 ND 10 160
14 C29 6.75 M C HW 4.5 6.6 0.4 1.32 3.5 1.7 1.5 0.6 <0.5 2 104 5.2 2.85 13.8 48 17 237 ND 27 ND 30 287
15 C25 10.92 M C HW 4 3.1 0.27 0.55111111 6.6 4.4 1.9 ND <0.5 3 74 5.4 2.88 14.1 39 7 212 ND 28 ND 13 106
16 C28 9.17 M C HW 4.1 1.7 0.15 0.30977778 3.4 1.9 1.3 ND <0.5 4 81 5.6 1.15 14.8 36 9 390 ND 22 ND 18 173
17 C20 7.08 M C HW 4.5 3.3 0.2 0.66 4.4 2.4 1.8 ND <0.5 2 75 4.9 1.06 13.2 34 11 209 ND 14 ND 11 568
18 C17 6.83 M C HW 4.1 6.9 0.3 1.25733333 3.9 2.2 1.6 ND <0.5 2 90 5.2 1.24 12 39 ND 199 ND 8.8 ND 22 205
19 C2 10.25 F C HW 4.3 3.7 0.23 0.70711111 4.7 2.1 2.3 0.7 <1.0 11 53 5 0.76 17.6 30 27 193 ND 24 ND 8 273
20 C34 9.92 F C HW 4.2 3 0.26 0.56 3.9 2.1 1.3 1 0.8 2 75 5.2 2.01 12.8 36 ND 175 ND 22 ND 39 310
21 C32 6.83 F C HW 3.6 2.1 0.15 0.336 3.9 2.5 1.2 0.4 <0.5 2 86 5.1 2.01 17.7 39 16 215 ND 15 ND 9 162
22 C27 7.50 F C HW 3.1 1.2 0.1 0.16533333 4.2 2.1 1.7 0.4 1.3 4 81 5.3 1.24 14 54 19 218 ND 24 ND 16 349
23 C26 9.75 F C HW 4 4.2 0.37 0.74666667 4.2 2.4 1.6 0.4 0.5 2 67 5.4 1.29 11.7 53 17 235 ND 36 ND 17 318
24 C8 9.75 F C HW ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
25 C19 6.00 F C HW 4.4 5.1 0.22 0.99733333 5.4 3.6 1.4 0.9 <0.5 13 36 5.5 3.79 13.8 38 10 250 ND 14 ND 19 286
26 C23 10.25 F C HW 4 7.5 0.4 1.33333333 4.5 3 1.2 0.6 2 5 107 5.4 1.16 11.6 46 18 235 ND 30 ND 16 282
27 C33 6.83 F C HW 4.1 1.7 0.15 0.30977778 4.1 2.3 1.6 0.4 <0.5 2 133 5.5 3.07 15.9 43 16 238 ND 12 ND 17 249
28 C45 8.87 F C HW 4.7 4.8 0.33 1.00266667 5.8 3.7 1.4 1.5 ND 5 81 ND ND ND 40 26 275 ND ND ND ND ND
29 C11 6.75 F C HW 3.2 1.2 0.16 0.17066667 4.3 2.6 1.5 0.4 <0.5 ND 62 5.6 1.91 12.6 44 ND 173 ND 16 3.3 8 187
30 C14 6.58 F C HW 4.2 4.2 0.28 0.784 4.1 2.6 1.1 0.8 <0.5 2 101 5.2 2.82 18.2 39 ND 234 ND 19 5.6 12 223
31 C21 8.50 F C HW 4.2 1.5 0.15 0.28 4.2 2.2 1.8 0.4 2.9 2 76 5.3 2.49 13.7 46 15 220 ND 13 ND 16 302
32 C36 6.58 F C HW 4 3.4 0.33 0.60444444 4.4 2.8 1.2 1 0.7 3 106 5.4 1.91 13.9 41 25 244 ND 20 ND 11 288
33 C43 11.48 F C HW 4 4.3 0.21 0.76444444 6.5 4.4 1.7 0.8 ND 6 124 ND ND ND 48 12 257 ND ND ND ND ND
34 C41 7.02 F C HW 2.8 0.4 <0.10 0.04977778 6.3 3.9 2 0.9 ND 5 103 ND ND ND 56 34 236 ND ND ND ND ND
HEALTHY WEIGHT DATA BLOOD TEST
224
243
No ID Age Years
Gender 
(M/F) Arm (A/B/C)
Obese 
(OB)/Healthy 
Weight (HW) RNA ID RNA [ng/ul] AR CAR COUP-TF1 COUP-TF2 DAX EAR2 ESR1 ESR2 ESRRA ESRRB ESRRG FXRa GCNF GR HNF4A HNF4G LRH-1 LXRa LXRb MR NOR1 NUR77 NURR1
1 C38 7.65 M C HW NO20223 305.50 7.79E-04 7.79E-04 7.79E-04 7.79E-04 7.79E-04 5.09E-02 6.98E-02 1.55E-02 0.14863746 8.08E-03 1.59211967 7.79E-04 1.96E-02 3.79551802 7.79E-04 7.79E-04 7.79E-04 2.32E-02 5.6722603 0.25237457 1.00308608 0.42818946 2.37306545
2 C4 10.17 M C HW NO15852 66.70 0.12426238 2.73E-03 2.73E-03 2.73E-03 2.73E-03 0.20100536 7.80E-02 4.07E-02 0.15064521 2.73E-03 2.73E-03 2.73E-03 3.47E-02 1.00134454 2.73E-03 2.73E-03 711.713016 0.10518715 5.96498686 0.12367095 8.82E-02 1.4650584 0.61338209
3 C1 6.33 M C HW NO15854 119.80 5.57E-02 1.72E-03 1.72E-03 1.72E-03 1.72E-03 0.19439282 0.13052038 1.59E-02 0.16108112 1.72E-03 1.72E-03 1.72E-03 1.72E-03 3.20592977 1.72E-03 1.72E-03 1.72E-03 5.06E-02 4.21572611 0.25969707 1.24E-02 0.59206881 0.12175608
4 C5 9.00 M C HW NO16199 222.60 2.86E-02 1.41E-03 1.41E-03 1.41E-03 1.41E-03 0.17964173 2.26E-02 1.99E-02 0.23975521 1.41E-03 1.41E-03 1.41E-03 2.64E-02 3.17678081 1.41E-03 1.41E-03 193.225876 0.11524875 3.16563708 0.225236 0.10742795 0.95498738 0.69532855
5 C3 9.00 M C HW NO16213 59.50 8.71E-02 9.96E-04 9.96E-04 9.96E-04 9.96E-04 5.19E-02 0.20628959 1.56E-02 0.16824043 9.96E-04 9.96E-04 9.96E-04 3.60E-02 4.02921712 9.96E-04 9.96E-04 227.17695 5.09E-02 2.93207533 0.30835097 0.18834501 0.64035789 0.44882272
6 C10 9.50 M C HW NO16788 97.80 3.06E-02 1.07E-03 1.07E-03 1.07E-03 1.07E-03 7.04E-02 5.07E-02 8.46E-03 0.10677157 1.07E-03 7.05117585 1.07E-03 1.14E-02 1.86537549 1.07E-03 1.07E-03 1.07E-03 5.43E-02 3.1105129 0.25475469 0.16499021 1.31228384 0.46892084
7 C15 10.17 M C HW NO17569 62.30 9.47E-02 1.80E-03 1.80E-03 1.80E-03 1.80E-03 9.50E-02 2.95E-02 7.29E-02 0.16741329 1.80E-03 1.80E-03 1.80E-03 2.84E-02 5.37063058 1.80E-03 1.80E-03 1.80E-03 8.03E-02 3.10562542 0.31655591 0.11364919 2.39254827 0.49435454
8 C16 7.33 M C HW NO17572 320.60 0.21909264 3.67E-03 3.67E-03 3.67E-03 3.67E-03 0.12638927 6.86E-02 3.67E-03 3.67E-03 3.67E-03 3.67E-03 3.67E-03 4.68E-02 9.03459926 3.67E-03 3.67E-03 119.452659 0.12322465 4.17914012 0.50369801 5.13E-02 0.67243083 0.20289349
9 C44 8.87 M C HW NO21074 272.60 1.26E-02 3.76E-04 3.76E-04 3.76E-04 34.0775433 7.35E-02 6.37E-02 6.99E-03 4.76E-02 3.76E-04 3.76E-04 3.76E-04 8.75E-03 3.95456687 3.76E-04 3.76E-04 3.76E-04 1.51E-02 4.32190668 0.17159078 0.91989302 0.46774715 3.88347344
10 C42 11.48 M C HW NO21073 325.00 4.82E-02 1.17E-03 1.17E-03 1.17E-03 1.17E-03 0.11693638 0.10491741 1.17E-03 9.54E-02 1.17E-03 1.17E-03 6.28797813 1.40E-02 4.92250001 1.17E-03 1.17E-03 1.17E-03 1.17E-03 3.68467711 0.19086759 0.46490569 0.59738972 5.25686775
11 C30 10.08 M C HW NO17913 265.70 5.79E-04 5.79E-04 5.79E-04 5.79E-04 5.79E-04 9.99E-02 0.1793513 2.91E-02 0.11138574 5.79E-04 29.3086443 5.79E-04 3.99E-02 5.39780291 5.79E-04 5.79E-04 5.79E-04 7.62E-02 3.1460857 0.35416111 0.127004 1.26615129 0.53356844
12 C18 6.58 M C HW NO19558 230.90 3.87E-02 6.21E-04 6.21E-04 6.21E-04 6.21E-04 6.73E-02 7.79E-02 1.07E-02 9.29E-02 1.70E-02 6.21E-04 6.21E-04 1.01E-02 4.40195062 6.21E-04 6.21E-04 6.21E-04 2.97E-02 5.54498439 0.23307181 0.79319115 0.65429847 1.66662238
13 C31 7.42 M C HW NO18823 210.4 1.27E-03 1.27E-03 1.27E-03 1.27E-03 1.27E-03 0.10082766 2.97E-02 1.43E-02 0.14794498 1.27E-03 1.27E-03 1.27E-03 1.27E-03 3.3988127 1.27E-03 1.27E-03 1.27E-03 6.76E-03 4.21654529 0.11344105 0.60843457 0.71552816 1.66646682
14 C29 6.75 M C HW NO18594 177.90 7.22E-02 8.82E-04 8.82E-04 8.82E-04 8.82E-04 7.89E-02 7.30E-02 2.48E-02 0.12884382 1.36E-02 8.82E-04 8.82E-04 0.14878915 7.43390953 8.82E-04 0.48955773 8.82E-04 9.05E-02 6.90772519 0.42807643 0.6121023 1.8263238 1.61475636
15 C25 10.92 M C HW NO18397 308.00 8.56E-02 2.00E-03 2.00E-03 2.00E-03 2.00E-03 0.10246445 2.00E-03 1.57E-02 0.22593757 2.00E-03 2.00E-03 2.00E-03 3.47258183 4.07609809 6.92E-02 0.6366763 2.00E-03 9.32E-02 2.30431906 2.00E-03 2.00E-03 0.35178414 0.10384574
16 C28 9.17 M C HW NO18347 308.90 5.05E-02 1.60E-03 1.60E-03 1.60E-03 1.60E-03 0.11171441 0.10263833 5.47E-02 0.16113751 1.60E-03 2.8852042 1.60E-03 5.62E-02 7.49316666 1.60E-03 1.60E-03 1.66E-02 9.58E-02 3.75632419 0.53991999 6.93E-02 0.82334011 0.88151291
17 C20 7.08 M C HW NO18456 123.90 0.16879066 2.14E-03 2.14E-03 2.14E-03 2.14E-03 6.81E-02 0.14854879 2.23E-02 0.14054066 2.14E-03 2.81310488 2.14E-03 2.54E-02 4.88002842 2.14E-03 2.14E-03 2.14E-03 7.24E-02 2.71227334 0.80730367 8.73E-02 0.61958752 1.03875559
18 C17 6.83 M C HW NO18266 251.4 8.61E-02 2.31E-03 2.31E-03 2.31E-03 2.31E-03 7.32E-02 2.31E-03 2.31E-03 0.13612111 2.31E-03 17.1103687 2.31E-03 2.90E-02 1.90653119 2.31E-03 2.31E-03 2.31E-03 0.10504722 4.1712888 0.10863866 7.40E-03 0.17178013 5.78E-02
19 C2 10.25 F C HW NO15727 42.70 1.67E-05 1.67E-05 1.67E-05 1.67E-05 1.67E-05 1.10E-03 1.67E-05 3.22E-04 7.74E-04 1.67E-05 1.67E-05 1.67E-05 1.67E-05 8.39E-03 1.67E-05 1.67E-05 1.67E-05 8.41E-04 3.16E-02 1.07E-03 1.67E-05 4.35E-03 8.87E-04
20 C34 9.92 F C HW NO18264 318.00 4.02E-06 4.02E-06 4.02E-06 4.02E-06 4.02E-06 8.99E-04 1.52E-03 1.18E-04 8.32E-04 4.02E-06 4.02E-06 4.02E-06 1.63E-04 5.62E-02 4.20E-05 4.02E-06 4.18652027 6.91E-04 1.53E-02 3.46E-03 1.96E-04 1.62E-03 8.45E-04
21 C32 6.83 F C HW NO18495 282.20 7.61E-04 4.11E-06 4.11E-06 4.11E-06 4.11E-06 1.12E-03 8.28E-04 1.75E-04 7.65E-04 4.11E-06 3.38E-02 4.11E-06 9.75E-05 4.66E-02 4.11E-06 4.11E-06 4.11E-06 5.66E-04 3.04E-02 4.58E-03 2.43E-03 8.37E-03 1.33E-02
22 C27 7.50 F C HW NO18869 205.30 9.32E-04 9.70E-06 9.70E-06 9.70E-06 9.70E-06 1.47E-03 1.50E-03 8.61E-05 1.80E-03 9.70E-06 0.20007579 9.70E-06 1.74E-04 5.91E-02 9.70E-06 1.28E-02 9.70E-06 1.05E-03 3.23E-02 6.35E-03 3.31E-03 2.88E-02 2.25E-02
23 C26 9.75 F C HW NO18870 366.80 7.98E-04 7.79E-06 7.79E-06 7.79E-06 7.79E-06 5.29E-04 8.45E-04 2.56E-04 1.03E-03 7.79E-06 0.79419353 7.79E-06 1.64E-04 3.69E-02 7.79E-06 7.79E-06 7.79E-06 9.83E-04 4.09E-02 5.50E-03 2.82E-04 6.41E-03 6.54E-03
24 C8 9.75 F C HW NO16406 77.90 7.01E-04 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.80E-03 5.22E-04 1.74E-05 9.38E-04 1.74E-05 1.74E-05 1.74E-05 2.98E-04 2.22E-02 1.74E-05 7.38E-02 1.74E-05 1.10E-03 3.27E-02 3.06E-03 4.74E-04 6.36E-03 3.28E-03
25 C19 6.00 F C HW NO18396 279.10 2.09E-06 2.09E-06 2.09E-06 2.09E-06 2.09E-06 1.39E-04 5.39E-04 9.89E-05 4.10E-04 2.09E-06 2.09E-06 6.99721116 2.45E-04 2.34E-02 2.09E-06 0.10146408 2.09E-06 3.07E-04 1.61E-02 2.21E-03 1.09E-03 4.46E-03 3.28E-03
26 C23 10.25 F C HW NO18868 161.40 1.68E-03 8.08E-05 8.08E-05 8.08E-05 8.08E-05 3.84E-03 1.93E-04 8.08E-05 8.08E-05 8.08E-05 0.18024409 8.08E-05 8.08E-05 4.60E-02 8.08E-05 8.08E-05 8.08E-05 6.17E-03 0.13610282 4.17E-03 6.04E-03 2.58E-02 1.88E-02
27 C33 6.83 F C HW NO19260 404.90 1.74E-03 8.44E-06 8.44E-06 8.44E-06 8.44E-06 6.55E-04 5.89E-04 8.44E-06 1.07E-03 8.44E-06 8.44E-06 8.44E-06 1.73E-04 4.26E-02 8.44E-06 8.44E-06 8.44E-06 8.49E-04 4.99E-02 4.37E-03 2.00E-03 4.83E-03 1.86E-02
28 C45 8.87 F C HW NO21072 378.60 4.91E-06 4.91E-06 4.91E-06 4.91E-06 4.91E-06 8.01E-04 8.90E-04 1.14E-04 6.88E-04 1.99E-04 4.91E-06 4.91E-06 1.64E-04 3.77E-02 4.91E-06 4.91E-06 0.99269212 1.94E-04 3.77E-02 1.56E-03 1.01E-02 6.73E-03 3.85E-02
29 C11 6.75 F C HW NO17571 118.30 3.64E-06 3.64E-06 3.64E-06 3.64E-06 3.64E-06 5.85E-04 7.64E-04 2.16E-04 5.19E-04 7.63E-05 3.64E-06 3.64E-06 8.66E-05 3.41E-02 3.64E-06 3.64E-06 3.64E-06 4.33E-04 2.53E-02 4.36E-03 9.67E-04 7.62E-03 5.13E-03
30 C14 6.58 F C HW NO17911 336.50 7.98E-04 4.56E-06 4.56E-06 4.56E-06 4.56E-06 1.20E-03 9.86E-04 1.66E-04 1.14E-03 4.56E-06 4.56E-06 4.56E-06 1.56E-04 2.33E-02 4.56E-06 4.56E-06 4.56E-06 1.21E-03 2.63E-02 2.65E-03 4.56E-06 7.90E-03 1.27E-03
31 C21 8.50 F C HW NO18458 300.80 1.04E-03 5.72E-06 5.72E-06 5.72E-06 5.72E-06 2.47E-03 3.81E-04 2.05E-04 9.28E-04 5.72E-06 0.18015145 5.72E-06 1.30E-04 5.02E-02 5.72E-06 6.14E-02 107.372046 1.05E-03 3.41E-02 6.61E-03 4.10E-04 4.11E-03 1.32E-03
32 C36 6.58 F C HW NO18821 32.10 3.25E-05 3.25E-05 3.25E-05 3.25E-05 3.25E-05 3.25E-05 3.25E-05 3.25E-05 3.62E-03 3.25E-05 3.25E-05 3.25E-05 3.25E-05 1.78E-02 3.25E-05 3.25E-05 3.25E-05 1.12E-04 4.23E-02 1.72E-03 5.83E-03 1.02E-02 9.75E-03
33 C43 11.48 F C HW NO21071 388.00 2.87E-04 8.80E-06 8.80E-06 8.80E-06 8.80E-06 1.15E-03 1.45E-03 2.51E-04 6.01E-04 8.80E-06 2.07E-02 8.80E-06 2.02E-04 6.26E-02 8.80E-06 8.80E-06 8.80E-06 3.85E-04 5.56E-02 2.73E-03 8.38E-03 6.26E-03 4.05E-02
34 C41 7.02 F C HW NO21075 138.90 2.35E-04 5.40E-06 5.40E-06 5.40E-06 5.40E-06 2.26E-04 9.44E-05 8.82E-05 5.34E-04 5.40E-06 5.40E-06 5.40E-06 4.87E-05 1.79E-02 5.40E-06 5.40E-06 5.40E-06 1.93E-04 3.21E-02 2.65E-04 1.02E-02 9.09E-03 2.68E-02
HEALTHY WEIGHT DATA NR GENE EXPRESSION (TLDA BASELINE ANALYSIS)
225
244
No ID Age Years
Gender 
(M/F) Arm (A/B/C)
Obese
(OB)/Health
y Weight 
(HW) PGR PNR PPARA PPARD PPARG PXR RARA RARB RARG REV-ERBa REV-ERBb RORA RORB RORC RXRA RXRB RXRG SF-1 SHP THRA THRB TLX TR2 TR4 VDR PXR THRA THRB
1 C38 7.65 M C HW 7.79E-04 7.79E-04 0.34039122 1.04570841 1.85E-02 1.36E-02 12.4921496 7.79E-04 3.66E-02 2.59454937 1.28475509 3.49507293 7.79E-04 0.39794187 2.46028383 0.40460371 7.79E-04 8.65E-03 7.79E-04 3.1203553 1.19E-02 7.79E-04 0.16406895 0.44326721 1.87025884 1.367 366.021 0.473
2 C4 10.17 M C HW 2.73E-03 2.73E-03 0.38244941 1.96416646 4.55E-02 2.73E-03 7.10986418 2.73E-03 0.15843575 2.22077732 8.52E-02 2.73E-03 3.09E-02 0.69020327 7.91628235 0.91804963 2.73E-03 2.73E-03 2.73E-03 2.20634896 2.73E-03 2.73E-03 2.73E-03 1.03412847 1.83374284 ND ND ND
3 C1 6.33 M C HW 1.72E-03 1.72E-03 0.33543785 1.67514683 1.72E-03 2.54E-02 3.77216742 1.72E-03 0.14220932 1.34565965 0.31322962 0.69805647 1.72E-03 0.25414751 4.32275637 0.99126803 1.72E-03 1.53E-02 1.72E-03 1.90441875 1.72E-03 1.72E-03 1.72E-03 1.43456672 1.18407099 2.152 268.874 0.178
4 C5 9.00 M C HW 644.213936 1.41E-03 0.36883138 1.31402838 1.43E-02 2.41E-02 4.48305342 3.09E-02 4.42E-02 1.17255374 0.52378623 2.09942838 2.79E-02 0.1895061 5.05820522 0.7705615 1.41E-03 1.41E-03 1.41E-03 1.16684971 1.41E-03 1.41E-03 0.34479008 1.0849204 1.00574237 1.039 205.185 0.717
5 C3 9.00 M C HW 444.809799 9.96E-04 0.43181899 1.38073124 9.25E-03 1.54E-02 2.97281229 9.96E-04 9.83E-02 1.45649284 0.86417944 5.27019338 1.14E-02 0.19770158 3.63834391 0.67829895 1.86947437 7.57E-03 2.32E-03 1.61521291 1.01E-02 9.96E-04 0.58931269 1.33960949 0.91488816 ND ND ND
6 C10 9.50 M C HW 1.07E-03 1.07E-03 0.25828692 1.1772493 1.07E-03 2.45E-02 2.68542102 1.07E-03 8.92E-02 1.38093501 0.21207119 1.07E-03 1.07E-03 0.27899116 2.95646066 0.48024504 1.07E-03 1.05E-02 1.07E-03 1.22285165 1.39E-02 1.07E-03 6.81E-02 1.00165357 0.74401499 ND ND ND
7 C15 10.17 M C HW 1.80E-03 1.80E-03 0.39041286 1.3699158 1.80E-03 3.16E-02 4.6605417 1.80E-03 4.13E-02 1.38807016 0.68525418 0.92349587 1.80E-03 0.28326655 5.5701114 0.41338518 1.80E-03 1.93E-02 1.80E-03 1.50732044 1.80E-03 1.80E-03 0.12090839 1.3155125 1.23328424 ND ND ND
8 C16 7.33 M C HW 3.67E-03 3.67E-03 0.46219179 2.1332536 3.67E-03 3.67E-03 5.12291307 3.67E-03 0.13002523 1.9983647 0.88730042 3.67E-03 3.67E-03 0.19110222 3.27924927 1.63231005 3.67E-03 3.45E-02 3.67E-03 2.83822169 3.67E-03 3.67E-03 0.23634191 2.1242511 1.39689942 ND ND ND
9 C44 8.87 M C HW 1461.20687 3.76E-04 0.16310407 0.663734 1.00E-02 5.97E-03 8.36598952 3.76E-04 6.71E-02 1.49150573 1.52605501 5.20916765 3.76E-04 0.24593578 1.4098893 0.2613022 3.76E-04 3.76E-04 3.76E-04 2.29346226 6.09E-03 3.76E-04 0.38467058 0.40017943 1.39885328 1.455 979.42 0.412
10 C42 11.48 M C HW 574.762593 1.17E-03 0.16096999 0.91541052 1.56E-02 1.17E-03 4.76008241 1.17E-03 7.03E-02 2.62434798 2.26178808 4.99054218 1.55E-02 0.12718131 0.93051026 0.22819628 1.17E-03 1.17E-03 1.17E-03 3.11110846 1.17E-03 1.17E-03 0.41526459 0.53024816 0.62642385 2.753 1180.993 0.83
11 C30 10.08 M C HW 5.79E-04 5.79E-04 0.48391924 1.91464273 1.01E-02 1.06E-02 3.6941371 5.79E-04 6.22E-02 1.28074904 0.76344101 4.52692175 7.98E-03 0.23172881 5.89860867 0.93588442 5.79E-04 5.15E-03 5.79E-04 1.76024689 3.50E-02 5.79E-04 0.76036865 1.65667958 1.33826387 3.484 537.747 1.748
12 C18 6.58 M C HW 6.21E-04 6.21E-04 0.28560826 1.18011046 7.15E-03 1.00E-02 10.1862843 6.21E-04 4.76E-02 2.0441788 1.96767148 4.48020377 6.21E-04 7.09E-02 2.31192856 0.40220268 6.21E-04 6.21E-04 6.21E-04 3.69185914 6.21E-04 6.21E-04 0.48971988 0.50745578 2.70816027 1.047 1176.907 0.788
13 C31 7.42 M C HW 633.074085 1.27E-03 0.17607365 0.90398639 2.55E-02 1.27E-03 7.40259741 1.27E-03 3.35E-02 3.63921458 1.44733482 2.30506746 1.27E-03 7.13E-02 1.81583682 0.30132982 1.27E-03 1.27E-03 1.27E-03 3.01907007 1.27E-03 1.27E-03 0.25839206 0.43951033 2.60352762 ND ND ND
14 C29 6.75 M C HW 8.82E-04 8.82E-04 0.5407402 2.148657 8.82E-04 2.84E-02 8.88458568 8.82E-04 7.65E-02 2.46361424 1.01833192 3.21969148 3.37E-02 0.16600328 10.4408796 1.06019736 8.82E-04 1.75E-02 8.82E-04 1.98046372 2.04E-02 8.82E-04 0.50146883 1.99927985 2.99298926 2.001 512.278 0.629
15 C25 10.92 M C HW 233.577656 2.00E-03 0.33629133 1.61511108 2.00E-03 2.00E-03 2.82858146 2.00E-03 7.16E-02 0.99109382 0.72218546 2.61624491 1.61437866 0.28295401 3.94554403 0.40764441 2.00E-03 2.00E-03 2.00E-03 0.95631635 2.97E-02 2.00E-03 2.00E-03 1.59763212 0.80648383 3.331 403.321 0.868
16 C28 9.17 M C HW 1.60E-03 1.60E-03 0.50706036 3.04520255 1.60E-03 1.60E-03 4.76998077 1.60E-03 0.10183817 2.62873111 1.49806026 2.95084686 1.87E-02 0.20867386 5.64684531 0.69100003 1.60E-03 1.60E-03 1.60E-03 2.21763155 2.79E-02 1.60E-03 1.60E-03 2.55937994 1.54631649 1.642 456.916 0.478
17 C20 7.08 M C HW 2.14E-03 2.14E-03 0.42517542 2.07052594 2.14E-03 2.14E-03 3.09807159 2.14E-03 9.57E-02 2.06168474 1.41075024 5.15196053 2.14E-03 0.26969939 3.28944151 0.76694303 2.14E-03 2.03E-02 2.14E-03 2.08732263 2.14E-03 2.14E-03 0.7352503 1.69583624 0.93316951 0.322 61.426 0.454
18 C17 6.83 M C HW 2.31E-03 2.31E-03 0.17649827 0.81275993 4.88E-02 2.31E-03 4.84755803 2.31E-03 4.87E-02 2.31E-03 0.1876375 0.10390506 2.31E-03 0.21119704 5.27600986 0.38160016 2.31E-03 2.31E-03 2.31E-03 0.42792492 2.31E-03 2.31E-03 5.23E-02 0.66417091 2.00631278 2.65 311.003 0.492
19 C2 10.25 F C HW 225.741568 1.67E-05 1.32E-03 9.00E-03 1.67E-05 1.67E-05 4.63E-02 1.67E-05 1.10E-03 1.26E-02 1.17E-03 1.91E-03 1.67E-05 4.76E-03 4.62E-02 6.38E-03 1.67E-05 1.34E-04 1.67E-05 1.08E-02 1.67E-05 1.67E-05 7.14E-04 4.23E-03 1.17E-02 ND ND ND
20 C34 9.92 F C HW 0.54820169 4.02E-06 4.69E-03 2.38E-02 2.18E-04 3.95E-04 4.76E-02 4.02E-06 7.72E-04 1.49E-02 9.25E-03 4.18E-02 4.59E-05 4.12E-03 3.44E-02 7.48E-03 4.02E-06 3.13E-05 4.02E-06 1.64E-02 1.25E-04 4.02E-06 7.15E-03 2.44E-02 1.20E-02 ND ND ND
21 C32 6.83 F C HW 4.11E-06 4.11E-06 4.49E-03 1.49E-02 6.11E-05 1.65E-04 4.11E-02 4.11E-06 6.63E-04 9.11E-03 6.97E-03 4.09E-02 1.33E-04 2.17E-03 4.77E-02 4.52E-03 4.11E-06 9.98E-05 4.11E-06 1.31E-02 1.78E-04 4.11E-06 4.54E-03 1.53E-02 9.70E-03 ND ND ND
22 C27 7.50 F C HW 9.70E-06 9.70E-06 4.80E-03 1.69E-02 1.40E-04 5.78E-04 5.90E-02 9.70E-06 1.37E-03 1.73E-02 1.34E-02 5.43E-02 3.80E-04 1.55E-03 5.84E-02 1.04E-02 9.70E-06 9.70E-06 9.70E-06 2.15E-02 1.78E-04 9.70E-06 6.98E-03 1.85E-02 1.44E-02 ND ND ND
23 C26 9.75 F C HW 7.79E-06 7.79E-06 3.59E-03 1.48E-02 9.25E-05 3.89E-04 5.27E-02 7.79E-06 8.48E-04 1.49E-02 8.61E-03 2.55E-02 7.79E-06 2.78E-03 5.59E-02 4.39E-03 7.79E-06 7.79E-06 7.79E-06 1.70E-02 7.79E-06 7.79E-06 4.05E-03 1.22E-02 9.70E-03 ND ND ND
24 C8 9.75 F C HW 1.74E-05 1.74E-05 2.66E-03 1.44E-02 1.74E-05 1.74E-05 3.85E-02 1.74E-05 8.38E-04 1.96E-02 1.80E-03 3.13E-03 1.74E-05 1.51E-03 3.56E-02 4.09E-03 1.74E-05 2.02E-04 1.74E-05 1.47E-02 1.74E-05 1.74E-05 1.11E-03 7.52E-03 1.16E-02 ND ND ND
25 C19 6.00 F C HW 2.09E-06 2.09E-06 1.70E-03 6.21E-03 6.02E-05 8.45E-05 1.59E-02 2.09E-06 8.82E-05 7.24E-03 3.91E-03 1.04E-02 2.09E-06 2.64E-04 3.05E-02 2.60E-03 2.09E-06 2.00E-05 2.09E-06 7.44E-03 4.46E-05 2.09E-06 2.76E-03 7.13E-03 7.16E-03 ND ND ND
26 C23 10.25 F C HW 8.08E-05 8.08E-05 4.78E-03 1.68E-02 8.08E-05 8.08E-05 0.15339682 8.08E-05 3.80E-03 3.23E-02 7.01E-03 8.08E-05 1.14E-03 8.08E-05 0.16656663 7.83E-03 8.08E-05 8.08E-05 8.08E-05 1.18E-02 8.08E-05 8.08E-05 1.98E-03 1.32E-02 7.27E-02 ND ND ND
27 C33 6.83 F C HW 8.44E-06 8.44E-06 2.95E-03 1.30E-02 8.44E-06 1.88E-04 6.03E-02 8.44E-06 8.60E-04 2.40E-02 1.08E-02 2.76E-02 8.44E-06 2.04E-03 4.66E-02 4.39E-03 8.44E-06 2.85E-04 8.44E-06 1.47E-02 2.48E-04 8.44E-06 4.35E-03 1.07E-02 1.18E-02 ND ND ND
28 C45 8.87 F C HW 4.91E-06 4.91E-06 1.58E-03 8.30E-03 7.06E-05 8.84E-05 6.08E-02 4.91E-06 4.05E-04 2.52E-02 2.41E-02 5.65E-02 8.28E-05 2.57E-03 1.41E-02 2.80E-03 7.36E-03 4.91E-06 4.91E-06 3.12E-02 4.91E-06 4.91E-06 4.99E-03 5.39E-03 1.53E-02 ND ND ND
29 C11 6.75 F C HW 3.64E-06 3.64E-06 3.13E-03 1.11E-02 3.64E-06 1.10E-04 1.75E-02 3.64E-06 2.96E-04 5.43E-03 6.56E-03 1.91E-02 4.40E-05 1.73E-03 2.96E-02 2.60E-03 3.64E-06 1.92E-04 3.64E-06 1.50E-02 9.59E-05 3.64E-06 1.95E-03 1.20E-02 7.69E-03 ND ND ND
30 C14 6.58 F C HW 4.56E-06 4.56E-06 2.53E-03 1.11E-02 6.50E-05 1.69E-04 4.33E-02 4.56E-06 5.89E-04 9.89E-03 3.00E-03 1.03E-02 6.40E-05 1.35E-03 6.13E-02 5.17E-03 4.56E-06 9.91E-05 4.56E-06 1.25E-02 7.82E-05 4.56E-06 2.72E-03 8.25E-03 1.34E-02 ND ND ND
31 C21 8.50 F C HW 1.16199004 5.72E-06 3.33E-03 1.63E-02 6.52E-05 1.38E-04 4.16E-02 5.72E-06 1.22E-03 1.21E-02 9.20E-03 2.93E-02 9.70E-05 7.30E-03 2.90E-02 7.27E-03 5.72E-06 7.49E-05 5.72E-06 1.56E-02 2.62E-04 5.72E-06 3.39E-03 1.84E-02 8.32E-03 ND ND ND
32 C36 6.58 F C HW 3.25E-05 3.25E-05 2.47E-03 4.14E-03 3.25E-05 3.25E-05 6.19E-02 3.25E-05 5.96E-04 1.95E-02 3.64E-03 6.88E-03 3.25E-05 1.01E-03 1.31E-02 2.55E-03 3.25E-05 3.25E-05 3.25E-05 1.26E-02 3.25E-05 3.25E-05 2.93E-04 2.19E-03 7.34E-03 ND ND ND
33 C43 11.48 F C HW 3.18119791 8.80E-06 2.32E-03 1.54E-02 8.63E-05 8.80E-06 7.93E-02 8.80E-06 9.51E-04 4.14E-02 3.54E-02 0.10233272 1.06E-04 4.28E-03 1.32E-02 6.71E-03 8.80E-06 8.80E-06 8.80E-06 4.37E-02 8.80E-06 8.80E-06 6.23E-03 9.59E-03 1.45E-02 ND ND ND
34 C41 7.02 F C HW 5.40E-06 5.40E-06 1.25E-03 5.12E-03 4.17E-05 5.40E-06 6.22E-02 5.40E-06 2.49E-04 9.28E-03 1.56E-02 2.11E-02 7.23E-05 1.17E-03 8.16E-03 1.02E-03 5.40E-06 5.40E-06 5.40E-06 8.53E-03 5.40E-06 5.40E-06 1.45E-03 2.28E-03 1.24E-02 ND ND ND
HEALTHY WEIGHT DATA NR GENE EXPRESSION (TLDA BASELINE ANALYSIS) NR GENE EXPRESSION (MANUAL)
226
245
No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW) ht wt bmi htsds wtsds bmisds wc wcsds Resistance %BodyFat Fat Weight
%Body 
Water
Total Body 
Water Lean
Dry Lean 
Wt
Impedence(
5Hz)
Impedence(
50Hz) Reactance FFM (kg) FM (kg) %fat
1 304B 9.02191781 M B OB 140 49 25 1.02 2.3 2.19 81.1 2.53419267 511 31.4 15.5 52.4 25.9 33.9 8 572 ND 49.7 31.216411 17.783589 36.2930389
2 133B 9.07 M B OB 150.8 60.8 26.74 2.64 2.83 2.33 70.2 2.19 520 29.4 17.9 53.8 32.7 42.9 10.2 596 523 54.1 34.7434 26.0566 42.85625
3 269A 9.59726027 M A OB 141.4 61.8 30.9093346 0.74 2.69 2.51 97 3.19667151 586 39.6 24.5 46 28.5 37.3 8.8 650 589 50.6 28.8537377 32.9462623 53.3111041
4 242B 11.1232877 M B OB 145.6 47.1 22.2176519 0.21 1.19 1.46 81 2.04604312 540 26.2 12.5 55.6 26.6 35.3 8.7 617 543 56.6 33.2315838 13.8684162 29.4446205
5 104A 8.06849315 M A OB 119.5 38.3 26.8202587 -1.55 1.96 2.5 78 2.61696139 599 43.9 16.8 43.1 16.5 21.5 5 667 602 52.8 21.132673 17.167327 44.8233081
6 252B 10.109589 M B OB 141 54 27.1616116 0.28 2.13 2.22 92 2.78816358 619 36.5 19.7 48.3 26.1 34.3 8.2 632 622 60.7 27.9011764 26.0988236 48.3311547
7 241B 9.55890411 M B OB 142.6 52.3 25.7195069 0.95 2.26 2.18 91 2.99817076 547 ND ND ND ND ND ND 624 550 58 30.8138464 21.4861536 41.0825117
8 117A 7.12 M A OB 128.6 37.2 22.5 1.11 2.39 2.29 78.5 3.01964312 655 39.5 14.6 46.5 17.2 22.4 5.2 722 658 55.1 21.403316 15.796684 42.4642042
9 262B 9.82191781 M B OB 149 85.1 38.3316067 1.69 3.25 2.72 118.2 3.62450673 474 40 34 45.8 ND 51 12.1 541 476 47.9 37.2733134 47.8266866 56.2005718
10 109B 8.48767123 M B OB 138.7 55.7 28.9535802 1.32 2.87 2.56 96 3.4486181 536 42.5 23.7 44.2 24.6 32 7.4 611 539 56.8 29.2509047 26.4490953 47.4849108
11 256A 11.3123288 M A OB 151.5 70.8 30.846649 0.88 2.49 2.35 102 2.87473261 514 34.7 24.3 49.3 34.5 45.7 7.2 584 517 51.2 36.8676024 33.9323976 47.9271152
12 250A 10.4219178 M A OB 134.5 44.3 24.4883293 -0.92 1.3 1.92 83.5 2.4183607 639 32.4 14.2 43.8 51.4 29.6 7.1 724 642 65.9 25.6385669 18.6614331 42.1251312
13 244B 10.7780822 M B OB 145.2 60.4 28.6486199 0.4 2.21 2.26 101.7 3.07495616 647 38.3 21.7 47 26.6 34.9 8.3 729 650 62.5 28.6598934 31.7401066 52.5498453
14 111A 8.35 M A OB 134.4 39.7 21.9781923 0.67 1.9 1.92 80 2.74584545 571 31.2 12.5 53 21.2 27.5 4 649 575 61.1 26.3904939 13.3095061 33.5252044
15 124A 9.14520548 M A OB 142.8 63.8 31.2870246 1.35 2.91 2.58 102 3.32932878 544 45.8 29.2 41.4 26.4 34.6 8.2 535 546 61.7 30.7339897 33.0660103 51.8276023
16 127A 8.12876712 M A OB 132.1 43.2 24.7558653 0.6 2.34 2.33 83.5 2.94420531 702 47.2 20.4 40.5 17.5 22.8 5.3 770 704 58.8 21.8353487 21.3646513 49.4552114
17 271B 9.80273973 M B OB 144.5 45.5 21.7909268 1.04 1.71 1.63 77.6 2.31187284 605 32.1 14.6 51.6 23.5 30.9 7.4 678 607 58.5 29.2491895 16.2508105 35.7160671
18 273B 12.1753425 M B OB 149.5 70 31.3195602 -0.09 2.18 2.32 101.5 2.7103242 562 38.9 27.2 46.1 32.3 42.8 10.5 638 565 55.8 34.2791662 35.7208338 51.0297626
19 303A 8.2109589 M A OB 133.1 39 22.0144833 0.68 1.95 1.97 78.2 2.63041383 616 34.4 13.4 50 19.5 25.6 6.1 690 619 56.7 24.4268717 14.5731283 37.3669956
20 263A 9.87671233 M A OB 143.8 53 25.6305601 0.88 2.18 2.12 85.7 2.77551118 590 40.8 21.6 45.1 23.9 31.4 7.5 670 593 63.3 29.6474966 23.3525034 44.0613272
21 300B 7.1890411 M B OB 125 40.8 26.112 0.38 2.68 2.65 85 3.39407621 598 42.2 17.2 44.4 18.1 23.6 5.5 670 601 63.4 22.0222436 18.7777564 46.0239128
22 126B 7.34520548 M B OB 131.2 52.4 30.4413296 1.31 3.3 2.84 96.1 3.83531947 513 42.4 22.2 44.3 23.2 30.2 7 571 515 50.4 26.9551413 25.4448587 48.5588907
23 131B1 6.36164384 M B OB 131.2 35.2 20.4491374 2.62 2.66 2.15 68.5 2.18625672 620 31.2 11 53.1 18.7 24.2 5.5 694 623 65.2 22.5222662 12.6777338 36.0162892
24 275B2 9.70136986 M B OB 139 45 23.2907199 0.29 1.72 1.88 82 2.58556012 601 36 16.2 48.9 22 28.8 6.8 663 603 50.8 27.6431877 17.3568123 38.5706939
25 273B2 6.05205479 M B OB 122.6 39.6 26.3459732 1.36 3.32 3.08 84 3.35900198 620 44.9 17.8 42.4 16.8 21.8 5 685 622 56.5 20.0234521 19.5765479 49.435727
26 272A 9.47671233 M A OB 147.4 67 30.8375478 1.75 2.9 2.52 96.5 3.18191896 548 45.8 30.7 41.3 27.7 36.3 8.6 607 550 47.8 32.3649564 34.6350436 51.694095
27 147B ND M B OB 147.6 48.8 22.6 86.2 ND ND 86.2 2.84 ND ND ND ND ND ND ND ND ND ND ND ND ND
28 277A 9.99452055 M A OB 134 56.4 31.4101136 -0.7 2.3 2.49 96.8 2.9441388 524 43.6 24.6 42.9 24.2 31.8 7.6 597 527 52.2 29.2199381 27.1800619 48.1915991
29 283A 11.1342466 M A OB 154.7 67.2 28.0794532 1.46 2.4 2.18 91.25 2.54357671 513 30.7 20.6 52.2 35.1 46.6 11.5 574 515 45.4 38.0445986 29.1554014 43.386014
30 264A 9.91506849 M A OB 149 53.6 24.1430566 1.62 2.19 1.95 90 2.95998701 658 40.2 19.4 45.5 22 28.9 6.9 741 661 62.8 28.8233256 24.7766744 46.2251388
31 276B ND M B OB 150.7 62.6 27.8 2.5 1.61 2.24 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
32 135A 8.23561644 M A OB 138.1 53.2 27.8948657 1.48 2.87 2.54 94.5 3.40096921 594 45.1 24 42.1 22.4 29.2 6.8 655 596 52.3 26.6198261 26.5801739 49.9627329
33 247A 10.7424658 M A OB 144.1 61.4 29.5692568 0.27 2.27 2.33 92.5 2.80591013 548 35.5 21.8 48.7 29.91 39.6 9.7 622 551 55.5 32.0846696 29.3153304 47.7448378
34 100B 9.17534247 F B OB 130.5 43 25.2491889 -0.53 1.68 2.11 81 2.48059096 678 46.7 20.2 41.2 17.6 22.8 5.2 756 681 63 18.9260369 24.0739631 55.9859606
35 108A 7.65753425 F A OB 145.2 59.2 28.0794421 3.14 3.27 2.59 91 3.17334742 526 39.7 23.5 46.8 27.7 35.7 8 590 523 53.9 31.4103096 27.7896904 46.9420446
36 246B 9.48767123 F B OB 138 47.8 25.099769 0.41 1.9 2.04 84 2.64814105 625 ND ND ND ND ND ND 688 627 50.4 26.4073764 21.3926236 44.7544426
37 105B 8.4109589 F B OB 135.6 47 25.6 0.93837312 2.37 2.27 86 2.86329721 592 40.8 18.3 46 20.6 26.5 5.9 596 592 66.8 26.0582764 20.9417236 44.5568588
38 119B 6.01643836 F B OB 124 38.1 24.7788762 1.69307158 2.85707927 2.62452266 84 2.90564269 589 ND ND ND ND ND ND 656 591 56.9 21.2095991 16.8904009 44.3317608
39 261A 9.48 F A OB 142.5 57.1 28.1 1.01 2.55 2.4 89 2.89 570 44 25.1 43.1 24.6 32 7.4 633 573 50 29.75265 27.34735 47.8937828
40 118A 8.01369863 F A OB 132.8 46.3 26.2533568 0.86 2.5 2.4 86 2.86329721 572 41.59 19.2 45.49 21.01 27.1 6.1 640 575 50 25.6400423 20.6599577 44.6219388
41 134A 8.92054795 F A OB 146.4 58.4 27.247753 2.14 2.78 2.34 98.5 3.30608931 566 43.2 25.2 43.8 28.5 33.2 7.6 633 568 53.7 30.8297959 27.5702041 47.2092536
42 132B 7.21643836 F B OB 126.3 37.8 23.6965488 0.6 2.24 2.28 81.3 2.77911192 635 41.3 15.6 45.8 17.3 22.2 ND 695 638 51.9 21.3856797 16.4143203 43.4241279
43 402B 7.2109589 F B OB 127.9 30.6 18.7059745 0.88 1.42 1.35 65 1.54777176 593 28.3 10.3 55.8 20.3 26.1 5.8 662 596 58.4 22.9842556 7.6157444 24.8880536
44 125B 7.99726027 F B OB 129.5 37.8 22.5399144 0.33 1.83 1.98 76 2.30887469 628 37.3 14.1 48.7 18.4 23.7 5.3 711 631 62 22.9458798 14.8541202 39.2966142
45 102A 7.70136986 F A OB 124.4 33.1 21.3888401 -0.25 1.47 1.85 64 1.43256693 ND 38.7 12.8 47.4 15.7 20.3 4.6 753 674 ND ND ND ND
46 106A 7.57260274 F A OB 128 40.2 24.5361328 0.5 2.27 2.31 75 2.41596226 594 39.3 15.8 47 18.91 24.4 5.5 659 597 52.5 23.2279894 16.9720106 42.2189319
47 301B 6.79452055 F B OB 124.4 43.8 28.3030572 0.76 2.88 2.73 87.1 3.03384675 598 47 20.6 41.3 18.1 23.2 5.1 668 601 57.6 21.5913175 22.2086825 50.7047547
48 107B 6.26849315 F B OB 125 34.7 22.208 1.53 2.44 2.28 81 2.76409753 724 44.4 15.4 43.5 15.1 19.3 4.2 800 726 59.1 18.440545 16.259455 46.8572191
49 270A 11.4410959 F A OB 160.3 62.4 24.2838502 1.96 2.06 1.74 95.5 2.69214339 509 23.9 14.9 57.4 35.8 47.5 11.7 572 511 46.3 40.7442055 21.6557945 34.7047988
50 249A 8.98630137 F A OB 135.6 58.1 31.5977933 0.44 2.74 2.62 94.5 3.10422871 515 44.1 25.6 43 25 32.5 7.5 600 518 57.2 29.4680325 28.6319675 49.2804948
51 251B 10.8986301 F B OB 150.3 61.8 27.3571287 0.97 2.12 2.06 90.5 2.84725485 553 30.8 18.8 53.3 32.5 42.2 9.7 631 556 59.1 34.1136155 27.6863845 44.7999749
52 116B 7.47945205 F B OB 132.3 40.7 23.2527713 1.32 2.36 2.18 73.6 2.31943589 643 40.8 16.6 45.9 18.7 24.1 5.4 728 646 61.7 22.9298664 17.7701336 43.6612618
53 259B 8.74794521 F B OB 137.4 45.1 23.8892809 0.92 2.07 2.02 84.5 2.79428749 589 36.6 16.5 ND 22 28.6 6.6 665 593 62.5 26.9325484 18.1674516 40.2825978
54 103B 6.48493151 F B OB 127.3 41.4 25.5472133 1.65 2.87 2.6 82.85 2.85357722 650 46.6 19.3 42.4 41.4 22.1 4.9 720 652 56.3 20.7650434 20.6349566 49.8428903
55 267A 10.0109589 F A OB 147.2 66.2 30.5521916 1.33 2.69 2.44 98.3 3.15633314 564 37.9 25.1 47.9 31.7 41.1 9.4 637 567 57.6 31.9292535 34.2707465 51.7684993
56 2A 7.34520548 F A OB 121.1 27.4 18.6836738 -0.46 0.82 1.31 61 1.04452643 674 31 8.5 53.3 14.6 18.9 4.3 744 677 59 19.2877464 8.1122536 29.606765
57 245A 8.79452055 F A OB 143.3 51.4 25.0305699 1.78 2.47 2.15 88 2.94907524 617 42 21.6 44.6 22.9 29.8 6.9 705 621 64.6 27.7634644 23.6365356 45.9854778
58 243A 9.96164384 F A OB 150 69.3 30.8 1.77 2.83 2.46 93 2.95519786 500 46.3 32.1 41.4 28.7 37.2 8.5 629 553 58.2 36.1739178 33.1260822 47.8009844
59 401B 9.70136986 F B OB 140 50.8 25.9183673 0.54 2.01 2.09 91 2.97124816 631 43.8 21.9 43.4 21.7 28.1 6.4 713 633 57.9 26.9371058 23.8628942 46.9742011
60 129B 8.03287671 F B OB 128.2 41.6 25.3114649 0.07 2.15 2.31 85.7 2.84982873 688 48.1 20 40.4 16.8 21.6 4.8 785 692 72.9 21.1398358 20.4601642 49.183087
61 403B 9.90958904 F B OB 144 48 23.1481481 0.96142005 1.70101353 1.69621544 83.5 2.6215841 576 35.2 16.9 49.4 23.7 31.1 7.4 671 591 58.5 30.2885205 17.7114795 36.8989155
62 309A 8.51780822 F A OB 145.1 70 33.2478231 2.3 3.35 2.75 105.7 3.48409261 545 44.3 31 43.3 30.3 39 8.7 609 547 49.1 31.0523967 38.9476033 55.6394332
63 281A 9.90136986 F A OB 148 68.2 31.1358656 1.54 2.82 2.49 104.1 3.4 568 48.1 32.8 39.9 27.2 35.4 8.2 634 571 52.1 31.9491287 36.2508713 53.1537702
64 307A 6.57534247 F A OB 129.8 42.6 25.2848403 1.96 2.91 2.06 74.1 2.35467062 644 44.8 19.1 43 18.3 23.5 5.2 721 646 57.6 21.6262422 20.9737578 49.2341733
65 121A 9.10958904 F A OB 141.1 49 24.6117249 1.19 2.17 2.04 88.4 2.86101305 671 45.5 22.3 42.2 20.7 26.7 6 756 675 69.1 25.6306405 23.3693595 47.6925704
66 253A 10.1945205 F A OB 141.3 77.6 38.8666758 0.33 3.05 2.8 108.25 3.45434242 547 44.4 34 42.8 32.8 42.6 9.8 616 549 56 30.8074997 46.7925003 60.2996137
67 3B 8.99178082 F B OB 121.9 31 20.9 -1.83 0.36 1.47 79 2.35704098 716 41.3 12.8 45.5 14.1 18.2 4.1 796 719 63.9 19.7542804 11.2457196 36.2765149
68 275B 9.70136986 F B OB 149.5 63.4 28.3665731 1.92 2.7 2.32 97.8 3.21558911 604 47 29.8 40.9 25.9 33.6 7.7 669 606 49.2 30.7993529 32.6006471 51.4205791
69 313A 8.78630137 F A OB 137.1 60.2 32.0273925 0.84 2.91 2.66 97 3.26310716 535 48.7 29.3 39.9 24 30.9 6.9 618 555 50.8 28.9614447 31.2385553 51.8912878
70 284A 9.17260274 F A OB 143.5 66.8 32.4393886 1.5 3.03 2.64 93.5 3.06789938 563 45.6 27.7 41.9 25.5 33.1 7.6 633 565 54.3 30.161726 36.638274 54.8477156
71 112A 7.06027397 F A OB 115.6 29.8 22.2997809 -1.17 1.4 2.13 75 2.41596226 599 ND 9.1 53.1 29 19.9 4.4 667 601 59 19.4521282 10.3478718 34.724402
72 260B 9.0109589 F B OB 135.2 38.9 21.2812051 0.35 1.38 1.55 78 2.29131465 682 ND ND ND ND ND ND 767 685 67 23.6988245 15.2011755 39.077572
OBESE DATA CLINICAL MEASUREMENTS (BASELINE)
227246
No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW)
12 MONTHS 
age ht wt bmi htsds wtsds bmisds wc wcsds Resistance %BodyFat Fat Weight
%Body 
Water
Total Body 
Water Lean
Dry Lean 
Wt
Impedence(
5Hz)
Impedence(
50Hz) Reactance FFM (kg) FM (kg) %fat
1 304B 9.02191781 M B OB 10 144.7 47 22.4 0.91 1.73 1.7 82.5 2.36464929 505 18.3 8.6 62.1 29.2 38.4 9.2 568 507 47.5 33.9 13.1 27.8723404
2 133B 9.07 M B OB 10 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
3 269A 9.59726027 M A OB 10.54 149 75.8 34.1 1.12 2.86 2.56 105 3.15004489 544 40.6 30.8 45.3 34.3 45 10.7 617 547 50.3 26.6769301 49.1230699 64.8061608
4 242B 11.1232877 M B OB 12.2219178 149.6 48.4 21.6262976 -0.11 0.73 1.14 78.5 1.65401845 550 21.7 10.5 58.9 28.5 37.9 9.4 629 554 58.4 33.76648 14.63352 30.2345455
5 104A 8.06849315 M A OB 9.10410959 126.1 43.8 27.5450736 -1.3 1.91 2.39 86.5 2.81253727 592 44.5 19.5 42.7 18.7 24.3 5.6 662 595 53.5 25.9200029 17.8799971 40.8219111
6 252B 10.109589 M B OB 11 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
7 241B 9.55890411 M B OB 10.6 148.7 58.6 26.5018187 1.04 2.19 2.11 92.5 2.80591013 546 31.2 18.3 52.4 28.6 40.3 9.6 627 549 57.2 26.4734405 32.1265595 54.8234804
8 117A 7.12 M A OB 8.1 137.4 44.6 23.6 1.55 2.47 2.22 87 3.11347708 643 40.5 17.8 45.9 20.2 26.2 6 702 645 50 26.442283 18.157717 40.7123698
9 262B 9.82191781 M B OB 10.8630137 155 99.8 41.54 1.72 3.35 2.74 126 3.46720561 457 41.7 41.6 44.4 44.3 58.2 13.9 519 459 42 39.8292254 59.9707746 60.0909565
10 109B 8.48767123 M B OB 9.48493151 145.3 61 28.89 1.43 2.69 2.42 98.5 3.23921383 560 44 27 42.7 26.2 34.3 8.1 631 563 53.6 32.0419538 28.9580462 47.4722069
11 256A 11.3123288 M A OB 12 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
12 250A 10.4219178 M A OB 11.4575342 140.6 63.4 32.0714516 -0.74 2.11 2.41 102 2.87473261 531 37.7 23.9 47 29.8 39.5 9.7 615 534 57.3 24.3485574 39.0514426 61.5953353
13 244B 10.7780822 M B OB 11.93 152.6 63.2 27.1 0.54 1.92 2.01 100.5 2.83667659 633 35.5 20.6 48.6 28.2 37.4 9.2 713 636 60.6 31.8532781 31.3467219 49.5992435
14 111A 8.35 M A OB 9.6 140.2 40.6 20.6552286 0.55 1.38 1.44 81 2.52834861 587 28.3 11.5 55.2 22.4 29.1 6.7 664 590 59 30.028032 10.571968 26.03933
15 124A 9.14520548 M A OB 10.1424658 150.3 62.2 27.5341975 1.63 2.52 2.25 98.4 2.98967665 577 34.7 21.6 49.7 30.9 40.6 9.7 647 579 52.6 32.1261083 30.0738917 48.3503082
16 127A 8.12876712 M A OB 9.24 139.8 53.2 27.2 0.79 2.44 2.34 92.5 3.05249871 653 48.3 25.7 39.5 21 27.5 6.5 718 655 56.5 26.5011279 26.6988721 50.1858499
17 271B 9.80273973 M B OB 10.8 149.7 49.6 22.1 1.02 1.54 1.5 81.5 2.30832397 502 18.1 9 62.3 30.9 40.6 9.7 567 504 48.5 35.4502488 46.0497512 56.5027622
18 273B 12.1753425 M B OB 13.25 154.7 73.8 30.84 -0.42 1.99 2.21 104.5 2.73842747 517 35.5 26.2 48.1 35.5 47.6 12.1 593 520 52.2 37.5827012 36.2172988 49.0749307
19 303A 8.2109589 M A OB 9.17 139.3 44.6 22.98 0.78 1.94 1.93 80.5 2.49870619 550 30.3 13.5 53.7 23.7 31.1 7.4 615 552 52 32.0925791 12.5074209 28.0435446
20 263A 9.87671233 M A OB 10.9315068 149.5 61.2 27.382244 0.79 2.44 2.34 91.5 2.77003488 607 36.6 22.4 48.4 29.6 38.8 9.2 694 610 63.7 30.3191461 30.8808539 50.4589116
21 300B 7.1890411 M B OB 8.19 128 40.6 24.8 -0.16 2.1 2.32 79.75 2.7303993 538 33.7 13.7 50.7 20.6 26.9 6.3 604 541 56.5 27.3782202 13.2217798 32.5659601
22 126B 7.34520548 M B OB 8.36 134.7 50.6 27.9 0.79 2.69 2.52 91.5 3.29659672 511 37.9 19.2 47.6 24.1 31.4 7.3 575 513 52.6 28.7987665 21.8012335 43.0854416
23 131B1 6.36164384 M B OB 7.3589 138.8 41.6 21.59 2.62 2.64 2.1 75.75 2.82396595 554 28.1 11.7 55.3 23 29.9 6.9 629 558 59.6 28.4386556 13.1613444 31.6378471
24 275B2 9.70136986 M B OB 10.82 144.7 51.8 24.74 0.3 1.69 1.89 87.5 2.6099269 532 26.6 13.8 55.8 28.9 38 9.1 587 533 44.2 30.7363048 21.0636952 40.6635042
25 273B2 6.05205479 M B OB 7.126 127.7 44.2 27.1 0.94 2.97 2.73 87 3.48923732 562 41.6 18.4 44.8 19.8 25.8 6 631 565 54.1 26.3683447 17.8316553 40.3431116
26 272A 9.47671233 M A OB 10.578 151.7 72 31.2868 1.48 2.74 2.44 103.75 3.12270077 526 36.5 26.3 48.3 34.8 45.7 10.9 586 528 45.6 33.4336619 38.5663381 53.5643584
27 147B ND M B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
28 277A 9.99452055 M A OB 10.95 139.5 65 33.4 -0.54 2.36 2.51 103.75 2.916434 472 34.8 22.6 49.7 32.3 42.4 10.1 538 475 48.8 26.9490731 38.0509269 58.5398875
29 283A 11.1342466 M A OB 12 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
30 264A 9.91506849 M A OB 10.9 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
31 276B ND M B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
32 135A 8.23561644 M A OB 9 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
33 247A 10.7424658 M A OB 11.7972603 151.7 70.8 30.7653667 0.52 2.33 2.31 103 2.89890351 552 37.7 26.7 46.9 33.2 44.1 10.9 623 555 52.8 27.2485118 43.5514882 61.5134014
34 100B 9.17534247 F B OB 10 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
35 108A 7.65753425 F A OB 8.65479452 154 67.6 28.5039636 3.47 3.24 2.48 96.7 96.7 514 39.6 26.8 46.7 31.6 40.8 9.2 586 517 52.1 30.1410506 37.4589494 55.4126471
36 246B 9.48767123 F B OB 10.5 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
37 105B 8.4109589 F B OB 9.4 139.8 48.2 24.66 1.18 2.23 2.09 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
38 119B 6.01643836 F B OB 7.05753425 131.3 42.2 24.4783984 1.62623642 2.65854031 2.39717283 84.5 2.92748312 621 41.4 17.4 45.5 19.1 24.6 5.5 624 58.2 18.1947641 24.0052359 56.8844453
39 261A 9.48 F A OB 10.8 150.5 68.4 30.2 1.31 2.51 2.31 98 3.14584872 513 34.1 23.2 50.7 34.7 45.1 10.4 573 515 46.1 33.6482705 34.7517295 50.8066221
40 118A 8.01369863 F A OB 9.14520548 142.4 55.2 27.2219417 1.36 2.53 2.31 87 2.79710677 576 43.3 23.9 44 24.3 31.3 7 642 579 53 30.3768889 24.8231111 44.9694042
41 134A 8.92054795 F A OB 9.9 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
42 132B 7.21643836 F B OB 8.16 130.7 40.6 23.8 0.38 2.01 2.11 82 2.6693774 570 36 14.6 49.8 20.2 26 5.8 629 572 47.7 19.6300325 20.9699675 51.6501664
43 402B 7.2109589 F B OB 8.21 134.5 36.4 20.12 0.94 1.57 1.48 74.25 2.18416207 593 28.3 10.3 55.8 20.3 26.1 5.8 662 596 58.4 25.5279105 10.8720895 29.8683779
44 125B 7.99726027 F B OB 9.42 139.5 46.4 23.8 0.69 1.83 1.89 82 2.53868734 560 34.5 16 50.4 23.4 30.4 7 630 563 53.4 28.3205902 53.6794098 65.4626949
45 102A 7.70136986 F A OB 8.75616438 131.5 36.8 21.2812098 -0.03 1.3 1.61 76 2.30887469 689 39.9 14.7 46.5 17.1 22.1 5 772 692 63.6 22.8690434 13.9309566 37.8558603
46 106A 7.57260274 F A OB 8.57260274 137.5 46.2 24.4363636 1.09 2.24 2.12 84 2.7703299 591 38.5 17.8 47.8 22.1 28.4 6.3 658 594 51.2 26.8978678 19.3021322 41.779507
47 301B 6.79452055 F B OB 7.7 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
48 107B 6.26849315 F B OB 7.66849315 134.3 37.4 20.74 1.45 1.97 1.74 78 2.60216986 762 42.9 15.1 44.3 15.6 20.1 4.5 831 765 58.4 15.5354573 21.8645427 58.461344
49 270A 11.4410959 F A OB 12.32 168.7 68.6 24.1 2.25 2.05 1.58 88.3 2.23487692 487 21.9 15 58.9 40.4 53.6 13.2 560 490 52 43.3497879 25.2502121 36.8078894
50 249A 8.98630137 F A OB 10.0794521 145 63.4 30.1545779 0.96 2.54 2.4 98 3.14584872 534 35.3 22.4 49.8 31.6 41 9.4 620 537 56.2 34.1198285 29.2801715 46.1832359
51 251B 10.8986301 F B OB 12.21 159.6 69.2 27.2 0.96 1.99 1.86 93.5 2.45352052 556 32.8 22.7 51.6 35.7 46.5 10.8 638 559 59 36.7826317 32.4173683 46.8459079
52 116B 7.47945205 F B OB 8.59178082 139.3 47.2 24.3242672 1.36 2.3 2.1 86 2.86329721 636 43.2 20.7 44.1 21.1 27.2 6.1 699 638 50.6 28.2844329 18.9155671 40.0753541
53 259B 8.74794521 F B OB 9.80821918 145.4 45.2 21.3800946 1.24 1.53 1.4 80 2.42008613 652 36.7 16.6 48.7 22 28.6 6.6 725 655 61.9 27.0687208 18.1312792 40.1134496
54 103B 6.48493151 F B OB 7.71 138.7 44.6 23.2 2.1 2.53 2.12 83 2.86051729 632 40.1 17.9 46.6 20.8 26.7 5.9 698 634 53.9 25.7780099 18.8219901 42.2017716
55 267A 10.0109589 F A OB 11 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
56 2A 7.34520548 F A OB 8.32 124.9 28.8 18.5 -0.077 0.42 1.01 61.5 0.86400867 657 29.5 8.5 54.5 15.7 20.3 4.6 730 660 61.3 15.5837998 13.2162002 45.8895839
57 245A 8.79452055 F A OB 9.87671233 149.7 55 24.5425163 1.81 2.19 1.9 92.5 3.0302689 702 47.5 26.1 40.5 22.3 28.9 6.6 787 705 63.2 26.5576833 28.4423167 51.713303
58 243A 9.96164384 F A OB 10.9452055 158.2 80.2 32.0450837 1.98 2.87 2.43 102 3.2778178 500 35.7 28.6 49.6 39.8 51.6 11.8 574 503 50.7 39.4015764 40.7984236 50.8708524
59 401B 9.70136986 F B OB 10.82 145 52.2 24.8 0.32 1.556 1.774 85.5 2.60091618 588 30.8 16.1 53.3 27.8 36.1 8.3 648 590 46.9 30.8346615 21.3653385 40.9297673
60 129B 8.03287671 F B OB 8.99726027 133.5 51.2 28.73 0.1 2.37 2.45 94.5 3.10422871 598 47.7 24.4 40.6 20.8 26.8 6 673 661 56.6 26.8796109 24.3203891 47.50076
61 403B 9.90958904 F B OB 10.964 152.5 55 23.649 1.198 1.683 1.5829 84.5 2.40792648 532 24.5 13.5 58 31.9 41.5 9.6 606 534 52.7 34.6827282 20.3172718 36.9404943
62 309A 8.51780822 F A OB 9.5 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
63 281A 9.90136986 F A OB 10.9 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
64 307A 6.57534247 F A OB 7.553 136 49.6 26.81 1.838 2.892 2.516 90.5 3.15667129 593 43.7 21.7 43.8 21.7 27.9 6.2 661 596 51.4 20.4238617 29.1761383 58.8228594
65 121A 9.10958904 F A OB 10.41 154.4 58.4 24.5 1.98 2.14 1.8 90 2.82453187 581 37.8 22.1 47.8 27.9 36.3 8.4 660 584 59.6 31.9565804 26.4434196 45.279828
66 253A 10.1945205 F A OB 11.2684932 149.8 84.2 37.5222148 0.53 2.9 2.67 108 3.3998197 504 41.6 35 44.8 37.7 49.2 11.5 561 505 39.9 36.1693278 48.0306722 57.0435537
67 3B 8.99178082 F B OB 9.99 127.7 37.6 23.1 -1.57 0.65 1.67 82.75 2.44510269 613 37.8 14.2 47.9 18 23.4 5.4 683 616 55 25.1041553 57.6458447 69.6626522
68 275B 9.70136986 F B OB 10.82 154.2 62 26.07 1.56 2.16 1.93 92.5 2.93433749 579 32.7 20.3 518 32.1 41.7 9.6 637 581 45.6 33.6365782 28.3634218 45.7474545
69 313A 8.78630137 F A OB 9.7 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
70 284A 9.17260274 F A OB 10 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
71 112A 7.06027397 F A OB 8.05753425 123.5 35.6 23.3408186 -0.77 1.57 2.08 82.5 2.69541166 661 42.5 15.1 44.8 15.9 20.4 4.5 742 664 63 15.1484304 20.4515696 57.4482292
72 260B 9.0109589 F B OB 10.0712329 142 46.2 22.91 0.53 1.47 1.63 88 2.72955993 674 35.6 20 49.6 27.9 36.2 8.3 677 66.7 25.0751174 21.1248826 45.7248542
OBESE DATA CLINICAL MEASUREMENTS (12 MONTHS)
228247
No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW)
Fasting 
glucose Insulin c-peptide HOMA Cholesterol LDL HDL TG CRP ESR VitD HbA1C TSH FT4 AST ALT ALP PAI-1 IGF-1 IGFBP-1 ACTH Cortisol
1 304B 9.02191781 M B OB 4.1 3.9 0.26 0.71066667 4.3 2.4 1.5 ND <0.5 2 69 5.4 1.96 11.1 43 11 390 ND 30 ND 13 154
2 133B 9.07 M B OB 4.1 12 0.6 2.18666667 4.6 2.7 1.4 ND 1.5 2 63 5.7 1.51 11.1 39 18 412 ND 36 ND 19 115
3 269A 9.59726027 M A OB 4.2 8.3 0.8 1.54933333 4.1 2.3 1.3 ND 0.8 2 ND 5.5 2.46 10.4 ND ND ND ND ND ND ND ND
4 242B 11.1232877 M B OB 4 3.2 0.46 0.56888889 5.3 3.8 1.4 ND <1 9 45 5.4 1.8 14.6 28 35 213 14.7 29 0.7 13 295
5 104A 8.06849315 M A OB 4.3 3.4 0.28 0.64977778 3.2 1.8 11 0.7 1.2 11 98 5.6 1.72 15.8 30 ND 220 14.4 12 2.4 21 238
6 252B 10.109589 M B OB 4.5 6 0.47 1.2 4.1 2.2 1.6 ND 1 5 133 4.9 1.1 13.6 43 29 308 25 28 0.8 20 400
7 241B 9.55890411 M B OB 4.3 5.8 0.5 1.10844444 5.5 3.9 0.9 ND 2.2 15 53 5.6 2.45 13.2 34 ND 224 14.6 15 1.3 19 206
8 117A 7.12 M A OB 4.7 8.9 0.6 1.85911111 4.4 2.8 1.2 ND 2.2 5 67 5.4 1.2 13.4 33 ND 323 ND 20 1.6 8 142
9 262B 9.82191781 M B OB 4.6 14 1 2.86222222 3.8 2.4 0.7 ND 0.6 4 116 5.4 0.01 24 33 ND 251 25.8 34 ND 34 396
10 109B 8.48767123 M B OB 4.4 5.8 0.7 1.13422222 4.2 2.4 1 ND 0.6 4 82 5.7 3.09 11.6 41 ND 247 ND 20 0.7 19 138
11 256A 11.3123288 M A OB 4.6 12 1.1 2.45333333 4.6 3.1 0.9 ND 5.6 13 60 5.6 2.64 15.2 43 ND 202 ND 15 0.6 27 440
12 250A 10.4219178 M A OB 4.6 2.9 0.18 0.59288889 4.9 2.5 2.2 ND 0.8 16 91 5.8 2.27 17.1 35 ND 243 ND 18 1.9 11 158
13 244B 10.7780822 M B OB 4.2 9.5 0.6 1.77333333 5.9 4.4 0.9 ND 1 3 74 5.3 2.84 11.6 29 ND 223 24.7 24 0.6 19 379
14 111A 8.35 M A OB 4.2 2.3 0.23 0.42933333 3 1.8 1 ND 0.5 2 121 5.3 2.44 12.9 43 ND 179 ND ND ND ND ND
15 124A 9.14520548 M A OB 4.5 6 0.5 1.2 3.8 2.1 1.4 ND <0.5 3 73 5.6 1.61 14.4 30 ND 363 ND 29 0.9 26 361
16 127A 8.12876712 M A OB 4.7 3.5 0.24 0.73111111 4 2.6 1.2 ND 2.4 6 71 5.4 1.38 15.8 37 ND 263 ND 20 1.8 14 197
17 271B 9.80273973 M B OB 4.4 4.7 0.33 0.91911111 3.7 1.7 1.7 0.6 <0.5 2 93 5.3 2.42 12.6 40 18 202 ND 22 ND 22 166
18 273B 12.1753425 M B OB 4.3 11 0.4 2.10222222 3.7 2.4 0.9 0.9 6.8 2 99 5.1 2.85 12.7 58 35 226 ND 15 ND 15 406
19 303A 8.2109589 M A OB 4 3.6 0.38 0.64 4.3 2.5 1.6 0.5 <0.5 2 92 4.8 0.81 12.3 39 10 320 ND 32 ND 17 345
20 263A 9.87671233 M A OB 4.1 4.6 0.42 0.83822222 4.7 2.9 1.6 ND 1.4 6 67 4.7 1.24 11.6 38 ND 264 ND 19 1.4 26 176
21 300B 7.1890411 M B OB 4 4.2 0.27 0.74666667 4.4 2.9 1.3 ND <0.5 6 87 5.6 1.78 14.5 40 25 185 ND 11 ND 11 175
22 126B 7.34520548 M B OB 4.2 ND 0.7 ND 4.9 2.9 1.3 ND 2.5 8 64 5.7 1.38 12.1 42 4 239 ND 7.9 ND 27 197
23 131B1 6.36164384 M B OB 4.4 8.5 0.5 1.66222222 4.8 2.8 1.4 ND 1.4 6 98 5.2 2.28 13 42 12 229 ND 19 ND 19 303
24 275B2 9.70136986 M B OB 4.3 4.2 0.47 0.80266667 4.8 2.9 1.5 ND <0.5 2 62 5.4 1.38 12.4 46 20 298 ND 25 ND 21 233
25 273B2 6.05205479 M B OB 4.8 8.6 0.44 1.83466667 3.6 1.9 1.3 0.8 0.5 7 110 ND 2.67 14.9 39 15 331 ND 22 ND 27 377
26 272A 9.47671233 M A OB 4.2 6.5 0.46 1.21333333 4.9 2.7 1.8 ND 0.7 4 67 5.1 3.52 14 33 14 215 ND 17 ND 28 301
27 147B ND M B OB 4.1 3.4 0.23 0.61955556 4.4 2.8 1.4 0.4 <0.5 3 102 5.4 1.78 12.5 35 28 239 ND 30 ND 15 203
28 277A 9.99452055 M A OB 4.5 12 0.9 2.4 4.2 2.6 1.2 0.9 1.1 3 65 5.1 1.44 14.3 33 24 226 ND 17 ND 22 195
29 283A 11.1342466 M A OB 4.5 7.9 0.6 1.58 4.2 2.6 1.4 ND 1.6 3 94 5.8 2.4 14.4 44 44 312 ND 22 ND 28 206
30 264A 9.91506849 M A OB 3.8 5.3 0.36 0.89511111 5 2.9 1.5 ND 2.4 ND 86 5.1 1.55 12 40 24 243 ND 27 ND 10 135
31 276B ND M B OB 6.1 12 0.9 3.25333333 4.8 2.1 1 3.8 1.9 12 100 7.1 4.15 12.6 33 16 266 ND 19 ND 22 235
32 135A 8.23561644 M A OB 4.2 8.4 0.6 1.568 4.6 1.9 0.7 4.5 <0.5 2 115 4.8 2.77 13.2 45 37 238 ND 24 ND 19 263
33 247A 10.7424658 M A OB 4.3 7.3 0.5 1.39511111 3.7 1.9 1 1.7 3.8 13 91 6 2.1 14.4 27 ND 284 ND 15 ND 26 390
34 100B 9.17534247 F B OB 4.3 3.6 0.43 0.688 4.3 2.6 1.2 1 1.5 2 111 5.4 1.03 15.8 30 21 309 ND 16 2.1 15 281
35 108A 7.65753425 F A OB 4.2 24 1.2 4.48 3.4 2.2 0.8 0.8 1.8 15 78 5.6 3.04 13.8 25 ND 275 19.5 29 0.1 14 191
36 246B 9.48767123 F B OB 4.2 6.4 0.35 1.19466667 4.9 3 1.5 1 8 30 131 6 1.6 14.5 41 ND 232 14.4 33 1.2 8 255
37 105B 8.4109589 F B OB 4.5 11 0.8 2.2 3.8 2.3 1.1 1 0.6 8 125 5.5 2.9 11.1 43 ND 222 21.6 25 0.7 18 292
38 119B 6.01643836 F B OB 4 2.5 0.22 0.44444444 4.7 3.4 1 0.7 <0.5 2 138 5.2 2.69 14.6 53 ND 267 14.9 30 1.7 15 196
39 261A 9.48 F A OB 4.8 15 0.8 3.2 5.2 3.2 1 2.2 1.6 9 79 5.6 2.93 13.9 37 ND 297 ND 26 0.8 19 355
40 118A 8.01369863 F A OB 4.5 9.5 0.5 1.9 5.3 3.8 1.1 1 0.9 11 92 5.7 1.42 9.4 40 ND 276 ND 27 0.9 9 114
41 134A 8.92054795 F A OB 4.1 16 0.7 2.91555556 4.8 2.9 1 1.9 0.8 5 76 4.9 1.47 10.6 31 16 282 ND 30 ND 11 97
42 132B 7.21643836 F B OB 4.4 5 0.37 0.97777778 4.1 2.8 1 0.7 <0.5 2 181 5.4 1.28 17.5 33 13 154 ND 19 ND 13 206
43 402B 7.2109589 F B OB 4.2 3.6 0.26 0.672 4.3 2.5 1.6 0.4 <0.5 3 73 5.6 2.82 11.5 45 ND 238 ND 21 ND 14 152
44 125B 7.99726027 F B OB 4.1 2.2 0.21 0.40088889 5.6 3.6 1.7 0.7 <0.5 7 82 5.4 2.04 14.8 44 16 244 ND 29 ND 8 119
45 102A 7.70136986 F A OB 4.4 6.4 0.36 1.25155556 3.9 1.9 1.6 1 7.5 22 45 5.3 3.51 12.6 79 95 233 42.2 25 0.8 14 320
46 106A 7.57260274 F A OB 3.7 1.4 0.15 0.23022222 2.7 1.5 1.1 0.3 18 10 76 5.1 1.62 16.3 39 ND 226 15 20 6.1 7 254
47 301B 6.79452055 F B OB 3.9 3.7 0.25 0.64133333 3.1 1.4 1.3 0.8 2.2 8 82 5.4 1.22 12.7 38 23 304 ND 13 ND 14 293
48 107B 6.26849315 F B OB 3.8 3.8 0.33 0.64177778 4.4 2.9 1 1.1 3 9 100 5.5 1.64 15 36 ND 324 11.4 21 2.1 10 183
49 270A 11.4410959 F A OB 4.5 12 0.7 2.4 3.4 2.1 0.7 1.3 4.8 11 92 6.5 3.74 13 33 18 294 ND 56 ND 27 287
50 249A 8.98630137 F A OB 3.9 24 1.4 4.16 4.7 2.5 0.8 3 2.2 10 180 5.3 4 15.6 32 ND 228 21.7 31 0.2 17 548
51 251B 10.8986301 F B OB 5 9.2 0.8 2.04444444 4.1 2.7 1.1 0.7 1.8 9 74 5.9 4.71 16.6 34 ND 272 21.9 13 0.6 16 157
52 116B 7.47945205 F B OB 4.1 5.2 0.4 0.94755556 4.5 3.2 0.8 1.1 0.5 6 108 5.3 1.91 15.1 38 ND 231 18.3 26 1.9 15 261
53 259B 8.74794521 F B OB 4.5 5.1 0.44 1.02 3.2 1.7 1.2 0.7 <0.5 3 108 5.7 2.59 16 38 ND 313 14.3 38 1.2 19 291
54 103B 6.48493151 F B OB 4.3 3.6 0.34 0.688 4.2 2.9 1 0.6 1.7 3 102 5.3 2.32 14.9 40 ND 507 15.5 18 2.4 19 317
55 267A 10.0109589 F A OB 4.5 13 0.8 2.6 6.4 4.2 1 2.6 4.3 5 37 5.4 3.35 14.6 38 ND 269 ND 35 0.2 39 500
56 2A 7.34520548 F A OB 3.1 2.1 0.11 0.28933333 4.4 2.7 1.4 0.6 <0.5 ND 129 5.1 2.7 14.7 51 ND 245 ND 11 ND 30 485
57 245A 8.79452055 F A OB 4.4 12 0.8 2.34666667 3.2 1.9 0.8 1.2 2.3 9 98 5.6 1.63 13.8 28 ND 250 25.6 31 0.6 9 101
58 243A 9.96164384 F A OB 4.6 6.7 0.7 1.36977778 4.4 2.6 0.9 2.1 4.7 13 78 5.4 1.75 12.6 45 45 205 33 37 0.3 28 180
59 401B 9.70136986 F B OB 4.2 8.4 0.6 1.568 5.8 4.2 1.3 0.7 23 9 61 5.6 0.61 13.8 43 20 309 ND 27 ND 18 601
60 129B 8.03287671 F B OB 3.8 15 0.9 2.53333333 4.7 2.9 1 1.7 1.5 4 38 5.1 2.48 15.6 46 27 244 ND 13 ND 35 166
61 403B 9.90958904 F B OB 4.2 8.3 0.45 1.54933333 4.4 2.2 1.5 1.5 11 11 80 5.8 1.58 12.6 38 14 241 ND 27 ND 31 705
62 309A 8.51780822 F A OB 4 16 1.1 2.84444444 3.6 1.7 1 1.9 <0.5 2 100 5.4 5.12 10.9 45 29 456 ND 26 ND 20 179
63 281A 9.90136986 F A OB 4.4 8.6 0.6 1.68177778 4.3 2.6 1.3 0.9 6 6 84 5.7 1.86 12.6 36 27 202 ND 26 ND 13 145
64 307A 6.57534247 F A OB 4 7.1 0.46 1.26222222 4.3 2.6 1.2 1.1 2.9 3 97 5.1 1.07 14.3 33 23 422 ND 19 ND 8 142
65 121A 9.10958904 F A OB 4.3 10 0.8 1.91111111 4.5 2.7 1.1 1.5 0.8 6 84 5.4 2.05 13.3 45 ND 257 ND 26 0.5 13 187
66 253A 10.1945205 F A OB 4.4 11 0.8 2.15111111 3.7 2.2 0.8 1.6 <0.5 9 47 5.4 2.11 11.4 42 51 332 18.1 43 ND 18 287
67 3B 8.99178082 F B OB 3.8 5.2 0.36 0.87822222 3.8 2.3 0.8 1.6 1.3 5 119 5.4 1.84 13.9 38 17 265 ND 13 ND 10 125
68 275B 9.70136986 F B OB 4.4 5.8 0.6 1.13422222 6.00 4.3 1.3 1 4 4 70 5.2 0.96 12.7 37 15 326 ND 23 ND 16 192
69 313A 8.78630137 F A OB 4.4 9.3 0.7 1.81866667 3.5 1.7 1.2 1.4 2.4 5 107 5.5 3.37 14.2 31 18 241 ND 19 ND 18 157
70 284A 9.17260274 F A OB 4.5 12 1 #REF! 4.2 2.6 1.1 1.1 12 10 70 5.4 1.36 13.6 27 19 254 ND 23 ND 14 110
71 112A 7.06027397 F A OB 4.3 4.2 0.39 0.80266667 4.7 2.8 1.5 0.8 1.3 11 93 5.1 3.53 12.1 47 42 281 16.1 24 1.3 14 214
72 260B 9.0109589 F B OB 4.3 3.6 0.23 0.688 3.8 2.1 1.6 0.2 1 2 129 5.3 1.49 14.1 33 ND 419 14 22 1.2 27 329
OBESE DATA BLOOD TEST (BASELINE)
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No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW)
12 MONTHS 
Fasting 
glucose Insulin c-peptide HOMA Cholesterol LDL HDL TG CRP ESR VitD HbA1C TSH FT4 AST ALT ALP PAI-1 IGF-1 IGFBP-1 ACTH Cortisol
1 304B 9.02191781 M B OB 4.6 4.9 0.24 1.00177778 4.9 2.8 1.7 ND ND 5 74 ND ND ND 58 36 298 ND ND ND ND ND
2 133B 9.07 M B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
3 269A 9.59726027 M A OB 4.1 9.6 0.6 1.74933333 4.2 2.8 1 ND ND 4 61 5.2 2.23 13.3 27 23 262 30.6 ND ND ND ND
4 242B 11.1232877 M B OB 4.1 3.3 0.3 0.6 5.1 3.5 1.3 ND <0.5 2 74 5.2 1.4 12.5 37 33 169 ND 29 ND 8 163
5 104A 8.06849315 M A OB 4.1 5 0.35 0.91111111 3.4 1.9 1.2 TD 1.7 ND 105 5.4 2.02 13 33 11 195 ND 11 ND 17 181
6 252B 10.109589 M B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
7 241B 9.55890411 M B OB 5 8.8 0.6 1.95555556 4.8 3.4 0.9 ND 4.5 15 72 5.7 3.16 14.3 38 31 232 ND 11 ND 28 222
8 117A 7.12 M A OB 4.5 7.4 0.5 1.48 4 2.5 1.1 0.9 4.2 2 84 5.4 0.87 12.4 31 22 290 ND 20 ND 13 170
9 262B 9.82191781 M B OB 4.5 17 1 3.4 4.8 3.2 0.8 ND 1.5 8 117 5.5 2.63 13.3 33 25 313 ND 24 ND 22 209
10 109B 8.48767123 M B OB 4.2 7.3 0.7 1.36266667 5 3.3 1 ND 0.7 2 95 5.6 1.94 12.8 40 27 243 ND 23 ND 25 184
11 256A 11.3123288 M A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
12 250A 10.4219178 M A OB 4.4 3.4 0.26 0.66488889 5.4 3.5 1.7 ND 4.4 15 105 5.7 2 15.7 32 24 280 ND 14 ND 9 106
13 244B 10.7780822 M B OB 4.3 7.5 0.41 1.43333333 6.6 5.1 0.9 ND ND 16 88 ND ND ND 32 27 218 ND ND ND ND ND
14 111A 8.35 M A OB 4.3 ND ND 3.8 3.5 2.3 0.9 ND ND 5 ND ND ND ND 37 28 145 ND ND ND ND ND
15 124A 9.14520548 M A OB 5 11 0.6 2.44444444 3.6 2 1.2 0.8 ND 4 72 ND ND ND 33 22 294 ND ND ND ND ND
16 127A 8.12876712 M A OB 4.8 ND 0.48 ND 4.7 3.1 1.3 ND ND ND 62 ND ND ND 60 59 278 ND ND ND ND ND
17 271B 9.80273973 M B OB 4.8 4.3 0.22 0.91733333 3.9 1.8 1.9 0.4 ND 7 86 ND ND ND 36 28 208 ND ND ND ND ND
18 273B 12.1753425 M B OB 5 15 0.7 3.33333333 5.3 3.7 1.2 0.8 ND 2 89 ND ND ND 38 30 262 ND ND ND ND ND
19 303A 8.2109589 M A OB 5.1 5.5 0.39 1.24666667 4.3 2.4 1.5 0.8 ND 2 84 ND ND ND 31 17 278 ND ND ND ND ND
20 263A 9.87671233 M A OB 4.5 6.2 0.46 1.24 5 3.3 1.3 ND 2.2 2 85 4.6 1.3 11.4 39 28 247 ND ND ND 20 ND
21 300B 7.1890411 M B OB 4.5 7.2 0.38 1.44 4.5 2.7 1.5 ND ND 9 93 ND ND ND 33 20 146 ND ND ND ND ND
22 126B 7.34520548 M B OB 4.5 6.4 0.38 1.28 3.9 2.5 1 ND ND 2 106 5.3 ND ND 33 9 182 ND ND ND ND ND
23 131B1 6.36164384 M B OB 4.6 8 0.44 1.63555556 5.3 3.3 1.7 ND ND 2 121 ND ND ND 36 13 300 ND ND ND ND ND
24 275B2 9.70136986 M B OB 5.1 9.6 0.6 2.176 4.7 2.9 1.4 ND ND 2 128 ND ND ND 40 25 302 ND ND ND ND ND
25 273B2 6.05205479 M B OB 5.3 8.7 0.45 2.04933333 4.1 2.5 1.2 ND ND 5 105 ND ND ND 32 21 279 ND ND ND ND ND
26 272A 9.47671233 M A OB 5.2 10 0.5 2.31111111 5.1 3.4 1.4 0.6 ND 2 79 ND ND ND 31 16 200 ND ND ND ND ND
27 147B ND M B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
28 277A 9.99452055 M A OB 5.3 22 1.2 5.18222222 4.2 2.7 1.2 ND ND 4 60 ND ND ND 37 47 247 ND ND ND ND ND
29 283A 11.1342466 M A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
30 264A 9.91506849 M A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
31 276B ND M B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
32 135A 8.23561644 M A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
33 247A 10.7424658 M A OB 4.6 6.8 0.47 1.39022222 3.7 2.2 1.1 ND ND 9 103 ND ND ND 34 34 302 ND ND ND ND ND
34 100B 9.17534247 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
35 108A 7.65753425 F A OB 4.7 38 1.4 7.93777778 4.5 2.9 0.9 1.6 0.8 10 74 5.6 1.8 13.3 29 20 277 ND 37 ND 13 179
36 246B 9.48767123 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
37 105B 8.4109589 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
38 119B 6.01643836 F B OB 4.5 4.7 0.42 0.94 5 3.1 1.4 1.2 5.3 9 140 5.4 2.18 14.4 46 24 288 ND 31 ND 8 128
39 261A 9.48 F A OB 4.6 8.6 0.5 1.75822222 4.9 2.9 0.9 2.4 ND 12 90 ND ND ND 37 24 315 ND ND ND ND ND
40 118A 8.01369863 F A OB 4.6 8.1 0.46 1.656 4.9 3.3 1.2 1 ND 7 104 ND ND ND 36 16 272 ND ND ND ND ND
41 134A 8.92054795 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
42 132B 7.21643836 F B OB 4.6 6.5 ND 1.32888889 4.8 3.4 1.1 0.6 ND 9 111 ND ND ND 34 24 149 ND ND ND ND ND
43 402B 7.2109589 F B OB 4.8 5.6 0.27 1.19466667 4.7 2.8 1.6 0.6 ND 12 82 ND ND ND 38 25 280 ND ND ND ND ND
44 125B 7.99726027 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
45 102A 7.70136986 F A OB 4.1 5.5 0.37 1.00222222 3.7 1.7 1.4 1.3 0.9 13 63 5.5 2.25 11.4 61 50 224 ND 21 ND 13 157
46 106A 7.57260274 F A OB 4.1 7.5 0.6 1.36666667 3.4 2 1.2 0.4 <0.5 2 67 4.8 2.12 12.8 37 18 235 ND 27 ND 10 122
47 301B 6.79452055 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
48 107B 6.26849315 F B OB 4.1 7.9 0.6 1.43955556 5 3.2 1.2 1.3 2 5 147 5.4 1.53 14.4 41 17 338 ND 29 ND 10 207
49 270A 11.4410959 F A OB 4.8 12 0.6 2.56 3.4 2.1 0.7 1.3 ND 5 84 ND ND ND 27 14 361 ND ND ND ND ND
50 249A 8.98630137 F A OB 4.4 16 1 3.12888889 4.9 3.5 0.9 1.2 2.2 5 121 5.1 1.6 14.9 32 28 235 ND 25 ND 9 284
51 251B 10.8986301 F B OB 5.2 16 1 3.69777778 4.7 3.2 1.2 0.7 ND 3 66 ND 5.84 11.9 27 16 309 ND ND ND ND ND
52 116B 7.47945205 F B OB 4.1 6.4 0.5 1.16622222 5.4 3.6 1.1 1.5 <0.5 ND 129 5.5 2.51 14 44 22 290 ND 25 ND 12 195
53 259B 8.74794521 F B OB 4.4 6.4 0.48 1.25155556 4.6 2.9 1.4 0.7 0.5 ND 100 5.9 2.93 15.4 39 23 301 ND 32 ND 15 189
54 103B 6.48493151 F B OB 4.5 4 0.34 0.8 4.4 3 1.1 0.6 ND 7 95 ND ND ND 34 20 469 ND ND ND ND ND
55 267A 10.0109589 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
56 2A 7.34520548 F A OB 4.5 ND ND ND 4.8 3.5 1.1 0.4 ND 13 90 ND ND ND 51 34 210 ND ND ND ND ND
57 245A 8.79452055 F A OB 4.4 5.6 0.39 1.09511111 3.7 2.1 1.1 1.1 0.7 2 75 5.4 1.4 17.6 32 24 355 ND 37 ND 15 179
58 243A 9.96164384 F A OB 4.9 19 1.1 4.13777778 4.5 2.1 0.9 3.4 3.7 10 44 5.4 0.87 12.5 45 33 191 ND 59 ND 26 138
59 401B 9.70136986 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
60 129B 8.03287671 F B OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
61 403B 9.90958904 F B OB 4.1 13 0.6 2.36888889 4.7 2.3 1.6 1.8 ND 2 99 ND ND ND 25 14 280 ND ND ND ND ND
62 309A 8.51780822 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
63 281A 9.90136986 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
64 307A 6.57534247 F A OB 4.4 7.7 0.5 1.50577778 4.4 2.6 1.1 1.6 ND 12 99 ND ND ND 27 31 361 ND ND ND ND ND
65 121A 9.10958904 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
66 253A 10.1945205 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
67 3B 8.99178082 F B OB 4.3 7.6 0.44 1.45244444 4.3 3 0.8 1.2 ND 15 92 ND ND ND 31 18 270 ND ND ND ND ND
68 275B 9.70136986 F B OB 4.6 5.8 0.47 1.18577778 5.80 4.3 1.2 0.7 ND 2 118 ND ND ND 31 17 292 ND ND ND ND ND
69 313A 8.78630137 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
70 284A 9.17260274 F A OB ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
71 112A 7.06027397 F A OB 4.6 7.1 0.6 1.45155556 4.5 2.8 1.3 0.8 2.6 9 104 5.2 3.83 13.9 49 34 273 ND 21 ND 13 289
72 260B 9.0109589 F B OB 4.2 4.4 0.29 0.82133333 4.2 2.6 1.4 0.5 2.4 2 118 5.4 1.92 14.4 32 21 480 ND 25 ND 20 242
OBESE DATA BLOOD TEST (12 MONTHS)
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No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW)
SAMPLE NO. 
(BASELINE)
SAMPLE 
NO. (12 
MONTHS) RNA [ng/ul] AR CAR COUP-TF1 COUP-TF2 DAX EAR2 ESR1 ESR2 ESRRA ESRRB ESRRG FXRa GCNF GR HNF4A HNF4G LRH-1 LXRa LXRb MR NOR1 NUR77 NURR1
1 304B 9.02191781 M B OB NO18093 NO20371 148.4 8.71E-04 8.71E-04 8.71E-04 8.71E-04 8.71E-04 0.18473337 4.56E-02 1.60E-02 0.19776034 3.93E-02 37.0128032 8.71E-04 2.44E-02 2.62629386 8.71E-04 8.71E-04 8.71E-04 0.12575727 4.54693059 0.29165307 2.28E-02 0.46967808 0.18871717
2 133B 9.07 M B OB NO18095 - 102.4 6.50E-04 6.50E-04 6.50E-04 6.50E-04 6.50E-04 0.18565335 0.11381965 3.42E-02 0.22697326 6.50E-04 21.8130927 6.50E-04 2.34E-02 3.00831173 6.50E-04 6.50E-04 6.50E-04 6.92E-02 3.24752918 0.25966842 6.50E-04 0.70275344 0.29558225
3 269A 9.59726027 M A OB NO19901 - 257.7 4.42E-04 4.42E-04 4.42E-04 4.42E-04 4.42E-04 0.10026177 5.85E-02 2.95E-02 0.16925926 4.42E-04 4.42E-04 5.91E-03 7.96E-03 4.23052301 4.42E-04 4.42E-04 4.42E-04 8.50E-02 3.74523615 0.29398406 2.77E-02 0.96803937 0.24231541
4 242B 11.1232877 M B OB NO16198 NO19404 * 192.3 4.35E-02 1.36E-03 1.36E-03 1.36E-03 1.36E-03 9.25E-02 0.1111406 8.94E-03 0.14931465 1.36E-03 1.36E-03 1.36E-03 1.11E-02 4.57231006 1.36E-03 1.36E-03 444.523081 7.30E-02 3.11761541 0.42480703 0.26614536 1.08413917 1.00525815
5 104A 8.06849315 M A OB NO16405 - 92.3 2.04E-03 2.04E-03 2.04E-03 2.04E-03 2.04E-03 0.15731796 3.37E-02 2.04E-03 0.11542746 2.04E-03 2.04E-03 2.04E-03 1.59E-02 2.93682559 2.04E-03 7.56414611 478.799352 4.01E-02 3.60974719 0.12353118 7.35E-02 0.79418863 0.47685883
6 252B 10.109589 M B OB NO17066 - 47.2 7.33E-02 1990.27517 1.77E-03 1.77E-03 1.77E-03 0.17368006 9.35E-02 2.86E-02 9.70E-02 1.77E-03 10.996395 1.77E-03 5.24E-02 4.89040538 1.77E-03 22.6552959 1.77E-03 9.29E-02 5.46603023 0.35450473 5.74E-02 0.48732952 0.18437359
7 241B 9.55890411 M B OB NO16851 - 260.1 0.13654489 1.98E-03 1.98E-03 1.98E-03 1.98E-03 0.15866271 5.14E-02 1.34E-02 0.13207075 1.98E-03 1.98E-03 1.98E-03 1.67E-02 3.95980896 1.98E-03 1.98E-03 229.19479 4.99E-02 4.41540477 0.15532503 0.37262414 0.88739317 0.72834528
8 117A 7.12 M A OB NO17306 - 187 6.57E-02 9.54E-04 9.54E-04 1.44E-02 9.54E-04 0.16111101 0.16663289 3.70E-02 0.254193 9.54E-04 9.54E-04 9.54E-04 5.09E-02 7.5539439 0.10435042 9.54E-04 9.54E-04 0.12775488 3.21901922 0.16457566 3.99E-02 0.22523974 0.10096052
9 262B 9.82191781 M B OB NO17114 NO19183 129.9 3.60E-02 5.67E-04 5.67E-04 5.67E-04 5.67E-04 5.36E-02 0.14050669 1.74E-02 0.11665231 5.67E-04 5.67E-04 5.67E-04 1.89E-02 4.20389772 5.67E-04 5.67E-04 1.21E-02 6.26E-02 2.42543617 0.27366225 0.11673461 0.69477516 0.3421214
10 109B 8.48767123 M B OB NO17115 NO19401 187.7 5.65E-02 1.13E-03 1.13E-03 1.13E-03 1.13E-03 7.29E-02 0.11697473 2.00E-02 0.16732998 1.13E-03 1.13E-03 1.13E-03 1.13E-03 5.75208881 1.13E-03 1.13E-03 1.13E-03 0.10407038 3.17733285 0.42615329 5.56E-02 0.75931442 0.17968733
11 256A 11.3123288 M A OB NO17223 - 350.7 1.12E-03 1.12E-03 1.12E-03 1.12E-03 1.12E-03 8.73E-02 6.21E-02 1.85E-02 0.32234195 1.12E-03 1.12E-03 1.12E-03 2.13E-02 4.18466435 1.12E-03 16.0240961 1.12E-03 0.10466741 3.10706999 0.25236854 3.05E-03 0.56435606 3.63E-02
12 250A 10.4219178 M A OB NO17224 NO18781 231.9 0.13269851 1.26E-03 1.26E-03 1.26E-03 1.26E-03 8.71E-02 7.32E-02 2.28E-02 0.35716267 1.26E-03 11.6991665 1.26E-03 6.84E-02 4.82688575 1.26E-03 56.4471231 1.23E-02 8.94E-02 3.05123843 0.33522986 5.58E-02 0.21424599 7.57E-02
13 244B 10.7780822 M B OB NO17268 - 73.6 9.04E-02 1.16E-03 1.16E-03 1.16E-03 1.16E-03 0.1022141 5.35E-02 2.71E-02 9.67E-02 1.16E-03 13.5830408 1.16E-03 2.32E-02 5.7240895 1.16E-03 1.16E-03 44.6412144 8.23E-02 2.96367001 0.24009033 2.15E-02 0.18872967 0.10187188
14 111A 8.35 M A OB NO17269 NO19556 158.3 4.34E-02 8.51E-04 8.51E-04 8.51E-04 8.51E-04 8.62E-02 0.1197689 5.11E-02 0.13082161 1.61E-02 8.51E-04 8.51E-04 1.58E-02 5.96526719 8.51E-04 10.2873318 2.95E-03 4.75E-02 2.82405667 0.34322156 3.49E-02 0.18731802 7.23E-02
15 124A 9.14520548 M A OB NO17488 NO19557 145.8 7.61E-02 1.90E-03 1.90E-03 1.90E-03 1.90E-03 0.12434241 0.16043421 3.94E-02 0.13647564 1.90E-03 1.90E-03 1.90E-03 3.84E-02 6.05660082 1.90E-03 1.90E-03 1.90E-03 7.29E-02 3.53051528 0.32029072 0.14091136 0.41937663 0.50832052
16 127A 8.12876712 M A OB NO17520 - 62.2 9.29E-02 1.63E-03 1.63E-03 1.63E-03 139.411098 0.10002109 0.1404911 4.25E-02 0.18878336 1.63E-03 1.63E-03 1.63E-03 0.14125862 8.43211831 1.63E-03 1.63E-03 265.433029 0.16426016 4.51473178 0.37532304 0.13307278 0.59806336 0.616055
17 271B 9.80273973 M B OB NO20494 - 390.7 2.72E-02 8.39E-04 8.39E-04 8.39E-04 8.39E-04 0.1568737 9.13E-02 2.62E-02 5.81E-02 3.09E-02 8.39E-04 8.39E-04 1.65E-02 4.71491241 8.39E-04 8.39E-04 164.423896 2.00E-02 9.07850109 0.25711457 1.35323015 0.83164233 3.03941619
18 273B 12.1753425 M B OB NO20816 - 150.4 4.92E-02 9.32E-04 9.32E-04 9.32E-04 9.32E-04 5.78E-02 2.91E-02 2.78E-02 7.88E-02 9.32E-04 9.32E-04 9.32E-04 1.63E-02 3.90809872 9.32E-04 9.32E-04 9.32E-04 4.80E-02 1.92264502 0.34437311 8.09E-02 0.2908046 0.51489067
19 303A 8.2109589 M A OB NO20860 - 557.1 3.61E-02 5.40E-04 5.40E-04 5.40E-04 5.40E-04 0.11806372 5.42E-02 1.02E-02 8.13E-02 5.40E-04 5.40E-04 5.40E-04 2.24E-02 3.85413931 5.40E-04 5.40E-04 3.35E-03 8.94E-02 3.75859479 0.43795541 0.29701992 0.23242702 1.21691911
20 263A 9.87671233 M A OB NO17568 - 31.5 1.57E-03 1.57E-03 1.57E-03 1.57E-03 1.57E-03 0.21584906 6.02E-02 1.57E-03 7.92E-02 1.57E-03 1.57E-03 1.57E-03 1.57E-03 5.42542551 1.57E-03 1.57E-03 1.57E-03 5.89E-02 3.75333583 0.44833245 7.42E-02 0.37296777 0.27389137
21 300B 7.1890411 M B OB NO18048 - 46 4.35E-02 9.02E-04 9.02E-04 9.02E-04 9.02E-04 0.25259938 0.12703999 7.10E-03 0.26066717 9.02E-04 9.02E-04 9.02E-04 3.46E-02 2.079069 9.02E-04 9.02E-04 462.290767 0.10173181 5.433779 0.38339911 0.24325813 0.61784311 0.59058497
22 126B 7.34520548 M B OB NO18092 NO20628 321.1 0.21947572 3.57E-03 3.57E-03 3.57E-03 3.57E-03 9.13E-02 0.13789841 3.57E-03 0.18150887 3.57E-03 7.09508383 3.57E-03 3.72E-02 5.5959313 3.57E-03 3.57E-03 3.57E-03 0.18893541 2.98192163 0.44673466 3.46E-02 0.52187206 0.43973077
23 131B1 6.36164384 M B OB NO18302 - 232.1 8.76E-02 1.93E-04 1.93E-04 1.93E-04 1.93E-04 7.62E-02 6.31E-02 1.96E-02 0.13108058 1.92E-03 1.93E-04 1.93E-04 1.74E-02 3.90213007 1.93E-04 2.79634544 5.32E-03 4.40E-02 3.2355724 0.21590253 2.56E-02 0.89381232 0.36945971
24 275B2 9.70136986 M B OB NO18193 - 266.2 8.33E-02 7.38E-04 7.38E-04 7.38E-04 7.38E-04 7.43E-02 0.17876354 2.90E-02 0.13660159 7.38E-04 7.38E-04 7.38E-04 5.13E-02 4.06530609 7.38E-04 7.38E-04 7.38E-04 5.09E-02 1.5895541 0.41515495 0.17085362 0.64876153 0.54825545
25 273B2 6.05205479 M B OB NO18497 NO20815 189.8 6.16E-02 8.77E-04 8.77E-04 1.31E-02 8.77E-04 7.34E-02 8.44E-02 8.77E-04 0.12218566 8.77E-04 0.78986037 8.77E-04 1.35E-02 5.95311676 8.77E-04 0.69357751 8.77E-04 4.46E-02 1.12145669 0.25356471 0.6076513 1.70820527 1.50808762
26 272A 9.47671233 M A OB NO18270 NO20626 245.6 9.27E-02 1.34E-03 1.34E-03 1.34E-03 1.34E-03 0.13936334 6.46E-02 1.34E-03 0.36482777 1.34E-03 1.34E-03 1.34E-03 3.62E-02 6.27293559 1.34E-03 1.34E-03 1.34E-03 0.139144 4.08532842 0.28644247 2.14E-02 0.89029025 0.15671283
27 147B ND M B OB NO18695 - 126.5 4.95E-04 4.95E-04 4.95E-04 4.95E-04 4.95E-04 3.78E-02 3.01E-02 1.56E-02 0.21448897 4.95E-04 4.95E-04 4.95E-04 1.52E-02 5.2765365 4.95E-04 4.95E-04 4.95E-04 6.17E-02 3.54773114 0.43708563 4.33E-02 1.01117133 0.54959489
28 277A 9.99452055 M A OB NO18640 NO20814 321 3.63E-02 5.23E-04 5.23E-04 5.23E-04 5.23E-04 7.48E-02 5.45E-02 1.98E-02 0.10819176 5.23E-04 5.23E-04 5.23E-04 7.37E-03 4.83714673 5.23E-04 5.23E-04 5.23E-04 5.89E-02 3.05322921 0.47372051 9.12E-02 0.58053762 0.56328117
29 283A 11.1342466 M A OB NO18696 - 97.6 5.02E-02 1.10E-03 1.10E-03 1.10E-03 1.10E-03 7.34E-02 9.95E-02 1.96E-02 0.21084755 1.10E-03 1.10E-03 1.10E-03 1.58E-02 4.63266268 1.10E-03 1.10E-03 1.10E-03 6.97E-02 2.81163666 0.25378075 0.10433044 0.79093988 0.53899085
30 264A 9.91506849 M A OB NO18047 - 34.7 4.27E-02 3.48E-04 3.48E-04 3.48E-04 3.48E-04 0.13381979 0.13105957 2.33E-02 0.10556205 6.42E-03 3.48E-04 3.48E-04 2.37E-02 4.70510507 3.48E-04 3.48E-04 3.48E-04 5.82E-02 6.76650644 0.60621996 0.44780505 0.78059511 1.13560061
31 276B ND M B OB NO19042 - 184.5 2.72E-04 2.72E-04 2.72E-04 2.72E-04 2.72E-04 6.25E-02 6.83E-02 2.46E-02 8.62E-02 2.72E-04 2.72E-04 2.72E-04 2.65E-02 4.11045124 2.72E-04 2.72E-04 2.72E-04 8.91E-02 2.26321736 0.47758671 0.1338116 0.69084498 0.7355681
32 135A 8.23561644 M A OB NO18823 - 211.4 8.89E-02 6.59E-04 6.59E-04 1.10E-02 6.59E-04 6.50E-02 0.10449414 1.11E-02 0.13454457 6.59E-04 6.59E-04 6.59E-04 9.81E-03 3.92706841 6.59E-04 6.59E-04 6.59E-04 6.29E-02 3.02898184 0.21745275 0.2235622 0.94385302 1.02426136
33 247A 10.7424658 M A OB NO19555 - 349.5 6.57E-02 4.93E-04 4.93E-04 4.93E-04 4.93E-04 5.61E-02 5.35E-02 4.73E-03 9.96E-02 1.08E-02 4.93E-04 4.93E-04 2.45E-02 3.20583552 4.93E-04 4.93E-04 4.93E-04 1.69E-02 5.96003623 0.1302116 0.44964149 0.69851497 1.70751961
34 100B 9.17534247 F B OB NO15855 - 132.9 1.42E-05 1.42E-05 1.42E-05 1.42E-05 1.42E-05 1.76E-03 7.67E-04 1.33E-04 7.55E-04 1.42E-05 3.63E-03 1.42E-05 3.22E-04 2.08E-02 1.42E-05 7.67E-03 1.42E-05 7.49E-04 2.26E-02 3.19E-03 2.58E-04 1.64E-03 6.76E-04
35 108A 7.65753425 F A OB NO16404 - 99 4.11E-04 1.15E-05 1.15E-05 1.15E-05 1.15E-05 3.25E-04 7.41E-04 1.15E-05 8.60E-04 1.15E-05 1.15E-05 1.15E-05 1.39E-04 2.42E-02 1.15E-05 1.15E-05 1.15E-05 7.06E-04 3.24E-02 2.45E-03 3.84E-04 3.07E-03 2.45E-03
36 246B 9.48767123 F B OB NO16787 - 247.8 3.45E-04 44.1413595 9.83E-06 9.83E-06 9.83E-06 1.08E-03 5.23E-04 9.83E-06 1.17E-03 2.54E-04 9.83E-06 9.83E-06 9.83E-06 1.43E-02 9.83E-06 9.83E-06 1.39E-04 6.15E-04 2.64E-02 2.56E-03 6.81E-04 8.46E-03 5.37E-03
37 105B 8.4109589 F B OB NO16852 - 112.3 1.55E-03 4.37E-05 4.37E-05 4.37E-05 4.37E-05 3.09E-03 7.51E-04 3.49E-04 1.73E-03 4.37E-05 4.37E-05 4.37E-05 5.85E-04 6.33E-02 4.37E-05 4.37E-05 4.37E-05 1.11E-03 5.35E-02 5.55E-03 1.15E-02 1.38E-02 2.44E-02
38 119B 6.01643836 F B OB NO17116 - 155.8 5.43E-04 7.99E-06 7.99E-06 7.99E-06 7.99E-06 3.63E-04 4.92E-04 6.15E-05 8.29E-04 7.99E-06 7.99E-06 7.99E-06 7.99E-06 3.12E-02 7.99E-06 7.99E-06 7.99E-06 6.09E-04 2.49E-02 2.74E-03 3.14E-04 5.40E-03 2.83E-03
39 261A 9.48 F A OB NO17307 - 125.9 5.07E-06 5.07E-06 5.07E-06 5.37E-05 5.07E-06 1.75E-03 1.44E-03 2.22E-04 2.83E-03 5.07E-06 0.1317963 5.07E-06 7.91E-04 8.06E-02 5.07E-06 5.07E-06 5.07E-06 9.87E-04 3.69E-02 3.74E-03 2.86E-04 3.35E-03 1.28E-03
40 118A 8.01369863 F A OB NO17427 - 149.8 3.89E-04 3.01E-06 3.01E-06 3.01E-06 3.01E-06 9.85E-04 6.10E-04 2.17E-04 6.61E-04 3.01E-06 8.11E-03 3.01E-06 1.14E-04 3.28E-02 3.01E-06 4.72E-03 3.01E-06 5.39E-04 2.31E-02 1.96E-03 7.78E-04 7.22E-03 4.64E-03
41 134A 8.92054795 F A OB NO18041 - 520.5 3.89E-04 6.66E-06 6.66E-06 6.66E-06 6.66E-06 2.33E-03 1.42E-03 3.15E-04 1.37E-03 2.50E-04 6.66E-06 6.66E-06 2.02E-04 3.45E-02 6.66E-06 6.66E-06 8.14E-05 8.40E-04 3.33E-02 2.65E-03 2.88E-04 3.17E-03 7.38E-04
42 132B 7.21643836 F B OB NO18152 - 151.5 4.81E-06 4.81E-06 4.81E-06 4.81E-06 4.81E-06 9.88E-04 1.54E-03 3.22E-04 1.82E-03 5.51E-05 4.81E-06 4.81E-06 2.99E-04 3.08E-02 4.81E-06 0.27088005 4.81E-06 1.10E-03 3.39E-02 3.90E-03 8.50E-04 4.70E-03 6.83E-03
43 402B 7.2109589 F B OB NO18265 - 347.9 6.28E-06 6.28E-06 6.28E-06 6.28E-06 5.70E-03 2.37E-03 1.86E-03 3.27E-04 8.88E-04 6.28E-06 6.28E-06 6.28E-06 9.32E-05 6.64E-02 6.28E-06 6.28E-06 6.28E-06 1.20E-03 3.32E-02 3.69E-03 5.97E-04 6.09E-03 1.50E-03
44 125B 7.99726027 F B OB NO18303 - 293.7 1.03E-03 1.99E-05 1.99E-05 1.99E-05 1.99E-05 3.75E-03 9.27E-04 4.84E-04 1.70E-03 1.99E-05 1.99E-05 1.99E-05 1.99E-05 4.42E-02 1.99E-05 1.99E-05 1.99E-05 1.04E-03 3.26E-02 2.88E-03 3.77E-04 4.26E-03 3.48E-03
45 102A 7.70136986 F A OB NO18457 - 305.5 1.55E-03 5.78E-06 5.78E-06 5.78E-06 5.78E-06 1.11E-03 5.26E-04 4.95E-05 5.78E-06 5.78E-06 5.78E-06 5.78E-06 5.78E-06 3.08E-02 5.78E-06 5.78E-06 5.78E-06 6.15E-04 2.93E-02 3.04E-03 1.37E-04 2.24E-03 1.11E-03
46 106A 7.57260274 F A OB NO18460 - 217.5 1.81E-03 2.65E-05 2.65E-05 2.65E-05 2.65E-05 1.69E-03 5.57E-04 2.65E-05 3.34E-03 2.65E-05 2.65E-05 2.65E-05 2.65E-05 3.28E-02 2.65E-05 2.65E-05 2.65E-05 2.65E-05 3.90E-02 4.50E-03 1.38E-03 1.42E-02 4.31E-03
47 301B 6.79452055 F B OB NO18642 - 235.7 5.38E-06 5.38E-06 5.38E-06 5.38E-06 5.38E-06 1.37E-03 1.13E-03 2.70E-04 1.24E-03 5.38E-06 5.38E-06 5.38E-06 2.51E-04 4.13E-02 5.38E-06 5.38E-06 5.38E-06 4.76E-04 2.41E-02 4.36E-03 4.46E-04 3.06E-03 4.05E-03
48 107B 6.26849315 F B OB NO16850 - 33.6 4.54E-04 7.36E-06 7.36E-06 7.36E-06 7.36E-06 6.13E-04 1.18E-03 5.92E-05 1.88E-03 2.01E-04 7.36E-06 7.36E-06 7.95E-02 3.74E-02 7.36E-06 7.36E-06 7.36E-06 2.54E-04 5.60E-02 1.96E-03 7.27E-03 5.42E-03 2.91E-02
49 270A 11.4410959 F A OB NO16028 - 117.9 1.41E-04 3.80E-06 3.80E-06 3.80E-06 3.80E-06 6.13E-04 3.80E-06 4.88E-05 7.60E-04 3.80E-06 7.24E-02 3.80E-06 1.25E-04 6.89E-03 3.80E-06 3.80E-06 3.80E-06 4.71E-04 3.77E-02 6.60E-04 1.17E-03 1.13E-02 3.57E-03
50 249A 8.98630137 F A OB NO16786 - 270.2 9.88E-04 1.35E-05 1.35E-05 1.35E-05 1.35E-05 2.62E-03 6.73E-04 1.00E-04 1.60E-03 1.35E-05 1.03802769 1.35E-05 2.82E-04 1.10E-02 1.35E-05 1.35E-05 1.35E-05 1.46E-03 5.90E-02 3.33E-03 1.35E-05 1.56E-02 7.31E-03
51 251B 10.8986301 F B OB NO16848 - 35.1 3.38E-04 4.26E-06 4.26E-06 4.26E-06 4.26E-06 5.92E-04 9.70E-04 2.15E-04 7.63E-04 8.15E-05 4.26E-06 4.26E-06 5.54E-04 4.11E-02 4.26E-06 4.26E-06 4.26E-06 4.69E-04 4.79E-02 1.69E-03 4.74E-03 9.63E-03 1.08E-02
52 116B 7.47945205 F B OB NO17065 - 42.4 9.14E-04 8.48E-06 8.48E-06 8.48E-06 8.48E-06 4.31E-04 1.13E-03 1.81E-04 6.67E-04 8.48E-06 8.48E-06 1.45E-03 3.42E-04 4.86E-02 8.48E-06 1.27E-03 8.48E-06 6.12E-04 3.20E-02 6.65E-03 1.47E-03 6.70E-03 6.10E-03
53 259B 8.74794521 F B OB NO17117 - 163.2 3.65E-04 5.29E-06 5.29E-06 5.29E-06 5.29E-06 3.54E-04 3.28E-04 9.39E-05 6.71E-04 5.29E-06 0.21633546 5.29E-06 1.02E-04 1.60E-02 5.29E-06 8.42E-02 5.29E-06 7.15E-04 3.18E-02 1.39E-03 1.52E-04 4.27E-03 1.78E-03
54 103B 6.48493151 F B OB NO17118 - 140.4 5.64E-04 1.54E-05 1.54E-05 1.54E-05 1.54E-05 1.14E-03 1.04E-03 1.54E-05 2.04E-03 1.54E-05 8.41E-04 1.54E-05 2.13E-04 2.29E-02 1.54E-05 1.54E-05 1.54E-05 5.53E-04 3.50E-02 1.54E-05 4.29E-04 1.24E-02 1.53E-03
55 267A 10.0109589 F A OB NO17308 - 146.3 3.73E-06 3.73E-06 3.73E-06 3.73E-06 3.73E-06 9.34E-04 5.82E-04 1.36E-04 7.99E-04 3.73E-06 3.73E-06 8.10E-03 7.21E-04 6.00E-02 1.13E-04 3.73E-06 1.34516655 6.51E-04 2.76E-02 1.90E-03 1.57E-04 3.10E-03 1.21E-03
56 2A 7.34520548 F A OB NO17522 - 149.1 7.56E-06 7.56E-06 7.56E-06 7.56E-06 7.56E-06 9.83E-04 1.61E-03 1.11E-04 1.15E-03 7.56E-06 8.25E-02 7.56E-06 9.84E-04 6.75E-02 7.56E-06 4.27E-02 6.71E-05 1.05E-03 3.59E-02 2.91E-03 4.90E-03 1.24E-02 7.92E-03
57 245A 8.79452055 F A OB NO16686 - 45.7 5.14E-06 5.14E-06 5.14E-06 5.14E-06 5.14E-06 5.11E-04 1.35E-03 8.11E-05 6.56E-04 5.14E-06 5.14E-06 5.14E-06 1.80E-04 3.89E-02 5.14E-06 5.14E-06 5.14E-06 4.28E-04 2.83E-02 3.83E-03 1.48E-04 2.12E-03 2.02E-03
58 243A 9.96164384 F A OB NO18153 - 252.5 3.27E-04 6.68E-06 6.68E-06 6.68E-06 6.68E-06 1.84E-03 9.36E-04 1.54E-04 2.96E-03 6.68E-06 6.68E-06 6.68E-06 3.97E-04 2.08E-02 6.68E-06 6.68E-06 6.68E-06 1.38E-03 5.18E-02 3.34E-03 1.64E-03 1.40E-02 2.98E-03
59 401B 9.70136986 F B OB NO18195 - 266.7 2.38E-04 2.84E-06 2.84E-06 2.84E-06 2.84E-06 1.07E-03 1.24E-03 1.21E-04 2.28E-03 2.84E-06 2.84E-06 7.56E-02 3.51E-04 4.42E-02 2.84E-06 2.84E-06 2.84E-06 1.26E-03 7.51E-02 2.79E-03 9.58E-03 1.88E-02 7.93E-03
60 129B 8.03287671 F B OB NO18269 - 382.8 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02
61 403B 9.90958904 F B OB NO18304 - 467.3 6.51E-04 3.28E-06 3.28E-06 3.28E-06 3.28E-06 6.93E-04 1.70E-04 8.66E-05 7.50E-04 3.28E-06 3.28E-06 3.28E-06 1.07E-04 3.04E-02 3.28E-06 3.28E-06 3.28E-06 4.19E-04 2.46E-02 7.18E-04 3.28E-06 3.42E-03 2.06E-03
62 309A 8.51780822 F A OB NO18496 - 408.4 6.92E-04 5.26E-06 5.26E-06 5.26E-06 5.26E-06 1.07E-03 1.03E-03 1.36E-04 1.29E-03 5.26E-06 5.26E-06 5.26E-06 1.85E-04 3.73E-02 5.26E-06 5.26E-06 5.26E-06 5.94E-04 3.42E-02 4.84E-03 7.10E-04 4.37E-03 6.18E-03
63 281A 9.90136986 F A OB NO18639 - 260.4 1.98E-04 2.04E-06 2.04E-06 2.04E-06 2.04E-06 6.79E-04 4.23E-04 8.30E-05 7.03E-04 4.56E-05 2.04E-06 1.17406427 2.66E-04 3.40E-02 2.04E-06 2.04E-06 3.51E-05 3.58E-04 3.08E-02 2.11E-03 1.53E-03 5.22E-03 6.92E-03
64 307A 6.57534247 F A OB NO18641 - 103.6 8.28E-06 8.28E-06 8.28E-06 8.28E-06 8.28E-06 9.12E-04 5.72E-04 1.90E-04 9.06E-04 8.28E-06 0.19728775 8.28E-06 4.43E-04 3.70E-02 8.28E-06 8.28E-06 8.28E-06 6.24E-04 3.25E-02 1.99E-03 8.28E-06 8.69E-03 6.41E-03
65 121A 9.10958904 F A OB NO17310 - 288.7 6.24E-04 3.12E-06 3.12E-06 3.12E-06 3.12E-06 5.09E-04 1.07E-03 1.89E-04 1.67E-03 3.12E-06 0.37793914 3.12E-06 3.90E-04 4.46E-02 3.12E-06 3.12E-06 3.12E-06 8.37E-04 2.49E-02 1.53E-03 1.73E-04 1.70E-03 4.21E-04
66 253A 10.1945205 F A OB NO17644 - 101.5 5.81E-04 5.79E-06 5.79E-06 5.79E-06 5.79E-06 6.53E-04 4.05E-04 1.63E-04 1.17E-03 5.79E-06 2.66E-02 5.79E-06 1.06E-04 4.31E-02 5.79E-06 5.79E-06 5.79E-06 6.70E-04 2.64E-02 2.25E-03 1.84E-04 1.47E-02 1.60E-03
67 3B 8.99178082 F B OB NO18094 - 310 7.62E-04 4.72E-06 4.72E-06 4.72E-06 4.72E-06 5.98E-04 9.55E-05 2.42E-04 1.03E-03 4.72E-06 4.72E-06 4.72E-06 4.61E-05 1.22E-02 4.72E-06 0.3284589 4.72E-06 1.08E-03 2.87E-02 1.30E-03 2.05E-04 3.16E-03 7.46E-04
68 275B 9.70136986 F B OB NO18194 - 312.6 1.15E-05 1.15E-05 1.15E-05 1.15E-05 1.15E-05 1.90E-03 2.77E-03 1.15E-05 2.06E-03 1.15E-05 1.81E-02 1.15E-05 3.55E-04 4.56E-02 1.15E-05 0.13091254 1.15E-05 1.24E-03 4.52E-02 5.25E-03 3.32E-03 1.21E-02 9.76E-03
69 313A 8.78630137 F A OB NO18778 - 183.2 1.98E-04 2.13E-06 2.13E-06 2.13E-06 2.13E-06 8.74E-04 4.40E-04 8.01E-05 7.58E-04 2.13E-06 3.61E-02 2.13E-06 2.01E-04 2.48E-02 2.13E-06 2.13E-06 1.23E-05 4.55E-04 2.36E-02 2.18E-03 7.55E-04 3.62E-03 3.44E-03
70 284A 9.17260274 F A OB NO18779 - 80.7 6.76E-04 2.14E-06 2.14E-06 2.14E-06 2.14E-06 7.99E-04 4.20E-04 9.21E-05 6.91E-04 2.14E-06 2.14E-06 2.14E-06 1.31E-04 2.08E-02 2.14E-06 2.14E-06 2.14E-06 5.12E-04 2.71E-02 1.51E-03 2.14E-06 4.09E-03 2.53E-03
71 112A 7.06027397 F A OB NO18780 - 404.2 4.21E-04 2.20E-06 2.20E-06 2.20E-06 2.20E-06 9.56E-04 3.70E-04 2.20E-06 1.01E-03 2.20E-06 2.20E-06 2.20E-06 1.71E-04 2.46E-02 2.20E-06 2.20E-06 3.47E-05 3.83E-04 2.42E-02 2.10E-03 3.83E-04 4.25E-03 2.60E-03
72 260B 9.0109589 F B OB NO19261 - 222.8 7.69E-04 2.22E-05 2.22E-05 2.22E-05 2.22E-05 1.93E-03 1.20E-03 2.27E-04 2.02E-03 2.22E-05 0.13799069 2.22E-05 1.01E-03 3.49E-02 2.22E-05 2.22E-05 2.22E-05 1.67E-03 5.09E-02 6.18E-03 2.55E-03 9.86E-03 1.10E-02
OBESE DATA NR GENE EXPRESSION (TLDA) [BASELINE]
231250
No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW) PGR PNR PPARA PPARD PPARG PXR RARA RARB RARG REV-ERBa REV-ERBb RORA RORB RORC RXRA RXRB RXRG SF-1 SHP THRA THRB TLX TR2 TR4 VDR
1 304B 9.02191781 M B OB 8.71E-04 8.71E-04 0.33012916 1.7316769 1.77E-02 1.43E-02 7.43486213 8.71E-04 6.00E-02 1.65645945 0.49381585 1.30344244 8.71E-04 0.36296018 9.62459131 0.90296293 8.71E-04 9.06E-03 8.71E-04 1.29322471 2.92E-02 14.5927899 0.38948246 1.04672148 2.86642768
2 133B 9.07 M B OB 6.50E-04 6.50E-04 0.28918682 1.32593704 6.50E-04 3.22E-02 4.92684772 6.50E-04 7.94E-02 2.39780969 0.61635165 2.33272532 1.29E-02 0.73083184 6.45330078 0.64448879 6.50E-04 6.78E-03 6.50E-04 1.65930973 1.44E-02 6.50E-04 0.4191964 1.08185905 2.00806731
3 269A 9.59726027 M A OB 4.42E-04 4.42E-04 0.34771896 1.1729281 6.62E-03 2.83E-02 4.11577701 4.42E-04 4.48E-02 1.14928259 0.73008563 2.43820306 1.10E-02 0.113082 5.89863815 0.6472367 4.42E-04 8.20E-03 4.42E-04 1.27076005 2.35E-02 4.42E-04 0.34310869 1.31255668 1.49266794
4 242B 11.1232877 M B OB 481.3746 1.36E-03 0.39986278 1.56371754 1.36E-03 5.90E-02 3.83888433 1.36E-03 0.13305045 1.65708399 1.20055365 5.83580889 3.24E-02 0.29902966 4.19649857 1.13790412 1.36E-03 1.09E-02 1.36E-03 1.91574436 3.55E-02 1.36E-03 0.67314861 1.68657105 1.11891826
5 104A 8.06849315 M A OB 599.574111 2.04E-03 0.26363087 1.06473286 1.71E-02 2.04E-03 4.06501586 2.04E-03 6.16E-02 1.24854346 0.36370111 1.06868676 1.76E-02 0.3122123 3.91269013 0.86407578 2.04E-03 2.04E-03 2.04E-03 1.37422939 3.20E-02 2.04E-03 2.04E-03 0.69632572 1.0708869
6 252B 10.109589 M B OB 1.77E-03 1.77E-03 0.42693393 2.07113165 1.77E-03 7.95E-02 4.71741685 1.77E-03 8.80E-02 1.81277843 0.52496296 1.77E-03 9.60850608 0.28841515 3.27434503 1.37215225 1.77E-03 1.38E-02 1.77E-03 1.71827708 3.02E-02 1.77E-03 0.16252248 1.54274805 1.15188114
7 241B 9.55890411 M B OB 253.826606 8.46E-02 0.32429453 1.19592767 3.09E-02 3.26E-02 5.54951876 1.98E-03 6.36E-02 2.6668556 1.13346325 3.15028587 1.45E-02 8.16E-02 4.87488954 0.85148277 1.98E-03 1.64E-02 1.98E-03 1.81308279 1.98E-03 1.98E-03 1.98E-03 0.9027978 3.05953275
8 117A 7.12 M A OB 9.54E-04 9.54E-04 0.52897515 1.69833614 1.06E-02 2.98E-02 3.71850762 9.54E-04 0.10304315 1.04881031 0.86636759 3.13784787 9.54E-04 0.3004367 6.92770881 1.20675092 9.54E-04 9.12436943 9.54E-04 1.49899637 3.76E-02 9.54E-04 0.66775107 2.09734409 1.79400424
9 262B 9.82191781 M B OB 460.126801 5.67E-04 0.25760409 1.60540621 2.10E-03 1.80E-02 3.15134344 5.67E-04 4.05E-02 0.87726082 0.76481498 2.9704322 1.86E-02 5.67E-04 3.89196396 0.57032766 3.72084461 4.74E-03 5.67E-04 1.03856114 1.68E-02 5.67E-04 5.67E-04 1.18713305 1.04820061
10 109B 8.48767123 M B OB 1.13E-03 1.13E-03 0.43120299 2.3626034 204.810494 4.04E-02 4.44788162 1.13E-03 8.69E-02 1.27288486 0.97587526 2.74576385 1.13E-03 0.21663058 4.18900481 0.91013357 11.3961517 8.59E-03 998.074585 1.70434707 3.79E-03 1.13E-03 1.13E-03 2.07785619 0.9906495
11 256A 11.3123288 M A OB 290.328605 1.12E-03 0.27839319 1.42781376 1.12E-03 3.22E-02 4.76575276 1.12E-03 7.10E-02 1.34130358 0.84794025 2.76218533 8.17E-03 0.62203959 6.31466312 0.81497616 2.72578269 8.81E-03 1.12E-03 1.24079871 1.12E-03 1.12E-03 0.53739856 1.46313567 1.80692045
12 250A 10.4219178 M A OB 804.681174 1.26E-03 0.51521033 1.71252142 1.40E-02 2.01E-02 3.3335956 1.26E-03 0.14169232 1.35747657 1.12687552 4.19147159 2.48E-02 0.49540896 5.03070938 1.38953938 1.26E-03 1.26E-03 1.26E-03 1.84883125 1.69E-02 1.26E-03 0.73774578 2.13649023 1.34805722
13 244B 10.7780822 M B OB 1.16E-03 1.16E-03 0.39510159 2.01350855 2.87E-02 1.16E-03 4.0468991 1.16E-03 6.73E-02 1.05643193 0.90142663 1.53171549 1.16E-03 0.28818668 6.33486594 0.96883415 1.16E-03 1.7263933 1.16E-03 1.12574915 1.85E-02 1.16E-03 1.16E-03 1.84982205 1.35731978
14 111A 8.35 M A OB 613.641771 8.51E-04 0.40720113 2.37426773 4.53E-03 1.46E-02 1.72693959 8.51E-04 0.13221216 1.45383236 1.20600762 3.39485621 4.22E-02 0.35702581 3.82995842 0.98993651 0.79628158 8.51E-04 8.51E-04 1.68699637 3.23E-02 8.51E-04 0.74541671 1.87414994 0.91538111
15 124A 9.14520548 M A OB 779.838435 1.90E-03 0.38460267 2.09112394 1.90E-03 1.90E-03 5.8271824 1.90E-03 0.13858163 2.26014988 1.20278467 4.87126129 2.27E-02 0.2794037 5.3367463 0.76493443 1.90E-03 6.10E-03 1.90E-03 2.00615147 3.17E-02 1.90E-03 0.6659665 1.63945658 1.84915982
16 127A 8.12876712 M A OB 6.42E-03 2.64683503 0.53509103 2.24156027 7.43E-02 2.80E-02 12.73477 1.63E-03 0.16991676 1.75334945 0.86315726 4.37990865 1.98E-02 0.48683955 12.7772932 1.19424158 0.53807527 1.71E-02 2.08E-02 2.15733261 1.63E-03 1.63E-03 0.81499224 1.92870515 2.39666698
17 271B 9.80273973 M B OB 2813.30636 8.39E-04 0.38263127 1.05333944 8.39E-04 1.17E-02 13.7265408 8.39E-04 0.10257413 4.25433818 2.38907705 5.25512398 1.65E-02 0.25845095 2.9823406 0.32466077 8.39E-04 8.39E-04 8.39E-04 4.37495495 1.85E-02 8.39E-04 0.28266949 0.69355392 1.94058022
18 273B 12.1753425 M B OB 707.757872 9.32E-04 0.31701285 1.163388 9.32E-04 4.30E-02 2.29694809 9.32E-04 0.10955066 1.202501 0.79904994 2.95840545 1.33E-02 0.23110408 2.63277908 0.4103397 9.32E-04 9.36E-03 9.32E-04 1.00357552 1.36E-02 9.32E-04 0.33435162 1.19193049 0.59616973
19 303A 8.2109589 M A OB 12239.6883 5.40E-04 0.32973936 1.11225298 5.40E-04 2.46E-02 1.70566936 5.40E-04 0.10098879 2.04532552 1.13098004 2.98583081 2.56E-03 0.27765411 4.26009431 0.34892264 5.40E-04 1.07E-02 5.40E-04 1.42655659 1.15E-02 5.40E-04 0.27451747 1.06565766 0.5917345
20 263A 9.87671233 M A OB 1.57E-03 1.57E-03 0.44205405 1.74247762 1.57E-03 3.26E-02 2.97236212 1.57E-03 0.20345672 2.50730976 1.11034452 3.19888141 1.57E-03 1.02558014 2.75132146 0.69494968 1.57E-03 1.57E-03 1.57E-03 1.50311675 2.66E-02 1.57E-03 0.26490761 1.62444899 1.07734577
21 300B 7.1890411 M B OB 9.02E-04 9.02E-04 0.2666063 1.32114926 6.84E-03 4.34E-02 6.27653391 9.02E-04 0.19647006 2.66830566 0.42329224 1.74042531 1.63E-03 1.29357745 4.73924479 0.86533053 9.02E-04 9.61E-03 9.02E-04 1.08083613 1.73E-02 9.02E-04 0.19987848 1.22461026 1.45831692
22 126B 7.34520548 M B OB 1695.23857 3.57E-03 0.58782531 2.66425858 3.57E-03 6.07E-02 5.39578573 3.57E-03 0.16396387 1.81772123 0.79789099 1.35468206 3.57E-03 0.23350422 8.03522287 1.44151479 3.57E-03 3.57E-03 3.57E-03 1.60384273 6.53E-02 3.57E-03 0.27887989 2.19448561 1.61453075
23 131B1 6.36164384 M B OB 1.93E-04 1.93E-04 0.28955879 1.03252717 2.90E-03 1.73E-02 3.2070023 1.93E-04 3.67E-02 0.68089726 0.66566843 2.17055131 6.71E-03 0.12736912 4.32724495 0.43568775 1.93E-04 6.15E-03 1.93E-04 1.105045 1.44E-02 0.32320016 0.43497274 1.20662475 1.39325052
24 275B2 9.70136986 M B OB 7.38E-04 7.38E-04 0.29776163 1.58509535 2.22E-02 2.46E-02 5.21935847 7.38E-04 7.60E-02 1.92492941 0.62610732 2.81919287 1.57E-02 0.24074435 6.05045404 0.72142562 7.38E-04 7.38E-04 7.38E-04 1.52146663 2.38E-02 7.38E-04 0.51551926 1.37662475 1.74979126
25 273B2 6.05205479 M B OB 3178.81716 8.77E-04 0.41690064 1.58903995 8.77E-04 8.77E-04 2.26798764 8.77E-04 8.74E-02 1.05185455 0.75879441 4.18867471 1.16E-02 0.30059974 4.83645944 0.57701182 8.77E-04 2.00E-02 8.77E-04 1.44855057 8.77E-04 8.77E-04 0.48794174 1.60905974 0.93979046
26 272A 9.47671233 M A OB 1.34E-03 1.34E-03 0.45340831 1.93369377 1.34E-03 2.76E-02 4.76535836 1.34E-03 0.20535355 1.45279303 1.07838408 3.70451735 1.34E-03 0.72969484 8.20957928 1.11282279 1.34E-03 1.34E-02 1.34E-03 1.40110459 2.10E-02 1.34E-03 0.63979002 2.14304511 2.46400183
27 147B ND M B OB 4.95E-04 4.95E-04 0.38665783 1.30353803 1.53E-02 3.50E-02 3.88261474 4.95E-04 5.46E-02 1.65605349 0.89958844 3.03515274 5.86E-03 0.28431037 5.69408978 0.54557279 4.95E-04 7.74E-03 4.95E-04 1.54102511 2.34E-02 4.95E-04 0.46931257 1.53728287 0.84471668
28 277A 9.99452055 M A OB 2381.92524 5.23E-04 0.38938717 1.43696853 3.46E-03 2.35E-02 2.78310425 5.23E-04 5.57E-02 2.24852908 1.14161572 3.22643815 5.23E-04 0.27521595 3.15710007 0.54133197 5.23E-04 9.43E-03 1.35E-02 1.65677845 8.32E-03 5.23E-04 0.61003978 1.57505878 0.75700264
29 283A 11.1342466 M A OB 1.10E-03 1.10E-03 0.3318989 1.03431607 4.44E-03 1.55E-02 2.27189801 1.10E-03 6.47E-02 1.8889665 0.76428185 2.79309337 1.10E-03 0.32388652 4.90373657 0.50037173 1.10E-03 9.27E-03 1.10E-03 1.19529049 1.89E-02 1.10E-03 0.32906693 1.41772047 1.32254904
30 264A 9.91506849 M A OB 988.717611 3.48E-04 0.32525965 1.26416061 3.66E-03 2.81E-02 5.16459038 3.48E-04 0.21238861 1.63614653 1.24701952 5.36426816 1.33E-02 1.17864785 3.58043667 1.00835014 3.48E-04 4.01E-03 3.48E-04 1.41238947 5.06E-03 0.44471585 0.46607496 2.1025197 1.05224069
31 276B ND M B OB 2.72E-04 2.72E-04 0.331834 1.31055268 8.48E-03 4.15E-02 3.77468896 2.72E-04 4.75E-02 1.60579463 1.30615112 3.7705904 4.14E-03 0.27236682 3.29577047 0.39612927 2.72E-04 3.20E-03 2.72E-04 1.49931082 3.48E-03 0.44471723 0.5057907 1.37954292 1.24503345
32 135A 8.23561644 M A OB 1914.34731 6.59E-04 0.31400242 0.97558229 6.59E-04 6.59E-04 3.66730755 6.59E-04 6.19E-02 1.41596011 0.79203947 2.78983535 6.59E-04 0.13992377 2.48598336 0.42870714 6.59E-04 1.73E-02 6.59E-04 1.35804663 2.58E-02 6.59E-04 0.35592232 1.06086071 1.11900311
33 247A 10.7424658 M A OB 4.93E-04 4.93E-04 0.20713249 0.76059783 1.26E-02 1.03E-02 7.46988628 4.93E-04 2.85E-02 2.31994842 1.50898781 3.52487317 4.93E-04 9.49E-02 1.7148482 0.31287894 4.93E-04 4.93E-04 4.93E-04 2.07127517 7.75E-03 4.93E-04 0.3605303 0.39657025 1.90070798
34 100B 9.17534247 F B OB 1.42E-05 1.42E-05 2.36E-03 1.86E-02 1.42E-05 2.92E-04 3.80E-02 1.42E-05 6.80E-04 1.50E-02 3.06E-03 7.99E-03 1.42E-05 3.99E-03 2.51E-02 5.66E-03 1.42E-05 1.42E-05 1.42E-05 1.60E-02 2.32E-04 1.42E-05 1.31E-03 9.56E-03 1.18E-02
35 108A 7.65753425 F A OB 1.15E-05 1.15E-05 2.42E-03 1.30E-02 1.15E-05 2.19E-04 3.64E-02 1.15E-05 5.31E-04 1.62E-02 2.78E-03 1.16E-02 1.57E-04 2.12E-03 3.53E-02 5.00E-03 1.15E-05 8.21E-05 1.15E-05 1.34E-02 2.97E-04 1.15E-05 1.59E-03 5.25E-03 6.18E-03
36 246B 9.48767123 F B OB 9.83E-06 9.83E-06 3.15E-03 1.58E-02 9.83E-06 2.07E-04 5.01E-02 9.83E-06 4.33E-04 1.63E-02 1.24E-03 4.06E-03 9.83E-06 3.92E-03 4.74E-02 3.60E-03 9.83E-06 9.83E-06 9.83E-06 2.01E-02 9.83E-06 9.83E-06 9.83E-06 8.51E-03 1.42E-02
37 105B 8.4109589 F B OB 4.37E-05 4.37E-05 4.41E-03 1.22E-02 4.37E-05 4.37E-05 5.83E-02 4.37E-05 4.05E-04 2.24E-02 9.83E-03 3.24E-02 4.37E-05 1.36E-03 7.66E-02 9.96E-03 4.37E-05 4.37E-05 4.37E-05 1.49E-02 4.37E-05 4.37E-05 5.66E-03 1.30E-02 2.92E-02
38 119B 6.01643836 F B OB 7.99E-06 7.99E-06 2.08E-03 1.14E-02 7.99E-06 7.99E-06 2.69E-02 7.99E-06 4.79E-04 6.36E-03 2.93E-03 6.70E-03 7.99E-06 3.02E-03 2.96E-02 3.20E-03 7.99E-06 2.62E-04 7.99E-06 7.87E-03 7.99E-06 7.99E-06 7.99E-06 7.54E-03 8.84E-03
39 261A 9.48 F A OB 5.07E-06 5.07E-06 5.73E-03 2.84E-02 1.82E-05 2.57E-04 6.46E-02 5.07E-06 1.57E-03 1.47E-02 1.38E-02 4.67E-02 1.31E-04 3.52E-03 5.81E-02 2.42E-02 5.07E-06 1.48E-04 5.07E-06 1.96E-02 3.58E-04 5.07E-06 6.98E-03 3.00E-02 2.42E-02
40 118A 8.01369863 F A OB 3.01E-06 3.01E-06 3.17E-03 1.16E-02 9.55E-05 9.97E-05 3.61E-02 3.01E-06 4.47E-04 9.37E-03 4.61E-03 2.15E-02 1.79E-04 1.35E-03 4.07E-02 3.36E-03 3.01E-06 3.01E-06 3.01E-06 1.16E-02 1.46E-04 3.01E-06 2.75E-03 1.24E-02 8.72E-03
41 134A 8.92054795 F A OB 26.9544788 6.66E-06 3.81E-03 1.64E-02 6.66E-06 2.37E-04 5.18E-02 6.66E-06 1.25E-03 2.08E-02 6.57E-03 3.35E-02 6.66E-06 1.21E-02 5.83E-02 6.41E-03 6.66E-06 7.71E-05 6.66E-06 1.64E-02 1.58E-04 6.66E-06 6.66E-06 1.42E-02 1.82E-02
42 132B 7.21643836 F B OB 1.44479959 4.81E-06 3.52E-03 1.52E-02 1.22E-04 2.96E-04 5.01E-02 4.81E-06 7.56E-04 1.47E-02 5.11E-03 1.82E-02 1.92E-04 1.99E-03 7.00E-02 7.34E-03 4.81E-06 1.72E-04 4.81E-06 1.45E-02 2.18E-04 4.81E-06 5.14E-03 1.17E-02 1.47E-02
43 402B 7.2109589 F B OB 6.28E-06 6.28E-06 5.51E-03 2.59E-02 1.55E-04 4.14E-04 6.20E-02 6.28E-06 1.77E-03 1.52E-02 1.17E-02 5.68E-02 2.06E-04 3.24E-03 7.10E-02 7.75E-03 6.28E-06 1.18E-04 6.28E-06 2.33E-02 2.16E-04 8.76E-03 6.36E-03 3.42E-02 1.85E-02
44 125B 7.99726027 F B OB 49.2605018 1.99E-05 2.79E-03 1.34E-02 1.99E-05 4.01E-04 5.76E-02 1.99E-05 1.03E-03 9.51E-03 4.47E-03 1.28E-02 1.40E-04 1.99E-05 5.46E-02 9.48E-03 1.99E-05 1.99E-05 1.99E-05 8.84E-03 1.99E-05 1.99E-05 3.24E-03 1.74E-02 2.05E-02
45 102A 7.70136986 F A OB 3.92952941 5.78E-06 2.36E-03 1.24E-02 5.78E-06 1.17E-04 3.54E-02 5.78E-06 1.19E-03 1.03E-02 4.15E-03 1.07E-02 1.20E-04 3.47E-03 4.33E-02 2.98E-03 5.78E-06 6.78E-05 5.78E-06 1.20E-02 1.67E-04 5.78E-06 1.16E-03 1.22E-02 9.47E-03
46 106A 7.57260274 F A OB 2.65E-05 2.65E-05 3.11E-03 1.08E-02 2.74E-04 4.56E-04 5.09E-02 2.65E-05 1.29E-03 1.41E-02 1.82E-03 4.13E-03 2.65E-05 6.86E-03 5.05E-02 7.09E-03 2.65E-05 2.65E-05 2.65E-05 6.85E-03 2.65E-05 2.65E-05 8.69E-04 1.03E-02 1.30E-02
47 301B 6.79452055 F B OB 5.38E-06 5.38E-06 3.60E-03 1.92E-02 1.21E-04 2.01E-04 3.71E-02 5.38E-06 6.21E-04 1.53E-02 7.39E-03 4.04E-02 3.63E-04 5.84E-03 3.84E-02 4.49E-03 5.38E-06 6.65E-05 5.38E-06 1.17E-02 1.65E-04 5.38E-06 5.85E-03 1.71E-02 1.45E-02
48 107B 6.26849315 F B OB 7.36E-06 7.36E-06 2.69E-03 9.28E-03 9.36E-05 7.36E-06 6.23E-02 7.36E-06 1.23E-03 2.45E-02 1.79E-02 7.05E-02 7.36E-06 3.30E-03 1.83E-02 2.45E-03 7.36E-06 7.36E-06 7.36E-06 2.80E-02 1.56E-04 7.36E-06 3.69E-03 5.83E-03 1.01E-02
49 270A 11.4410959 F A OB 114.444885 3.80E-06 1.02E-03 4.97E-03 3.80E-06 7.94E-05 3.04E-02 3.80E-06 2.29E-04 9.66E-03 7.91E-04 3.01E-03 3.80E-06 1.07E-03 3.25E-02 3.37E-03 3.80E-06 3.30E-05 3.80E-06 1.02E-02 6.36E-05 3.80E-06 3.80E-06 2.24E-03 6.13E-03
50 249A 8.98630137 F A OB 1.35E-05 1.35E-05 2.60E-03 9.44E-03 1.35E-05 1.35E-05 4.74E-02 1.35E-05 1.66E-03 2.25E-02 2.08E-03 4.81E-03 1.35E-05 4.07E-03 6.79E-02 6.92E-03 1.35E-05 1.47E-04 1.35E-05 1.76E-02 1.35E-05 1.35E-05 3.67E-04 6.71E-03 1.30E-02
51 251B 10.8986301 F B OB 4.26E-06 4.26E-06 2.19E-03 8.84E-03 1.19E-04 4.26E-06 6.54E-02 4.26E-06 4.40E-04 1.47E-02 6.71E-03 2.48E-02 1.05E-04 1.46E-03 5.30E-02 3.15E-03 4.26E-06 4.26E-06 1.48E-05 1.20E-02 3.67E-04 4.26E-06 3.33E-03 7.21E-03 3.21E-02
52 116B 7.47945205 F B OB 8.48E-06 8.48E-06 4.12E-03 1.59E-02 8.48E-06 1.19E-04 2.38E-02 8.48E-06 9.35E-04 2.11E-02 6.60E-03 1.13E-02 9.84E-05 3.92E-03 3.25E-02 5.28E-03 8.48E-06 1.10E-04 8.48E-06 2.08E-02 2.07E-04 8.48E-06 2.87E-03 1.47E-02 8.18E-03
53 259B 8.74794521 F B OB 5.29E-06 5.29E-06 1.35E-03 5.19E-03 6.14E-05 1.21E-04 2.18E-02 5.29E-06 6.01E-04 1.25E-02 1.09E-03 4.45E-03 1.82E-05 3.10E-03 3.67E-02 3.08E-03 5.29E-06 5.29E-06 5.29E-06 8.39E-03 5.29E-06 5.29E-06 4.61E-04 4.74E-03 6.07E-03
54 103B 6.48493151 F B OB 1.54E-05 1.54E-05 2.05E-03 7.82E-03 1.46E-04 2.35E-04 4.14E-02 1.54E-05 6.17E-04 1.04E-02 1.17E-03 1.54E-05 1.54E-05 1.88E-03 3.48E-02 9.60E-03 1.54E-05 1.54E-05 1.54E-05 7.92E-03 1.54E-05 1.54E-05 8.06E-04 4.56E-03 1.00E-02
55 267A 10.0109589 F A OB 1.22706107 3.73E-06 3.71E-03 1.31E-02 3.73E-06 1.18E-04 4.73E-02 3.73E-06 6.25E-04 1.16E-02 6.06E-03 2.19E-02 1.10E-04 4.50E-03 8.70E-02 5.43E-03 3.73E-06 4.78E-05 3.73E-06 1.10E-02 9.81E-05 3.73E-06 4.54E-03 1.54E-02 2.24E-02
56 2A 7.34520548 F A OB 2.13242219 7.56E-06 4.66E-03 1.96E-02 1.20E-05 1.28E-04 9.12E-02 7.56E-06 7.62E-04 1.21E-02 1.03E-02 4.12E-02 2.59E-04 2.64E-03 8.94E-02 9.25E-03 7.56E-06 5.84E-05 7.56E-06 1.67E-02 1.24E-04 2.74E-05 5.33E-03 2.01E-02 2.42E-02
57 245A 8.79452055 F A OB 5.14E-06 5.14E-06 3.27E-03 1.08E-02 5.14E-06 2.29E-04 3.86E-02 5.14E-06 7.73E-04 1.35E-02 7.05E-03 3.15E-02 5.14E-06 5.10E-03 4.69E-02 3.74E-03 5.14E-06 5.14E-06 5.14E-06 1.16E-02 1.55E-04 5.14E-06 4.04E-03 1.31E-02 1.18E-02
58 243A 9.96164384 F A OB 1.85989925 6.68E-06 2.83E-03 1.07E-02 2.43E-04 2.32E-04 6.20E-02 6.68E-06 8.74E-04 2.26E-02 3.78E-03 1.66E-02 6.68E-06 1.59E-03 0.10008503 9.59E-03 6.68E-06 6.85E-05 6.68E-06 1.66E-02 2.53E-04 6.68E-06 4.56E-03 8.50E-03 2.78E-02
59 401B 9.70136986 F B OB 2.84E-06 2.84E-06 2.30E-03 6.86E-03 3.62E-05 2.21E-04 0.12953974 2.84E-06 7.90E-04 5.72E-03 5.01E-03 2.75E-02 1.11E-04 2.19E-03 0.10280537 3.42E-03 2.84E-06 3.24E-05 2.84E-06 6.46E-03 6.37E-05 5.59E-05 2.89E-03 1.37E-02 3.50E-02
60 129B 8.03287671 F B OB 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 0.1509544 3.66E-02 3.66E-02 31537.5468 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02 3.66E-02
61 403B 9.90958904 F B OB 16.4480389 3.28E-06 1.90E-03 6.11E-03 1.40E-04 3.28E-06 3.58E-02 3.28E-06 4.32E-04 4.45E-03 3.23E-03 1.02E-02 3.94E-05 9.28E-04 4.79E-02 2.48E-03 3.28E-06 3.28E-06 3.28E-06 3.89E-03 5.06E-05 3.28E-06 1.62E-03 8.16E-03 2.28E-02
62 309A 8.51780822 F A OB 5.26E-06 5.26E-06 2.73E-03 1.27E-02 8.34E-05 2.11E-04 3.18E-02 5.26E-06 7.17E-04 2.05E-02 7.06E-03 1.47E-02 6.77E-05 1.75E-03 5.28E-02 5.49E-03 5.26E-06 6.59E-05 5.26E-06 1.48E-02 9.55E-05 5.26E-06 3.60E-03 1.17E-02 1.09E-02
63 281A 9.90136986 F A OB 2.04E-06 2.04E-06 2.81E-03 8.45E-03 5.19E-05 8.18E-05 3.60E-02 2.04E-06 5.75E-04 9.47E-03 6.10E-03 1.96E-02 1.56E-04 1.65E-03 6.92E-02 2.90E-03 2.04E-06 2.51E-05 2.04E-06 9.75E-03 2.04E-06 2.04E-06 3.21E-03 1.23E-02 1.15E-02
64 307A 6.57534247 F A OB 8.28E-06 8.28E-06 2.90E-03 8.20E-03 3.00E-04 3.07E-04 5.53E-02 8.28E-06 8.88E-04 1.17E-02 4.98E-03 1.73E-02 1.47E-04 1.77E-03 7.63E-02 5.31E-03 8.28E-06 9.08E-05 8.28E-06 7.80E-03 1.16E-04 8.28E-06 2.88E-03 1.03E-02 1.14E-02
65 121A 9.10958904 F A OB 3.12E-06 3.12E-06 2.65E-03 1.08E-02 5.86E-05 1.26E-04 4.26E-02 3.12E-06 4.68E-04 6.65E-03 5.35E-03 1.01E-02 9.37E-05 1.28E-03 7.23E-02 5.50E-03 3.12E-06 5.04E-05 3.12E-06 7.77E-03 3.12E-06 3.12E-06 3.48E-03 1.15E-02 1.44E-02
66 253A 10.1945205 F A OB 3.11950573 5.79E-06 3.92E-03 1.31E-02 5.79E-06 1.34E-04 3.68E-02 5.79E-06 6.13E-04 6.78E-03 4.95E-03 2.81E-02 1.17E-04 1.35E-03 3.70E-02 4.85E-03 5.79E-06 5.79E-06 5.79E-06 1.21E-02 8.59E-05 5.79E-06 3.26E-03 1.19E-02 1.04E-02
67 3B 8.99178082 F B OB 4.72E-06 4.72E-06 1.75E-03 8.76E-03 5.57E-05 8.91E-05 4.24E-02 4.72E-06 6.89E-04 9.63E-03 1.38E-03 4.37E-03 4.72E-06 3.89E-03 4.87E-02 2.22E-03 4.72E-06 7.18E-05 4.72E-06 9.46E-03 4.72E-06 4.72E-06 9.33E-04 5.16E-03 1.23E-02
68 275B 9.70136986 F B OB 1.15E-05 1.15E-05 4.22E-03 1.94E-02 1.15E-05 3.65E-04 6.51E-02 1.15E-05 1.02E-03 2.46E-02 7.35E-03 4.85E-02 1.69E-04 3.47E-03 7.42E-02 1.35E-02 1.15E-05 1.15E-05 1.15E-05 1.84E-02 3.03E-04 1.15E-05 6.12E-03 1.68E-02 1.93E-02
69 313A 8.78630137 F A OB 2.13E-06 2.13E-06 2.35E-03 7.93E-03 1.22E-04 1.64E-04 3.33E-02 2.13E-06 2.95E-04 7.20E-03 4.32E-03 1.73E-02 7.30E-05 7.95E-04 4.61E-02 2.40E-03 2.13E-06 5.48E-05 2.13E-06 7.45E-03 9.28E-05 2.13E-06 2.52E-03 8.29E-03 1.04E-02
70 284A 9.17260274 F A OB 2.14E-06 2.14E-06 2.85E-03 8.54E-03 3.98E-05 2.14E-06 4.14E-02 2.14E-06 4.96E-04 1.16E-02 5.02E-03 1.19E-02 3.43E-05 1.91E-03 6.62E-02 2.79E-03 2.14E-06 2.43E-05 2.14E-06 9.94E-03 3.74E-05 2.14E-06 2.56E-03 8.18E-03 1.62E-02
71 112A 7.06027397 F A OB 2.20E-06 2.20E-06 2.58E-03 9.50E-03 2.20E-06 6.24E-05 4.45E-02 2.20E-06 5.70E-04 9.98E-03 5.10E-03 1.30E-02 4.10E-05 1.24E-03 5.88E-02 2.42E-03 2.20E-06 2.65E-05 2.20E-06 7.95E-03 8.07E-05 2.20E-06 3.05E-03 8.79E-03 1.10E-02
72 260B 9.0109589 F B OB 2.22E-05 2.22E-05 3.56E-03 1.43E-02 2.22E-05 5.61E-04 7.19E-02 2.22E-05 1.44E-03 2.14E-02 6.47E-03 3.16E-02 2.22E-05 1.85E-03 6.72E-02 1.07E-02 2.22E-05 2.22E-05 2.22E-05 1.64E-02 4.38E-04 2.22E-05 4.22E-03 1.38E-02 2.46E-02
OBESE DATA NR GENE EXPRESSION (TLDA) [BASELINE]
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No ID Age (years) Gender Arms A/B/C
Obese (OB)/ 
Healthy 
Weight 
(HW) PXR (B) THRA (B) THRB (B) PXR (12) THRA (12) THRB (12)
1 304B 9.02191781 M B OB 5.68 439.825 1.592 1.153 972.655 1.953
2 133B 9.07 M B OB ND ND ND ND ND ND
3 269A 9.59726027 M A OB ND ND ND ND ND ND
4 242B 11.1232877 M B OB 2.064 268.847 0.355 3.933 763.13 0.21
5 104A 8.06849315 M A OB ND ND ND ND ND ND
6 252B 10.109589 M B OB ND ND ND ND ND ND
7 241B 9.55890411 M B OB ND ND ND ND ND ND
8 117A 7.12 M A OB ND ND ND ND ND ND
9 262B 9.82191781 M B OB 2.299 184.923 0.416 2.734 439.825 1.538
10 109B 8.48767123 M B OB 3.645 243.164 0.228 1.072 989.657 0.395
11 256A 11.3123288 M A OB ND ND ND ND ND ND
12 250A 10.4219178 M A OB 0.31 276.433 0.542 2.438 276.433 0.937
13 244B 10.7780822 M B OB ND ND ND ND ND ND
14 111A 8.35 M A OB 5.524 444.421 2.568 0.656 449.066 0.667
15 124A 9.14520548 M A OB 2.447 232.451 0.351 1.047 939.523 0.579
16 127A 8.12876712 M A OB ND ND ND ND ND ND
17 271B 9.80273973 M B OB ND ND ND ND ND ND
18 273B 12.1753425 M B OB ND ND ND ND ND ND
19 303A 8.2109589 M A OB ND ND ND ND ND ND
20 263A 9.87671233 M A OB ND ND ND ND ND ND
21 300B 7.1890411 M B OB ND ND ND ND ND ND
22 126B 7.34520548 M B OB 2.072 302.499 3.342 5.819 140.146 2.101
23 131B1 6.36164384 M B OB ND ND ND ND ND ND
24 275B2 9.70136986 M B OB ND ND ND ND ND ND
25 273B2 6.05205479 M B OB 2.072 271.684 0.821 0.889 219.151 0.49
26 272A 9.47671233 M A OB 1.748 303.549 1.099 2.108 228.458 0.841
27 147B ND M B OB ND ND ND ND ND ND
28 277A 9.99452055 M A OB 5.245 288.172 0.22 1.377 223.756 0.198
29 283A 11.1342466 M A OB ND ND ND ND ND ND
30 264A 9.91506849 M A OB ND ND ND ND ND ND
31 276B ND M B OB ND ND ND ND ND ND
32 135A 8.23561644 M A OB ND ND ND ND ND ND
33 247A 10.7424658 M A OB ND ND ND ND ND ND
34 100B 9.17534247 F B OB ND ND ND ND ND ND
35 108A 7.65753425 F A OB ND ND ND ND ND ND
36 246B 9.48767123 F B OB ND ND ND ND ND ND
37 105B 8.4109589 F B OB ND ND ND ND ND ND
38 119B 6.01643836 F B OB ND ND ND ND ND ND
39 261A 9.48 F A OB ND ND ND ND ND ND
40 118A 8.01369863 F A OB ND ND ND ND ND ND
41 134A 8.92054795 F A OB ND ND ND ND ND ND
42 132B 7.21643836 F B OB ND ND ND ND ND ND
43 402B 7.2109589 F B OB ND ND ND ND ND ND
44 125B 7.99726027 F B OB ND ND ND ND ND ND
45 102A 7.70136986 F A OB ND ND ND ND ND ND
46 106A 7.57260274 F A OB ND ND ND ND ND ND
47 301B 6.79452055 F B OB ND ND ND ND ND ND
48 107B 6.26849315 F B OB ND ND ND ND ND ND
49 270A 11.4410959 F A OB ND ND ND ND ND ND
50 249A 8.98630137 F A OB ND ND ND ND ND ND
51 251B 10.8986301 F B OB ND ND ND ND ND ND
52 116B 7.47945205 F B OB ND ND ND ND ND ND
53 259B 8.74794521 F B OB ND ND ND ND ND ND
54 103B 6.48493151 F B OB ND ND ND ND ND ND
55 267A 10.0109589 F A OB ND ND ND ND ND ND
56 2A 7.34520548 F A OB ND ND ND ND ND ND
57 245A 8.79452055 F A OB ND ND ND ND ND ND
58 243A 9.96164384 F A OB ND ND ND ND ND ND
59 401B 9.70136986 F B OB ND ND ND ND ND ND
60 129B 8.03287671 F B OB ND ND ND ND ND ND
61 403B 9.90958904 F B OB ND ND ND ND ND ND
62 309A 8.51780822 F A OB ND ND ND ND ND ND
63 281A 9.90136986 F A OB ND ND ND ND ND ND
64 307A 6.57534247 F A OB ND ND ND ND ND ND
65 121A 9.10958904 F A OB ND ND ND ND ND ND
66 253A 10.1945205 F A OB ND ND ND ND ND ND
67 3B 8.99178082 F B OB ND ND ND ND ND ND
68 275B 9.70136986 F B OB ND ND ND ND ND ND
69 313A 8.78630137 F A OB ND ND ND ND ND ND
70 284A 9.17260274 F A OB ND ND ND ND ND ND
71 112A 7.06027397 F A OB ND ND ND ND ND ND
72 260B 9.0109589 F B OB ND ND ND ND ND ND
OBESE DATA NR GENE EXPRESSION (MANUAL)
233252
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9.2 Appendix B 
Chapter 5: Metabonomics OPLS analysis S-plots 
M3: A vs. B                                                              M6: A vs. C 
 
 
 
 
 
 
 
 
M9: B vs. C                                                              M12: AB vs. C 
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M15: LW vs. HW                                                      M18: GW vs. HW 
 
 
 
 
 
 
 
 
M21: GW vs. LW                                                     M24: Male Clinical  
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M33: Male Nuclear Receptor                                     M36: Female Nuclear Receptor 
  
 
 
 
 
 
 
M39: Combined Nuclear Receptor 
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Chapter 6: Pairwise Analysis O2PLS S-plots 
M1: N vs. C (combined) 
 
 
 
 
 
 
M2: N vs. M (combined) 
 
 
 
 
 
 
M3: C vs. M (combined) 
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M4: N vs. C (male) 
 
 
 
 
 
 
 
 
M5: N vs. M (male) 
 
 
 
 
 
 
 
 
M6: C vs. M (male) 
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M7: N vs. C (female) 
 
 
 
 
 
 
 
 
M8: N vs. M (female) 
 
 
 
 
 
 
 
 
M9: C vs. M (female) 
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Chapter 6: Integration analysis O2PLS S-plots 
M10: N+C vs. M (combined) 
 
 
 
 
 
 
 
 
M11: N+M vs. C (combined) 
 
 
 
 
 
 
 
 
M12: C+M vs. N (combined) 
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M13: N+C vs. M (male) 
 
 
 
 
 
 
 
 
M14: N+M vs. C (male) 
 
 
 
 
 
 
 
 
M15: C+M vs. N (male) 
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M16: N+C vs. M (female)  
 
 
 
 
 
 
 
 
M17: N+M vs. C (female) 
 
 
 
 
 
 
 
 
M18: C+M vs. N (female) 
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